<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001843.pub5" GROUP_ID="INCONT" ID="293299090210052391" MERGED_FROM="" MODIFIED="2015-01-26 11:33:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Short title (no longer in use): Post prostatectomy urinary incontinence&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2015-01-26 11:33:32 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0001" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2015-01-26 11:33:32 +0000" MODIFIED_BY="[Empty name]">
<TITLE>Conservative management for postprostatectomy urinary incontinence</TITLE>
<CONTACT>
<PERSON ID="17046" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Kathleen</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Hunter</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>kathleen.hunter@ualberta.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Nursing</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>3rd Floor Clinical Sciences Building</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edmonton</CITY>
<ZIP>T6G 2G3</ZIP>
<REGION>AB</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+ 1 780 492 8941</PHONE_1>
<PHONE_2/>
<FAX_1>+ 1 780 492 2551</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-01-26 11:21:59 +0000" MODIFIED_BY="Muhammad Imran Omar">
<PERSON ID="z1305150947349967423275053018785" ROLE="AUTHOR">
<PREFIX>Miss</PREFIX>
<FIRST_NAME>Coral</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Anderson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>coral.anderson.09@aberdeen.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Academic Urology Unit</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="74740356430336605589110415170237" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Muhammad Imran</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Omar</LAST_NAME>
<SUFFIX/>
<POSITION>Managing Editor Cochrane Incontinence Review Group</POSITION>
<EMAIL_1>m.i.omar@abdn.ac.uk</EMAIL_1>
<EMAIL_2>drimran@yahoo.com</EMAIL_2>
<URL>http://www.abdn.ac.uk/urology/staff/details/m.i.omar</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Academic Urology Unit</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>Health Sciences Building (second floor)</ADDRESS_1>
<ADDRESS_2>Foresterhill</ADDRESS_2>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION>Scotland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0) 122 4438126</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="156DB8CC82E26AA201BA4B54421F27DB" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Susan</FIRST_NAME>
<MIDDLE_INITIALS>E</MIDDLE_INITIALS>
<LAST_NAME>Campbell</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Susan.Campbell@uea.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Health Sciences</DEPARTMENT>
<ORGANISATION>University of East Anglia</ORGANISATION>
<ADDRESS_1>Edith Cavell Building</ADDRESS_1>
<ADDRESS_2>Norwich Research Park</ADDRESS_2>
<CITY>Norwich</CITY>
<ZIP>NR4 7TJ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)1603 597102</PHONE_1>
<PHONE_2/>
<FAX_1>+44 (0)1603 597019</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17046" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Kathleen</FIRST_NAME>
<MIDDLE_INITIALS>F</MIDDLE_INITIALS>
<LAST_NAME>Hunter</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1>kathleen.hunter@ualberta.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Faculty of Nursing</DEPARTMENT>
<ORGANISATION>University of Alberta</ORGANISATION>
<ADDRESS_1>3rd Floor Clinical Sciences Building</ADDRESS_1>
<ADDRESS_2/>
<CITY>Edmonton</CITY>
<ZIP>T6G 2G3</ZIP>
<REGION>AB</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>+ 1 780 492 8941</PHONE_1>
<PHONE_2/>
<FAX_1>+ 1 780 492 2551</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7298" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>June</FIRST_NAME>
<MIDDLE_INITIALS>D</MIDDLE_INITIALS>
<LAST_NAME>Cody</LAST_NAME>
<SUFFIX/>
<POSITION>Review Author</POSITION>
<EMAIL_1>djunecody@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL>http://www.otago.ac.nz/cure</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Cochrane Incontinence Review Group</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>2nd Floor, Health Sciences Building</ADDRESS_1>
<ADDRESS_2>Health Sciences Building</ADDRESS_2>
<CITY>Foresterhill</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION>Aberdeen</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 438126</PHONE_1>
<PHONE_2>+44 1224 438128</PHONE_2>
<FAX_1>+44 1224 438165</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7513" ROLE="AUTHOR">
<PREFIX>A/Prof</PREFIX>
<FIRST_NAME>Cathryn</FIRST_NAME>
<MIDDLE_INITIALS>MA</MIDDLE_INITIALS>
<LAST_NAME>Glazener</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>c.glazener@abdn.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Health Services Research Unit</DEPARTMENT>
<ORGANISATION>University of Aberdeen</ORGANISATION>
<ADDRESS_1>3rd Floor, Health Sciences Building</ADDRESS_1>
<ADDRESS_2>Foresterhill</ADDRESS_2>
<CITY>Aberdeen</CITY>
<ZIP>AB25 2ZD</ZIP>
<REGION>Scotland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1224 438168</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1224 438165</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-01-20 13:10:41 +0000" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Minor update: 2/20/07&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Conclusions changed: 5/10/06&lt;/p&gt;" NOTES_MODIFIED="2015-01-20 13:10:41 +0000" NOTES_MODIFIED_BY="Muhammad Imran Omar">
<UP_TO_DATE>
<DATE DAY="5" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="2" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1999"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-01-26 11:33:32 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2015-01-26 11:33:32 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="26" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>Incorporated following sentence in the abstract "It seems unlikely that men benefit from one-to-one PFMT therapy after TURP."</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-01-26 11:32:46 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-01-26 11:32:46 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>In this update, the review authors have added 13 new trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>). Risk of bias assessment was performed on all 50 trials in accordance with the current methodology. Overall, 37/50 trials were also included in the previous update (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>) and 13/50 trials were identified in this update. Quality of evidence was assessed by adopting the GRADE approach.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-01-26 11:32:44 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="19" MONTH="1" YEAR="2015"/>
<DESCRIPTION>
<P>In this update, the review authors have added 13 new trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>). Risk of bias assessment was performed on all 50 trials in accordance with the current methodology. Overall, 37/50 trials were also included in the previous update (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>) and 13/50 trials were identified in this update. Quality of evidence was assessed by adopting the GRADE approach.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-06-17 14:42:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>18 new trials added</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2014-06-17 14:41:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="8" YEAR="2011"/>
<DESCRIPTION>
<P>In this update, 18 new trials have been added (of which 1 was a previously excluded trial). The total number of trials included is now 37.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-13 13:48:46 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-04-13 16:18:47 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="21" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment. In this update (Issue 2 2007), 7 trials were added to the review. The total number of studies included was 17. In this update, comparisons were separated on the basis of type of surgery and as well whether the intervention occurred pre- or post-operatively.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-04-13 16:17:52 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="25" MONTH="2" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive update Issue 2 2004. In this update, five trials were added to the review. One trial previously listed as included was excluded after attempts to contact the author to access data were unsuccessful. The total number of studies included was 10. 7 extra studies were excluded.<BR/>
</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2008-10-10 12:59:13 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="1" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive update Issue 2 2001</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-01-19 10:28:41 +0000" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2015-01-19 10:28:41 +0000" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2015-01-19 10:28:41 +0000" MODIFIED_BY="[Empty name]">
<NAME>University of Alberta, Edmonton, Alberta</NAME>
<COUNTRY CODE="CA">Canada</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-04-04 11:17:02 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-04-04 11:16:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>National Institute for Health Research (NIHR)</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Incontinence Group.</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2014-04-04 11:16:31 +0100" MODIFIED_BY="[Empty name]">
<NAME>Chief Scientist Office, Scottish Executive Health Department</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-01-26 11:32:33 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-01-19 09:34:25 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-10 13:20:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Add following headings:&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;Importance of the review or background on the condition&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;The main findings of the review &lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;Adverse effects&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;b&gt;Any limitations of the review&lt;/b&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-10 13:20:57 +0100" NOTES_MODIFIED_BY="[Empty name]">Conservative management for men with urinary incontinence after prostate surgery</TITLE>
<SUMMARY_BODY MODIFIED="2015-01-19 09:34:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<I>
<B>Background information</B>
</I>
</P>
<P>The prostate is a male sex gland that surrounds the outlet of the bladder. Two main diseases of the prostate (cancer of the prostate, and benign (non-cancerous) prostatic enlargement) can be treated by surgery but some men suffer leakage of urine (urinary incontinence) afterwards. Conservative treatments of the leakage such as pelvic floor muscle training with or without biofeedback or anal electrical stimulation are thought to help men control this leakage.</P>
<P>
<I>
<B>The main findings of the review </B>
</I>
</P>
<P>The review of trials found that there was conflicting evidence about the benefit of therapists teaching men to contract their pelvic floor muscles for either prevention or treatment of urine leakage after radical prostate surgery for cancer. However, information from one large trial suggested that men do not benefit from seeing a therapist to receive pelvic floor muscle training after transurethral resection (TURP) for benign prostatic enlargement. Overall, there was insufficient evidence to demonstrate a beneficial effect from pelvic floor muscle training.</P>
<P>Of three external compression devices tested, one penile clamp seemed to be better than the others.</P>
<P>
<I>
<B>Adverse effects</B>
</I>
</P>
<P>This one penile clamp needed to be used cautiously because of safety risks.</P>
<P>
<I>
<B>Any limitations of the review</B>
</I>
</P>
<P>In future updates it may be worth considering two separate reviews, looking separately at 'treatment' and 'prevention' trials. More research that is of better quality is also needed to assess conservative management.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-01-26 11:32:33 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2015-01-05 15:38:47 +0000" MODIFIED_BY="[Empty name]">
<P>Urinary incontinence is common after radical prostatectomy and can also occur in some circumstances after transurethral resection of the prostate (TURP). Conservative management includes pelvic floor muscle training with or without biofeedback, electrical stimulation, extra-corporeal magnetic innervation (ExMI), compression devices (penile clamps), lifestyle changes, or a combination of methods.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-01-05 15:38:53 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of conservative management for urinary incontinence up to 12 months after transurethral, suprapubic, laparoscopic, radical retropubic or perineal prostatectomy, including any single conservative therapy or any combination of conservative therapies.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-01-19 09:30:11 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Register (5 February 2014), CENTRAL (2014, Issue 1), EMBASE (January 2010 to Week 3 2014), CINAHL (January 1982 to 18 January 2014), ClinicalTrials.gov and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (both searched 29 January 2014), and the reference lists of relevant articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-11-18 15:48:42 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised or quasi-randomised controlled trials evaluating conservative interventions for urinary continence in men after prostatectomy.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-01-19 09:30:13 +0000" MODIFIED_BY="[Empty name]">
<P>Two or more review authors assessed the methodological quality of the trials and abstracted data. We tried to contact several authors of included studies to obtain extra information.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-01-26 11:32:33 +0000" MODIFIED_BY="[Empty name]">
<P>Fifty trials met the inclusion criteria, 45 in men after radical prostatectomy, four trials after TURP and one trial after either operation. The trials included 4717 men of whom 2736 had an active conservative intervention. There was considerable variation in the interventions, populations and outcome measures. Data were not available for many of the pre-stated outcomes. Men's symptoms improved over time irrespective of management.</P>
<P>There was no evidence from eight trials that pelvic floor muscle training with or without biofeedback was better than control for men who had urinary incontinence up to 12 months after radical prostatectomy; the quality of the evidence was judged to be moderate (for example 57% with urinary incontinence in the intervention group versus 62% in the control group, risk ratio (RR) for incontinence after 12 months 0.85, 95% confidence interval (CI) 0.60 to 1.22). One large multi-centre trial of one-to-one therapy showed no difference in any urinary or quality of life outcome measures and had narrow CIs. It seems unlikely that men benefit from one-to-one PFMT therapy after TURP. Individual small trials provided data to suggest that electrical stimulation, external magnetic innervation, or combinations of treatments might be beneficial but the evidence was limited. </P>
<P>Amongst trials of conservative treatment for all men after radical prostatectomy, aimed at both treatment and prevention, there was moderate evidence of an overall benefit from pelvic floor muscle training versus control management in terms of reduction of urinary incontinence (for example 10% with urinary incontinence after one year in the intervention groups versus 32% in the control groups, RR for urinary incontinence 0.32, 95% CI 0.20 to 0.51). However, this finding was not supported by other data from pad tests. The findings should be treated with caution because the risk of bias assessment showed methodological limitations. </P>
<P>Men in one trial were more satisfied with one type of external compression device, which had the lowest urine loss, compared to two others or no treatment. The effect of other conservative interventions such as lifestyle changes remained undetermined as no trials involving these interventions were identified.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-01-20 13:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>The value of the various approaches to conservative management of postprostatectomy incontinence after radical prostatectomy remains uncertain. The evidence is conflicting and therefore rigorous, adequately powered randomised controlled trials (RCTs) which abide by the principles and recommendations of the CONSORT statement are still needed to obtain a definitive answer. The trials should be robustly designed to answer specific well constructed research questions and include outcomes which are important from the patient's perspective in decision making and are also relevant to the healthcare professionals. Long-term incontinence may be managed by an external penile clamp, but there are safety problems.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-01-20 14:21:41 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-01-19 10:41:51 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2015-01-19 10:41:51 +0000" MODIFIED_BY="[Empty name]">
<P>It is not uncommon for men to have urinary incontinence (UI) after prostatectomy. UI can be divided into three groups of urgency urinary incontinence (UUI), stress urinary incontinence (SUI) and mixed urinary incontinence (MUI). UUI is described by the International Continence Society (ICS) as the complaint of involuntary leakage of urine associated with a sudden desire to void urine (<LINK REF="REF-Altman-2013" TYPE="REFERENCE">Altman 2013</LINK>). SUI is defined as the involuntary leakage of urine with concurrent coughing, sneezing or physical exertion, whilst MUI, as the name suggests, is a mixture of the symptoms found in both of these types (<LINK REF="REF-Altman-2013" TYPE="REFERENCE">Altman 2013</LINK>). The reported frequency varies depending on the type of surgery and surgical technique (<LINK REF="REF-Grise-2001" TYPE="REFERENCE">Grise 2001</LINK>; <LINK REF="REF-Peyromaure-2002" TYPE="REFERENCE">Peyromaure 2002</LINK>), the definition and quantification of incontinence (<LINK REF="REF-Grise-2001" TYPE="REFERENCE">Grise 2001</LINK>; <LINK REF="REF-Peyromaure-2002" TYPE="REFERENCE">Peyromaure 2002</LINK>), the timing of the evaluation relative to the surgery, and who evaluates the presence or absence of incontinence (physician or patient) (<LINK REF="REF-Donnellan-1997" TYPE="REFERENCE">Donnellan 1997</LINK>; <LINK REF="REF-McCammon-1999" TYPE="REFERENCE">McCammon 1999</LINK>). Furthermore, the costs associated with UI can be substantial. The annual cost to the National Health Service (NHS) in the UK for treating clinically significant storage symptoms in men was estimated to be GBP 303 million (<LINK REF="REF-Turner-2004" TYPE="REFERENCE">Turner 2004</LINK>) and the annual direct cost of UI in the US was estimated to be USD 3.8 billion (<LINK REF="REF-Wilson-2001" TYPE="REFERENCE">Wilson 2001</LINK>).</P>
<P>The prevalence of UI after radical prostatectomy is widely reported, ranging from 2% to 60%, albeit at varying times after operation (<LINK REF="REF-Milsom-2009" TYPE="REFERENCE">Milsom 2009</LINK>). For example, in one study at three months after radical prostatectomy (<LINK REF="REF-Donnellan-1997" TYPE="REFERENCE">Donnellan 1997</LINK>) 51% were subjectively wet (self-report) but 36% were wet on pad testing (objective reporting). By 12 months, 20% were subjectively still wet but only 16% were classed as wet using objective criteria.</P>
<P>UI is less common after transurethral resection of the prostate (TURP) for benign prostate disease (<LINK REF="REF-Omar-2014" TYPE="REFERENCE">Omar 2014</LINK>) and most cases are due to persistent incontinence pre-dating the surgery. Early UUI affects up to 30% to 40% of men but late SUI is rare affecting less than 0.5% of men (<LINK REF="REF-Rassweiler-2006" TYPE="REFERENCE">Rassweiler 2006</LINK>). This is a less invasive operation than a radical prostatectomy and usually does not involve damage to pelvic nerves. Due to these clinical differences, we have analysed data relating to TURP separately.</P>
<P>After both types of operation the problem tends to improve with time, so that it declines and plateaus within one to two years postoperatively (<LINK REF="REF-Hunskaar-2002" TYPE="REFERENCE">Hunskaar 2002</LINK>). However, some men are left with incontinence that persists for years afterwards.</P>
<SUBSECTION>
<HEADING LEVEL="3">Continence mechanisms</HEADING>
<P>Urinary continence depends on a complex interaction of smooth and striated muscle fibres blended together to form the continence mechanism. Considerable debate has existed in the literature as to whether incontinence after prostatectomy is due to an effect on the detrusor (bladder) muscle or on the sphincter, as commonly these abnormalities coexist (<LINK REF="REF-Peyromaure-2002" TYPE="REFERENCE">Peyromaure 2002</LINK>). New detrusor overactivity and intrinsic sphincter deficiency due to sphincteric injury (<LINK REF="REF-Ficazzola-1998" TYPE="REFERENCE">Ficazzola 1998</LINK>; <LINK REF="REF-Groutz-2000" TYPE="REFERENCE">Groutz 2000</LINK>; <LINK REF="REF-McGuire-1990" TYPE="REFERENCE">McGuire 1990</LINK>) or weakness (<LINK REF="REF-Majoros-2006" TYPE="REFERENCE">Majoros 2006</LINK>) are cited as the most important causes of persistent incontinence after radical prostatectomy. Debate continues on whether detrusor overactivity is a primary or secondary factor. Whereas some report overactivity as the primary cause of postprostatectomy incontinence (<LINK REF="REF-Golubuff-1995" TYPE="REFERENCE">Golubuff 1995</LINK>; <LINK REF="REF-Leach-1995" TYPE="REFERENCE">Leach 1995</LINK>) others argue strongly that even if other factors play a role, intrinsic sphincter deficiency is the primary cause of UI after radical prostatectomy (<LINK REF="REF-Aboseif-1996" TYPE="REFERENCE">Aboseif 1996</LINK>; <LINK REF="REF-Chao-1995" TYPE="REFERENCE">Chao 1995</LINK>; <LINK REF="REF-Groutz-2000" TYPE="REFERENCE">Groutz 2000</LINK>; <LINK REF="REF-Gudziak-1996" TYPE="REFERENCE">Gudziak 1996</LINK>; <LINK REF="REF-Kondo-2002" TYPE="REFERENCE">Kondo 2002</LINK>; <LINK REF="REF-Majoros-2006" TYPE="REFERENCE">Majoros 2006</LINK>; <LINK REF="REF-Winters-1997" TYPE="REFERENCE">Winters 1997</LINK>).</P>
<P>Risk factors for postprostatectomy UI after radical prostatectomy include pre-existing abnormalities of detrusor contractility (<LINK REF="REF-Leach-1995" TYPE="REFERENCE">Leach 1995</LINK>) and older age (<LINK REF="REF-Kondo-2002" TYPE="REFERENCE">Kondo 2002</LINK>). This is possibly because in older men there is evidence of rhabdosphincter atrophy and neural degeneration (<LINK REF="REF-Burnett-1998" TYPE="REFERENCE">Burnett 1998</LINK>; <LINK REF="REF-Chao-1995" TYPE="REFERENCE">Chao 1995</LINK>). Other risk factors include previous TURP (<LINK REF="REF-Jacobsen-2007" TYPE="REFERENCE">Jacobsen 2007</LINK>); pre-operative radiotherapy (<LINK REF="REF-Kondo-2002" TYPE="REFERENCE">Kondo 2002</LINK>; <LINK REF="REF-Rainwater-1988" TYPE="REFERENCE">Rainwater 1988</LINK>); trauma; a spinal cord lesion; new obstruction due to recurrence, bladder neck contracture, or urethral stricture (<LINK REF="REF-Litwiller-1997" TYPE="REFERENCE">Litwiller 1997</LINK>); Parkinson's disease (<LINK REF="REF-Kondo-2002" TYPE="REFERENCE">Kondo 2002</LINK>); dementia; and medications (<LINK REF="REF-Khan-1991" TYPE="REFERENCE">Khan 1991</LINK>). A surgeon's inadequate skill and expertise can determine post-operative incontinence rates (<LINK REF="REF-Eastham-1996" TYPE="REFERENCE">Eastham 1996</LINK>). In addition, having surgery in a hospital which performs fewer than 20 radical prostatectomies a year may be a factor (<LINK REF="REF-Albertsen-1997" TYPE="REFERENCE">Albertsen 1997</LINK>).</P>
<P>After TURP, UI is thought most likely to be due to pre-existing abnormalities of bladder function, such as poor compliance or detrusor overactivity, rather than direct sphincter injury (<LINK REF="REF-Abrams-1991" TYPE="REFERENCE">Abrams 1991</LINK>), possibly because removal of the prostatic tissue removed some of the protective mechanism for continence.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-01-19 09:37:32 +0000" MODIFIED_BY="[Empty name]">
<P>Many of the treatments used in current practice for postprostatectomy UI are 'conservative', which is usually considered as not involving drugs or surgery. Treatments such as biofeedback with surface intra-anal probes are defined as non-invasive in this context, as opposed to surgical interventions. Five categories of conservative management are considered in this review, both singly and in combination when appropriate.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Pelvic floor muscle training (PFMT)</HEADING>
<P>This involves any method of training the pelvic floor muscles to contract. It includes teaching performance of an accurate voluntary pelvic floor muscle contraction using biofeedback and co-ordinating and timing the contraction against increases in intra-abdominal pressure, often called functional PFMT.</P>
<P>Traditionally, biofeedback involves the use of equipment to provide visual or auditory feedback about the pelvic floor muscle function to enable one to train, strengthen and increase endurance and co-ordination of the pelvic floor muscle contractions. Simple auditory biofeedback can also be provided by the therapist informing the patient when a contraction is felt through digital anal examination during the pelvic floor muscle contraction. Additionally, pelvic floor muscle contraction electromyography (EMG) can be used as a surrogate for biofeedback, as well as for measuring the intra-rectal pressure.</P>
<P>The theoretical basis of PFMT is that repeated, volitional contractions of selected pelvic floor muscles may improve their strength and efficiency during periods of increased intra-abdominal pressure and can inhibit detrusor activity. In a systematic review of the literature on female UI, Berghmans and colleagues noted that a pelvic floor muscle contraction may raise the urethra and press it towards the symphysis pubis, prevent urethral descent, and improve structural support of the pelvic organs (<LINK REF="REF-Berghmans-1998" TYPE="REFERENCE">Berghmans 1998</LINK>). They further pointed out that PFMT may result in hypertrophy of the peri-urethral striated muscles thereby increasing the 'external mechanical pressure' on the urethra.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Electrical stimulation (non-invasive) delivered via surface electrodes</HEADING>
<P>Electrical stimulation (ES) works by activating the motor fibres of the pudendal nerve, which can result in contraction of the pelvic floor muscles or the striated peri-urethral musculature, supporting the intrinsic part of the urethral sphincter closing mechanism (<LINK REF="REF-Berghmans-2013" TYPE="REFERENCE">Berghmans 2013</LINK>). This may be important in the management of men with SUI by stimulating the intrinsic sphincter, strengthening the pelvic muscles and raising the patient's awareness of these muscles in a similar way to biofeedback. ES can also be helpful in men with detrusor overactivity or UUI because it can stimulate afferent fibres of the pudendal nerve, decreasing the sensation of urgency and inhibiting parasympathetic activity which results in a decrease in involuntary detrusor contractions (<LINK REF="REF-Berghmans-2013" TYPE="REFERENCE">Berghmans 2013</LINK>). Two types of non-invasive ES are detailed below. The parameters of the ES used in studies vary depending on the type of UI and ES. Parameters include pulse width and duration, current intensity, stimulus frequency, current source, pulse shape, duration of treatment and total number of sessions, and rest to work ratio.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="4">Anal electrical stimulation (ES)</HEADING>
<P>Any type of ES using a non-invasive surface anal probe designed for the therapy. The intention of ES is to facilitate contraction of the peri-urethral striated muscle by inserting the probe into the anal canal (<LINK REF="REF-Jabs-2001" TYPE="REFERENCE">Jabs 2001</LINK>).<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sticky patch electrodes, also called transcutaneous electrical nerve stimulation (TENS)</HEADING>
<P>TENS is a low intensity, sensory nerve stimulation used for detrusor overactivity. It is delivered at various sites using patch electrodes. Sites include the sacral dermatomes, dorsal penile nerve, hamstring and quadriceps muscle, and the posterior tibial or perineal nerves (<LINK REF="REF-Berghmans-2013" TYPE="REFERENCE">Berghmans 2013</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Lifestyle adjustment</HEADING>
<P>This includes fluid adjustment, healthy diet, avoiding excessive caffeine, physical exercise, weight loss and cessation of smoking.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Extra-corporeal magnetic innervation</HEADING>
<P>This involves the use of a magnetic chair to stimulate contraction of the pelvic floor muscles and sacral nerve roots, without the discomfort of inserting an anal probe (<LINK REF="REF-Galloway-2000" TYPE="REFERENCE">Galloway 2000</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. External penile compression devices (penile clamps)</HEADING>
<P>These devices use an external clamp to achieve non-surgical compression of the urethra.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Timing of the intervention</HEADING>
<P>Conservative treatment can be started before or after surgery. In general, when it is delivered to all men (whether before or after) the aim is to prevent the development or persistence of UI. We have therefore distinguished between treatment of all men who do have UI (treatment) as opposed to a mixed population of men some of whom do not have UI (prevention).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2015-01-19 09:37:57 +0000" MODIFIED_BY="[Empty name]">
<P>All of these interventions, apart from lifestyle adjustment and a penile clamp, work by inducing contraction of pelvic muscles to increase their strength and efficiency, whilst improving co-ordination and bladder control by inhibiting overactive detrusor activity. Repetitive contractions can raise urethral closure pressure at rest and during an increase in intra-abdominal pressure.</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-01-19 09:38:03 +0000" MODIFIED_BY="[Empty name]">
<P>The uncertainty about the benefit of conservative treatment for men with UI after prostate surgery was confirmed in the initial Cochrane review, first published in 1999 (<LINK REF="REF-Moore-1999b" TYPE="REFERENCE">Moore 1999b</LINK>) and updated in 2001 (<LINK REF="REF-Moore-2001" TYPE="REFERENCE">Moore 2001</LINK>). The review originally only considered post-operative PFMT, biofeedback and electrical stimulation. In a subsequent update (<LINK REF="REF-Hunter-2004" TYPE="REFERENCE">Hunter 2004</LINK>) the review was broadened to include trials evaluating lifestyle adjustment, external penile compression devices and extracorporeal magnetic innervation. The most recent update also included trials on men after TURP (<LINK REF="REF-Hunter-2007" TYPE="REFERENCE">Hunter 2007</LINK>) but still did not provide reliable evidence on the effects of conservative treatment. The current update includes 13 new trials.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-01-19 09:38:08 +0000" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness of conservative management for urinary incontinence (UI) up to 12 months after transurethral or radical retropubic prostatectomy, including any single conservative therapy or any combination of conservative therapies.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-01-19 09:39:25 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2015-01-19 09:38:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials and quasi-randomised trials of conservative management to prevent or treat UI after TURP or radical prostatectomy were included. Trials were included if they used any single conservative therapy or any combination of conservative therapies. Other forms of clinical trials were excluded. Analysis of trials in men having radical prostatectomy was done separately from those in men having a TURP.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-01-19 09:38:18 +0000" MODIFIED_BY="[Empty name]">
<P>Adult men with UI following prostatectomy.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-01-19 09:38:49 +0000" MODIFIED_BY="[Empty name]">
<P>PFMT; biofeedback (verbal or machine-mediated); electrical stimulation (ES) via a surface electrode (e.g. anal probe ES, sticky patch electrode, transcutaneous electrical nerve stimulation (TENS)); extra-corporeal magnetic innervation (ExMI); lifestyle adjustment; and external penile compression devices. These interventions could be compared with no treatment or with each other, alone or in combination.</P>
<P>The following comparisons were made for treatment or prevention of UI after prostatectomy.</P>
<SUBSECTION>
<HEADING LEVEL="4">Radical prostatectomy</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Treatment (of men with UI after radical prostatectomy)</HEADING>
<P>(1) Treatment of UI after radical prostatectomy: PFMT plus or minus biofeedback versus no treatment or sham therapy or verbal instruction</P>
<P>(2) Treatment of UI after radical prostatectomy: electric or magnetic energy (e.g. anal ES (EStim), perineal ES, transcutaneous electrical nerve stimulation (TENS), extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment</P>
<P>(3) Treatment of UI after radical prostatectomy: lifestyle interventions versus no treatment or sham treatment</P>
<P>(4) Treatment of UI after radical prostatectomy: combinations of treatments versus no treatment or sham treatment</P>
<P>(5) Treatment of UI after radical prostatectomy: one treatment versus another active treatment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prevention (of UI in men after radical prostatectomy)</HEADING>
<P>(6) Prevention of UI after radical prostatectomy: PFMT plus or minus biofeedback versus no treatment or sham therapy or verbal instruction</P>
<P>(7) Prevention of UI after radical prostatectomy: electric or magnetic energy (e.g. anal ES (EStim), perineal ES, TENS, extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment</P>
<P>(8) Prevention of UI after radical prostatectomy: lifestyle interventions versus no treatment or sham treatment</P>
<P>(9) Prevention of UI after radical prostatectomy: combinations of treatments versus no treatment or sham treatment</P>
<P>(10) Prevention of UI after radical prostatectomy: one treatment versus another active treatment</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">TURP</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Treatment (of men with UI after TURP)</HEADING>
<P>(11) Treatment of UI after TURP: PFMT plus or minus biofeedback versus no treatment or sham therapy or verbal instruction</P>
<P>(12) Treatment of UI after TURP: electric or magnetic energy (e.g. anal ES (EStim), perineal ES, TENS, extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment</P>
<P>(13) Treatment of UI after TURP: lifestyle interventions versus no treatment or sham treatment</P>
<P>(14) Treatment of UI after TURP: combinations of treatments versus no treatment or sham treatment</P>
<P>(15) Treatment of UI after TURP: one treatment versus another active treatment</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Prevention (of UI in men after TURP)</HEADING>
<P>(16) Prevention of UI after TURP: pre or post-operative PFMT plus or minus biofeedback versus no treatment or sham therapy or verbal instruction</P>
<P>(17) Prevention of UI after TURP: electric or magnetic energy (e.g. anal ES (EStim), perineal ES, TENS,extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment</P>
<P>(18) Prevention of UI after TURP: lifestyle interventions versus no treatment or sham treatment</P>
<P>(19) Prevention of UI after TURP: combinations of treatments versus no treatment or sham treatment</P>
<P>(20) Prevention of UI after TURP: one treatment versus another active treatment</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Containment of urinary incontinence (UI) from any cause</HEADING>
<P>(21) External penile compression devices (penile clamps) versus no treatment or sham treatment</P>
<P>We have not listed all possible comparisons here. As and when new trials address new comparisons these will be added to the review.</P>
<P>Pharmacological agents will be considered in separate reviews. Verbal or written instructions, as well as sham therapy, were considered as 'no treatment'. The use of the term 'sham therapy' in this review meant any therapy that could not influence the pelvic floor muscles such as placing an ES probe in the anus but not turning it on.</P>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-01-19 09:39:25 +0000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-01-19 09:39:07 +0000" MODIFIED_BY="[Empty name]">
<UL>
<LI>Number of men reporting urinary incontinence (UI) after 12 months</LI>
<LI>Quality of life assessed using the International Consultation on Incontinence Questionnaire Urinary Incontinence Short Form (ICIQ-UI-SF) or (ICIQ-SF)</LI>
<LI>Number of men reporting adverse effects</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-01-19 09:39:25 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">1. Participant reported observations</HEADING>
<UL>
<LI>Number of men reporting UI (number not cured, in the short, medium or long term)</LI>
<LI>Number of men with no improvement in UI (number not cured or improved)</LI>
<LI>Self-report of satisfaction with method</LI>
<LI>Compliance</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">2. Quantification of symptoms</HEADING>
<UL>
<LI>Standardised pad test (24 hour or 1 hour) measuring grams of urine lost</LI>
<LI>Frequency of micturitions per 24 hours</LI>
<LI>Number of pad or clothing changes (pad changes per 24 hours)</LI>
<LI>Frequency of UI from self-report or diary (incontinent episodes per 24 hours)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">3. Clinician reported urinary outcome measures</HEADING>
<UL>
<LI>Objective or observed leakage</LI>
<LI>Urodynamic outcome measures</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">4. Quality of life</HEADING>
<UL>
<LI>Impact of UI e.g. Incontinence Impact Questionnaire (<LINK REF="REF-Uebersax-1995" TYPE="REFERENCE">Uebersax 1995</LINK>)</LI>
<LI>General health status e.g. Short Form 36 (<LINK REF="REF-Ware-1993" TYPE="REFERENCE">Ware 1993</LINK>)</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">5. Adverse effects</HEADING>
<UL>
<LI>Pain or discomfort</LI>
</UL>
<UL>
<LI>Other adverse outcomes as reported by individual trials and judged to be important</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">6. Health economics outcomes</HEADING>
<UL>
<LI>Cost of intervention</LI>
<LI>Resource implications of differences in outcome</LI>
<LI>Cost effective analysis</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">7. Other outcomes</HEADING>
<UL>
<LI>Non-prespecified outcomes judged important when performing the review</LI>
</UL>
<P>The quality of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>; <LINK REF="REF-Guyatt-2011b" TYPE="REFERENCE">Guyatt 2011b</LINK>; <LINK REF="REF-Guyatt-2013" TYPE="REFERENCE">Guyatt 2013</LINK>; <LINK REF="REF-Guyatt-2013a" TYPE="REFERENCE">Guyatt 2013a</LINK>). This approach divides the quality of evidence into four categories: high, moderate, low and very low. Randomised controlled trials (RCTs) start as high quality evidence and non-randomised trials begin as low quality evidence. The quality of evidence can be rated down for RCTs and up or down for non-RCTs depending on predefined characteristics. The factors considered when assessing the quality of evidence included:</P>
<OL>
<LI>limitations in study design and implementation;</LI>
<LI>indirectness of evidence;</LI>
<LI>unexplained heterogeneity or inconsistency of results;</LI>
<LI>imprecision of results;</LI>
<LI>high probability of publication bias.</LI>
</OL>
<P>Primary and secondary outcomes were classified as critical, important or not important for decision making from the man&#8217;s perspective. The GRADE working group strongly advises a maximum of seven outcomes in a systematic review (<LINK REF="REF-Guyatt-2011a" TYPE="REFERENCE">Guyatt 2011a</LINK>). The critical outcomes for assessing quality of evidence included in this review were:</P>
<OL>
<LI>number of men reporting UI after 12 months;</LI>
<LI>quality of life assessed using the ICIQ-UI-SF;</LI>
<LI>number of men reporting adverse effects;</LI>
<LI>cost effective analysis.</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-01-19 09:40:15 +0000" MODIFIED_BY="[Empty name]">
<P>We did not impose any language or other limits on the searches. Details of the search methods used for the previous versions of this review can be found in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> and <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>.</P>
<ELECTRONIC_SEARCHES MODIFIED="2015-01-19 09:40:15 +0000" MODIFIED_BY="[Empty name]">
<P>This review has drawn on the search strategy developed for the Incontinence Review Group. Relevant trials were identified from the Incontinence Review Group Specialised Register of controlled trials which is described, along with the Group's search strategy, in the Incontinence Group's <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/INCONT/frame.html">module</A> in <I>The Cochrane Library</I>. The register contains trials identified from the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, MEDLINE In-Process, and handsearching of journals and conference proceedings. The Incontinence Group Specialised Register was searched using the Group's own keyword system; the search terms used were:<BR/>({design.cct*} OR {design.rct*})<BR/>AND<BR/>({topic.urine.incon.postprost*})<BR/>(All searches were of the keyword field of <LINK REF="REF-Reference-Manager-2012" TYPE="REFERENCE">Reference Manager 2012</LINK>).<BR/>The date of the most recent search of the Specialised Register for this review was 5 February 2014. Most of the trials in the Incontinence Group Specialised Register are also contained in CENTRAL.</P>
<P>Specific searches were also performed for this update of the review.</P>
<UL>
<LI>CENTRAL (OvidSP) (2014, Issue 1) was searched on 26 February 2014.</LI>
<LI>EMBASE (OvidSP) (January 2010 to Week 3 2014) was searched on 20 January 2014.</LI>
<LI>CINAHL (EBSCOhost) (January 1982 to 18 January 2014) was searched on 22 January 2014.</LI>
<LI>ClinicalTrials.gov (via the Cochrane Register of Studies (CRS) interface) and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (both searched on 29 January 2014).</LI>
</UL>
<P>The strategies used to search these databases can be found in <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2015-01-15 07:33:34 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Reference lists of relevant articles</HEADING>
<P>The reference lists of relevant articles were searched for other possibly relevant trials.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Contact with investigators in the field</HEADING>
<P>We contacted investigators to ask for other possibly relevant trials, published or unpublished.</P>
</SUBSECTION>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]">
<P>Comparisons of the outcomes of the chosen interventions with no treatment, with each other, and in combination were planned a priori for the review update. Data were not available for all planned comparisons. There was considerable diversity in the length of time interventions were carried out for and in the timing of outcome measurements relative to randomisation. The data were therefore reported at three monthly time points.</P>
<STUDY_SELECTION MODIFIED="2015-01-19 09:40:35 +0000" MODIFIED_BY="[Empty name]">
<P>The list of abstracts for each update was reviewed independently by two review authors and results compared. The full text articles of references or abstracts identified as potentially relevant by either review author were retrieved and reviewed by both. Reference lists of relevant review articles were reviewed to identify any further trials. References were assessed based on the population, interventions, control management, outcomes and overall study design. Using the full texts of the potentially relevant published studies and abstracts, the same two review authors independently reviewed the studies for relevance and inclusion. Authors were contacted for further data or clarification of methods. Disagreements were resolved through discussion; third party arbitration was not required.</P>
<P>Attempts were made to contact authors of trial reports if clarification was necessary. Studies were excluded from the review if they made comparisons other than those pre-specified or if data were unavailable. Excluded studies were listed with reasons for their exclusion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]">
<P>Data for the trials were extracted independently by two review authors using a standard form developed for this purpose. The following information was included:<BR/>
</P>
<UL>
<LI>study method and characteristics (design, method of randomisation, inclusion and exclusion criteria, withdrawals and dropouts);</LI>
<LI>participants (type of surgery, age, timing of randomisation, baseline incontinence or not);</LI>
<LI>type of intervention, timing (before or after surgery, or both) and duration of therapy, co-interventions;</LI>
<LI>control (no treatment or sham therapy or other active treatment);</LI>
<LI>outcomes (types of outcome measures, reported outcomes, adverse events).</LI>
</UL>
<P>Extracted data were compared by two review authors for completeness and accuracy, and cross-checked by another review author if necessary. Disagreements were resolved through discussion and review of the trial report. New data were entered using RevMan5 software.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-01-19 09:40:49 +0000" MODIFIED_BY="[Empty name]">
<P>The risk of bias of the trials was assessed using the Cochrane 'risk of bias' tool.</P>
<P>The following methodological parameters were recorded:<BR/>1) identification of study as randomised or quasi-randomised;<BR/>2) description of inclusion and exclusion criteria;<BR/>3) potential for selection bias (method of sequence generation, adequacy of random allocation concealment) rating;<BR/>4) potential for bias around the time of treatment or during outcome assessment (blinding of participants, personnel, outcome assessors);<BR/>5) potential for selection bias in the analysis (description of withdrawals, dropouts, participants lost to follow up, analysis based on intention to treat).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-01-19 09:40:57 +0000" MODIFIED_BY="[Empty name]">
<P>Analyses were based on available data from all included trials that were relevant to the comparisons and outcomes of interest. Meta-analysis was undertaken where data were available from more than one study assessing the same outcome. A fixed-effect model was used for calculations of pooled estimates and their 95% confidence intervals (CIs), or a random-effects model if there was heterogeneity. For categorical outcomes we related the numbers reporting an outcome to the numbers at risk in each group to calculate a risk ratio (RR) with 95% CI. For continuous variables we used means and standard deviations to calculate a mean difference (MD) with 95% CI. If similar outcomes were reported on different scales, we calculated the standardised mean difference (SMD). We reversed the direction of effect if needed to ensure consistency across trials. If data to calculate RRs or MDs were not given, we utilised the most detailed numerical data available to calculate the actual numbers or means and standard deviations (for example test statistics, P values).</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2014-05-13 15:14:18 +0100" MODIFIED_BY="[Empty name]">
<P>The primary analysis was per man randomised. </P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2015-01-19 09:41:12 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis of the data was on an intention-to-treat basis to the furthest possible extent. This meant all participants were analysed in the groups to which they were randomised. If this was not the case, we considered whether to exclude the trial. Attempts were made to obtain missing data from the original trialists. However, if this was not possible data were reported as given in the studies, except if there was evidence of differential loss to follow up from the randomised groups. In that case, the use of imputation of missing data was considered. If trials reported sufficient detail to calculate MDs but gave no information on the associated standard deviation (SD), the outcome was assumed to have a SD equal to the highest SD from other trials within the same analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-01-19 09:41:19 +0000" MODIFIED_BY="[Empty name]">
<P>Trials were only combined if they were thought to be clinically similar. We assessed heterogeneity between studies by visual inspection of plots of the data, the Chi<SUP>2</SUP> test for heterogeneity and I<SUP>2</SUP>statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used the thresholds for interpretation of the I<SUP>2</SUP> statistic in accordance with the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2015-01-05 15:51:42 +0000" MODIFIED_BY="[Empty name]">
<P>Due to the difficulty of detecting and correcting for publication bias and other reporting biases, the authors aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being careful to watch for duplication of data. Funnel plots could not be utilised because there were fewer than 10 trials in each meta-analysis.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-01-19 09:41:27 +0000" MODIFIED_BY="[Empty name]">
<P>Included trial data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>For dichotomous outcomes, data were summarised (for example number of people for whom an outcome is present or not) and risk ratios (RR) calculated with their 95% CIs. For continuous outcomes, each trial was summarised using the mean value for each group and SD, and combined as mean difference (MD) if the same scale (for example pad test in grams of urine) was used for the outcome measurement in more than one trial. A fixed-effect model was used to calculate the summary statistic and the 95% CI. Heterogeneity was assessed visually and using the Chi<SUP>2</SUP> test for heterogeneity and the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Forest plots were examined and potential sources influencing heterogeneity identified. Possible sources of heterogeneity were explored statistically through subgroup analysis. Where synthesis was deemed not appropriate, a narrative overview was planned.</P>
<P>Trials were combined if interventions were based on similar clinical criteria. To combine trial data, a meta-analysis was conducted and a fixed-effect model approach to the analysis was utilised unless there was evidence of heterogeneity across studies, in which case a random-effects model was used.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2015-01-19 09:41:36 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to perform subgroup analysis based on cancer stage but there were not enough data.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2015-01-19 09:41:36 +0000" MODIFIED_BY="[Empty name]">
<P>We planned to perform sensitivity analysis to investigate the effect of including or excluding trials at high risk of bias, however not enough trials were in the meta-analysis.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-01-20 14:21:34 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;I count 6 studies waiting classification (8 reports of 6 studies) what about Simeit and Zellner?&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:13:43 +0000" NOTES_MODIFIED_BY="[Empty name]">
<P>For the current update (2014) of the review 764 possibly relevant articles and abstracts were identified. Sources and numbers of potentially eligible titles were:</P>
<UL>
<LI>Incontinence Review Group Specialised Register (193);</LI>
</UL>
<UL>
<LI>CENTRAL (37);</LI>
</UL>
<UL>
<LI>updated search of EMBASE (354);</LI>
</UL>
<UL>
<LI>CINAHL (23);</LI>
</UL>
<UL>
<LI>ClinicalTrials.gov (125);</LI>
</UL>
<UL>
<LI>WHO ICTRP (32).</LI>
</UL>
<P>Overall 96 reports of 50 studies were included in the qualitative synthesis. Fifty-nine reports of 27 studies were included in the quantitative synthesis. Four trials are awaiting further information from the authors (<LINK REF="STD-Crivellaro-2011" TYPE="STUDY">Crivellaro 2011</LINK>
<I>; </I>
<LINK REF="STD-Delmastro-2010" TYPE="STUDY">Delmastro 2010</LINK>; <LINK REF="STD-Lilli-2006-NEW" TYPE="STUDY">Lilli 2006 NEW</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) and eight trials are ongoing (<LINK REF="STD-Burnett-2012" TYPE="STUDY">Burnett 2012</LINK>; <LINK REF="STD-Burnett-2013" TYPE="STUDY">Burnett 2013</LINK>
<I>; </I>
<LINK REF="STD-Fode-2012-NEW" TYPE="STUDY">Fode 2012 NEW</LINK>
<I>; </I>
<LINK REF="STD-Goode-2014" TYPE="STUDY">Goode 2014</LINK>
<I>; </I>
<LINK REF="STD-Mina-2013" TYPE="STUDY">Mina 2013</LINK>; <LINK REF="STD-Ng-2011" TYPE="STUDY">Ng 2011</LINK>
<I>; </I>
<LINK REF="STD-Terrone-2007" TYPE="STUDY">Terrone 2007</LINK>; <LINK REF="STD-Zopf-2012" TYPE="STUDY">Zopf 2012</LINK>).</P>
<P>Forty-one reports of 36 studies were excluded and reasons are given in the 'Characteristics of excluded studies' table. The flow of the literature through the assessment process is shown in the PRISMA study flow chart (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">New included trials</HEADING>
<P>After abstract and full text screening 13 relevant new trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>
<I>; </I>
<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>
<I>; </I>
<LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>) were identified. We also identified 12 new reports of the trials which were already identified in the previous update (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>). The trialists were contacted for additional information and data.</P>
<P>One previously included trial published as an abstract was updated with data from a full publication (<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>).</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Types of populations</HEADING>
<P>The trials included 4717 men, of whom 2736 had an active conservative intervention.</P>
<SUBSECTION>
<HEADING LEVEL="5">Surgery</HEADING>
<P>Forty-five trials involved patients undergoing radical prostatectomy (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>
<I>; </I>
<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>
<I>; </I>
<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>
<I>; </I>
<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>
<I>; </I>
<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>
<I>; </I>
<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>
<I>; </I>
<LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>
<I>; </I>
<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>
<I>; </I>
<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>
<I>; </I>
<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>
<I>; </I>
<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>
<I>; </I>
<LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>
<I>; </I>
<LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>
<I>; </I>
<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>
<I>; </I>
<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>
<I>; </I>
<LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>
<I>; </I>
<LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>
<I>; </I>
<LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>
<I>; </I>
<LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>
<I>; </I>
<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>
<I>; </I>
<LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>
<I>; </I>
<LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>
<I>; </I>
<LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>
<I>; </I>
<LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>
<I>; </I>
<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>
<I>; </I>
<LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>
<I>; </I>
<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>
<I>; </I>
<LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>
<I>; </I>
<LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>
<I>; </I>
<LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>
<I>; </I>
<LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>
<I>; </I>
<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>
<I>; </I>
<LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>
<I>; </I>
<LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>
<I>; </I>
<LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>
<I>; </I>
<LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>
<I>; </I>
<LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>
<I>; </I>
<LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>
<I>; </I>
<LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>
<I>; </I>
<LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>
<I>; </I>
<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>
<I>; </I>
<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>
<I>; </I>
<LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>
<I>; </I>
<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>
<I>; </I>
<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</P>
<P>One very small trial included one patient having a TURP while the rest were radical prostatectomy patients (<LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>) but this was included in the radical prostatectomy group for analysis. Also, as all the men in this trial were incontinent for some time after surgery, they may have represented a group with persistent (longer than one to two years) UI. There were many potentially confounding variables in this trial, acknowledged by the author.</P>
<P>Four trials involved patients after TURP (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>
<I>; </I>
<LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>
<I>; </I>
<LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>
<I>; </I>
<LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>).</P>
<P>The trials involving post-TURP patients only (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>) were analysed separately from the trials amongst men having radical prostatectomy.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Continence status of populations</HEADING>
<P>There was variation in continence status, which led to different populations being studied separately: those with persistent UI and those with all men undergoing surgery (many of whom were likely to recover continence spontaneously). The comparisons were therefore structured to reflect this: trials which included only men with post-operative incontinence were deemed to be trials of treatment, while trials in which all men were treated (irrespective of continence status) were deemed to be trials of prevention.</P>
<UL>
<LI>Twenty-three treatment trials enrolled only men with post-operative UI (diagnosis of UI varied with recruitment time) (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
<LI>Twenty-seven prevention trials included all men who underwent surgery, some of whom m.ay have been dry or become dry spontaneously (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of recruitment</HEADING>
<P>As the populations and the type and timing of interventions varied so greatly among the trials, the decision was made by the authors to also identify the timing of the recruitment to the trials and the timing of the intervention (before or after surgery):</P>
<UL>
<LI>only post-operative treatment for UI (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) or containment (<LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>); and</LI>
<LI>pre-operative recruitment of all men undergoing surgery, which included a pre-operative intervention with or without a post-operative intervention (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>).</LI>
</UL>
<P>Time of recruitment of participants to the trial relative to the time of their surgery also varied:</P>
<UL>
<LI>pre-operatively (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>within days or up to two weeks post-operatively or after catheter removal (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>);</LI>
<LI>weeks to months after surgery (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of interventions</HEADING>
<P>In the included trials, there was considerable variation in the type and intensity of interventions. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> gives the exact details of the interventions used in each trial. The duration of the treatment varied from four weeks up to one year. The interventions included:</P>
<UL>
<LI>PFMT alone (<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>);</LI>
<LI>PFMT plus biofeedback (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
<LI>ESl with PFMT (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>);</LI>
<LI>ES with PFMT and biofeedback (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>);</LI>
<LI>extra-corporeal magnetic innervation (ExMI) with PFMT (<LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>);</LI>
<LI>extra-corporeal magnetic innervation (ExMI) with PFMT or ES with PFMT (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>);</LI>
<LI>penile compression (<LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>);</LI>
<LI>transcutaneous mechanical nerve stimulation by vibration with PFMT (<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>).</LI>
</UL>
<P>No trials testing lifestyle changes alone were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of comparators</HEADING>
<P>There was considerable variation in the types of comparators. <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> provides the details of the comparators used in each trial. The comparators included:</P>
<UL>
<LI>no treatment, verbal or written instructions or sham therapy (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>);</LI>
<LI>active treatment (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of outcome measures</HEADING>
<P>There was a lack of consistency in the reporting of outcome measures. In terms of the primary outcomes of interest in this review these included:</P>
<UL>
<LI>number of men with incontinence, for radical surgery (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) and for TURP (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
<LI>number not cured (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) (assumed to indicate number of incontinent men);</LI>
<LI>time until continent (<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>);</LI>
<LI>number of pad changes over 24 hours (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
<LI>number of men using pads (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>);</LI>
<LI>number of incontinence episodes per day (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
<LI>pad test weights, grams of urine lost in 24 hours (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>), 1 hour (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>), 20 minutes (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>);</LI>
<LI>number with severe incontinence (pad test weight &gt; 150 g) (<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>);</LI>
<LI>quality of life (condition-specific such as incontinence scores): ICIQ-SF score (<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>), severity of UI (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>), I-QoL (<LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>), ICI-Q-SF (<LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>), IIQ (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>), ICIQ-SF QoL score (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>), EPIC-UI (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>), KHQ (<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>);</LI>
<LI>pelvic floor muscle strength (<LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>);</LI>
<LI>carrying out PFMT or compliance (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
</UL>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-01-19 09:52:30 +0000" MODIFIED_BY="[Empty name]">
<P>In total 36 studies were excluded. The majority of the studies that did not meet the inclusion criteria were excluded because the study design was not appropriate or the intervention was not relevant for the population of interest. See the <LINK TAG="EXCLUDED_STUDIES_DESCR" TYPE="SECTION">Excluded studies </LINK>table for a more detailed description.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-01-19 09:53:20 +0000" MODIFIED_BY="[Empty name]">
<P>The assessment criteria of The Cochrane Collaboration assume that the avoidance of bias is best achieved by: a randomised trial with an adequate method of random sequence generation; secure concealment of allocation prior to formal entry; adequate blinding of patients, healthcare providers and outcome assessors; description of reasons and numbers of withdrawals and dropouts; and analysis on an intention-to-treat basis. None of the early trials fulfilled all these criteria. However recent trials have fared much better in terms of secure concealment of allocation and blinding but overall this continues to be problematic in many trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).<BR/>
</P>
<ALLOCATION MODIFIED="2015-01-19 09:52:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Sequence generation</HEADING>
<P>Although all trials were identified as RCTs only 24 trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) described a method of adequate sequence generation (for example computer generated random numbers) and were assessed as low risk of bias. The remainder did not provide enough information to make a judgement and were assessed as unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<P>Only 20 trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) adequately described a technique of allocation concealment (for example sealed envelopes or computerised randomisation) and were assessed as low risk of bias. The remainder did not provide enough information to make a judgement and were assessed as unclear.</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2015-01-19 09:53:03 +0000" MODIFIED_BY="[Empty name]">
<P>Blinding was not described in most trials. In complex interventions such as physical therapy it is not possible to blind either the clinicians or the participants from the intervention, however, if blinding did not take place in trials they were judged to be at high risk of bias. This may have an impact on the outcome of interest and was considered while assessing the quality of evidence. <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK> used a sham device for the control group and this was the only trial that was deemed to be at low risk of bias in terms of blinding of participants.</P>
<P>In terms of blinding of personnel:</P>
<UL>
<LI>9 trials (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) were deemed to be at low risk of bias;</LI>
<LI>17 trials (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>) were deemed to be at high risk of bias; and</LI>
<LI>23 trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) were at unclear risk.</LI>
</UL>
<P>
<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK> and <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK> indicated that a single therapist, blinded to control group outcomes, provided all treatment. <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK> and <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK> reported that the post-operative physiotherapist was blinded to allocation and physical therapy provided by the pre-operative therapist.</P>
<P>In terms of blinding of outcome assessment:</P>
<UL>
<LI>7 trials (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) were deemed to be at low risk of bias because they had outcome assessors who were not involved in the provision of the intervention or were not aware of allocation when entering data;</LI>
<LI>1 trial (<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>) was found to be at high risk of bias; and</LI>
<LI>42 trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) were at unclear risk because this information was not provided.</LI>
</UL>
<P>
<LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK> used a sham device for the control group but there was no statement of whether assessors were aware of this or not.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2015-01-19 09:53:11 +0000" MODIFIED_BY="[Empty name]">
<P>Several trials gave no description or did not report dropouts (<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>), or did not have withdrawals or dropouts (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>).</P>
<P>All others reported the number of withdrawals or dropouts, although the reasons were not consistently reported and few, except <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK> and <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>, discussed how this was dealt with in the analysis. In one trial, outcomes beyond eight weeks were not available for the control group because all the men were treated, and data were not available for over a third of the men in the other two intervention groups (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>). Two trials were thought to be at risk of bias because of differential dropout from the randomised groups (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>). One trial (<LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>) that was judged to be at high risk of bias reported that the survey questionnaire used for one of their outcomes was completed correctly but returned by fewer than 10% of the men.</P>
<P>Six trials (<LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>) did not provide any usable data. Three of these trials (<LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>) did not report how many men were randomised to each group.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2014-05-13 15:06:57 +0100" MODIFIED_BY="[Empty name]">
<P>There was significant difficulty in assessing selective outcome reporting because the protocols for most of the included trials were not available for assessment or could not be found. For a few of the trials, data were not available for some of the outcomes stated in the methods section. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2015-01-19 09:53:20 +0000" MODIFIED_BY="[Empty name]">
<P>Information about funding was available for 27 of the included studies (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) and the studies were judged to be at low risk of bias. The rest of the trials were judged to be at unclear risk of bias because there was a lack of information even after contacting the authors.</P>
<P>Thirty-two trials reported obtaining approval from a medical ethics committee (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>) and were judged to be at low risk of bias. The remaining 18 trials did not report their source of medical ethical approval and were judged to be at unclear risk of bias after no further information was provided by the authors.</P>
<P>Fourteen trials were deemed to be at unclear risk of bias in terms of obtaining informed consent (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>; <LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>; <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>). These authors were contacted but no further information on this matter was provided. The other trials did report obtaining informed consent from patients and therefore were deemed to be at low risk of bias for this domain.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-01-20 14:21:34 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Radical prostatectomy: treatment of incontinent men after surgery</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Treatment of UI after radical prostatectomy: post-operative PFMT with or without biofeedback versus no treatment or sham therapy or verbal instruction (Comparison 1)</HEADING>
<P>Nine trials (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>) compared PFMT with or without biofeedback to no treatment (sham or verbal instruction) amongst men who had UI after radical prostatectomy. The quality of the evidence is given in <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Differences between trials</HEADING>
<P>All the men were incontinent at baseline.</P>
<P>In one trial (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>) there was evidence of unexplained differential dropout from the control group (13 of 53 men, while there were no dropouts from the 54 in the intervention group). The missing men have therefore been assumed to be dry for the purpose of an intention-to-treat analysis. The other trials have been analysed as reported since dropouts (if any) were balanced between the groups.</P>
<SUBSECTION>
<HEADING LEVEL="6">Sources of heterogeneity</HEADING>
<P>(1) Definition of incontinence varied with each trial:</P>
<UL>
<LI>more than 1 g urine on one hour pad test (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>);</LI>
<LI>more than 8 g urine loss on 24 hour pad test (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>);</LI>
<LI>more than 2 g urine loss on one hour (<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>) or 24 hour pad test (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>);</LI>
<LI>men who were not pad free (<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>);</LI>
<LI>a visual analogue score of 10 = completely incontinent and 0 = completely continent (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>); or</LI>
<LI>no leakage based on bladder diaries (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>).</LI>
</UL>
<P>(2) The type of PFMT regimens differed between the trials:</P>
<UL>
<LI>four trials (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) evaluated PFMT alone (without biofeedback);</LI>
<LI>three trials evaluated PFMT with biofeedback, verbal instruction (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) or ES (<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>);</LI>
<LI>two trials (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>) used PFMT with biofeedback via a perineal patch (surface) EMG.</LI>
</UL>
<P>Formal PFMT post-operative sessions directed by a therapist ranged from: twice a week for 12 weeks (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>); three times a week for three weeks (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>); in up to nine sessions (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>); weekly for 24 weeks (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>); four sessions over eight weeks (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>); five sessions over 16 weeks (<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>); to as long as the UI persisted (<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>). Men received only four therapy sessions in three months in one of these trials (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>) and men in another trial were seen weekly for up to six months (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>).</P>
<P>(3) Control interventions differed between the trials and included:</P>
<UL>
<LI>information (verbal or written) about PFMT only (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>);</LI>
<LI>no treatment (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>);</LI>
<LI>sham placebo PFMT and contact with therapist (<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>);</LI>
<LI>monitoring of UI only (e.g. by bladder diary or phone calls) (<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>).</LI>
</UL>
<P>(4) The participants differed between the trials.</P>
<P>Two trials (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>) recruited participants with persistent incontinence (some longer than one year) post-operatively, and these participants may have differed from those enrolled pre-operatively (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) but still incontinent at four weeks after surgery) or from those recruited within a week or two of catheter removal (<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>
<I>; </I>
<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>
<I>; </I>
<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>) or up to six weeks after radical prostatectomy (<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Incontinence in men and incontinence episodes</HEADING>
<P>Because there was evidence of significant statistical heterogeneity between the trials included in this comparison (see below), meta-analysis was carried out using a random-effects model, therefore widening the CI. There were no significant differences at any time period in the UI rates, and the CIs were wide (for example RR for UI up to 12 months 0.91, 95% CI 0.73 to 1.14, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.3; and after 12 months 57% with UI versus 62% in the control group, RR 0.85, 95% CI 0.60 to 1.22, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4). Only two trials (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>) favoured the treatment and of these, only one (<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>) used biofeedback. The estimates from the other trials had CIs that did not rule out clinically important effects. Overall, as one of the pre-defined GRADE-specific outcomes, the quality of evidence for the outcome 'number of incontinent men after 12 months' was found to be moderate.</P>
<P>The meta-analysis was dominated by the <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK> trial, which was a large pragmatic multi-centre trial conducted in a context where information on PFMT was widely available. This showed no good evidence to support one-to-one training by a therapist (for example RR for UI after 12 months 0.98, 95% CI 0.87 to 1.09, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4) (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>). This one large trial had narrow CIs which did not include a clinically significant difference, pre-specified to be 15%. One other trial (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) was in line with the <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK> findings but had wider CIs (RR 1.02, 95% CI 0.70 to 1.48, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4) (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>).</P>
<P>In one large trial (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>), men did not report differences in UI episodes at any time period, based on urinary diary data (for example after 12 months MD 0.1, 95% CI -0.82 to 1.02, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.4). Alternatively, one trial (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>) did report a significant difference, however this measurement was obtained at less than 3 months (MD -1.14, 95% CI -1.46 to -0.82, <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Use of pads</HEADING>
<P>Use of pads could be considered to be a measure of more severe incontinence. There was no statistically significant difference in the number of men using pads in one large trial (40% in intervention group versus 42% in control group after 12 months, RR 0.94, 95% CI 0.72 to 1.22, <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>). <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK> used number of pad changes over 24 hours as the outcome measure, with no statistically significant difference in the MD between treatment and control groups at any time period (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Urinary incontinence score and effect on quality of life</HEADING>
<P>In one large trial (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>), there was no evidence of a difference in the ICIQ-SF (a composite score of frequency, amount and effect of UI on quality of life) at any time period after the intervention up to or beyond one year (MD after 12 months -0.5, 95% CI -1.35 to 0.35, <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>) or quality of life as a single score from 0 to 10 (MD -0.30, 95% CI -0.73 to 0.13, <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>), however the quality of evidence for this outcome was found to be low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pad tests</HEADING>
<P>Two trials (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) reported 24 hour pad test results and one (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>) reported a one hour pad test. <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK> and <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK> also measured urine loss on a 24 hour pad test, but did not report SDs and therefore these data could not be included in the meta-analysis. Amongst the two trials which gave 24 hour pad test data, there were no statistically significant differences between the groups at 3, 6 or 12 months, or after 12 months (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>). Similarly, using a one hour pad test (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>), there were no statistically significant differences between the groups up to six months (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>). In the smaller trials (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) the SDs were often larger than the means, suggesting highly skewed data.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Treatment of UI after radical prostatectomy: post-operative interventions using electric or magnetic energy (for example post-operative anal ES, perineal ES, TENS, extra-corporeal magnetic innervation (ExMI) versus no treatment or sham treatment (Comparison 2)</HEADING>
<P>Four trials were identified which addressed this comparison (<LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>). These trials compared anal ES with oral (verbal) PFMT. The control group in Moore's trial received oral information about PFMT only, whereas in Yamanishi's trial the control group also received sham ES. The quality of the evidence is given in <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="5">Number of incontinent men</HEADING>
<P>In the short term (less than three months), there were fewer incontinent men in the intervention groups in two trials (64% versus 84% in the control groups, RR 0.77, 95% CI 0.60 to 0.98, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.1) (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) and the quality of the evidence for this outcome was deemed to be moderate. This remained the same at 6 to 12 months (19% versus 53% in the control groups, RR 0.37, 95% CI 0.18 to 0.73, <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.3) and after 12 months (7% versus 33% in the control groups of three trials, RR 0.26, 95% CI 0.09 to 0.74). However, the data were too few to be reliable in the longer term.</P>
<P>
<B>Adverse effects</B>
</P>
<P>One small trial (<LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) reported adverse effects, with two men in the active ES group and four men in the group receiving sham treatment reporting anal pain or discomfort. No statistically significant differences were found between the groups (RR 0.58, 95% CI 0.11 to 2.90, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pad test</HEADING>
<P>There were no statistically significant differences between the groups on grams of urine lost (24 hour pad test) at any of the time points (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>). SSs were large, indicating skewed distribution of data, and the CIs were wide with evidence of significant statistical heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">UI score</HEADING>
<P>Men in the intervention group in one trial (<LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) had lower (better) UI scores using a quality of life outcome combined with amount and frequency of urine lost (for example MD -3.9, 95% CI -7.15 to -0.65, <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>.3, at one year) though this did not quite reach statistical significance when quality of life was analysed on its own (MD -0.40, 95% CI -2.02 to 1.22, <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Time until continence achieved</HEADING>
<P>Men achieved continence on average about 5 months sooner in the intervention group of one trial (MD -4.11 months, 95% CI -6 to -2.23, <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>) (<LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3. Treatment of UI after radical prostatectomy: post-operative lifestyle adjustment versus no treatment or sham treatment (Comparison 3)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4. Treatment of UI after radical prostatectomy: post-operative combinations of treatments versus no treatment or sham treatment (Comparison 4)</HEADING>
<P>Two trials reported using PFMT with anal ES as well as biofeedback (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>) versus control management. <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK> compared behavioural therapy comprising biofeedback and ES for eight weeks with a control group. <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK> treated incontinent men in the intervention group with two sessions of ES with biofeedback as well as continuing the PFMT taught to both groups at six weeks after radical prostatectomy. The quality of the evidence is given in <LINK REF="SOF-03" TYPE="SOF">Summary of findings table 3</LINK>.</P>
<P>
<B>Number of incontinent men</B>
</P>
<P>
<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK> reported fewer incontinent men in the intervention group compared with the control group (83% versus 94% in the control group at less than 3 months, RR 0.88, 95% CI 0.78 to 0.99, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.1). In the other trial (<LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>), four men in total had incontinence at 3 to 6 months, with 3/20 in the intervention group and 1/19 in the control group, but this was not statistically significant (RR 2.85, 95% CI 0.32 to 25.07, <LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>). Overall, the quality of evidence for this outcome was very low.</P>
<P>
<B>Adverse events</B>
</P>
<P>There were two adverse events (haemorrhoidal irritation) reported by men receiving ES in one trial (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>), and the quality of evidence for this outcome was deemed to be of low quality with wide CIs indicating uncertainty (RR 4.86, 95% CI 0.24 to 99.39, <LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>.1).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5. Treatment of UI after radical prostatectomy: post-operative use of one treatment versus another active treatment (Comparison 5)</HEADING>
<P>Nine trials comparing one active treatment to another were identified (<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).<BR/>
</P>
<UL>
<LI>PFMT plus anal ES (EStim) (<LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>).</LI>
<LI>PFMT plus perineal ES (EStim) (<LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>).</LI>
<LI>PFMT plus visual biofeedback (<LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
<LI>PFMT plus visual biofeedback plus support group (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
<LI>PFMT plus oral (verbal) biofeedback (<LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>).</LI>
<LI>PFMT plus biofeedback plus ES(Estim) (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>).</LI>
<LI>PFMT alone (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>; <LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>).</LI>
<LI>Extra-corporeal Magnetic Innervation (ExMI) (<LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>).</LI>
</UL>
<P>The quality of the evidence is given in <LINK REF="SOF-04" TYPE="SOF">Summary of findings table 4</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Number of incontinent men</HEADING>
<P>Four small trials provided data for this outcome (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>). The definition of incontinence varied with each trial:</P>
<UL>
<LI>no urine loss recorded in bladder diaries (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>);</LI>
<LI>less than 8 g urine loss on 24 hour pad test (<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>);</LI>
<LI>'urine loss' (<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>); and</LI>
<LI>use of pad or brief (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>).</LI>
</UL>
<P>There was no difference in the incontinence rates in the trials at any time period, but CIs were wide, up to 3 months (RR 0.96, 95% CI 0.83 to 1.12, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>); 3 to 6 months (RR 0.59, 95% CI 0.33 to 1.05, <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>); 6 to 12 months (RR 2, 95% CI 0.21 to 18.23, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>) and the quality of evidence was deemed to be of very low quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pad tests</HEADING>
<P>For the majority of the comparisons there were no statistically significant differences between the groups, SDs were large, indicating skewed distribution of data, and the CIs were wide.</P>
<P>However, men having extra-corporeal magnetic innervation (ExMI) compared to PFMT alone had less urine loss on the 24 hour pad test at 3 to 6 months in one small trial (<LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>) (compared to PFMT alone, MD -36 g, 95% CI -55 to -17, <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>.3) and used fewer pads per day (MD -0.5, 95% CI -0.79 to -0.21, <LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>.1) (<LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>In another small trial (<LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>) men receiving PFMT plus biofeedback plus ES reported better quality of life using the Incontinence Quality of life score than those receiving PFMT alone (MD -28.63, 95% CI -34.60 to -22.66, <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>.1).</P>
<P>In a third trial (<LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>), PFMT supplemented by extra-corporeal magnetic innervation (ExMI) seemed to be better than PFMT alone in terms of quality of life assessed using the ICIQ-SF score (MD -1.60, 95% CI -2.73 to -0.47, <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>.1) but the quality of the evidence for this outcome was judged to be of low quality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>Two men in one trial (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>) had an adverse event with ES (haemorrhoidal irritation, RR 5, 95% CI 0.24 to 102.30, <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>.1) but the evidence for this outcome was judged to be of low quality.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Radical prostatectomy: prevention of UI in all men having surgery, intervention before or after prostatectomy or both</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">6. Prevention of UI after radical prostatectomy: PFMT ± biofeedback versus no treatment or sham therapy or verbal instruction (Comparison 6)</HEADING>
<P>Ten trials addressed this comparison (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>). The quality of the evidence is given in <LINK REF="SOF-05" TYPE="SOF">Summary of findings table 5</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Differences between trials</HEADING>
<P>The participants were not selected because they were incontinent so included a mixed population of men with and without incontinence after surgery.</P>
<SUBSECTION>
<HEADING LEVEL="6">Sources of heterogeneity</HEADING>
<P>(1) The type of PFMT regimens differed between the trials:<BR/>
</P>
<UL>
<LI>PFMT plus biofeedback (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
</UL>
<UL>
<LI>PFMT alone (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>).</LI>
</UL>
<P>Biofeedback was delivered via surface electrodes (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>) or via a digital or anal probe (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>). In one trial (<LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>) the type of biofeedback was not described.</P>
<P>(2) Control interventions differed between the trials and included:</P>
<UL>
<LI>no treatment (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>);</LI>
<LI>post-operative verbal or written instruction on PFMT only (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
<LI>usual care with simple instructions to interrupt the stream when voiding (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>).</LI>
</UL>
<P>(3) The timing of the interventions relative to surgery also varied:</P>
<UL>
<LI>two trials delivered an intervention before surgery only (<LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>);</LI>
</UL>
<UL>
<LI>five trials delivered their intervention before and after surgery (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>);</LI>
</UL>
<UL>
<LI>three trials delivered their intervention after surgery only (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Number of men with UI</HEADING>
<P>Data describing UI were reported by 8 of the 10 trials. While there was no statistically significant difference at 3 months (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.1), there was evidence from the findings of this systematic review of an overall benefit from PFMT in the number of men with UI within 6 to 12 months (24% versus 52%, RR 0.51, 95% CI 0.35 to 0.75, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.3) and after 1 year (10% versus 32%, RR 0.32, 95% CI 0.20 to 0.51, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.4), but the quality of evidence was judged to be moderate. The data were driven mainly by two trials (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>), neither of which included biofeedback. One of these trials did not disclose details of allocation concealment (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>) and the other was small (<LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>). The remaining trials showed conflicting results and there was statistically significant heterogeneity, hence the use of a random-effects model.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pad changes and pad tests</HEADING>
<P>In the four trials which reported these outcomes (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>) there was statistical heterogeneity. One small trial favoured PFMT (<LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>) but using a random-effects model there was only a significant difference at 6 to 12 months (MD -15 g less urine loss on 24 hour pad test with treatment, 95% CI -18 to -11, <LINK REF="CMP-006.04" TYPE="ANALYSIS">Analysis 6.4</LINK>.3). Men in the intervention group in this trial received PFMT plus biofeedback weekly for three months until they were continent or until three months. The findings from the <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK> and <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK> trials (no significant difference in pad weights) was in contrast to their report of fewer incontinent men with active treatment (RR 0.32, 95% CI0.20 to 0.51, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.4). However, the SDs were large and the CIs were wide. <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK> did not find a significant difference up to 12 months when using a 1 hour pad test (MD 19.80, 95% CI -9.15 to 48.75, <LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>) and comparing PFMT with no standard treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean number of incontinence episodes per day</HEADING>
<P>
<LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK> favoured PFMT at all time points (MD -1.43, 95% CI -2.35 to -0.51, <LINK REF="CMP-006.05" TYPE="ANALYSIS">Analysis 6.5</LINK>) when quantifying episodes of UI in men each day, with men in the intervention group suffering fewer mean numbers of episodes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>Quality of life was assessed using the ICIQ-SF by two trials (<LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>) but the quality of the evidence was found to be very low. No significant difference was found within 6 to 12 months (MD -0.69, 95% CI -3.19 to 1.81, <LINK REF="CMP-006.06" TYPE="ANALYSIS">Analysis 6.6</LINK>).</P>
<P>
<LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK> also assessed quality of life using the IIQ, favouring the intervention at 3 to 6 months (MD -2.70, 95% CI -4.88 to -0.52, <LINK REF="CMP-006.07" TYPE="ANALYSIS">Analysis 6.7</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7. Prevention of UI after radical prostatectomy: electric or magnetic energy (for example anal ES (EStim), perineal ES, TENS, extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment (Comparison 7)</HEADING>
<P>One small trial that delivered the intervention pre-operatively only was identified (<LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>). There was no significant difference using a 1 hour pad test at 6 to 12 months (MD -1.15, 95% CI -9.11 to 6.81, <LINK REF="CMP-007.01" TYPE="ANALYSIS">Analysis 7.1</LINK>) or when assessing quality of life using the ICIQ-SF (MD 1.60, 95% CI -2.15 to 5.35, <LINK REF="CMP-007.02" TYPE="ANALYSIS">Analysis 7.2</LINK>), but the quality of evidence for this outcome was judged to be very low (<LINK REF="SOF-06" TYPE="SOF">Summary of findings table 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8. Prevention of UI after radical prostatectomy: lifestyle interventions versus no treatment or sham treatment (Comparison 8)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">9. Prevention of UI after radical prostatectomy: combinations of treatments versus no treatment or sham treatment (Comparison 9)</HEADING>
<P>Only one small trial (<LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>) looked at this comparison. Men in the intervention group received PFMT plus ES with biofeedback post-operatively and men in the control group received verbal and written instructions on PFMT. There was a statistical difference with regards to:</P>
<UL>
<LI>number of incontinent men within 6 to 12 months (RR 0.10, 95% CI 0.01 to 0.73, <LINK REF="CMP-009.02" TYPE="ANALYSIS">Analysis 9.2</LINK>);</LI>
<LI>using a 24 hour pad test (MD -24.30, 95% CI -45.02 to -3.58, <LINK REF="CMP-009.04" TYPE="ANALYSIS">Analysis 9.4</LINK>); and</LI>
<LI>time until UI was regained (MD -1.50, 95% CI -2.44 to -0.56, <LINK REF="CMP-009.05" TYPE="ANALYSIS">Analysis 9.5</LINK>).</LI>
</UL>
<P>However, the quality of evidence for the primary outcome (number of incontinent men) was found to be low (<LINK REF="SOF-07" TYPE="SOF">Summary of findings table 7</LINK>).</P>
<P>
<B>Adverse events</B>
</P>
<P>Adverse events were not reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">10. Prevention of UI after radical prostatectomy: one treatment versus another active treatment (Comparison 10)</HEADING>
<P>Eight trials were identified (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK> <LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>). Five of these were new in this update (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>) and one was updated with new information (<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>).</P>
<UL>
<LI>
<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK> was a three-armed trial, with patients receiving PFMT plus TENS with biofeedback or TENS only or guided PFMT only.</LI>
<LI>
<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK> compared PFMT before and after surgery with PFMT delivered after surgery only.</LI>
<LI>
<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK> compared pre-operative guided PFMT with biofeedback versus post-operative written instructions on PFMT; however all men received PFMT plus biofeedback plus ES if they were still incontinent after six weeks.</LI>
<LI>
<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK> compared PFMT + penile vibration before and after surgery with PFMT alone before and after surgery: all men received a phosphodiesterase type 5 (PDE5) inhibitor after the first month.</LI>
<LI>
<LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK> compared PFMT plus biofeedback versus active PFMT.</LI>
<LI>
<LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK> compared extra-corporeal magnetic innervation (ExMI) versus PFMT alone but did not provide any useable data.</LI>
<LI>
<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK> compared post-operative PFMT plus general exercise versus post-operative PFMT alone.</LI>
<LI>
<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>, a three-arm trial, compared PFMT plus ES versus PFMT plus ES plus anal probe biofeedback versus PFMT alone.</LI>
</UL>
<P>The trials were generally small and few were similar enough to combine in a meta-analysis. The quality of the evidence is illustrated in <LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Number of incontinent men</HEADING>
<P>This outcome was reported by six trials (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>).</P>
<P>In one trial, <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK> reported fewer incontinent men at less than 3 months and within 3 to 6 months when PFMT was delivered pre and post-operatively, compared with post-operatively only, and this correlated with a statistically significant better quality of life score (MD -3.70, 95% CI -6.00 to -1.40, <LINK REF="CMP-010.15" TYPE="ANALYSIS">Analysis 10.15</LINK>.1; MD -4.10, 95% CI -6.64 to -1.56, <LINK REF="CMP-010.16" TYPE="ANALYSIS">Analysis 10.16</LINK>.1). However, when combined with the data from <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>, who used the same interventions, there was no statistically significant difference between the interventions at 3 months (RR 0.86, 0.69 to 1.06, <LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>.1) or 3 to 6 months (RR 0.75, 95% CI 0.54 to 1.04, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>.1). It should be noted that the CIs were very wide.</P>
<P>
<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK> compared three different treatments (PFMT plus transcutaneous electrical stimulation with biofeedback; TENS only; and guided PFMT only) and found no statistically significant differences between the interventions in terms of number of men with UI (<LINK REF="CMP-010.01" TYPE="ANALYSIS">Analysis 10.1</LINK>, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>; <LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>) except that at 6 to 12 months PFMT plus ES plus biofeedback proved to be significantly better than PFMT only (RR 0.10, 95% CI 0.01 to 0.76, <LINK REF="CMP-010.03" TYPE="ANALYSIS">Analysis 10.3</LINK>.3).</P>
<P>One small trial (<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>) found that general exercise added to PFMT was statistically significantly better than PFMT alone within 3 to 6 months (RR 0.48, 95% CI 0.23 to 0.99, <LINK REF="CMP-010.02" TYPE="ANALYSIS">Analysis 10.2</LINK>.3).</P>
<P>Four trials reported the number of incontinent men after 12 months (<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>
<I>; </I>
<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>
<I>; </I>
<LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>
<I>; </I>
<LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>). The quality of the evidence was moderate (<LINK REF="SOF-08" TYPE="SOF">Summary of findings table 8</LINK>). Three of these trials, comparing pre and post-operative PFMT to post-operative PFMT only, found that more men were incontinent after 12 months when PFMT began before surgery (15.3% versus 10.7% with post-operative training alone) but this did not reach statistical significance (RR 1.32, 95% CI 0.78 to 2.25, <LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>.1). The <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK> study was too small to identify a difference between PFMT plus penile vibratory stimulation pre and post-operatively compared with pre and post-operative PFMT (<LINK REF="CMP-010.04" TYPE="ANALYSIS">Analysis 10.4</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Pad tests</HEADING>
<P>In general, the short-duration pad tests did not distinguish between the various interventions being compared, apart from in one trial. At 6 months (but not at 3 months), <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK> found that PFMT plus anal ES both with and without extra biofeedback were both better than PFMT alone using a 20 minute pad test (MD urine lost -3 g, 95% CI -6 to -0.5 in both comparisons, <LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>.1 and <LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>.2), while there was little to choose between the two more intensive interventions (<LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>.3). However, the trial was small, the SDs large and the CIs wide.</P>
<P>Using a longer-duration 24 hour pad test, the groups receiving ES were generally better than those only having PFMT or only having ES (<LINK REF="CMP-010.12" TYPE="ANALYSIS">Analysis 10.12</LINK>; <LINK REF="CMP-010.13" TYPE="ANALYSIS">Analysis 10.13</LINK>; <LINK REF="CMP-010.14" TYPE="ANALYSIS">Analysis 10.14</LINK>) but the interventions were to dissimilar to combine. At three to six months, one small trial (<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>) did not find significant benefit when comparing PFMT plus general exercise with PFMT alone (<LINK REF="CMP-010.13" TYPE="ANALYSIS">Analysis 10.13</LINK>.4).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ICIQ-SF</HEADING>
<P>The ICIQ-SF score is a mixed measure of both incontinence severity and effect on quality of life. One small trial (<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>) found that there was a significant benefit in terms of the ICIQ-SF and the intervention PFMT plus general exercise versus PFMT alone, but the evidence for this outcome was found to be very low (MD in scores -4.00, 95% CI -5.41 to -2.59, <LINK REF="CMP-010.16" TYPE="ANALYSIS">Analysis 10.16</LINK>.2).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">King&#8217;s Health Questionnaire</HEADING>
<P>For all domains of the King&#8217;s Health Questionnaire, <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK> did not find a statistically significant difference between PFMT given pre and post-operatively and PFMT given post-operatively only (<LINK REF="CMP-010.18" TYPE="ANALYSIS">Analysis 10.18</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">SF-36</HEADING>
<P>In contrast, one trial (<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>) found that the intervention PFMT with general exercise was favoured at 3 to 6 months when using the health status measure SF-36 (MD -9.00, 95% CI -11.17 to -6.83, <LINK REF="CMP-010.19" TYPE="ANALYSIS">Analysis 10.19</LINK>.1) compared with PFMT alone. This may have been more of a measure of an effect of exercise on general health than on incontinence itself.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>One trial (<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>) was in the meta-analysis and the authors stated that 5/30 men reported adverse effects in the intervention group using the group with a penile vibratory stimulation device. The quality of evidence for this outcome was deemed to be low. Adverse effects included:</P>
<UL>
<LI>red spots on the glans penis;</LI>
<LI>small laceration with some bleeding;</LI>
<LI>soreness;</LI>
<LI>frank pain.</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">TURP: treatment of incontinent men, after surgery</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">11. Treatment of UI after TURP: PFMT ± biofeedback versus no treatment or sham therapy or verbal instruction (Comparison 11)</HEADING>
<P>One large trial compared PFMT with or without biofeedback to no treatment (sham or verbal instruction) amongst men who had UI after TURP (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>). All the men were incontinent at randomisation, six weeks after surgery, and received four one-to-one sessions with a trained therapist over a three month period. The quality of the evidence is illustrated in <LINK REF="SOF-11" TYPE="SOF">Summary of findings table 11</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="5">Incontinence in men and incontinence episodes</HEADING>
<P>There were no significant differences at any time period in the incontinence rates (for example RR for incontinence up to 12 months 1.04, 95% CI 0.90 to 1.20, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>.3; and after 12 months, 65% with UI versus 62% in the control group, RR 1.05, 95% CI 0.91 to 1.23, <LINK REF="CMP-011.01" TYPE="ANALYSIS">Analysis 11.1</LINK>.4). The evidence was judged to be moderate.</P>
<P>In one large trial (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>) men did not report differences in incontinence episodes at any time period, based on urinary diary data (for example after 12 months MD 0.2, 95% CI -0.27 to 0.67, <LINK REF="CMP-011.02" TYPE="ANALYSIS">Analysis 11.2</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Use of pads</HEADING>
<P>Use of pads could be considered to be a measure of more severe incontinence. There was no statistically significant difference in the number of men using pads in one large trial (16% in intervention group versus 18% in control group after 12 months, RR 0.93, 95% CI 0.56 to 1.56, <LINK REF="CMP-011.03" TYPE="ANALYSIS">Analysis 11.3</LINK>) (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Urinary incontinence score and effect on quality of life</HEADING>
<P>In one large trial (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>), there was no evidence of a difference in the ICIQ-SF (a composite score of frequency, amount and effect of UI on quality of life) at any time period after the intervention up to or beyond one year (for example MD after 12 months -0.1, 95% CI -0.89 to 0.69, <LINK REF="CMP-011.04" TYPE="ANALYSIS">Analysis 11.4</LINK>) or quality of life as a single score from 0 to 10 (MD -0.1, 95% CI -0.51 to 0.31, <LINK REF="CMP-011.05" TYPE="ANALYSIS">Analysis 11.5</LINK>). The quality of evidence for this outcome was deemed to be low.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>No adverse events were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">12. Treatment of UI after TURP: electric or magnetic energy (for example anal ES (EStim), perineal ES, TENS, extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment (Comparison 12)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">13. Treatment of UI after TURP: lifestyle interventions versus no treatment or sham treatment (Comparison 13)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">14. Treatment of UI after TURP: combinations of treatments versus no treatment or sham treatment (Comparison 14)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">15. Treatment of UI after TURP: one treatment versus another active treatment (Comparison 15)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">TURP: prevention of UI in all men having surgery, intervention before or after prostatectomy, or both</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">16. Prevention of UI after TURP: pre or post-operative PFMT ± biofeedback versus no treatment or sham therapy or verbal instruction (Comparison 16)</HEADING>
<P>Three small trials enrolled men before TURP for benign prostatic hyperplasia (<LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>). Men in the intervention groups in both trials received one session with a therapist before surgery to teach them the correct contractions (using verbal biofeedback) and they were expected to practice PFMT afterwards. In the second trial (<LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>), men also attended three group teaching sessions. The control groups received information only. The quality of the evidence is illustrated in <LINK REF="SOF-12" TYPE="SOF">Summary of findings table 12</LINK>.</P>
<P>There were no statistically significant differences between the groups in the number of men with incontinence at less than 3 months or 3 to 6 months, but the CIs were wide and the quality of evidence was very low (&lt; 3 months RR 0.60, 95% CI 0.21 to 1.77, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>.1; 3 to 6 months RR 0.51, 95% CI 0.14 to 1.89, <LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>.2).</P>
<SUBSECTION>
<HEADING LEVEL="5">Quality of life</HEADING>
<P>One trial (<LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>) measured quality of life using a health status measure Short-Form 36 (SF-36) questionnaire at three to six months. No statistically significant differences were found on any of the domains apart from those associated with mental health (<LINK REF="CMP-016.02" TYPE="ANALYSIS">Analysis 16.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">17. Prevention of UI after TURP: electric or magnetic energy (for example anal ES (EStim), perineal ES, TENS, extra-corporeal magnetic innervation (ExMI)) versus no treatment or sham treatment (Comparison 17)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">18. Prevention of UI after TURP: lifestyle interventions versus no treatment or sham treatment (Comparison 18)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">19. Prevention of UI after TURP: combinations of treatments versus no treatment or sham treatment (Comparison 19)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">20. Prevention of UI after TURP: one treatment versus another active treatment (Comparison 20)</HEADING>
<P>No trials were identified.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Containment of UI (all men with residual UI)</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">21. External penile compression devices (penile clamps) versus no treatment or sham treatment (Comparison 21)</HEADING>
<P>One trial compared three different penile compression devices (Cunningham clamp, U-Tex Male Adjustable Tension Band, and C3 penile compression device) with a control period of no device (<LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>). A randomised block assignment was used with a multiple period cross-over design, so that each of the 12 participants had a control period of no device and three periods in which the different devices were used.</P>
<P>All external compression devices reduced the weight of urine lost on a four hour pad test compared to the control period (P &lt; 0.05, <LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>), but none completely eliminated urine loss. Satisfaction was based on ease of application, comfort and efficacy. The device preferred by the largest number of men (<LINK REF="CMP-021.01" TYPE="ANALYSIS">Analysis 21.1</LINK>) was also that with the lowest urine loss (the Cunningham clamp) (<LINK REF="CMP-021.02" TYPE="ANALYSIS">Analysis 21.2</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Adverse events</HEADING>
<P>The Cunningham clamp was also the device with the greatest reduction in systolic blood flow velocity (P &lt; 0.05 versus control period, <LINK REF="CMP-021.03" TYPE="ANALYSIS">Analysis 21.3</LINK>; <LINK REF="CMP-021.04" TYPE="ANALYSIS">Analysis 21.4</LINK>), raising the possibility of safety issues if applied too tightly. In the trial, men were able to judge when to release the device. The authors recommended that its use should therefore be limited to men who were cognitively intact, aware of bladder filling, had normal genital sensation and intact penile skin, and had sufficient manual dexterity to open and close the device (<LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>).</P>
<P>In another trial with no useable data (<LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>), men provided qualitative information which suggested that pads were most highly rated compared with sheath catheters (P = 0.31), clamps (P &lt; 0.01) and the body-worn urinal (P &lt; 0.001). The clamp was rated as more secure, less leaky and less restrictive on clothing choice than the others (P &lt; 0.05) but was more painful than the rest (P &lt; 0.002).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-01-20 14:21:41 +0000" MODIFIED_BY="[Empty name]">
<P>This review incorporates a broad array of possible interventions under the umbrella term of conservative management of postprostatectomy UI. The populations studied included men undergoing prostatectomy for both benign (TURP) and malignant (radical prostatectomy) disease. The interventions were delivered pre-operatively, post-operatively or both. In some trials all the men were incontinent at baseline, while at least some were dry in other trials which recruited all men having surgery (these were classed as prevention of incontinence trials). Seven trials (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) included men who had been incontinent for a considerable time after surgery while the rest recruited men around the time of surgery. More recent trials have focused on the pre-operative or post-operative period immediately after catheter removal. It is acknowledged that UI after prostatectomy will resolve over time in many men.</P>
<P>Conservative interventions tend to be resource-intensive strategies that require people, equipment and clinic space, so administrators will look for evidence of efficacy. Funding has been an issue given the inconclusive nature of the evidence to date. For example, in the United States, the centres for both Medicare and Medicaid services have considered whether to withdraw funding for biofeedback and pelvic floor electrical stimulation (ES) in the treatment of UI of any etiology based on a lack of evidence regarding effectiveness. Through a lobbying effort from service providers and manufacturers, these modalities continued to be covered in the United States (<LINK REF="REF-Thompson-2002" TYPE="REFERENCE">Thompson 2002</LINK>). However, as controversy about funding is likely to continue, there is a need for continued research in the area to determine which groups of patients are most likely to benefit from conservative interventions.</P>
<P>The findings of this review should continue to be treated with caution. The effectiveness of conservative measures in the longer term or in men with persistent UI remain inconclusive.</P>
<SUMMARY_OF_RESULTS MODIFIED="2015-01-20 14:21:41 +0000" MODIFIED_BY="[Empty name]">
<P>Fifty trials met the inclusion criteria, 45 trials amongst men after radical prostatectomy, four trials after TURP, and one small trial which included one man with benign disease but was classed as a radical prostatectomy trial. There was considerable variation in the interventions, populations and outcome measures. Given this clinical heterogeneity it was decided to differentiate the trials and the comparisons, by type of surgery (TURP or radical prostatectomy) and by whether the intervention was partly preventative (in that not all men were incontinent, for example if all men before or after surgery were recruited, N = 27 trials), for treatment only (when all included men were incontinent at baseline, N = 23 trials) or for containment (external penile compression devices, N = 2 trials). Although the International Prostate Score (IPSS) was used in many of the trials, the authors felt that this questionnaire did not assess UI and therefore was not included in the outcome of quality of life.</P>
<SUBSECTION>
<HEADING LEVEL="3">Treatment trials for urinary incontinence after radical prostatectomy</HEADING>
<P>Twenty-one trials investigated the effects of PFMT versus no treatment or a variety of other means of stimulating the pelvic floor muscles. There was considerable clinical and statistical heterogeneity in the populations and the timing and frequency of the interventions, hence a random-effects model was chosen for most of the comparisons where meta-analysis was possible. Only two trials (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>) showed a statistically significant benefit from active treatment versus no treatment control groups (at 12 months and within 6 to 12 months respectively), and the other trials showed conflicting results. There was differential dropout from the control group in the <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK> trial (these men were assumed to be dry for analysis purposes). Additionally, men in the experimental group in the <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK> trial received one session of PFMT in hospital before discharge and were then seen by a physiotherapist for one to two weeks, whereas those in the Manassero 2007 trial were taught PFMT by two urologists using verbal feedback and instructed to perform contractions at home. Because of the heterogeneity a random-effects model was used, which led to wider confidence intervals (CIs).</P>
<P>Overall, there was not enough evidence to say whether or not PFMT with or without biofeedback was effective as the CIs were wide (for example number of men with incontinence in the intervention groups 193/339 (57%) versus 203/326 (62%) in the control groups, RR for incontinence after 12 months 0.85, 95% CI 0.60 to 1.22, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4).</P>
<P>The meta-analysis was dominated by the <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK> trial, which was a large pragmatic multi-centre trial conducted in a context where information on PFMT was widely available. This showed no good evidence to support one-to-one training by a therapist (for example RR for UI after 12 months 0.98, 95% CI 0.87 to 1.09, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4) (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>). This one large trial had narrow CIswhich did not include a clinically significant difference, pre-specified to be 15%. The only other large trial (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) was in line with the <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK> findings but with wider CIs (RR 1.02, 95% CI 0.70 to 1.48, <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>.4) (<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>) despite a more intensive intervention. While men in the <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK> trial had four therapy sessions over three months, in the <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK> trial men were seen weekly for up to six months. The findings in these two trials concurred despite different intensities of intervention, and the quality of evidence for this GRADE-specific outcome was moderate. Data from quality of life measures and use of pads and pad tests supported the finding of no differences between intervention and control groups.</P>
<P>Three small trials provided data and the meta-analysis suggested that ES was better than control interventions in terms of less incontinence, regaining continence more quickly and better quality of life, at least in the short term up to six months. The quality of evidence was deemed to be moderate, however less information was available for the longer term.</P>
<P>Individual small trials provided data to suggest that extra-corporeal magnetic innervation (ExMI) or combinations of treatments might be beneficial but the evidence was limited.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prevention trials for urinary incontinence after radical prostatectomy</HEADING>
<P>Nineteen trials, some of which enrolled men before surgery and others all men as soon as the catheter was removed, included a mixed population of men with and without incontinence after surgery. Again a random-effects model was chosen to compensate for the considerable clinical and statistical heterogeneity between the trials. Including the information from the quasi-randomised trial (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>), the chance of incontinence appeared to be lower in the intervention groups in two trials with data after 12 months. The quality of evidence was judged to be moderate (number of men with UI after one year 10.2% versus 32.1% in the control groups, RR 0.32, 95% 0.20 to 0.51, <LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>.4).</P>
<P>The meta-analysis of prevention trials included a number of small trials with wide CIs apart from <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>, which was out of line with the others. This was the only large trial to favour the intervention group. The worry is that this trial may have been biased due to a lack of reporting on concealment of allocation.</P>
<P>One small trial (<LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>) suggested that men were more likely to be carrying out PFMT, at least soon after the intervention (<LINK REF="CMP-006.09" TYPE="ANALYSIS">Analysis 6.9</LINK>), though this was not reflected in significant differences in higher anal squeeze pressures (<LINK REF="CMP-006.08" TYPE="ANALYSIS">Analysis 6.8</LINK>). Another trial of anal ES was too small to be conclusive (<LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>). One small trial (<LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>) reported that adding anal ES and biofeedback to PFMT was beneficial. One further small trial (<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) found that PFMT plus anal ES with and without extra biofeedback were both better than PFMT alone at six months, but there was little to choose between the two more intensive interventions (<LINK REF="CMP-010.08" TYPE="ANALYSIS">Analysis 10.8</LINK>). <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK> found that pre-operative PFMT was associated with a reduction in number of incontinence episodes per day, but this was a small trial and larger sample sizes would be needed to draw reliable conclusions.</P>
<P>Nine trials compared one active treatment with another active treatment. Overall there did not seem to be one intervention that proved to be statistically significantly better than another.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Treatment trials for urinary incontinence after TURP</HEADING>
<P>One large trial addressed this comparison (<LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>), comparing four sessions of one-to-one therapy with standard management in a context where information about PFMT was widely available. The quality of evidence for the number of incontinent men was moderate but there were no differences between the groups in any of the outcome measures except for performance of PFMT, suggesting that the intervention had changed behaviour but not incontinence or other clinical outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Prevention trials for urinary incontinence after TURP</HEADING>
<P>Three small trials enrolled men before TURP to receive a minimal PFMT intervention before and after surgery. There were no statistically significant differences in terms of number of incontinent men between the groups but the quality of evidence was deemed to be very low (<LINK REF="CMP-016.01" TYPE="ANALYSIS">Analysis 16.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Containment of urinary incontinence</HEADING>
<P>One alternative intervention, a clamp fitted to the shaft of the penis, can be used to control unwanted leakage. Men in one trial reported a preference for one type of external compression device compared to two others or no treatment; a Cunningham clamp proved satisfactory to 10 of 12 men with intractable UI (<LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>). This may be a viable alternative for some cognitively capable men providing they take into account safety issues such as adequate sensation and the ability to remove the device when it feels too tight or the bladder is full. Another trial which compared pads, sheath catheters, body-worn urinals and clamps also reported that men found the clamps most effective but painful (<LINK REF="STD-Fader-2013" TYPE="STUDY">Fader 2013</LINK>).</P>
<P>Men whose incontinence cannot be otherwise controlled can use absorbent pads (<LINK REF="REF-Fader-2007" TYPE="REFERENCE">Fader 2007</LINK>; <LINK REF="REF-Fader-2008" TYPE="REFERENCE">Fader 2008</LINK>) or a variety of external sheath devices with leg bags. An alternative is an indwelling urinary catheter (<LINK REF="REF-Jahn-2007" TYPE="REFERENCE">Jahn 2007</LINK>; <LINK REF="REF-Moore-2007" TYPE="REFERENCE">Moore 2007</LINK>; <LINK REF="REF-Ni_x00eb_l_x002d_Weise-2005" TYPE="REFERENCE">Niël-Weise 2005</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Lifestyle changes</HEADING>
<P>The effect of other conservative interventions such as lifestyle changes remains undetermined as no trials involving these interventions were identified.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-01-19 10:06:34 +0000" MODIFIED_BY="[Empty name]">
<P>Few trials used the primary outcomes of interest, patient reported symptoms and the standardised pad test. Most used a variety of subjective outcomes derived from patient reported symptoms to define continence. There were no trials which examined lifestyle adjustments in alleviating UI after prostatectomy.</P>
<P>Attrition bias may have played a role in the results of some of the included trials and therefore affected the outcome of this review. One of the smaller trials (<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>) lost half of the randomised participants by the end of the data collection period. Although most of those trials that lost participants provided an explanation of these losses, none accounted for the missing data in their primary analyses. The intention-to-treat principle mandates, at minimum, that patients stay in the group to which they are randomised (<LINK REF="REF-Juni-2001" TYPE="REFERENCE">Juni 2001</LINK>), which the included trials appeared to do. It is also suggested that primary outcomes for all patients randomised to groups should be recorded or estimated if not available. Three of the included trials (<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>) reported an analysis using the intention-to-treat principle, and one trial (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>) used survivor analysis in the original trial analysis. In one trial where there was clear evidence of differential dropout (<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>), the review authors elected to assume that the men whose data were missing were continent. However, attrition bias may have affected a number of the other trials which did not present relevant data or discuss the issue.</P>
<P>In 21 trials in this review, men who were all incontinent were analysed together. However, in seven of these trials (<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>; <LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>; <LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>) men had longstanding or persistent incontinence. It is possible that they might respond differently to the interventions compared to men recruited around the time of prostate surgery.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-01-19 10:06:50 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Trial quality and methodological assessment</HEADING>
<P>The quality of the estimated treatment effect of any intervention is determined partly by methodological assessment. Methodological flaws within the included trials of this review were assessed using the reports of the trials and therefore were reliant on the quality of reporting. Data were not available in all the trials for many of the pre-stated outcomes. CIs tended to be wide except for the more recent large trials, and it was difficult to reliably identify or rule out a useful effect.</P>
<P>All trials claimed to be randomised, but only 24 out of 50 trials provided details of adequate sequence generation (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>). Only 20 of the 50 trials provided details of adequate concealment of randomisation (<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>; <LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>; <LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>; <LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>; <LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>; <LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>) and were subsequently judged to be at low risk of selection bias. Additionally, blinding to PFMT was not possible, and blinding of outcome assessment appeared to be absent in many trials as it was not discussed. Therefore, many trials were judged to be at high risk of performance and detection bias.</P>
<P>The quality of the evidence was downgraded for the following.</P>
<UL>
<LI>Study design i.e. there was evidence of methodological flaws in the study design.</LI>
<LI>Indirectness i.e. a surrogate outcome was selected when a GRADE-specific outcome was not reported.</LI>
<LI>Inconsistency, when there was evidence of statistical (either clinical or methodological) heterogeneity.</LI>
<LI>Imprecision, when the CIwas wide and crossed the line of no effect.</LI>
<LI>Publication bias. We planned to use funnel plot for publication bias, however, there were fewer than 10 trials in the meta-analysis and the funnel plot could not be used.</LI>
</UL>
<P>The quality of the evidence for the critical outcomes ranged from moderate to very low, as evident in the summary of findings tables.</P>
</SUBSECTION>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-01-19 10:06:57 +0000" MODIFIED_BY="[Empty name]">
<P>All relevant databases were searched and no language restriction was imposed during the search process, which enabled as many potentially eligible trials as possible to be included. Some reports of trials may not be published and therefore the full extent of the data may not have been obtained. One of the review authors was involved in four of the included trials and another review author was involved in two of the included trials. In order to account for this potential bias in the review process, data extraction and risk of bias assessment were performed by two independent review authors, one of whom was not involved in any of the included trials.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-01-19 10:07:06 +0000" MODIFIED_BY="[Empty name]">
<P>A systematic review conducted by Macdonald et al (<LINK REF="REF-MacDonald-2007" TYPE="REFERENCE">MacDonald 2007</LINK>) was identified which addressed conservative management of post-prostatectomy urinary incontinence. Macdonald and colleagues included 11 trials (<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>; <LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>; <LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>; <LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>; <LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>; <LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>; <LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>), all of which were included in this review. They did not distinguish between treatment and prevention trials. Macdonald and colleagues' review analysed PFMT and PFMT with biofeedback, focusing on any additional benefit from biofeedback. The authors concluded that the use of guided PFMT was associated with superior patient outcomes compared with no treatment, which differs from the findings of this review. The Macdonald and colleagues review did not include more recent trials because the MEDLINE search only included trials up to 2006. Additionally, the conclusions made in Macdonald's review may have differed because the authors did not utilise the GRADE approach, suggesting the quality of the evidence was not assessed.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-01-20 12:31:05 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2015-01-20 12:31:05 +0000" MODIFIED_BY="[Empty name]">
<P>In keeping with conclusions from earlier versions of this review, at this point there remains no clear support that conservative management of any type is helpful for postprostatectomy UI whether delivered as treatment to men who are incontinent or as prevention to all men undergoing radical prostatectomy. The individual result of one large multi-centre trial on its own did have narrow confidence intervals which did not include a clinically significant difference (of 15%) in the rate of incontinence between the groups. It seems unlikely that men benefit from one-to-one PFMT therapy after TURP.  </P>
<P>Some small trials provided data to suggest that electrical stimulation was better than control interventions (in one trial including sham electrical stimulation), or active interventions which did not include electrical stimulation, at least in the short term up to six months. Individual small trials provided data to suggest that extra-corporeal magnetic innervation (ExMI) or combinations of treatments might be beneficial but the evidence was limited.</P>
<P>The trials suffered from a lack of standardised outcome measures. Definitions of incontinence, measurement of quality of life and types of pad tests (20 minute, 1 hour, 24 hour, number of pads, weight of pads, number of men using pads and so on) varied in almost every trial. The timing for measuring the primary outcome should be at least 1 year.</P>
<P>No trials have tested the effect of lifestyle changes alone. Long-term UI may be managed by absorbent pads or external penile clamps, but there are safety problems with clamps.</P>
<P>This review did not find sufficient evidence as to whether or not conservative management is effective in treating or preventing postprostatectomy UI.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-01-19 10:07:20 +0000" MODIFIED_BY="[Empty name]">
<P>Urinary incontinence (UI) after prostatectomy is a distressing problem and, although conclusive evidence does not exist, conservative approaches form part of current management. Well-designed clinical trials are still needed to clarify the role of these therapies. In addition, men with persistent severe UI could consider surgical treatment for example with an artificial urinary sphincter or male sling. However, these surgical options should also be tested in RCTs as there is currently not enough evidence to support their use (<LINK REF="REF-Silva-2011" TYPE="REFERENCE">Silva 2011</LINK>).</P>
<P>As there are known differences in the cause and prevalence of UI between men after TURP and after radical prostatectomy, these groups of men should continue to be studied separately. Prevention trials in all men having surgery should be evaluated separately from treatment trials of men who all have urinary incontinence after surgery.</P>
<P>Most of the trials included in this review used very different protocols, of intervention type, timing and intensity. In order to determine the effects of specific protocols and modalities, large adequately powered trials using common protocols and common standardised outcome measures are needed. Replication studies using similar protocols in different populations would also assist in identifying the populations in which specific conservative management approaches may be effective.</P>
<P>Definitions and measurement of outcomes varied in the included trials. Future trials must attempt to use broadly accepted validated outcome measures, such as those of the International Continence Society (ICS). The primary outcome measure should be the participant's self-reported UI or its effects on his quality of life. Other objective measures such as the pad test or urinary diaries can be used to determine if continence has been achieved. Researchers must also focus on either the 1 hour or 24 hour pad test, as the results of these two measurements are not equivalent.</P>
<P>Lastly, authors should be encouraged to ensure appropriate measures are taken to avoid the risk of bias from selection, performance, detection and attrition bias, in particular adequate sequence generation and secure concealment of allocation for randomisation, and blinding of outcome measurement, and to report these adequately using the guidelines of the CONSORT statement.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-08-28 19:38:16 +0100" MODIFIED_BY="[Empty name]">
<P>Katherine Moore was supported by a postdoctoral fellowship from the Leverhulme Trust, London, England in 1998 thereby allowing the time for the original review (first published 1998). Authors of nine trials (<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>; <LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>; <LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>; <LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>; <LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>; <LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>, <LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>; <LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>) generously shared further data so that their trials could be included in this review. We thank Neil Scott for the translation of a German language article (arranged by Sheila Wallace) as well as Matthew Tripp for another. Peter Herbison provided expertise in the area of statistics and assisted in interpreting data provided by authors.</P>
<P>For the 2014 update of the review, the review authors would like to acknowledge Ying Hao for the translation of two Chinese language articles. Authors of five trials (<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>; <LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>; <LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>; <LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>; <LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>; <LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>) kindly provided further data. The review authors would also like to acknowledge Katherine Moore for her contribution to the previous versions of the review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-01-19 10:09:23 +0000" MODIFIED_BY="[Empty name]">
<P>Coral A Anderson: none known</P>
<P>Muhammad Imran Omar: none known</P>
<P>Susan E Campbell: none known</P>
<P>Kathleen F Hunter has been a speaker at the Jewish General Hospital (Montreal, Canada) and is currently a local co-investigator on a multi-national drug trial funded by Astelles</P>
<P>June D Cody: none known</P>
<P>Cathryn MA Glazener was the Chief Investigator on one of the included trials, MAPS (<LINK REF="STD-Glazener-RP-2011" TYPE="STUDY">Glazener RP 2011</LINK>; <LINK REF="STD-Glazener-TURP-2011" TYPE="STUDY">Glazener TURP 2011</LINK>)</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-01-19 10:13:43 +0000" MODIFIED_BY="[Empty name]">
<P>For the updates in 2004 and 2006, the original lead review author (KNM) and an additional review author (KFH) independently undertook the quality assessment, data extraction and collation. KFH took the lead in updating the text and completed the data entry, which were then checked and commented upon by the other review authors.</P>
<P>For the earlier versions, two of the original review authors undertook the quality assessment of the trials and the data extraction independently. This information was then collated and checked by the original lead review author (KNM) for agreement and, in the few instances where this did not occur, consensus was reached after checking with the other review authors. For the 2004 and 2006 updates, KFH updated the text and entered the data. These were checked by the other review authors, whose additional comments and edits were then incorporated.</P>
<P>For the update in 2012, CG and SC undertook quality assessment and data abstraction for the 18 new included trials, revised the previous data as appropriate, analysed the data and wrote the review text assisted by JC. All review authors contributed to writing or editing the text of the review.</P>
<P>For this update in 2014, CA, MO and CG undertook abstract and full text screening. CA and CG performed data abstraction, cross-checked by MO. CA, MO and CG performed risk of bias assessment of trials. Quality of evidence was assessed by CA and MO. Previous data were updated, if necessary, and previously included trials were re-assessed with the additional risk of bias domains. CA took the lead in drafting the manuscript of the review. All review authors contributed to the analysis of data and made comments and suggestions on the manuscript, which were incorporated in the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2015-01-19 10:10:05 +0000" MODIFIED_BY="[Empty name]">
<P>Trials were reclassified as 'treatment' or 'prevention' trials in a previous version of this review, and hence trials amongst men having radical prostatectomy or TURP were analysed separately. The trials of containment (penile clamps) were analysed separately from those of PFMT and its variations.</P>
<P>In the current update, the GRADE method was used to assess quality of evidence.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-01-19 10:41:00 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-01-19 10:26:34 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2015-01-19 10:24:52 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmed-2012" MODIFIED="2014-08-26 20:40:36 +0100" MODIFIED_BY="[Empty name]" NAME="Ahmed 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-02-19 09:08:27 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;2012609903&lt;br&gt;English, Turkish&lt;br&gt;Journal: Article&lt;br&gt;201244&lt;/p&gt;" NOTES_MODIFIED="2014-02-19 09:08:27 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmed MT, Mohammed AH, Amansour A</AU>
<TI>Effect of pelvic floor electrical stimulation and biofeedback on the recovery of urinary continence after radical prostatectomy</TI>
<SO>Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi</SO>
<YR>2012</YR>
<VL>58</VL>
<NO>3</NO>
<PG>170-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47262"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-14 13:38:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Omar M, Mohammed AH</AU>
<TI>Effect of pelvic floor exercises, electrical stimulation and biofeedback on urinary incontinence after radical prostatectomy: single blind randomized clinical trial</TI>
<SO>ANZCTR (http://www.anzctr.org.au/ACTRN12610000975099.aspx)</SO>
<YR>2010</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:19:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:19:32 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ACTRN12610000975099"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bales-2000" MODIFIED="2015-01-19 10:14:24 +0000" MODIFIED_BY="[Empty name]" NAME="Bales 2000" YEAR="">
<REFERENCE MODIFIED="2015-01-19 10:14:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bales G, Gerber G, Minor T, Mhoon D, McFarland J, Hyung L, et al</AU>
<TI>Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>56</VL>
<PG>627-30</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:23:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:23:40 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT11831"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Burgio-2006" MODIFIED="2015-01-17 08:27:10 +0000" MODIFIED_BY="[Empty name]" NAME="Burgio 2006" YEAR="2005">
<REFERENCE MODIFIED="2015-01-17 08:27:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Goode P, Urban D. Umlauf M, Locher J, Bueschen A, Redden D</AU>
<TI>Preoperative biofeedback-assisted behavioural training to reduce post-prostatectomy incontinence: A randomized controlled trial [abstract]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>5/6</NO>
<PG>477</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:24:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:24:03 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT20970"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:24:24 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Burgio KL, Goode P, Urban D. Umlauf M, Locher J, Bueschen A, Redden D</AU>
<TI>Preoperative biofeedback-assisted behavioural training to reduce post-prostatectomy incontinence: A randomized controlled trial</TI>
<SO>Journal of Urology</SO>
<YR>2006</YR>
<VL>175</VL>
<NO>1</NO>
<PG>196-201</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:24:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:24:24 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT21637"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Centemero-2009" MODIFIED="2014-08-26 20:43:28 +0100" MODIFIED_BY="[Empty name]" NAME="Centemero 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-18 13:47:37 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Centemero A, Rigatti L, Andrea L, Gallina A, Lughezzani G, Montorsi F, et al</AU>
<TI>Effectiveness of pre-operative pelvic floor muscle training for post-prostatectomy early incontinence recovery (Abstract number 1642)</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>4 (Suppl 1)</NO>
<PG>591</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:47:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:47:37 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT34592"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 13:48:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Centemero A, Rigatti L, Giraudo D, Lazzeri M, Lughezzani G, Zugna D, et al</AU>
<TI>Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: a randomised controlled study</TI>
<SO>European Urology</SO>
<YR>2010</YR>
<VL>57</VL>
<NO>6</NO>
<PG>1039-43</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:48:21 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:48:21 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT40316"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dijkstra_x002d_Eshuis-2013" MODIFIED="2014-08-26 20:44:04 +0100" MODIFIED_BY="[Empty name]" NAME="Dijkstra-Eshuis 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-03 14:35:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 71126781&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Conference Abstract&lt;br&gt;EM - 201333&lt;br&gt;DD - 20130805&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:35:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dijkstra-Eshuis J, Splinter R, Zonneveld W, Putter H, Van Den Bos T, Bevers R, et al</AU>
<TI>Effect of preoperative pelvic floor muscle therapy with biofeedback versus standard care on stress urinary incontinence and quality of life in men undergoing laparoscopic radical prostatectomy (Abstract number 137)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>6</NO>
<PG>712-3</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49210"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-14 13:38:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20131119&lt;br&gt;IS - 1520-6777 (Electronic)&lt;br&gt;IS - 0733-2467 (Linking)&lt;br&gt;LA - ENG&lt;br&gt;PT - JOURNAL ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2014-05-14 13:38:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Dijkstra-Eshuis J, van den Bos TW, Splinter R, Bevers RF, Zonneveld WC, Putter H, et al</AU>
<TI>Effect of preoperative pelvic floor muscle therapy with biofeedback versus standard care on stress urinary incontinence and quality of life in men undergoing laparoscopic radical prostatectomy: A randomised control trial [epub ahead of print published online 19 November 2013]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2013</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49547"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-07 13:51:11 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;71032306&lt;br&gt;(Voorham- Van Der Zalm, Dijkstra- Eshuis, Splinter, Putter, Bevers, Pelger) LeidenNetherlands&lt;br&gt;0022-5347&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201316&lt;/p&gt;" NOTES_MODIFIED="2014-05-07 13:51:11 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Voorham-Van Der Zalm P, Dijkstra-Eshuis J, Splinter R, Putter H, Bevers RFM, Pelger RCM</AU>
<TI>Effect of preoperative pelvic floor muscle therapy versus standard care on stress urinary incontinence in men undergoing radical laparoscopic prostatectomy (Abstract number 1365)</TI>
<SO>Journal of Urology</SO>
<YR>2013</YR>
<VL>189</VL>
<NO>4 Suppl 1</NO>
<PG>e558-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont50002"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-26 15:43:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Voorham-Van Der Zalm PJ, Stoetman AM, Putter H, Bevers RFM, Pelger RCM</AU>
<TI>Effect of preoperative pelvic floor physiotherapy versus standard care on incontinence in men undergoing radical laparoscopic prostatectomy: an ongoing study (Abstract number 590)</TI>
<SO>Proceedings of the Joint Meeting of the International Continence Society (ICS) and the International Urogynecological Association, 2010 Aug 23-27, Toronto, Canada</SO>
<YR>2010</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT40184"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Dubbelman-2004" MODIFIED="2015-01-19 10:14:52 +0000" MODIFIED_BY="[Empty name]" NAME="Dubbelman 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-12-18 13:49:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubbelman Y, Groen J, Wildhagen M, Rikken B, Bosch R</AU>
<TI>The recovery of urinary continence after radical retropubic prostatectomy: a randomized trial comparing the effect of physiotherapist-guided pelvic floor muscle exercises with guidance by an instruction folder only</TI>
<SO>BJU International</SO>
<YR>2010</YR>
<VL>106</VL>
<NO>4</NO>
<PG>515-22</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:49:14 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:49:14 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT40056"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:14:40 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22488499&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Neurourol Urodyn. 31(5):637-41, 2012 Jun&lt;br&gt;JC - brq, 8303326&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;br&gt;DC - 20120615&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:14:40 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubbelman Y, Groen J, Wildhagen M, Rikken B, Bosch R</AU>
<TI>UPDATE Quantification of changes in detrusor function and pressure-flow parameters after radical prostatectomy: relation to postoperative continence status and the impact of intensity of pelvic floor muscle exercises</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>5</NO>
<PG>637-41</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="srincont45959"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:24:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubbelman YD, Groen J, Bosch R</AU>
<TI>Post prostatectomy incontinence: Significance of the pre-operative urethral pressure profile and the role of physiotherapy [abstract]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>5-6</NO>
<PG>471</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:24:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:24:57 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT19009"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:14:52 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22488800&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Neurourol Urodyn. 31(5):646-51, 2012 Jun&lt;br&gt;JC - brq, 8303326&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;br&gt;DC - 20120615&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:14:52 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dubbelman YD, Groen J, Wildhagen MF, Rikken B, Bosch JL</AU>
<TI>UPDATE Urodynamic quantification of decrease in sphincter function after radical prostatectomy: relation to postoperative continence status and the effect of intensive pelvic floor muscle exercises</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>5</NO>
<PG>646-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="srincont45958"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fader-2013" MODIFIED="2014-08-26 20:47:21 +0100" MODIFIED_BY="[Empty name]" NAME="Fader 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-19 20:59:37 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Embase&lt;br&gt;UI - 71126908&lt;br&gt;LG - English&lt;br&gt;PT - Journal: Conference Abstract&lt;br&gt;EM - 201333&lt;br&gt;DD - 20130805&lt;/p&gt;" NOTES_MODIFIED="2014-03-19 20:59:37 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fader M, Macaulay M, Broadbridge J, Cottenden A, Birch B, Moore KN</AU>
<TI>A trial of devices for the management of urinary incontinence following treatment for prostate cancer (Abstract number 264)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2013</YR>
<VL>32</VL>
<NO>6</NO>
<PG>891-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49194"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Filocamo-2005" MODIFIED="2015-01-19 10:22:20 +0000" MODIFIED_BY="[Empty name]" NAME="Filocamo 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-19 11:44:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{21063}&lt;/p&gt;" NOTES_MODIFIED="2013-12-19 11:44:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Del Popolo G, Filocamo MT, Li Marzi V, Cecconi F, Marzocco M, Tosto A et al</AU>
<TI>Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence (Abstract number 610)</TI>
<SO>Proceedings of the International Continence Society (ICS), 35th Annual Meeting, 2005 Aug 28-Sep 2, Montreal, Canada</SO>
<YR>2005</YR>
<IDENTIFIERS MODIFIED="2013-12-19 11:44:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-19 11:44:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT21063"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:22:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{21252}&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:22:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Filocamo MT, Li Marzi V, Del Popolo G, Cecconi F, Marzocco M, Tosto A, et al</AU>
<TI>Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence</TI>
<SO>European Urology</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>5</NO>
<PG>734-8</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:26:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:26:41 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT21252"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Floratos-2002" MODIFIED="2013-12-18 15:27:12 +0000" MODIFIED_BY="[Empty name]" NAME="Floratos 2002" YEAR="">
<REFERENCE MODIFIED="2013-12-18 15:27:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foratos DL, Sonke GS, Rapidou CA, Alivizatos GJ, Deliveliotis C, Constantinides CA et al</AU>
<TI>Biofeedback versus verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy</TI>
<SO>British Journal of Urology International</SO>
<YR>2002</YR>
<VL>89</VL>
<NO>7</NO>
<PG>714-9</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:27:12 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:27:12 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT15333"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fode-2014" MODIFIED="2014-08-26 20:57:18 +0100" MODIFIED_BY="[Empty name]" NAME="Fode 2014" YEAR="2012">
<REFERENCE MODIFIED="2014-05-14 13:38:55 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20140122&lt;br&gt;IS - 1464-410X (Electronic)&lt;br&gt;IS - 1464-4096 (Linking)&lt;br&gt;LA - ENG&lt;br&gt;PT - JOURNAL ARTICLE&lt;/p&gt;" NOTES_MODIFIED="2014-05-14 13:38:55 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fode M, Borre M, Ohl DA, Lichtbach J, Sonksen J</AU>
<TI>Penile vibratory stimulation in the recovery of urinary continence and erectile function after nerve-sparing radical prostatectomy: a randomized, controlled trial [epub ahead of print] [first published online 22 Jan 2014]</TI>
<SO>BJU International</SO>
<YR>2014</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01067261"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont50324"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-14 16:21:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Sonksen JR</AU>
<TI>Transcutaneous Mechanical Nerve Stimulation (TMNS) by Vibration in the Preservation and Restoration of Urinary Continence and Erectile Function and in the Treatment of Erectile Dysfunction and Urinary Incontinence in Conjunction With Nerve Sparing Radical Prostatectomy</TI>
<SO>http://clinicaltrials.gov/show/NCT01067261</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2014-05-14 16:21:40 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:21:40 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT01067261"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47825"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:22:07 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:22:07 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01067261"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Franke-1998" MODIFIED="2015-01-19 10:15:10 +0000" MODIFIED_BY="[Empty name]" NAME="Franke 1998" YEAR="1998">
<REFERENCE MODIFIED="2015-01-19 10:15:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{9180}&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:15:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Franke JJ, Gilbert WB, Grier J, Koch MO, Shyr Y, Smith JA Jr</AU>
<TI>Early post-prostatectomy pelvic floor biofeedback</TI>
<SO>Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<NO>1</NO>
<PG>191-3</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:27:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:27:45 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT9180"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:15:10 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Franke JJ, Grier J, Koch MO, Smith JA. Biofeedback-enhanced pelvic floor exercises in the early post prostatectomy period. J Urol 1998;159(Suppl 5):37. {5734}&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:15:10 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Franke JJ, Grier J, Koch MO, Smith JA</AU>
<TI>Biofeedback-enhanced pelvic floor exercises in the early post prostatectomy period</TI>
<SO>Journal of Urology</SO>
<YR>1998</YR>
<VL>159 Suppl 5</VL>
<PG>37</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:28:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:28:06 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT5734"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geraerts-2013" MODIFIED="2014-08-26 20:58:23 +0100" MODIFIED_BY="[Empty name]" NAME="Geraerts 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-01-20 11:36:55 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 23357349&lt;br&gt;ST - In-Process&lt;br&gt;CM - Comment in: Eur Urol. 2013 Nov;64(5):773-5; discussion 775-6; PMID: 23499365&lt;br&gt;AS - Eur Urol. 64(5):766-72, 2013 Nov&lt;br&gt;JC - enm, 7512719&lt;br&gt;CP - Switzerland&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20131011&lt;/p&gt;" NOTES_MODIFIED="2014-01-20 11:36:55 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Geraerts I, van Poppel H, Devoogdt N, Joniau S, van Cleynenbreugel B, De Groef A, et al</AU>
<TI>Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial</TI>
<SO>European Urology</SO>
<YR>2013</YR>
<VL>64</VL>
<NO>5</NO>
<PG>766-72</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NTR1953"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49488"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ghanem-2013" MODIFIED="2014-08-28 15:13:39 +0100" MODIFIED_BY="[Empty name]" NAME="Ghanem 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-19 09:43:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ghanem A, Khallaf M, Assem A, Hassan A</AU>
<TI>Does preoperative pelvic floor muscle exercise improve post prostatectomy urinary incontinence? (Abstract number 695)</TI>
<SO>Proceedings of the 43rd Annual Meeting of the International Continence Society (ICS), 2013 Aug 26-30, Barcelona, Spain</SO>
<YR>2013</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49728"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazener-RP-2011" MODIFIED="2015-01-19 10:22:50 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener RP 2011" YEAR="2010">
<REFERENCE MODIFIED="2013-12-19 11:50:07 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorey G, Glazener C, Buckley B, Cochran C, Moore K</AU>
<TI>Developing a pelvic floor muscle training regimen for use in a trial intervention</TI>
<SO>Physiotherapy</SO>
<YR>2009</YR>
<VL>95</VL>
<NO>3</NO>
<PG>199-209</PG>
<IDENTIFIERS MODIFIED="2013-12-19 11:50:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-19 11:50:07 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT32096"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 13:50:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al</AU>
<TI>A randomized controlled trial of conservative treatment (pelvic floor muscle training and bladder training) for urinary incontinence in men after prostate surgery (MAPS) (Abstract number 200)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1093-4</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:50:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:50:04 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT40156"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 13:51:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21640056&lt;br&gt;ST - In-Process&lt;br&gt;AS - Health Technol Assess. 15(24):1-290, iii-iv, 2011 Jun&lt;br&gt;JC - cao, 9706284&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20110606&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 13:51:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al</AU>
<TI>Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials</TI>
<SO>Health Technology Assessment (Winchester, England)</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>24</NO>
<PG>1-290</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:51:35 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:51:35 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT41754"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 13:50:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21741700&lt;br&gt;ST - In-Process&lt;br&gt;CM - Comment in: Lancet. 2011 Jul 23;378(9788):293-4; PMID: 21741698&lt;br&gt;AS - Lancet. 378(9788):328-37, 2011 Jul 23&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SI - ISRCTN&lt;br&gt;SA - ISRCTN/ISRCTN87696430&lt;br&gt;NO - (United Kingdom Chief Scientist Office)&lt;br&gt;LG - English&lt;br&gt;DC - 20110725&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 13:50:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al</AU>
<TI>Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<NO>9788</NO>
<PG>328-37</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:50:53 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:50:53 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT41752"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:22:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Glazener CMA</AU>
<TI>MAPS (Men After Prostate Surgery): Conservative Treatment for Men With Urinary Incontinence After Prostate Surgery; Multicentre Randomised Controlled Trial of Pelvic Floor Muscle Training and Biofeedback [MAPS]</TI>
<SO>http://clinicaltrials.gov/show/NCT00632138</SO>
<YR>2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00632138"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47844"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:15:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagen S, Glazener C, Cochran C, Campbell L</AU>
<TI>Continence care for men having prostate surgery: advice and care before and after radical prostatectomy and transurethral resection of prostate (Abstract number 96)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>690-1</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:29:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:29:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT34583"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 10:28:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Update Buckley B, Lapitan MCM, Glazener C</AU>
<TI>The effect of urinary incontinence on health utility and health related quality of life in men following prostate surgery (Abstract number 542)</TI>
<SO>Proceedings of the 41st Annual Meeting of the International Continence Society (ICS), 2011 Aug 29 to Sept 2, Glasgow, Scotland</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN87696430"/>
<IDENTIFIER TYPE="OTHER" VALUE="MAPS"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont47758"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:15:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22396387&lt;br&gt;ST - In-Process&lt;br&gt;AS - Neurourol Urodyn. 31(4):465-9, 2012 Apr&lt;br&gt;JC - brq, 8303326&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20120420&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:15:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Update Buckley BS, Lapitan MC, Glazener CM, MAPS Trial Group</AU>
<TI>The effect of urinary incontinence on health utility and health-related quality of life in men following prostate surgery</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>4</NO>
<PG>465-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN87696430"/>
<IDENTIFIER TYPE="OTHER" VALUE="MAPS"/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00632138"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont44658"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 13:50:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Update Glazener C, Boachie C, Hagen S, Kilonzo M, Cochran C, Buckley B, et al</AU>
<TI>Clinical outcomes two years after a randomised controlled trial of pelvic floor muscle training after radical prostatectomy or TURP: men after prostate surgery trial (MAPS) (Abstract number 254)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1150-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MAPS"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont:42203"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:22:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:22:44 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00632138"/>
<IDENTIFIER MODIFIED="2013-12-18 13:13:19 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN87696430"/>
<IDENTIFIER MODIFIED="2013-12-18 13:12:51 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="MAPS"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Glazener-TURP-2011" MODIFIED="2015-01-19 10:15:50 +0000" MODIFIED_BY="[Empty name]" NAME="Glazener TURP 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-12-02 13:09:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dorey G, Glazener C, Buckley B, Cochran C, Moore K</AU>
<TI>Developing a pelvic floor muscle training regimen for use in a trial intervention</TI>
<SO>Physiotherapy</SO>
<YR>2009</YR>
<VL>95</VL>
<NO>3</NO>
<PG>199-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-02 13:09:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al</AU>
<TI>A randomized controlled trial of conservative treatment (pelvic floor muscle training and bladder training) for urinary incontinence in men after prostate surgery (MAPS) (Abstract number 200)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1093-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-02 13:09:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21640056&lt;br&gt;ST - In-Process&lt;br&gt;AS - Health Technol Assess. 15(24):1-290, iii-iv, 2011 Jun&lt;br&gt;JC - cao, 9706284&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20110606&lt;/p&gt;" NOTES_MODIFIED="2011-12-02 13:09:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al</AU>
<TI>Conservative treatment for urinary incontinence in Men After Prostate Surgery (MAPS): two parallel randomised controlled trials</TI>
<SO>Health Technology Assessment (Winchester, England)</SO>
<YR>2011</YR>
<VL>15</VL>
<NO>24</NO>
<PG>1-290</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-02 13:09:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21741700&lt;br&gt;ST - In-Process&lt;br&gt;CM - Comment in: Lancet. 2011 Jul 23;378(9788):293-4; PMID: 21741698&lt;br&gt;AS - Lancet. 378(9788):328-37, 2011 Jul 23&lt;br&gt;JC - 2985213r, l0s, 0053266&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;SI - ISRCTN&lt;br&gt;SA - ISRCTN/ISRCTN87696430&lt;br&gt;NO - (United Kingdom Chief Scientist Office)&lt;br&gt;LG - English&lt;br&gt;DC - 20110725&lt;/p&gt;" NOTES_MODIFIED="2011-12-02 13:09:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Glazener C, Boachie C, Buckley B, Cochran C, Dorey G, Grant A, et al</AU>
<TI>Urinary incontinence in men after formal one-to-one pelvic-floor muscle training following radical prostatectomy or transurethral resection of the prostate (MAPS): two parallel randomised controlled trials</TI>
<SO>Lancet</SO>
<YR>2011</YR>
<VL>378</VL>
<NO>9788</NO>
<PG>328-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:15:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hagen S, Glazener C, Cochran C, Campbell L</AU>
<TI>Continence care for men having prostate surgery: advice and care before and after radical prostatectomy and transurethral resection of prostate (Abstract number 96)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>690-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-10 13:31:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Update Buckley B, Lapitan MCM, Glazener C</AU>
<TI>The effect of urinary incontinence on health utility and health related quality of life in men following prostate surgery (Abstract number 542)</TI>
<SO>Proceedings of the 41st Annual Meeting of the International Continence Society (ICS), 2011 Aug 29 to Sept 2, Glasgow, Scotland</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN87696430"/>
<IDENTIFIER TYPE="OTHER" VALUE="MAPS"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont47758"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:15:50 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22396387&lt;br&gt;ST - In-Process&lt;br&gt;AS - Neurourol Urodyn. 31(4):465-9, 2012 Apr&lt;br&gt;JC - brq, 8303326&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20120420&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:15:50 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Update Buckley BS, Lapitan MC, Glazener CM, MAPS Trial Group</AU>
<TI>The effect of urinary incontinence on health utility and health-related quality of life in men following prostate surgery</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>4</NO>
<PG>465-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="ISRCTN87696430"/>
<IDENTIFIER TYPE="OTHER" VALUE="MAPS"/>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00632138"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont44658"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-10 13:31:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Update Glazener C, Boachie C, Hagen S, Kilonzo M, Cochran C, Buckley B, et al</AU>
<TI>Clinical outcomes two years after a randomised controlled trial of pelvic floor muscle training after radical prostatectomy or TURP: men after prostate surgery trial (MAPS) (Abstract number 254)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>6</NO>
<PG>1150-1</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="MAPS"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont:42203"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:23:01 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:23:01 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00632138"/>
<IDENTIFIER MODIFIED="2013-12-18 13:11:51 +0000" MODIFIED_BY="[Empty name]" TYPE="ISRCTN" VALUE="ISRCTN87696430"/>
<IDENTIFIER MODIFIED="2013-12-18 13:12:27 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="MAPS"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-2009" MODIFIED="2015-01-19 10:15:57 +0000" MODIFIED_BY="[Empty name]" NAME="Goode 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-01-19 10:15:57 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode P, Burgio K, Johnson T, Roth D, Clay O, Burkhardt J, et al</AU>
<TI>Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent post-prostatectomy incontinence - a randomized controlled trial (Abstract number 87)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>681-2</PG>
<IDENTIFIERS MODIFIED="2013-12-18 14:40:02 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 14:40:02 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT34582"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-02 13:31:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goode PS, Burgio KL, Johnson TM, Clay OJ, Roth DL, Markland AD, et al</AU>
<TI>Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2011</YR>
<VL>305</VL>
<NO>2</NO>
<PG>151-9</PG>
<IDENTIFIERS MODIFIED="2011-12-02 13:31:58 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 13:31:58 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT40806"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-14 13:39:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Goode PS</AU>
<TI>Conservative Treatment of Postprostatectomy Incontinence</TI>
<SO>http://clinicaltrials.gov/show/NCT00212264</SO>
<YR>2003</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00212264"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47864"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-18 13:52:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:52:55 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00212264"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hoffman-2005" MODIFIED="2013-12-18 15:30:06 +0000" MODIFIED_BY="[Empty name]" NAME="Hoffman 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-18 15:30:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann W, Liedke S, Dombo O, Otto U</AU>
<TI>Electrical stimulation to treat postoperative incontinence: Therapeutic benefit in regard to quality of life</TI>
<TO>Die Electrostimulation in der Therapie der posopertiven Harninkontinenz. Therapeutischer Nutzen unter Berucksichtigung der Lebensqualitat</TO>
<SO>Urologe</SO>
<YR>2004</YR>
<VL>44</VL>
<PG>33-40</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:30:06 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:30:06 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT20402"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hou-2013" MODIFIED="2014-08-28 15:14:49 +0100" MODIFIED_BY="[Empty name]" NAME="Hou 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-03 09:40:11 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 23766642&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Clin Interv Aging. 8:667-73, 2013&lt;br&gt;JC - 101273480&lt;br&gt;CP - New Zealand&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20130614&lt;/p&gt;" NOTES_MODIFIED="2014-02-03 09:40:11 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hou CP, Chen TY, Chang CC, Lin YH, Chang PL, Chen CL, et al</AU>
<TI>Use of the SF-36 quality of life scale to assess the effect of pelvic floor muscle exercise on aging males who received transurethral prostate surgery</TI>
<SO>Clinical Interventions In Aging</SO>
<YR>2013</YR>
<VL>8</VL>
<PG>667-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont48064"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Joseph-2000" MODIFIED="2013-12-18 15:30:29 +0000" MODIFIED_BY="[Empty name]" NAME="Joseph 2000" YEAR="">
<REFERENCE MODIFIED="2013-12-18 15:30:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joseph AC, Chang MK</AU>
<TI>Comparison of behavior therapy methods for urinary incontinence following prostate surgery: a pilot study</TI>
<SO>Urologic Nursing</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>3</NO>
<PG>203-4</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:30:29 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:30:29 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT15334"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koo-2009" MODIFIED="2015-01-19 10:16:11 +0000" MODIFIED_BY="[Empty name]" NAME="Koo 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-01-19 10:16:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kim YH, Hwang EG, Shin JH, Kim YW, Lim JS, Na YG, Song KH, Sul CK</AU>
<TI>Effect of extracorporeal magnetic innervation (ExMI) pelvic floor therapy for urinary incontinence after radical prostatectomy</TI>
<SO>Urology</SO>
<YR>2009</YR>
<VL>74 Suppl 4A</VL>
<PG>S227</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:54:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:54:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42741"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 13:54:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koo D, So SM, Lim JS</AU>
<TI>Effect of Extracorporeal Magnetic Innervation (ExMI) pelvic floor therapy on urinary incontinence after radical prostatectomy [Korean]</TI>
<SO>Korean Journal of Urology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>1</NO>
<PG>23-7</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:54:56 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:54:56 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT34595"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laurienzo-2013" MODIFIED="2015-01-19 10:16:04 +0000" MODIFIED_BY="[Empty name]" NAME="Laurienzo 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-01-19 10:16:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 23683683&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Int Braz J Urol. 39(2):182-8, 2013 Mar-Apr&lt;br&gt;JC - 101158091&lt;br&gt;CP - Brazil&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20130520&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:16:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laurienzo CE, Sacomani CA, Rodrigues TR, Zequi Sde C, Guimaraes GC, Lopes A</AU>
<TI>Results of preoperative electrical stimulation of pelvic floor muscles in the continence status following radical retropubic prostatectomy</TI>
<SO>International Brazilian Journal of Urology</SO>
<YR>2013</YR>
<VL>39</VL>
<NO>2</NO>
<PG>182-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont48139"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu--2008" MODIFIED="2013-12-18 15:30:54 +0000" MODIFIED_BY="[Empty name]" NAME="Liu  2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-18 15:30:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu F</AU>
<TI>[Extracorporeal magnetic innervation in the treatment of urinary incontinence after radical prostatectomy]</TI>
<SO>Journal of Clinical Rehabilitative Tissue Engineering Research</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>17</NO>
<PG>3289-92</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:30:54 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:30:54 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT34489"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manassero--2007" MODIFIED="2015-01-19 10:16:17 +0000" MODIFIED_BY="[Empty name]" NAME="Manassero  2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-19 10:16:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17487874&lt;br&gt;IN - Department of Urology, University of Pisa, Pisa, Italy. francy_manassero@hotmail.com&lt;br&gt;AS - Neurourol Urodyn. 26(7):985-9, 2007&lt;br&gt;JC - brq, 8303326&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:16:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manassero F, Traversi C, Ales V, Pistolesi D, Panicucci E, Valent F, et al</AU>
<TI>Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: results of a prospective controlled randomized trial</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2007</YR>
<VL>26</VL>
<NO>7</NO>
<PG>985-9</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:31:11 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:31:11 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT23915"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marchiori-2010" MODIFIED="2014-08-28 15:15:59 +0100" MODIFIED_BY="[Empty name]" NAME="Marchiori 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-01-06 13:55:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marchiori D, Bertaccini A, Manferrari F, Ferri C, Martorana G</AU>
<TI>Pelvic floor rehabilitation for continence recovery after radical prostatectomy: role of a personal training re-educational program</TI>
<SO>Anticancer Research</SO>
<YR>2010</YR>
<VL>30</VL>
<NO>2</NO>
<PG>553-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mariotti-2009" MODIFIED="2015-01-19 10:23:05 +0000" MODIFIED_BY="[Empty name]" NAME="Mariotti 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-18 15:31:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mariotti G, Sciarra A, Gentilucci A, Salciccia S, Alfarone A, Pierro GD, et al</AU>
<TI>Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>4</NO>
<PG>1788-93</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:31:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:31:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT31079"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:23:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sciarra A, Salciccia S, Gentilucci A, Alfarone A, Di Pierro GB, Mariotti G, et al</AU>
<TI>Early recovery of urinary continence after radical prostatectomy using early pelvic floor electric stimulation and biofeedback associated treatment</TI>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>4 Suppl 1</NO>
<PG>680</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:32:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:32:07 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT42739"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 14:14:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sciarra A, Salciccia S, Gentilucci A, Alfarone A, Mariotti G, Cattarino S, et al</AU>
<TI>Early recovery of urinary continence after radical prostatectomy using early pelvic floor electric stimulation and biofeedback associated treatment (Abstract number 412)</TI>
<SO>European Urology Supplements</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>4</NO>
<PG>223</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT42738"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martini-2011" MODIFIED="2015-01-19 10:16:25 +0000" MODIFIED_BY="[Empty name]" NAME="Martini 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-01-19 10:16:25 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70530401&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201100&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:16:25 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martini M, Bernardini S, Blanc E, Piretta K, Tappero R</AU>
<TI>Relationship between integrity of pelvic floor function and recovery of continence after laparoscopic prostatectomy and effects of preventive pelvic floor training in males with pelvic floor weakness (Abstract number 14)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30 Suppl 1</VL>
<PG>11-2</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47398"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathewson_x002d_Chapman-97" MODIFIED="2013-12-18 15:32:57 +0000" MODIFIED_BY="[Empty name]" NAME="Mathewson-Chapman 97" YEAR="1997">
<REFERENCE MODIFIED="2013-12-18 15:32:37 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{5381} {5911}dupl&lt;br&gt;Mathewson-Chapman M. Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: an education program. J Cancer Educ 1997;12(4):218-23.&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:32:37 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mathewson-Chapman M</AU>
<TI>Pelvic muscle exercise/biofeedback for urinary incontinence after prostatectomy: an education program</TI>
<SO>Journal of Cancer Education</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>4</NO>
<PG>218-23</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:32:37 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:32:37 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT5381"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:32:57 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{11221}&lt;br&gt;Mathewson-Chapman M. The effect of pelvic muscle exercises with biofeedback for urinary incontinence post-prostatectomy. [Unpublished PhD dissertation] University of Florida, Gainsville, Florida, USA, 1995.&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:32:57 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Mathewson-Chapman M</AU>
<SO>The effect of pelvic muscle exercises with biofeedback for urinary incontinence post-prostatectomy. [Unpublished PhD dissertation]</SO>
<YR>1995</YR>
<PB>University of Florida</PB>
<CY>Gainsville</CY>
<IDENTIFIERS MODIFIED="2013-12-18 15:32:57 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:32:57 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT11221"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Moore-1999" MODIFIED="2015-01-19 10:16:32 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 1999" YEAR="1997">
<REFERENCE MODIFIED="2015-01-19 10:16:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{5677}&lt;br&gt;Moore KN, Griffiths DJ, Hughton A. A randomised controlled trial of pelvic muscle exercises or pelvic muscle exercises plus electrical stimulation for post radical prostatectomy urinary incontinence. [abstract] Neurourol Urodyn 1998;17:424-6.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:16:32 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore KN, Griffiths DJ, Hughton A</AU>
<TI>A randomised controlled trial of pelvic muscle exercises or pelvic muscle exercises plus electrical stimulation for post radical prostatectomy urinary incontinence [abstract]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>424-6</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:33:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:33:18 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT5677"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:33:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{5730}&lt;br&gt;Moore KN, Griffiths DJ, Hughton A. Urinary incontinence after post radical prostatectomy: A randomised controlled trial comparing pelvic muscle exercises with pelvic muscle exercises plus electrical stimulation. BJU Int 1999;83:57-65.&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:33:36 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Moore KN, Griffiths DJ, Hughton A</AU>
<TI>Urinary incontinence after post radical prostatectomy: A randomised controlled trial comparing pelvic muscle exercises with pelvic muscle exercises plus electrical stimulation</TI>
<SO>British Journal of Urology International</SO>
<YR>1999</YR>
<VL>83</VL>
<PG>57-65</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:33:36 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:33:36 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT5730"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:34:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{8006}&lt;br&gt;Moore KN. The effect of urinary incontinence on the quality of life following radical prostatectomy [Unpublished Doctoral Thesis], University of Alberta, Edmonton, Canada, 1997.&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:34:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Moore KN</AU>
<SO>The effect of urinary incontinence on the quality of life following radical prostatectomy [Unpublished PhD Thesis]</SO>
<YR>1997</YR>
<PB>University of Alberta</PB>
<CY>Edmonton</CY>
<IDENTIFIERS MODIFIED="2013-12-18 15:34:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:34:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT8006"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Moore-2004" MODIFIED="2015-01-19 10:16:39 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-01-19 10:16:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore KN, Schieman S, Ackerman T, Drus H, Metcalfe JB, Voaklander DC</AU>
<TI>Assessing the comfort, safety and patient satisfaction with three commonly used penile compression devices</TI>
<SO>Urology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>1</NO>
<PG>150-4</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:34:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:34:32 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT19156"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Moore-2008" MODIFIED="2011-12-02 13:35:33 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2008" YEAR="2008">
<REFERENCE MODIFIED="2011-12-02 13:35:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Moore KN, Valiquette L, Chetner MP, Byrniak S, Herbison GP</AU>
<TI>Return to continence after radical retropubic prostatectomy: A randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy</TI>
<SO>Urology</SO>
<YR>2008</YR>
<VL>72</VL>
<NO>6</NO>
<PG>1280-6</PG>
<IDENTIFIERS MODIFIED="2011-12-02 13:35:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 13:35:24 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT26907"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-28 14:32:03 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;not sure what date data 'received' so provisional put 11 May 2006 - check with Katherine Moore.&lt;/p&gt;" NOTES_MODIFIED="2008-10-28 14:32:03 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Moore KN</AU>
<TI>The effectiveness of biofeedback assisted pelvic floor muscle exercises in the treatment of incontinence post radical prostatectomy. [Personal Communication] (as supplied 11 May 2006)</TI>
<SO>Data on file</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morihiro-2011" MODIFIED="2014-08-28 19:36:28 +0100" MODIFIED_BY="[Empty name]" NAME="Morihiro 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-18 16:27:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morihiro N, Masatsugu I, Shinji K, Kenichi T, Kazumasa M, Shiro B</AU>
<TI>Effectiveness of sacral surface therapeutic electrical stimulation (SSTES) on early recovery of urinary incontinence after laparoscopic radical prostatectomy: a prospective study (Abstract number 64)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>6</NO>
<PG>889-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT42173"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nowak--2007" MODIFIED="2013-12-18 15:35:01 +0000" MODIFIED_BY="[Empty name]" NAME="Nowak  2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-18 15:35:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nowak M, Jordan M, Haberl S, Herwig R, Kuehhas F, Brausi M, et al</AU>
<TI>Prospective study of extracorporeal magnetic innervation pelvic floor therapy (EXMI) versus standard pelvic floor training following radical prostatectomy: Impact on timing and magnitude of recovery of continence (Abstract number 482)</TI>
<SO>European Urology Supplements</SO>
<YR>2007</YR>
<VL>6</VL>
<NO>2</NO>
<PG>143</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:35:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:35:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT34792"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opsomer-1994" MODIFIED="2015-01-19 10:16:47 +0000" MODIFIED_BY="[Empty name]" NAME="Opsomer 1994" YEAR="1994">
<REFERENCE MODIFIED="2015-01-19 10:16:47 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{2687}&lt;br&gt;Opsomer RJ, Castille Y, Abi Aad AS, van Cangh PJ. Urinary incontinence after radical prostatectomy: Is professional pelvic floor training necessary? Neurourol Urodyn 1994;13(4);382-4.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:16:47 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opsomer RJ, Castille Y, Abi Aad AS, van Cangh PJ</AU>
<TI>Urinary incontinence after radical prostatectomy: Is professional pelvic floor training necessary?</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1994</YR>
<VL>13</VL>
<NO>4</NO>
<PG>382-4</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:35:18 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:35:18 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT2687"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overgard-2008" MODIFIED="2015-01-19 10:17:01 +0000" MODIFIED_BY="[Empty name]" NAME="Overgard 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-01-19 10:16:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morkved S, Overgard M, Lydersen S, Angelsen A</AU>
<TI>Does pelvic floor muscle training with follow up instructions by a physiotherapist reduce urinary incontinence after radical prostatectomy? - A randomised controlled trial (Abstract number 15)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2008</YR>
<VL>27</VL>
<NO>7</NO>
<PG>587-8</PG>
<IDENTIFIERS MODIFIED="2013-12-19 12:16:10 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-19 12:16:10 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT31841"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-05-14 13:39:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Morkved S</AU>
<TI>Urinary Incontinence After Radical Prostatectomy. - Effect of Pelvic Floor Muscle Training. A Randomised Controlled Trial</TI>
<SO>http://clinicaltrials.gov/show/NCT00239824</SO>
<YR>2005</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00239824"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47830"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 14:48:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overgard M, Angelsen A, Lydersen S, Morkved S</AU>
<TI>Does physiotherapist-guided pelvic floor muscle training reduce urinary incontinence after radical prostatectomy?: A randomised controlled trial</TI>
<SO>European Urology</SO>
<YR>2008</YR>
<VL>54</VL>
<PG>438-48</PG>
<IDENTIFIERS MODIFIED="2013-12-18 14:48:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 14:48:23 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT26906"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 10:28:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Update Angelsen A, Nilssen S, Overgard M, Lydersen S, Morkved S</AU>
<TI>Does physiotherapist-guided pelvic floor muscle training increase the quality of life in patients after radical prostatectomy? A randomized clinical study (Abstract number 733)</TI>
<SO>Proceedings of the 42nd Annual Meeting of the International Continence (ICS), 2012 Oct 15 to 19, Beijing, China</SO>
<YR>2012</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00239824"/>
<IDENTIFIER TYPE="OTHER" VALUE="srincont47938"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:17:01 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22746358&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Scand J Urol Nephrol. 46(6):397-404, 2012 Dec&lt;br&gt;JC - uda, 0114501&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20121204&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:17:01 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Update Nilssen SR, Morkved S, Overgard M, Lydersen S, Angelsen A</AU>
<TI>Does physiotherapist-guided pelvic floor muscle training increase the quality of life in patients after radical prostatectomy? A randomized clinical study</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>2012</YR>
<VL>46</VL>
<NO>6</NO>
<PG>397-404</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00239824"/>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT46190"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2013-12-18 14:49:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 14:49:24 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00239824"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Parekh-2003" MODIFIED="2013-12-18 15:35:40 +0000" MODIFIED_BY="[Empty name]" NAME="Parekh 2003" YEAR="">
<REFERENCE MODIFIED="2013-12-18 15:35:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Parekh AR, Feng Mi, Kirages D, Bremner H, Kaswick J, Aboseif S</AU>
<TI>The role of pelvic floor exercises on post-prostatectomy incontinence</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>170</VL>
<PG>130-3</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:35:40 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:35:40 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT16004"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Park-2012" MODIFIED="2014-08-28 19:37:06 +0100" MODIFIED_BY="[Empty name]" NAME="Park 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-03 15:30:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park S-W, Park C-S, Kim T-N, Lee W, Nam J-K</AU>
<TI>The effects of a 12-week's combined exercise intervention on physical function and mental health after radical prostatectomy in elderly patients with prostate cancer: a prospective, randomised controlled study (Abstract number 1309)</TI>
<SO>Journal of Urology</SO>
<YR>2011</YR>
<VL>185</VL>
<NO>4S</NO>
<PG>e524</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT42511"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-28 15:31:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22749425&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Urology. 80(2):299-306, 2012 Aug&lt;br&gt;JC - wsy, 0366151&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20120803&lt;/p&gt;" NOTES_MODIFIED="2014-01-28 15:31:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Park SW, Kim TN, Nam JK, Ha HK, Shin DG, Lee W, et al</AU>
<TI>Recovery of overall exercise ability, quality of life, and continence after 12-week combined exercise intervention in elderly patients who underwent radical prostatectomy: a randomized controlled study</TI>
<SO>Urology</SO>
<YR>2012</YR>
<VL>80</VL>
<NO>2</NO>
<PG>299-306</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT45132"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perissinotto-2008" MODIFIED="2013-12-18 15:36:01 +0000" MODIFIED_BY="[Empty name]" NAME="Perissinotto 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-18 15:36:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Perissinotto MCR, D'Ancona CAL, Campos RM, Lucio AC, Silva JrW</AU>
<TI>Physiotherapeutic for treatment of post radical prostatectomy urinary incontinence (Abstract number 265)</TI>
<SO>Proceedings of the International Continence Society (ICS), 38th Annual Meeting, 2008 Oct 20-24, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS MODIFIED="2013-12-18 15:36:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:36:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT31843"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Porru-2001" MODIFIED="2015-01-19 10:23:20 +0000" MODIFIED_BY="[Empty name]" NAME="Porru 2001" YEAR="2001">
<REFERENCE MODIFIED="2015-01-19 10:23:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;medline ui not yet assigned in premed&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:23:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Porru D, Campus G, Caria A, Madeddu, Cucchi A, Rovereto B, et al</AU>
<TI>Impact of early pelvic floor rehabilitation after transurethral resection of the prostate</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2001</YR>
<VL>20</VL>
<PG>53-9</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:36:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:36:20 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT11849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ribeiro-2008" MODIFIED="2015-01-19 10:23:34 +0000" MODIFIED_BY="[Empty name]" NAME="Ribeiro 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-05-07 13:37:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ribeiro LH, Prota C, Gomes CM, de Bessa J Jr, Boldarine MP, Dall'Oglio MF, et al</AU>
<TI>Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: a prospective, randomized, controlled trial</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>184</VL>
<NO>3</NO>
<PG>1034-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT40040"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:36:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ribeiro LS, Prota C, Gomes CM, Dall'Oglio MF, Bruschini H, Srougi M</AU>
<TI>Effect of early postoperative pelvic-floor biofeedback on continence in men undergoing radical prostatectomy: A randomized, controlled trial (Abstract number 1412)</TI>
<SO>Journal of Urology</SO>
<YR>2008</YR>
<VL>179</VL>
<NO>4 Suppl S</NO>
<PG>483</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:36:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:36:41 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT26921"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:23:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ribiero LS, Prota C, Gomes CM, Boldarine MP, Nakano E, Dall'Oglio M, et al</AU>
<TI>Early pelvic-floor biofeedback training promotes long-term improvement of urinary continence after radical prostatectomy (Abstract number 1882)</TI>
<TO>.</TO>
<SO>Journal of Urology</SO>
<YR>2009</YR>
<VL>181</VL>
<NO>4 Suppl</NO>
<PG>680</PG>
<IDENTIFIERS MODIFIED="2011-12-02 13:51:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 13:51:09 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT42736"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2008" MODIFIED="2014-02-26 15:43:34 +0000" MODIFIED_BY="[Empty name]" NAME="Robinson 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-18 15:37:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson JP, Bradway CW, Nuamah I, Pickett M, McCorkle R</AU>
<TI>Systematic pelvic floor training for lower urinary tract symptoms post-prostatectomy: a randomized clinical trial</TI>
<SO>Internatonal Journal of Urological Nursing</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>1</NO>
<PG>3-13</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:37:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:37:04 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT34593"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2009" MODIFIED="2015-01-19 10:17:08 +0000" MODIFIED_BY="[Empty name]" NAME="Robinson 2009" YEAR="2009">
<REFERENCE MODIFIED="2015-01-19 10:17:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson J, Weiss R, Avi-Itzhak T, McCorkle R</AU>
<TI>Pilot-testing of a theory-based pelvic floor training intervention for radical prostatectomy patients (Abstract number 88)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>7</NO>
<PG>682-3</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:37:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:37:23 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT34587"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seleme-2008" MODIFIED="2013-12-18 15:37:44 +0000" MODIFIED_BY="[Empty name]" NAME="Seleme 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-18 15:37:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Seleme M, Ribeiro V, Moreno A, Berghmans B, Bendhack M</AU>
<TI>Efficacy of physiotherapy after radical prostatectomy (Abstract number 256)</TI>
<SO>Proceedings of the International Continence Society (ICS), 38th Annual Meeting, 2008 Oct 20-24, Cairo, Egypt</SO>
<YR>2008</YR>
<IDENTIFIERS MODIFIED="2013-12-18 15:37:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:37:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT31842"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tibaek-2007" MODIFIED="2015-01-19 10:23:47 +0000" MODIFIED_BY="[Empty name]" NAME="Tibaek 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-19 10:17:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tibaek S, Klarskov P, Hansen BL, Thomsen H, Andresen H, Jensen CS, et al</AU>
<TI>Pelvic floor muscle training before transurethral resection of the prostate: A randomized, controlled, blinded study</TI>
<SO>Scandinavian Journal of Urology and Nephrology</SO>
<YR>2007</YR>
<VL>41</VL>
<NO>4</NO>
<PG>329-34</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:38:08 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:38:08 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT23879"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:23:47 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tibaek S, Klarskov P, Lund Hanzen B, Thomsen H,Andresen H, Schmidt Jensen C, et al</AU>
<TI>Pelvic floor muscle training before transurethral resection of the prostate (Abstract number 31).</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>546-7</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:56:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:56:43 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT26614"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tienforti-2012" MODIFIED="2015-01-19 10:24:08 +0000" MODIFIED_BY="[Empty name]" NAME="Tienforti 2012" YEAR="2011">
<REFERENCE MODIFIED="2014-01-06 14:02:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacco E, Tienforti D, D'Addessi A, Racioppi M, Gulino G, Pinto F, et al</AU>
<TI>Efficacy of a supervised, affordable program of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial (Abstract number 138)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30</VL>
<NO>6</NO>
<PG>995-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT42188"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:24:08 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70863091&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201238&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:24:08 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sacco E, Tienforti D, Marangi F, D'Addessi A, Racioppi M, Gulino G, et al</AU>
<TI>Efficacy of a supervised low-intensity regimen of perioperative pelvic floor muscle training in reducing postprostatectomy urinary incontinence: A randomized controlled trial (Abstract number 286)</TI>
<SO>European Urology Supplements</SO>
<YR>2012</YR>
<VL>11</VL>
<NO>1</NO>
<PG>e286</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47271"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-27 10:40:43 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22332815&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - BJU Int. 110(7):1004-10, 2012 Oct&lt;br&gt;JC - dcu, 100886721&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20120907&lt;/p&gt;" NOTES_MODIFIED="2014-01-27 10:40:43 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tienforti D, Sacco E, Marangi F, D'Addessi A, Racioppi M, Gulino G, et al</AU>
<TI>Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial</TI>
<SO>BJU International</SO>
<YR>2012</YR>
<VL>110</VL>
<NO>7</NO>
<PG>1004-10</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT45339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tobia-2008" MODIFIED="2015-01-19 10:24:37 +0000" MODIFIED_BY="[Empty name]" NAME="Tobia 2008" YEAR="2008">
<REFERENCE MODIFIED="2015-01-19 10:24:37 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 18972914&lt;br&gt;IN - Servicio de Urologia, Hospital Italiano de Buenos Aires, Buenos Aires, Republica Argentina. ignacio.tobia@hospitalitaliano.org.ar&lt;br&gt;OT - Estudio randomizado sobre continencia urinaria postprostatectomia radical con rehabilitacion perineal kiesica previa&lt;br&gt;AS - Arch Esp Urol. 61(7):793-8, 2008 Sep&lt;br&gt;JC - 6zw, 0064757&lt;br&gt;SB - IM&lt;br&gt;CP - Spain&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;LG - Spanish&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:24:37 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tobia I, Gonzalez MS, Martinez P, Tejerizo JC, Gueglio G, Damia O, et al</AU>
<TI>[Randomized study on urinary continence after radical prostatectomy with previous kinesic perineal physiotherapy]. [Spanish]</TI>
<SO>Archivos Espanoles de Urologia</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>7</NO>
<PG>793-8</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:38:34 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:38:34 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT27688"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-van-Kampen-1998" MODIFIED="2015-01-19 10:17:21 +0000" MODIFIED_BY="[Empty name]" NAME="van Kampen 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-12-18 13:57:23 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{9919}&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 13:57:23 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Van Kampen M, De Weerdt W, Van Poppel H, Baert L</AU>
<TI>Urinary incontinence after radical prostatectomy can be treated by pelvic floor re-education and predicted by measuring urine loss at catheter withdrawal: a controlled study</TI>
<SO>Proceedings of the International Continence Society (ICS), 29th Annual Meeting; 1999 Aug 22-26; Denver, Colorado</SO>
<YR>1999</YR>
<PG>246-7</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:57:23 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:57:23 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT9919"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:39:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{9012}&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:39:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L</AU>
<TI>Effect of pelvic floor re-education on duration and degree of incontinence after radical prostatectomy: a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>355</VL>
<NO>9198</NO>
<PG>98-102</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:39:04 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:39:04 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT9012"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:17:21 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{5681}&lt;br&gt;Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert, L. The efficacy of physiotherapy on the degree and the duration of incontinence after radical prostatectomy: a randomised controlled study. [abstract] Neurourol Urodyn 1998;17(4):49-50.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:17:21 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert, L</AU>
<TI>The efficacy of physiotherapy on the degree and the duration of incontinence after radical prostatectomy: a randomised controlled study [abstract]</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>4</NO>
<PG>49-50</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:39:22 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:39:22 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT5681"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:39:41 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{5733}&lt;br&gt;Van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L. The efficacy of physiotherapy on the degree and the duration of incontinence after radical prostatectomy: a randomised controlled study. [Unpublished doctoral thesis], University of Leuven, Belgium, 1998.&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:39:41 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>van Kampen M, De Weerdt W, Van Poppel H, De Ridder D, Feys H, Baert L</AU>
<SO>The efficacy of physiotherapy on the degree and the duration of incontinence after radical prostatectomy: a randomised controlled study. [Unpublished doctoral thesis]</SO>
<YR>1998</YR>
<PB>University of Leuven</PB>
<CY>Belgium</CY>
<IDENTIFIERS MODIFIED="2013-12-18 15:39:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:39:41 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT5732"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Wille-2003" MODIFIED="2015-01-19 10:24:52 +0000" MODIFIED_BY="[Empty name]" NAME="Wille 2003" YEAR="">
<REFERENCE MODIFIED="2015-01-19 10:24:52 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{16931}&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:24:52 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wille S, Sobottka A, Heidenreich A, Hofmann R</AU>
<TI>Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: Results of a prospective randomized trial</TI>
<SO>Journal of Urology</SO>
<YR>2003</YR>
<VL>170</VL>
<NO>2 Part 1</NO>
<PG>490-3</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:40:07 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:40:07 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT16931"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:17:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wille S, Sobottka A, Olbert P, Heidenreich A, Hofmann R</AU>
<TI>Impact of electrical stimulation or biofeedback on quality of life after radical prostatectomy: Results of a prospective randomized trial (Abstract number 167)</TI>
<SO>Journal of Urology</SO>
<YR>2004</YR>
<VL>171</VL>
<NO>4 Suppl</NO>
<PG>44</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:40:26 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:40:26 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT27408"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamanishi-2006" MODIFIED="2015-01-19 10:17:46 +0000" MODIFIED_BY="[Empty name]" NAME="Yamanishi 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-01-19 10:17:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi K, Mizuno T, Sakakibara R, Uchiyama T, Ito Y, Yamamoto T, et al</AU>
<TI>A randomized, placebo-controlled, double-blind study of electrical stimulation with pelvic floor muscle training for the treatment of urinary incontinence after radical prostatectomy (Abstract number 30)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>545-6</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:40:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:40:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT26613"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:17:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yamanishi T, Mizuno T, Watanabe M, Honda M, Yoshida K-I</AU>
<TI>Randomized, placebo controlled study of electrical stimulation with pelvic floor muscle training for severe urinary incontinence after radical prostatectomy</TI>
<SO>Journal of Urology</SO>
<YR>2010</YR>
<VL>184</VL>
<NO>5</NO>
<PG>2007-12</PG>
<IDENTIFIERS MODIFIED="2013-12-18 13:58:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 13:58:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT40344"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yokoyama-2004" MODIFIED="2015-01-19 10:17:54 +0000" MODIFIED_BY="[Empty name]" NAME="Yokoyama 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-01-19 10:17:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yokoyama T, Nishiguchi J, Watanabe T, Nose H, Nozaki K, Fujita O, Inoue M, et al</AU>
<TI>Comparative study of effects of extracorporeal magnetic innervation versus electrical stimulation for urinary incontinence after radical prostatectomy</TI>
<SO>Urology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>2</NO>
<PG>264-7</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:41:05 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:41:05 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT17116"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2013-12-18 15:42:30 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-18 15:42:30 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 19042267&lt;br&gt;IN - School of Nursing, Case Western Reserve University, Cleveland, OH 44106-4904, USA. Amy.Zhang@case.edu&lt;br&gt;AS - J Psychosoc Oncol. 26(3):97-112, 2008&lt;br&gt;JC - 8309337&lt;br&gt;SB - IM&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:42:30 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang AY, Galanek J, Strauss GJ, Siminoff LA</AU>
<TI>What it would take for men to attend and benefit from support groups after prostatectomy for prostate cancer: a problem-solving approach</TI>
<SO>Journal of Psychosocial Oncology</SO>
<YR>2008</YR>
<VL>26</VL>
<NO>3</NO>
<PG>97-112</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:42:30 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:42:30 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT29254"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:41:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 17562632&lt;br&gt;IN - Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, OH, USA. amy.zhang@case.edu&lt;br&gt;AS - Oncol Nurs Forum. 34(1):47-53, 2007 Jan&lt;br&gt;JC - 7809033, 7809033&lt;br&gt;SB - IM, N&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2013-12-18 15:41:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang AY, Strauss GJ, Siminoff LA</AU>
<TI>Effects of combined pelvic floor muscle exercise and a support group on urinary incontinence and quality of life of postprostatectomy patients</TI>
<SO>Oncology Nursing Forum Online</SO>
<YR>2007</YR>
<VL>34</VL>
<NO>1</NO>
<PG>47-53</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:41:44 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:41:44 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT31506"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-12-18 15:42:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang AY, Strauss GJ, Siminoff LA</AU>
<TI>Intervention of urinary incontinence and quality of life outcome in prostate cancer patients</TI>
<SO>Journal of Psychosocial Oncology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>17-30</PG>
<IDENTIFIERS MODIFIED="2013-12-18 15:42:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 15:42:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SRINCONT22147"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-01-19 10:26:02 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett-1997" MODIFIED="2011-12-06 18:50:22 +0000" MODIFIED_BY="[Empty name]" NAME="Bennett 1997" YEAR="1997">
<REFERENCE MODIFIED="2011-12-06 18:50:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{7981}&lt;br&gt;Bennett JK, Foote JE, Green BG, Killorin EW, Martin SH. Effectiveness of biofeedback/electrostimualtion in the treatment of post prostatectomy urinary incontinence. Abstract only in the proceedings of the Urodynamics Society Annual Meeting, 1997.&lt;/p&gt;" NOTES_MODIFIED="2011-12-06 18:50:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Bennett JK, Foote JE, Green BG, Killorin EW, Martin SH</AU>
<TI>Effectiveness of biofeedback/electrostimulation in the treatment of post prostatectomy urinary incontinence [abstract]</TI>
<SO>Proceedings of the Urodynamics Society Annual Meeting</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bocker-2002" MODIFIED="2015-01-09 14:01:29 +0000" MODIFIED_BY="[Empty name]" NAME="Bocker 2002" YEAR="">
<REFERENCE MODIFIED="2015-01-09 14:01:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bocker B, Smolenski UC</AU>
<TO>Physikalische therapie der beckenbodeninsuffizienz- methodenvergleich</TO>
<SO>Journal fur Urologie und Urogynakologie</SO>
<YR>2002</YR>
<VL>2</VL>
<PG>20-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burkert-2011" MODIFIED="2014-03-03 13:51:20 +0000" MODIFIED_BY="[Empty name]" NAME="Burkert 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-03-03 13:51:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21807446&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Soc Sci Med. 73(5):783-92, 2011 Sep&lt;br&gt;JC - ut9, 8303205&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;br&gt;DC - 20110826&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 13:51:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burkert S, Scholz U, Gralla O, Roigas J, Knoll N</AU>
<TI>Dyadic planning of health-behavior change after prostatectomy: a randomized-controlled planning intervention</TI>
<SO>Social Science &amp; Medicine</SO>
<YR>2011</YR>
<VL>73</VL>
<NO>5</NO>
<PG>783-92</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="srincont46861"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Ceresoli-2002" MODIFIED="2015-01-19 10:25:08 +0000" MODIFIED_BY="[Empty name]" NAME="Ceresoli 2002" YEAR="">
<REFERENCE MODIFIED="2015-01-19 10:25:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Ceresoli A, Kartalas Goumas J, Colombo F, Barbetti E, Dell'Aglio F, Bonacina P, et al</AU>
<TI>Daily transcutaneous electrical nerve stimulation (DTENS) after radical perineal prostatectomy: A free cost effective biofeedback technique in the treatment of post operative urinary incontinence (abstract)</TI>
<SO>Proceedings of the 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30; Heidelberg, Germany</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chang-1998" NAME="Chang 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chang PL, Tsai LH, Huang ST, Hsieh ML, Tsui KH</AU>
<TI>The early effect of pelvic floor muscle exercise after transurethral prostatectomy</TI>
<SO>Journal of Urology</SO>
<YR>1998</YR>
<VL>160</VL>
<NO>2</NO>
<PG>402-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornel-2005" NAME="Cornel 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornel EB, de Wit R, Witjes JA</AU>
<TI>Evaluation of early pelvic floor physiotherapy on the duration and degree of urinary incontinence after radical retropubic prostatectomy in a non-teaching hospital</TI>
<SO>World Journal of Urology</SO>
<YR>2005</YR>
<VL>23</VL>
<PG>353-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cornu-2011" MODIFIED="2011-12-06 14:50:33 +0000" MODIFIED_BY="[Empty name]" NAME="Cornu 2011" YEAR="2011">
<REFERENCE MODIFIED="2011-12-01 14:43:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cornu JN, Merlet B, Ciofu C, Mouly S, Peyrat L, Sebe P, et al</AU>
<TI>Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial</TI>
<SO>European Urology</SO>
<YR>2011</YR>
<VL>59</VL>
<NO>1</NO>
<PG>148-54</PG>
<IDENTIFIERS MODIFIED="2011-12-01 14:43:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-01 14:43:41 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT41370"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-01 14:44:09 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Crevenna-2003" NAME="Crevenna 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crevenna R, Zoch C, Kellani M, Quittan M, Fialka-Moser V</AU>
<TI>Implementation of a physical rehabilitation group for post-prostatectomy urinary incontinence patients and its effects on quality of life</TI>
<SO>Physikalische Medicin Rehabilitationsmedizin Kurotmedizin</SO>
<YR>2003</YR>
<VL>13</VL>
<NO>6</NO>
<PG>339-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dieperink-2013" MODIFIED="2014-03-03 14:29:31 +0000" MODIFIED_BY="[Empty name]" NAME="Dieperink 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-03 14:29:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 24169342&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - Br J Cancer. 109(12):3005-13, 2013 Dec 10&lt;br&gt;JC - av4, 0370635&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20131211&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:29:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dieperink KB, Johansen C, Hansen S, Wagner L, Andersen KK, Minet LR, et al</AU>
<TI>The effects of multidisciplinary rehabilitation: RePCa-a randomised study among primary prostate cancer patients</TI>
<SO>British Journal of Cancer</SO>
<YR>2013</YR>
<VL>109</VL>
<NO>12</NO>
<PG>3005-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eren-2013" MODIFIED="2015-01-19 10:18:04 +0000" MODIFIED_BY="[Empty name]" NAME="Eren 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-17 10:22:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Alan C, Ersay AR, Eren AE, Altintas R, Kocoglu H, Basturk G</AU>
<TI>Efficacy of early duloksetin therapy in urinary incontinence occurred after radical prostatectomy (Abstract number 704)</TI>
<SO>Proceedings of the 43rd Annual Meeting of the International Continence Society (ICS), 2013 Aug 26-30, Barcelona, Spain</SO>
<YR>2013</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49727"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:18:04 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;71166244&lt;br&gt;(Eren, Alan, Bastruk) Canakkale Onsekiz Mart University, Medical Faculty, Department of Urology, Turkey&lt;br&gt;1464-4096&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201339&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:18:04 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eren AE, Alan C, Bastruk G</AU>
<TI>Efficacy of early duloxetine therapy in urinary incontinence occurred after radical prostatectomy (Abstract number 25226)</TI>
<SO>BJU International</SO>
<YR>2013</YR>
<VL>112 Suppl S1</VL>
<PG>18-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49943"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-17 10:21:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;71275194&lt;br&gt;(Eren, Ersay, Alan, Basturk) Comu Medicine Faculty, Dept. of Urology, Canakkale, Turkey&lt;br&gt;1569-9056&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201402&lt;/p&gt;" NOTES_MODIFIED="2014-02-17 10:21:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eren AE, Ersay AR, Alan C, Basturk G</AU>
<TI>Efficacy of early Duloksetin therapy in urinary incontinence occurred after radical prostatectomy (Abstract number S90)</TI>
<SO>European Urology Supplements</SO>
<YR>2013</YR>
<VL>12</VL>
<NO>4</NO>
<PG>e1198</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49916"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Filocamo-2007" MODIFIED="2015-01-19 10:18:10 +0000" MODIFIED_BY="[Empty name]" NAME="Filocamo 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-01-19 10:18:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Del Popolo G, Filocamo M, Li Marzi V, Cecconi F, Marzocco M, Nicita G</AU>
<TI>Stress incontinence after radical prostatectomy: a randomized controlled trial on combination of duloxetine and rehabilitation versus rehabilitation alone (Abstract number 29)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>6</NO>
<PG>544-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT26612"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-02-17 10:18:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 16942833&lt;br&gt;IN - Clinica Urologica II, University of Florence, Florence, Italy. mt.fil@libero.it&lt;br&gt;AS - Eur Urol. 51(6):1559-64, 2007 Jun&lt;br&gt;JC - enm, 7512719&lt;br&gt;SB - IM&lt;br&gt;CP - Switzerland&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2014-02-17 10:18:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Filocamo MT, Li Marzi V, Del Popolo G, Cecconi F, Villari D, Marzocco M, et al</AU>
<TI>Pharmacologic treatment in postprostatectomy stress urinary incontinence</TI>
<SO>European Urology</SO>
<YR>2007</YR>
<VL>51</VL>
<NO>6</NO>
<PG>1559-64</PG>
<IDENTIFIERS MODIFIED="2011-11-29 15:36:55 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-11-29 15:36:55 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="23000"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Griebling-1999" MODIFIED="2013-12-18 14:00:01 +0000" MODIFIED_BY="[Empty name]" NAME="Griebling 1999" YEAR="1999">
<REFERENCE MODIFIED="2013-12-18 14:00:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Griebling TL, Kreder KJ, Sueppel CA, See WA</AU>
<TI>Timing of biofeedback and pelvic floor muscle exercise training for men undergoing radical prostatectomy (Abstract number 322)</TI>
<SO>Proceedings of the 29th Annual Meeting of the International Continence Society; 1999 Aug 22-26; Denver, Colorado</SO>
<YR>1999</YR>
<PG>401</PG>
<IDENTIFIERS MODIFIED="2013-12-18 14:00:01 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-12-18 14:00:01 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT9928"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sueppel C, Kreder K, See W</AU>
<TI>Improved continence outcomes with preoperative pelvic floor muscle strengthening exercises</TI>
<SO>Urologic Nursing</SO>
<YR>2001</YR>
<VL>21</VL>
<PG>201-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hotston-2006" MODIFIED="2014-02-17 10:13:22 +0000" MODIFIED_BY="[Empty name]" NAME="Hotston 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-02-17 10:13:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hotston MR, Hurley K, Patel S, Persad R</AU>
<TI>The use of duloxetine for stress incontinence after prostatectomy</TI>
<SO>BJU International</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>4</NO>
<PG>916-7</PG>
<IDENTIFIERS MODIFIED="2014-02-17 10:13:22 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-17 10:13:22 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="26028"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ip-2004" NAME="Ip 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ip V</AU>
<TI>Evaluation of a patient education tool to reduce the incidence of incontinence post-prostate surgery</TI>
<SO>Urologic Nursing</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>5</NO>
<PG>401-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kahihara-2006" MODIFIED="2014-05-14 16:25:43 +0100" MODIFIED_BY="[Empty name]" NAME="Kahihara 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-05-14 16:25:43 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DA - 20061211&lt;br&gt;IS - 0004-0614 (Print)&lt;br&gt;LA - spa&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;SB - IM&lt;/p&gt;" NOTES_MODIFIED="2014-05-14 16:25:43 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kahihara CT, Ferreira U, Pedro RN, Matheus WE, Netto NR</AU>
<TI>[Early versus delayed physiotherapy in the treatment of post-prostatectomy male urinary incontinence]</TI>
<SO>Archivos Espanoles de Urologia</SO>
<YR>2006</YR>
<VL>59</VL>
<NO>8</NO>
<PG>773-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2012" MODIFIED="2014-03-03 13:54:20 +0000" MODIFIED_BY="[Empty name]" NAME="Lin 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-03 13:54:20 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21915042&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Cancer Nurs. 35(2):106-14, 2012 Mar-Apr&lt;br&gt;JC - 7805358, cnc&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20120222&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 13:54:20 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin YH, Yu TJ, Lin VC, Wang HP, Lu K</AU>
<TI>Effects of early pelvic-floor muscle exercise for sexual dysfunction in radical prostatectomy recipients</TI>
<SO>Cancer Nursing</SO>
<YR>2012</YR>
<VL>35</VL>
<NO>2</NO>
<PG>106-14</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT46858"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McGlynn-2004" MODIFIED="2015-01-19 10:25:28 +0000" MODIFIED_BY="[Empty name]" NAME="McGlynn 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-01-19 10:25:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McGlynn B, Al-Saffar N, Begg H, Gurun M, Hollins G, McPhee S, et al</AU>
<TI>Management of urinary incontinence following radical prostatectomy</TI>
<SO>Urologic Nursing</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>475-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mishel-2002" MODIFIED="2014-03-03 14:27:22 +0000" MODIFIED_BY="[Empty name]" NAME="Mishel 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-03-03 14:27:22 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - MEDLINE&lt;br&gt;UI - 11920549&lt;br&gt;IN - School of Nursing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA. mishel@email.unc.edu&lt;br&gt;AS - Cancer 2002 Mar 15;94(6):1854-66&lt;br&gt;JC - 0374236, clz&lt;br&gt;SB - AIM, IM&lt;br&gt;CP - United States&lt;br&gt;PT - Clinical Trial&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;LG - English&lt;br&gt;NO - R01 NR/CA03782 (NINR)&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:27:22 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mishel MH, Belyea M, Germino BB, Stewart JL, Bailey DE Jr, Robertson C, et al</AU>
<TI>Helping patients with localized prostate carcinoma manage uncertainty and treatment side effects: nurse-delivered psychoeducational intervention over the telephone</TI>
<SO>Cancer</SO>
<YR>2002</YR>
<VL>94</VL>
<NO>6</NO>
<PG>1854-66</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont15336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nehra-2001" MODIFIED="2015-01-19 10:25:43 +0000" MODIFIED_BY="[Empty name]" NAME="Nehra 2001" YEAR="">
<REFERENCE MODIFIED="2015-01-19 10:25:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nehra A, Rovner E, Wein A, Lange P, Ellis W, Keane R, et al</AU>
<TI>Interim analysis of a multi-center study of extracorporeal magnetic innervation (ExMI) for the treatment of urinary incontinence following radical prostatectomy (Abstract)</TI>
<SO>Proceedings of the 31st Annual Meeting of the International Continence Society; 2001 Sept 18-21; Seoul, Korea</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ottenbacher-2013" MODIFIED="2014-02-17 10:27:02 +0000" MODIFIED_BY="[Empty name]" NAME="Ottenbacher 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-02-17 10:27:02 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22879576&lt;br&gt;ST - In-Process&lt;br&gt;AS - Integ Cancer Ther. 12(3):206-12, 2013 May&lt;br&gt;JC - 101128834&lt;br&gt;CP - United States&lt;br&gt;PT - Clinical Trial, Phase II&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;NO - CA63782 (United States NCI NIH HHS)&lt;br&gt;NO - CA74000 (United States NCI NIH HHS)&lt;br&gt;NO - M01-RR-30 (United States NCRR NIH HHS)&lt;br&gt;NO - R01 CA081191 (United States NCI NIH HHS)&lt;br&gt;NO - R01 CA81191 (United States NCI NIH HHS)&lt;br&gt;LG - English&lt;br&gt;DC - 20130419&lt;/p&gt;" NOTES_MODIFIED="2014-02-17 10:27:02 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ottenbacher A, Sloane R, Snyder DC, Kraus W, Sprod L, Demark-Wahnefried W</AU>
<TI>Cancer-specific concerns and physical activity among recently diagnosed breast and prostate cancer survivors</TI>
<SO>Integrative Cancer Therapies</SO>
<YR>2013</YR>
<VL>12</VL>
<NO>3</NO>
<PG>206-12</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont50477"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pemberton-2006" MODIFIED="2009-10-23 10:46:43 +0100" MODIFIED_BY="[Empty name]" NAME="Pemberton 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-10-23 10:46:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pemberton P, Brooks A, Eriksen CM, Frost S, Graham S, Greenman L, et al</AU>
<TI>A comparative study of two types of urinary sheath</TI>
<SO>Nursing Times</SO>
<YR>2006</YR>
<VL>102</VL>
<NO>7</NO>
<PG>36-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prota-2012" MODIFIED="2014-03-03 14:17:09 +0000" MODIFIED_BY="[Empty name]" NAME="Prota 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-03 14:17:09 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22573231&lt;br&gt;ST - In-Process&lt;br&gt;AS - Int J Impot Res. 24(5):174-8, 2012 Sep&lt;br&gt;JC - bux, 9007383&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Research Support, Non-U.S. Gov't&lt;br&gt;LG - English&lt;br&gt;DC - 20120914&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:17:09 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prota C, Gomes CM, Ribeiro LH, de Bessa J Jr, Nakano E, Dall'Oglio M, et al</AU>
<TI>Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial</TI>
<SO>International Journal of Impotence Research</SO>
<YR>2012</YR>
<VL>24</VL>
<NO>5</NO>
<PG>174-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT45891"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pulker-2002" MODIFIED="2008-10-28 14:33:06 +0000" MODIFIED_BY="[Empty name]" NAME="Pulker 2002" YEAR="">
<REFERENCE MODIFIED="2008-10-28 14:33:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pulker E</AU>
<TI>Long term results of physiotherapy in men with urinary stress incontinence after radical prostatectomy (Abstract)</TI>
<SO>Proceedings of the 32nd Annual Meeting of the International Continence Society; 2002 Aug 28-30; Heidelburg, Germany</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ribeiro-2013" MODIFIED="2014-05-14 16:26:59 +0100" MODIFIED_BY="[Empty name]" NAME="Ribeiro 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-14 16:26:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ribeiro AM, Oliveira HF</AU>
<TI>Pelvic Floor Muscles Training in Urinary Disorders in Men With Prostate Cancer Undergoing Radiotherapy</TI>
<SO>http://clinicaltrials.gov/show/NCT01762956</SO>
<YR>2013</YR>
<IDENTIFIERS MODIFIED="2014-05-14 16:26:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:26:33 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT01762956"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47831"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:26:59 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:26:59 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01762956"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ricci-2004-NEWa" MODIFIED="2015-01-19 10:18:20 +0000" MODIFIED_BY="[Empty name]" NAME="Ricci 2004 NEWa" YEAR="2004">
<REFERENCE MODIFIED="2015-01-19 10:18:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ricci L, Minardi D, Romoli M, Galosi AB, Muzzonigro G</AU>
<TI>Acupuncture reflexotherapy in the treatment of sensory urgency that persists after transurethral resection of the prostate: a preliminary report</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>1</NO>
<PG>58-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT16645"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-2012" MODIFIED="2015-01-19 10:18:29 +0000" MODIFIED_BY="[Empty name]" NAME="Robinson 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-01-19 10:18:29 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22825573&lt;br&gt;ST - In-Process&lt;br&gt;AS - J Wound Ostomy Continence Nurs. 39(5):545-51, 2012 Sep-Oct&lt;br&gt;JC - bv2, 9435679&lt;br&gt;CP - United States&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20120907&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:18:29 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Robinson JP, Burrell SA, Avi-Itzhak T, McCorkle R</AU>
<TI>Validity testing of the stopwatch urine stream interruption test in radical prostatectomy patients</TI>
<SO>Journal of Wound, Ostomy &amp; Continence Nursing</SO>
<YR>2012</YR>
<VL>39</VL>
<NO>5</NO>
<PG>545-51</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT45900"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salinas-Casado-1991" MODIFIED="2015-01-19 10:26:02 +0000" MODIFIED_BY="[Empty name]" NAME="Salinas Casado 1991" YEAR="">
<REFERENCE MODIFIED="2015-01-19 10:26:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salinas Casado J, Varela E, Prieto Chaparro L, Virseda Rodriguez M, Salomon S, Guerrero A, et al</AU>
<TI>Results of perineal electric stimulation in stress urinary incontinence</TI>
<TO>Resultatos de la estimulacion electrica perineal en la incontinencia urinaria de esfuerzo</TO>
<SO>Archivos Espanoles di Urologia</SO>
<YR>1991</YR>
<VL>44</VL>
<NO>4</NO>
<PG>437-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salinas-Casado-1996" NAME="Salinas Casado 1996" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salinas Casado J, Virseda Chamorro M, Salomon Mohamed S, Bravo de Rueda C, Aristizabal JM, Resel Estevez L</AU>
<TI>Results of electrical stimulation in the treatment of post-prostatectomy urinary incontinence</TI>
<SO>Actas Urologicas Espanolas</SO>
<YR>1996</YR>
<VL>20</VL>
<NO>6</NO>
<PG>544-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seki-2005" NAME="Seki 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Seki N, Kai N, Takano N, Naito S, Kawajiri M, Kira J, Tobimatsu S</AU>
<TI>Efficacy of high-frequency magnetic stimulation of the sacral root in patients with stress urinary incontinence following radical prostatectomy [abstract]</TI>
<SO>35th Annual Meeting of International Continence Society; 2005 Aug 29 - Sep 2; Montreal, Canada</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shen-2012-NEWa" MODIFIED="2015-01-19 10:18:35 +0000" MODIFIED_BY="[Empty name]" NAME="Shen 2012 NEWa" YEAR="2012">
<REFERENCE MODIFIED="2015-01-19 10:18:35 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - CCTR&lt;br&gt;AN - CN-00842207 NEW&lt;br&gt;PT - English Abstract. Journal Article. Randomized Controlled Trial. Research Support, Non-U.S. Gov't&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:18:35 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shen YZ, Lin X, Lin Q</AU>
<TI>[Overactive bladder after transurethral resection of prostate treated with electroacupuncture therapy and tolterodine]</TI>
<SO>Zhongguo Zhen Jiu = Chinese acupuncture &amp; moxibustion</SO>
<YR>2012</YR>
<VL>32</VL>
<NO>5</NO>
<PG>404-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT47454"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Traeger-2013" MODIFIED="2014-03-03 14:19:53 +0000" MODIFIED_BY="[Empty name]" NAME="Traeger 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-03-03 14:19:53 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21932396&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Psychooncology. 22(2):250-9, 2013 Feb&lt;br&gt;JC - cps, 9214524&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Randomized Controlled Trial&lt;br&gt;PT - Research Support, N.I.H., Extramural&lt;br&gt;NO - 1P50CA84944 (United States NCI NIH HHS)&lt;br&gt;NO - U01CA861 (United States NCI NIH HHS)&lt;br&gt;LG - English&lt;br&gt;DC - 20130204&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:19:53 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Traeger L, Penedo FJ, Benedict C, Dahn JR, Lechner SC, Schneiderman N, et al</AU>
<TI>Identifying how and for whom cognitive-behavioral stress management improves emotional well-being among recent prostate cancer survivors</TI>
<SO>Psycho-Oncology</SO>
<YR>2013</YR>
<VL>22</VL>
<NO>2</NO>
<PG>250-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont48709"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yang-2010-NEWa" MODIFIED="2014-03-03 14:31:28 +0000" MODIFIED_BY="[Empty name]" NAME="Yang 2010 NEWa" YEAR="2010">
<REFERENCE MODIFIED="2014-03-03 14:31:28 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21092614&lt;br&gt;ST - MEDLINE&lt;br&gt;AS - Chung Hua Wai Ko Tsa Chih. 48(17):1325-7, 2010 Sep 1&lt;br&gt;JC - d86, 0153611&lt;br&gt;CP - China&lt;br&gt;PT - Controlled Clinical Trial&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;LG - Chinese&lt;br&gt;DC - 20101124&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:31:28 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yang BS, Ye DW, Yao XD, Peng JY, Zhang SL, Dai B, et al</AU>
<TI>[The study of electrical acupuncture stimulation therapy combined with pelvic floor muscle therapy for postprostatectomy incontinence]. [Chinese]</TI>
<SO>Chung-Hua Wai Ko Tsa Chih [Chinese Journal of Surgery]</SO>
<YR>2010</YR>
<VL>48</VL>
<NO>17</NO>
<PG>1325-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT42595"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2012" MODIFIED="2014-02-17 10:24:31 +0000" MODIFIED_BY="[Empty name]" NAME="Yao 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-02-17 10:24:31 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70836066&lt;br&gt;(Yao) Urological Cancer Outcomes Centre, Westmead Hospital, University of Sydney, Sydney, Australia (Hirschhorn, Mungovan) Westmead Private Physiotherapy Services, Westmead Private Hospital, Westmead, Australia (Patel) Urological Cancer Outcomes Centre, Discipline of Surgery, University of Sydney, Sydney, Australia&lt;br&gt;0733-2467&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201235&lt;/p&gt;" NOTES_MODIFIED="2014-02-17 10:24:31 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Yao J, Hirschhorn AD, Mungovan SF, Patel MI</AU>
<TI>Preoperative pelvic floor physiotherapy improves continence following radical prostatectomy (Abstract number 182)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31</VL>
<NO>6</NO>
<PG>964-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont50072"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zahariou-2009" MODIFIED="2014-03-03 14:34:17 +0000" MODIFIED_BY="[Empty name]" NAME="Zahariou 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-03 14:34:17 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Times Cited: 0&lt;br&gt;ELSEVIER SCIENCE BV&lt;br&gt;PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS&lt;br&gt;AMSTERDAM&lt;br&gt;Meeting Abstract&lt;br&gt;630PL&lt;br&gt;English&lt;br&gt;Cited References Count: 0&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 14:34:17 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zahariou A, Kyriakides A</AU>
<TI>Intensive pelvic floor muscle training after radical prostatectomy improves continence outcomes (Abstract number S40)</TI>
<SO>European Urology Supplements</SO>
<YR>2009</YR>
<VL>8</VL>
<NO>8</NO>
<PG>620</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49168"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zermann-1999" MODIFIED="2011-12-06 18:53:11 +0000" MODIFIED_BY="[Empty name]" NAME="Zermann 1999" YEAR="">
<REFERENCE MODIFIED="2008-10-28 14:37:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Zermann DH, Ishgooka M, Wunderlich H, Wilhelm S, Schubert J</AU>
<TI>Post-prostatectomy incontinence and pelvic floor dysfunction (abstract)</TI>
<SO>Proceedings of the 29th Annual Meeting of the International Continence Society; 1999 Aug 22-26; Denver, Colorado</SO>
<YR>1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2011-12-06 18:53:11 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zermann DH, Ishigooka M, Wunderlich H, Reichelt O, Schubert J</AU>
<TI>A study of pelvic floor function pre-and post radical prostatectomy using clinical neurourological investigations, urodynamics and electromyography</TI>
<SO>European Urology</SO>
<YR>2000</YR>
<VL>37</VL>
<PG>72-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2009" MODIFIED="2014-05-14 16:27:51 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-05-14 13:40:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Zhang A, O'Neill J</AU>
<TI>Improving Continence and Quality of Life in Prostate Cancer Patients (StayDry)</TI>
<SO>http://clinicaltrials.gov/show/NCT01365182</SO>
<YR>2009</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01365182"/>
<IDENTIFIER TYPE="OTHER" VALUE="StayDry"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47806"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:27:51 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:27:51 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01365182"/>
</IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2015-01-19 10:19:16 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Crivellaro-2011" MODIFIED="2015-01-19 10:18:54 +0000" MODIFIED_BY="[Empty name]" NAME="Crivellaro 2011" YEAR="2011">
<REFERENCE MODIFIED="2015-01-19 10:18:44 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70806690&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201230&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:18:44 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abbinante M, Crivellaro S, Palazzetti A, Tosco L, Frea B</AU>
<TI>Efficacy of ultrasound-guided pelvic muscle training (Abstract number 45)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2012</YR>
<VL>31 Suppl 1</VL>
<PG>S35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47301"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:18:49 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70863090&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201238&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:18:49 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Crivellaro S, Abbinante M, Palazzetti A, Tosco L, Frea B</AU>
<TI>Efficacy of ultrasound-guided pelvic muscle training (Abstract number 285)</TI>
<SO>European Urology Supplements</SO>
<YR>2012</YR>
<VL>11</VL>
<NO>1</NO>
<PG>e285a</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47272"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-01-19 10:18:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;70530403&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201100&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:18:54 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Crivellaro S, Lorenzo T, Abbinante M, Martinez G, Palazzetti A, Frea B</AU>
<TI>Efficacy of pelvic training under transrectal ultrasonography (Abstract number 16)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2011</YR>
<VL>30 Suppl 1</VL>
<PG>13-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47397"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Delmastro-2010" MODIFIED="2015-01-19 10:19:00 +0000" MODIFIED_BY="[Empty name]" NAME="Delmastro 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-01-19 10:19:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Delmastro F, Marchisio C, Lamberti G, Giraudo D</AU>
<TI>Urinary incontinence after radical prostatectomy: a randomized controlled trial comparing preoperative intensive pelvic muscle exercises with or without proprioceptive training (Abstract)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2010</YR>
<VL>29</VL>
<NO>2 Suppl</NO>
<PG>62-3</PG>
<IDENTIFIERS MODIFIED="2011-12-01 14:45:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-01 14:45:13 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SR-INCONT39878"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-12-01 14:45:21 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lilli-2006-NEW" MODIFIED="2014-04-03 09:46:09 +0100" MODIFIED_BY="[Empty name]" NAME="Lilli 2006 NEW" YEAR="2006">
<REFERENCE MODIFIED="2014-04-03 09:46:09 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lilli P, Mercuriali M, Fiori M, Hanitzsch H, Gunelli R, Bercovich E</AU>
<TI>Impact of preoperative biofeedback on incontinence in cancer patients undergoing radical prostatectomy</TI>
<SO>Archivio Italiano di Urologia e Andrologia</SO>
<YR>2006</YR>
<VL>78</VL>
<NO>3</NO>
<PG>92-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT25089"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Simeit-2010-NEW" MODIFIED="2015-01-17 08:59:33 +0000" MODIFIED_BY="[Empty name]" NAME="Simeit 2010 NEW" YEAR="2010">
<REFERENCE MODIFIED="2015-01-17 08:59:33 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 20533148&lt;br&gt;ST - MEDLINE&lt;br&gt;OT - Die Lebensqualitat und die Bedeutung der Inkontinenz bei Mannern mit Prostatakarzinom nach radikaler retropubischer Prostatektomie&lt;br&gt;AS - Rehabilitation (Stuttg). 49(3):180-9, 2010 Jun&lt;br&gt;JC - 0401273, r3p, 0401273&lt;br&gt;CP - Germany&lt;br&gt;PT - Comparative Study&lt;br&gt;PT - Controlled Clinical Trial&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;LG - German&lt;/p&gt;" NOTES_MODIFIED="2015-01-17 08:59:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Simeit R, Deck R, Drechsler T, Fiedrich M, Schonrock-Nabulsi P</AU>
<TI>[Quality of life and impact of incontinence in male patients with prostate carcinoma after radical retropubic prostatectomy]. [German]</TI>
<SO>Rehabilitation</SO>
<YR>2010</YR>
<VL>49</VL>
<NO>3</NO>
<PG>180-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT40661"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zellner-2011-NEW" MODIFIED="2014-04-02 11:25:41 +0100" MODIFIED_BY="[Empty name]" NAME="Zellner 2011 NEW" YEAR="2011">
<REFERENCE MODIFIED="2014-04-02 11:25:41 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 21472620&lt;br&gt;ST - In-Process&lt;br&gt;OT - Inkontinenz nach radikaler Prostatektomie und Zystektomie : Sind apparatives Kombinationstraining und Ganzkorpervibration effektiv?&lt;br&gt;AS - Urologe A. 50(4):433-44, 2011 Apr&lt;br&gt;JC - wsj, 1304110&lt;br&gt;CP - Germany&lt;br&gt;PT - English Abstract&lt;br&gt;PT - Journal Article&lt;br&gt;LG - German&lt;br&gt;DC - 20110407&lt;/p&gt;" NOTES_MODIFIED="2014-04-02 11:25:41 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zellner M</AU>
<TI>[Incontinence after radical prostatectomy and cystectomy: are combined training with mechanical devices and whole body vibration effective?]. [German]</TI>
<SO>Urologe (Ausg.A)</SO>
<YR>2011</YR>
<VL>50</VL>
<NO>4</NO>
<PG>433-44</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT41808"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2013" MODIFIED="2015-01-19 10:19:16 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-01-19 10:19:16 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;71175981&lt;br&gt;(Zhang) Case Western Reserve University, Cleveland, OH, United States&lt;br&gt;1057-9249&lt;br&gt;English&lt;br&gt;Journal: Conference Abstract&lt;br&gt;201340&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:19:16 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang A</AU>
<TI>The problem-solving therapy and urinary incontinence in prostate cancer patients (Abstract number 14-5)</TI>
<SO>Psycho-Oncology</SO>
<YR>2013</YR>
<VL>22 Suppl 2</VL>
<PG>33-4</PG>
<IDENTIFIERS MODIFIED="2014-05-14 16:28:34 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:28:34 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NCT01365182"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49941"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:28:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:28:46 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01365182"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2015-01-19 10:26:34 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Burnett-2012" MODIFIED="2015-01-19 10:26:17 +0000" MODIFIED_BY="[Empty name]" NAME="Burnett 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-01-19 10:26:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01748110, Burnett AL, Segal RL, Cheskin LJ, Blitz JU</AU>
<TI>Health Interventions in Men Undergoing Radical Prostatectomy - A Randomized Controlled Clinical Trial</TI>
<SO>http://clinicaltrials.gov/show/NCT01748110</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 11:50:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 11:50:46 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01748110"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burnett-2013" MODIFIED="2015-01-19 10:26:34 +0000" MODIFIED_BY="[Empty name]" NAME="Burnett 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-01-19 10:26:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Burnett AL, Tajkarimi K</AU>
<TI>Study of non-invasive Viberect© penile vibratory stimulation regimen to enhance recovery of erectile function/rigidity and urinary control/continence after nerve sparing radical prostatectomy (RP) for clinically localized prostate cancer</TI>
<SO>http://clinicaltrials.gov/show/NCT01718704</SO>
<YR>2013</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01718704"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49360"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:29:29 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:29:29 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01718704"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fode-2012-NEW" MODIFIED="2014-05-14 16:30:03 +0100" MODIFIED_BY="[Empty name]" NAME="Fode 2012 NEW" YEAR="2012">
<REFERENCE MODIFIED="2014-05-14 13:41:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Fode M</AU>
<TI>Mechanical nerve stimulation in the treatment of post prostatectomy incontinence</TI>
<SO>http://clinicaltrials.gov/show/NCT01540656</SO>
<YR>2012</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01540656"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49358"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:30:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:30:03 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01540656"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-2014" MODIFIED="2014-05-14 16:30:38 +0100" MODIFIED_BY="[Empty name]" NAME="Goode 2014" YEAR="2014">
<REFERENCE MODIFIED="2014-05-14 13:42:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Goode PS</AU>
<TI>Perioperative Post-Prostatectomy Incontinence Home Telehealth Program (ProsTel)</TI>
<SO>http://clinicaltrials.gov/show/NCT01960998</SO>
<YR>2014</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01960998"/>
<IDENTIFIER TYPE="OTHER" VALUE="ProsTel"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont49364"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:30:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:30:38 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01960998"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mina-2013" MODIFIED="2014-05-14 16:33:57 +0100" MODIFIED_BY="[Empty name]" NAME="Mina 2013" YEAR="2013">
<REFERENCE MODIFIED="2014-05-14 13:42:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT02036684, Mina DS, Matthew AG, Carli F</AU>
<TI>A Multicentre, Pilot Randomized Controlled Trial to Examine the Effects of Prehabilitation on Functional Outcomes After Radical Prostatectomy</TI>
<SO>http://clinicaltrials.gov/show/NCT02036684</SO>
<YR>2013</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:33:57 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:33:57 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT02036684"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ng-2011" MODIFIED="2014-05-14 16:34:47 +0100" MODIFIED_BY="[Empty name]" NAME="Ng 2011" YEAR="2011">
<REFERENCE MODIFIED="2014-05-14 13:42:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ng S-I</AU>
<TI>A Randomized Controlled Trial Study of the Efficacy of Intensive Preoperative Pelvic Floor Muscle Training to Decrease Post-prostatectomy Urinary Incontinence</TI>
<SO>http://clinicaltrials.gov/show/NCT01338584</SO>
<YR>2011</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT01338584"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47833"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:34:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:34:47 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT01338584"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terrone-2007" MODIFIED="2014-05-14 16:36:13 +0100" MODIFIED_BY="[Empty name]" NAME="Terrone 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-05-14 13:42:43 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Terrone C, Cisari C</AU>
<TI>Prevention of Urinary Incontinence After Prostatectomy</TI>
<SO>http://clinicaltrials.gov/show/NCT00982098</SO>
<YR>2007</YR>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NCT00982098"/>
<IDENTIFIER TYPE="OTHER" VALUE="sr-incont47873"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:36:13 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:36:13 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00982098"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zopf-2012" MODIFIED="2014-05-14 16:36:56 +0100" MODIFIED_BY="[Empty name]" NAME="Zopf 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-03-03 15:29:36 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 22827935&lt;br&gt;ST - In-Data-Review&lt;br&gt;AS - BMC Cancer. 12:312, 2012&lt;br&gt;JC - 100967800&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;br&gt;DC - 20120809&lt;/p&gt;" NOTES_MODIFIED="2014-03-03 15:29:36 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zopf EM, Braun M, Machtens S, Zumbe J, Bloch W, Baumann FT</AU>
<TI>Implementation and scientific evaluation of rehabilitative sports groups for prostate cancer patients: study protocol of the ProRehab Study</TI>
<SO>BMC Cancer</SO>
<YR>2012</YR>
<VL>12</VL>
<PG>312</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="DRKS00004184"/>
<IDENTIFIER TYPE="OTHER" VALUE="SR-INCONT45125"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2014-05-14 16:36:56 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 16:36:56 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="DRKS00004184"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-01-19 10:41:00 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-01-19 10:41:00 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aboseif-1996" NAME="Aboseif 1996" NOTES="&lt;p&gt;Aboseif SR, O'Connell HE, Usui A, McGuire EJ. Collagen injection for intrinsic sphincteric deficiency in men. J Urol 1996;155:10-3.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Aboseif SR, O'Connell HE, Usui A, McGuire EJ</AU>
<TI>Collagen injection for intrinsic sphincteric deficiency in men</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>155</VL>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Abrams-1991" NAME="Abrams 1991" NOTES="&lt;p&gt;Abrams PH. Investigation of post prostatectomy problems. Urol 1991;15:209-12.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Abrams PH</AU>
<TI>Investigation of post prostatectomy problems</TI>
<SO>Urology</SO>
<YR>1991</YR>
<VL>15</VL>
<PG>209-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Albertsen-1997" MODIFIED="2015-01-19 10:19:25 +0000" MODIFIED_BY="[Empty name]" NAME="Albertsen 1997" NOTES="&lt;p&gt;Albertsen PC, Lu-Yao GL, Warren J. Risk of complication and readmission associated with radical prostatectomy in community practice: A Medicare claims analysis. J Urol 1997;157(Suppl 4):93.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:19:25 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Albertsen PC, Lu-Yao GL, Warren J</AU>
<TI>Risk of complication and readmission associated with radical prostatectomy in community practice: A Medicare claims analysis</TI>
<SO>Journal of Urology</SO>
<YR>1997</YR>
<VL>157 Suppl 4</VL>
<PG>93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-2013" MODIFIED="2015-01-19 10:19:31 +0000" MODIFIED_BY="[Empty name]" NAME="Altman 2013" TYPE="BOOK_SECTION">
<AU>Altman D, Cartwright R, Lapitan MC, Nelson R, Sillen U, Tikkinen K</AU>
<TI>Epidemiology of Urinary Incontinence (UI) and other Lower Urinary tract Symptoms (LUTS), Pelvic organ Prolapse (POP) and Anal Incontinence (AI)</TI>
<SO>Incontinence: 5th International Consultation on Incontinence. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence; 2012 Feb 23-25; Paris</SO>
<YR>2013</YR>
<PG>27-9</PG>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>International Consultation on Urological Diseases</PB>
<CY>Belgium</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-1998" NAME="Berghmans 1998" NOTES="&lt;p&gt;Berghmans LC, Hendriks, HJ, Bo K, Hay-Smith EJ, de Bie RA, van Waalwijk van Doorn ES. Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials. BJU 1998;82:181-91.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Berghmans LC, Hendriks HJ, Bo K, Hay-Smith EJ, de Bie RA, van Waalwijk van Doorn ES</AU>
<TI>Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials</TI>
<SO>British Journal of Urology</SO>
<YR>1998</YR>
<VL>82</VL>
<PG>181-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berghmans-2013" MODIFIED="2014-05-14 13:36:11 +0100" MODIFIED_BY="[Empty name]" NAME="Berghmans 2013" TYPE="COCHRANE_REVIEW">
<AU>Berghmans B, Hendriks E, Bernards A, de Bie R, Omar MI</AU>
<TI>Electrical stimulation with non-implanted electrodes for urinary incontinence in men</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>13</YR>
<NO>6</NO>
<IDENTIFIERS MODIFIED="2014-05-14 13:36:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-05-14 13:36:11 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001202.pub5"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Burnett-1998" MODIFIED="2015-01-19 10:19:38 +0000" MODIFIED_BY="[Empty name]" NAME="Burnett 1998" TYPE="JOURNAL_ARTICLE">
<AU>Burnett AL, Mostwin JL</AU>
<TI>In situ anatomical study of the male urethral sphincteric complex: relevance to continence preservation following major pelvic surgery</TI>
<SO>Journal of Urology</SO>
<YR>1998</YR>
<VL>160</VL>
<NO>4</NO>
<PG>1301-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chao-1995" NAME="Chao 1995" NOTES="&lt;p&gt;Chao R, Mayo ME. Incontinence after radical prostatectomy: Detrusor or sphincter causes? J Urol 1995;154:16-8.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chao R, Mayo ME</AU>
<TI>Incontinence after radical prostatectomy: Detrusor or sphincter causes?</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>154</VL>
<PG>16-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donnellan-1997" MODIFIED="2015-01-19 10:26:48 +0000" MODIFIED_BY="[Empty name]" NAME="Donnellan 1997" NOTES="&lt;p&gt;{9905} libbu&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:26:48 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Donnellan SM, Duncan HJ, MacGregor RJ, Russell JM</AU>
<TI>Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis</TI>
<SO>Urology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>2</NO>
<PG>225-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eastham-1996" MODIFIED="2015-01-19 10:27:29 +0000" MODIFIED_BY="[Empty name]" NAME="Eastham 1996" NOTES="&lt;p&gt;Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156(5):1707-13.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:27:29 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Eastham JA, Kattan MW, Rogers E, Goad JR, Ohori M, Boone TB, et al</AU>
<TI>Risk factors for urinary incontinence after radical prostatectomy</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>156</VL>
<NO>5</NO>
<PG>1707-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fader-2007" MODIFIED="2011-12-06 14:47:48 +0000" MODIFIED_BY="[Empty name]" NAME="Fader 2007" TYPE="COCHRANE_REVIEW">
<AU>Fader M, Cottenden Alan M, Getliffe K</AU>
<TI>Absorbent products for light urinary incontinence in women</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2011-12-06 14:47:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001406.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD001406"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Fader-2008" MODIFIED="2011-12-06 14:47:48 +0000" MODIFIED_BY="[Empty name]" NAME="Fader 2008" TYPE="COCHRANE_REVIEW">
<AU>Fader M, Cottenden Alan M, Getliffe K</AU>
<TI>Absorbent products for moderate-heavy urinary and/or faecal incontinence in women and men</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2011-12-06 14:47:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD007408"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD007408"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ficazzola-1998" NAME="Ficazzola 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ficazzola MA, Nitti VW</AU>
<TI>The etiology of post-radical prostatectomy incontinence and correlation of symptoms with urodynamic findings</TI>
<SO>Journal of Urology</SO>
<YR>1998</YR>
<VL>160</VL>
<PG>1317-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galloway-2000" NAME="Galloway 2000" TYPE="JOURNAL_ARTICLE">
<AU>Galloway N, El-Galley R, Sand P, Appell R, Russell H, Carlan S</AU>
<TI>Update on extracorporeal magnetic innervation (ExMI) therapy for stress urinary incontinence</TI>
<SO>Urology</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>6A</NO>
<PG>82-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Golubuff-1995" NAME="Golubuff 1995" NOTES="&lt;p&gt;Golubuff ET, Chang DT, Olsson CA, Kaplan SA. Urodynamics and the etiology of post-prostatectomy urinary incontinence: The initial Columbia experience. J Urol 1995;153:1034-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Golubuff ET, Chang DT, Olsson CA, Kaplan SA</AU>
<TI>Urodynamics and the etiology of post-prostatectomy urinary incontinence: The initial Columbia experience</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>153</VL>
<PG>1034-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grise-2001" NAME="Grise 2001" TYPE="JOURNAL_ARTICLE">
<AU>Grise P, Thurman S</AU>
<TI>Urinary incontinence following treatment of localized prostate cancer</TI>
<SO>Cancer Control</SO>
<YR>2001</YR>
<VL>8</VL>
<NO>6</NO>
<PG>532-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Groutz-2000" NAME="Groutz 2000" TYPE="JOURNAL_ARTICLE">
<AU>Groutz A, Blaivais JG, Chaikin DC, Weiss JP, Verhaaren M</AU>
<TI>The pathophysiology of post-radical prostatectomy incontinence: a clinical and video urodynamic study</TI>
<SO>Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<NO>6</NO>
<PG>1767-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gudziak-1996" NAME="Gudziak 1996" NOTES="&lt;p&gt;Gudziak MR, McGuire EJ, Gormley EA. Urodynamic assessment of urethral sphincter function in post-prostatectomy incontinence. J Urol 1996;156:1131-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gudziak MR, McGuire EJ, Gormley EA</AU>
<TI>Urodynamic assessment of urethral sphincter function in post-prostatectomy incontinence</TI>
<SO>Journal of Urology</SO>
<YR>1996</YR>
<VL>156</VL>
<PG>1131-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011a" MODIFIED="2014-05-27 11:07:59 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A</AU>
<TI>GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>4</NO>
<PG>380-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2011b" MODIFIED="2014-05-27 11:08:06 +0100" MODIFIED_BY="[Empty name]" NAME="Guyatt 2011b" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Sultan S, Glasziou P, Akl EA, Alonso-Coello P, et al</AU>
<TI>GRADE guidelines: 9. Rating up the quality of evidence</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>12</NO>
<PG>1311-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013" MODIFIED="2015-01-19 10:26:57 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2013" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al</AU>
<TI>GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles - continuous outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>173-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2013a" MODIFIED="2015-01-19 10:27:41 +0000" MODIFIED_BY="[Empty name]" NAME="Guyatt 2013a" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Santesso N, Helfand M, Vist G, Kunz R, et al</AU>
<TI>GRADE guidelines: 12. Preparing Summary of Findings tables - binary outcomes</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2013</YR>
<VL>66</VL>
<NO>2</NO>
<PG>158-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2015-01-19 10:19:46 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" NOTES="&lt;p&gt;I-squared statistic&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:19:46 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2015-01-19 10:28:12 +0000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunskaar-2002" NAME="Hunskaar 2002" TYPE="CONFERENCE_PROC">
<AU>Hunskaar S, Burgio K, Diokno AC, Herzog AR, Hjalmas K, Lapitan MC</AU>
<TI>Epidemiology and natural history of urinary incontinence</TI>
<SO>Incontinence: 2nd International Consultation on Incontinence</SO>
<YR>2002</YR>
<PG>165-200</PG>
<EN>2nd</EN>
<ED>Abrams P, Cardozo L, Khoury S, Wein A</ED>
<PB>Health Publications</PB>
<CY>Plymouth, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jabs-2001" MODIFIED="2014-05-14 13:31:56 +0100" MODIFIED_BY="[Empty name]" NAME="Jabs 2001" NOTES="&lt;p&gt;UI - 21190055&lt;br&gt;LA - eng&lt;br&gt;PT - Journal Article&lt;br&gt;PT - Review&lt;br&gt;PT - Review, Tutorial&lt;br&gt;DA - 20010410&lt;br&gt;IS - 0937-3462&lt;br&gt;SB - IM&lt;br&gt;CY - England&lt;/p&gt;" NOTES_MODIFIED="2014-05-14 13:31:56 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Jabs CF, Stanton SL</AU>
<TI>Urge incontinence and detrusor instability</TI>
<SO>International Urogynecology Journal and Pelvic Floor Dysfunction</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>1</NO>
<PG>58-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jacobsen-2007" NAME="Jacobsen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Jacobsen NE, Moore KN, Estey E, Voaklander D</AU>
<TI>Open versus laparoscopic radical prostatectomy: a prospective comparison of postoperative urinary incontinence rates</TI>
<SO>Journal of Urology</SO>
<YR>2007</YR>
<VL>177</VL>
<NO>2</NO>
<PG>615-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jahn-2007" MODIFIED="2011-12-06 14:47:48 +0000" MODIFIED_BY="[Empty name]" NAME="Jahn 2007" TYPE="COCHRANE_REVIEW">
<AU>Jahn P, Preuss M, Kernig A, Langer G, Seifert-Huehmer A</AU>
<TI>Types of indwelling urinary catheters for long-term bladder drainage in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2011-12-06 14:47:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004997.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD004997"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Juni-2001" NAME="Juni 2001" TYPE="BOOK_SECTION">
<AU>Juni P, Altman DG, Egger M</AU>
<TI>Assessing the quality of randomized controlled trials</TI>
<SO>Systematic Reviews in Health Care: Meta-analysis in context</SO>
<YR>2001</YR>
<PG>87-108</PG>
<EN>2nd</EN>
<ED>Egger M, Davey Smith G, Altman DG</ED>
<PB>BMJ Books</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khan-1991" NAME="Khan 1991" TYPE="JOURNAL_ARTICLE">
<AU>Khan Z, Mieza M, Starer P, Singh VK</AU>
<TI>Post-prostatectomy incontinence. A urodynamic and fluoroscopic point of view</TI>
<SO>Urology</SO>
<YR>1991</YR>
<VL>38</VL>
<NO>5</NO>
<PG>483-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kondo-2002" NAME="Kondo 2002" TYPE="CONFERENCE_PROC">
<AU>Kondo A, Lin TL, Nordling J, Siroky M, Tammela T</AU>
<TI>Conservative management in men</TI>
<SO>Incontinence: 2nd International Consultation on Incontinence</SO>
<YR>2002</YR>
<PG>553-68</PG>
<EN>2nd</EN>
<ED>Abrams P, Cardoza L, Khoury S, Wein A</ED>
<PB>Health Publications</PB>
<CY>Plymouth, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leach-1995" NAME="Leach 1995" NOTES="&lt;p&gt;Leach GE. Post-prostatectomy incontinence: the importance of bladder dysfunction. J Urol 1995;153(3 Pt 2):1038.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Leach GE</AU>
<TI>Post-prostatectomy incontinence: the importance of bladder dysfunction</TI>
<SO>Journal of Urology</SO>
<YR>1995</YR>
<VL>153</VL>
<NO>3 Pt 2</NO>
<PG>1038</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Litwiller-1997" NAME="Litwiller 1997" NOTES="&lt;p&gt;Litwiller SE, McIntire DD, Schnitzer B, Roehrborn CG. Risk factors for incontinence following radical prostatectomy in a community practice setting. Abstract Urodynamics Society Meeting, New Orleans, April 1997.&lt;/p&gt;" TYPE="CONFERENCE_PROC">
<AU>Litwiller SE, McIntire DD, Schnitzer B, Roehrborn CG</AU>
<TI>Risk factors for incontinence following radical prostatectomy in a community practice setting [abstract]</TI>
<SO>Urodynamics Society Meeting</SO>
<YR>April 1997</YR>
<CY>New Orleans</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-MacDonald-2007" MODIFIED="2014-05-15 11:50:13 +0100" MODIFIED_BY="[Empty name]" NAME="MacDonald 2007" TYPE="JOURNAL_ARTICLE">
<AU>MacDonald R, Fink HA, Huckabay C, Monga M, Wilt TJ</AU>
<TI>Pelvic floor muscle training to improve urinary incontinence after radical prostatectomy: a systematic review of effectiveness</TI>
<SO>BJU International</SO>
<YR>2007</YR>
<VL>100</VL>
<PG>76&#8211;81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Majoros-2006" NAME="Majoros 2006" TYPE="JOURNAL_ARTICLE">
<AU>Majoros A, Bach D, Keszthelyi A, Hamvas A, Romics I</AU>
<TI>Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study)</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>2006</YR>
<VL>25</VL>
<PG>2-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McCammon-1999" NAME="McCammon 1999" TYPE="JOURNAL_ARTICLE">
<AU>McCammon KA, Kolm P, Main B, Schellhammer PF</AU>
<TI>Comparative quality of life analysis after radical prostatectomy or external beam radiation for localized prostate cancer</TI>
<SO>Urology</SO>
<YR>1999</YR>
<VL>54</VL>
<NO>3</NO>
<PG>509-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McGuire-1990" NAME="McGuire 1990" NOTES="&lt;p&gt;McGuire EJ. Editorial comment: Pathophysiology of urinary incontinence after radical prostatectomy. J Urol 1990;143:978.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>McGuire EJ</AU>
<TI>Editorial comment: Pathophysiology of urinary incontinence after radical prostatectomy</TI>
<SO>Journal of Urology</SO>
<YR>1990</YR>
<VL>143</VL>
<PG>978</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Milsom-2009" MODIFIED="2015-01-19 10:28:27 +0000" MODIFIED_BY="[Empty name]" NAME="Milsom 2009" TYPE="BOOK_SECTION">
<AU>Milsom I, Altman D, Lapitan MC, Nelson R, Sillen U, Thom D</AU>
<TI>Epidemiology of urinary (UI) and faecal (FI) incontinence and pelvic organ prolapse (POP)</TI>
<SO>Incontinence: 4th International Consultation on Incontinence</SO>
<YR>2009</YR>
<PG>35-112</PG>
<PB>Health Publication Ltd</PB>
<CY>Paris, France</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moore-2007" MODIFIED="2015-01-19 10:19:59 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2007" TYPE="COCHRANE_REVIEW">
<AU>Moore KN, Fader M, Getliffe K</AU>
<TI>Long-term bladder management by intermittent catheterisation in adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2011-12-06 14:47:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD006008.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD006008"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ni_x00eb_l_x002d_Weise-2005" MODIFIED="2015-01-19 10:20:05 +0000" MODIFIED_BY="[Empty name]" NAME="Niël-Weise 2005" TYPE="COCHRANE_REVIEW">
<AU>Niël-Weise BS, van den Broek PJ</AU>
<TI>Urinary catheter policies for long-term bladder drainage</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>1</NO>
<PB>John Wiley &amp; Sons, Ltd</PB>
<IDENTIFIERS MODIFIED="2011-12-06 14:47:41 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD004201.pub2"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD004201"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Omar-2014" MODIFIED="2015-01-19 10:41:00 +0000" MODIFIED_BY="[Empty name]" NAME="Omar 2014" TYPE="JOURNAL_ARTICLE">
<AU>Omar MI, Lam T, Alexander C, Graham J, Mamoulakis C, Imamura M, et al</AU>
<TI>Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP)</TI>
<SO>BJU International</SO>
<YR>2014</YR>
<VL>113</VL>
<PG>24&#8211;35</PG>
<IDENTIFIERS MODIFIED="2015-01-19 10:39:43 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-01-19 10:39:38 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1111/bju.12281"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Peyromaure-2002" NAME="Peyromaure 2002" TYPE="JOURNAL_ARTICLE">
<AU>Peyromaure M, Ravery V, Boccon-Gibod I</AU>
<TI>The management of stress urinary incontinence after radical prostatectomy</TI>
<SO>British Journal of Urology International</SO>
<YR>2002</YR>
<VL>90</VL>
<NO>2</NO>
<PG>155-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rainwater-1988" NAME="Rainwater 1988" NOTES="&lt;p&gt;Rainwater LM, Zincke H. Radical prostatectomy after radiation for cancer of the prostate: feasibility and prognosis. J Urol 1988;140(6):1455-9.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rainwater LM, Zincke H</AU>
<TI>Radical prostatectomy after radiation for cancer of the prostate: feasibility and prognosis</TI>
<SO>Journal of Urology</SO>
<YR>1988</YR>
<VL>140</VL>
<NO>6</NO>
<PG>1455-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rassweiler-2006" MODIFIED="2015-01-19 10:20:13 +0000" MODIFIED_BY="[Empty name]" NAME="Rassweiler 2006" TYPE="JOURNAL_ARTICLE">
<AU>Rassweiler J, Teber D, Kuntz R, Hofmann R</AU>
<TI>Complications of Transurethral Resection of the Prostate (TURP) &#8211; Incidence, management, and prevention</TI>
<SO>European Association of Urology</SO>
<YR>2006</YR>
<VL>50</VL>
<PG>969-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reference-Manager-2012" MODIFIED="2014-02-26 16:53:48 +0000" MODIFIED_BY="[Empty name]" NAME="Reference Manager 2012" TYPE="OTHER">
<TI>Reference Manager Professional Edition Version 12</TI>
<SO>New York: Thomson Reuters</SO>
<YR>2012</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silva-2011" MODIFIED="2011-12-07 13:19:03 +0000" MODIFIED_BY="[Empty name]" NAME="Silva 2011" TYPE="COCHRANE_REVIEW">
<AU>Silva LA, Andriolo RB, Atallah ÁN, da Silva EMK</AU>
<TI>Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-07 13:19:03 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-07 13:19:03 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD008306.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2002" MODIFIED="2015-01-19 10:20:21 +0000" MODIFIED_BY="[Empty name]" NAME="Thompson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Thompson DL</AU>
<TI>The national coverage decision for reimbursement for biofeedback and pelvic floor electrical stimulation for treatment for urinary incontinence</TI>
<SO>Journal of Wound, Ostomy &amp; Continence Nursing</SO>
<YR>2002</YR>
<VL>29</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Turner-2004" MODIFIED="2014-05-14 13:31:25 +0100" MODIFIED_BY="[Empty name]" NAME="Turner 2004" NOTES="&lt;p&gt;DB - Ovid MEDLINE(R)&lt;br&gt;UI - 15180616&lt;br&gt;IN - Department of Health Sciences, University of Leicester, Leicester, UK. dat3@leicester.ac.uk&lt;br&gt;AS - BJU Int. 2004 Jun;93(9):1246-52&lt;br&gt;JC - dcu, 100886721&lt;br&gt;SB - IM&lt;br&gt;CP - England&lt;br&gt;PT - Journal Article&lt;br&gt;LG - English&lt;/p&gt;" NOTES_MODIFIED="2014-05-14 13:31:25 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Turner DA, Shaw C, McGrother CW, Dallosso HM, Cooper NJ, MRC Incontinence Team</AU>
<TI>The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK</TI>
<SO>BJU International</SO>
<YR>2004</YR>
<VL>93</VL>
<NO>9</NO>
<PG>1246-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Uebersax-1995" NAME="Uebersax 1995" NOTES="&lt;p&gt;Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. The Continence Program for Women Research Group. Short forms to assess life quality and symptom distress for urinary incontinence in women: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn 1995; 14:131-39.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA</AU>
<TI>The Continence Program for Women Research Group. Short forms to assess life quality and symptom distress for urinary incontinence in women: The Incontinence Impact Questionnaire and the Urogenital Distress Inventory</TI>
<SO>Neurourology and Urodynamics</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>131-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ware-1993" MODIFIED="2015-01-19 10:20:29 +0000" MODIFIED_BY="[Empty name]" NAME="Ware 1993" NOTES="&lt;p&gt;Ware JE. Measuring patients' views: the optimum outcome measure. BMJ 1993;306(6890):1429-30.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:20:29 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE</AU>
<TI>Measuring patients' views: the optimum outcome measure</TI>
<SO>BMJ</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6890</NO>
<PG>1429-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilson-2001" MODIFIED="2015-01-19 10:20:34 +0000" MODIFIED_BY="[Empty name]" NAME="Wilson 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wilson L, Brown J, Shin GP, Luc K, Subak L</AU>
<TI>Annual direct cost of urinary incontinence</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2001</YR>
<VL>98</VL>
<NO>3</NO>
<PG>398-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winters-1997" MODIFIED="2015-01-19 10:20:40 +0000" MODIFIED_BY="[Empty name]" NAME="Winters 1997" NOTES="&lt;p&gt;Winters JC, Rackley RR, Fralick RA, Simich SC, Appell RA. Urodynamic findings in post-prostatectomy incontinence [Abstract 398]. J Urol 1997;157(Suppl 4):102.&lt;/p&gt;" NOTES_MODIFIED="2015-01-19 10:20:40 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Winters JC, Rackley RR, Fralick RA, Simich SC, Appell RA</AU>
<TI>Urodynamic findings in post-prostatectomy incontinence [Abstract 398]</TI>
<SO>Journal of Urology</SO>
<YR>1997</YR>
<VL>157 Suppl 4</VL>
<PG>102</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-02-26 16:39:35 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Campbell-2012" MODIFIED="2014-02-26 16:39:32 +0000" MODIFIED_BY="[Empty name]" NAME="Campbell 2012" TYPE="COCHRANE_REVIEW">
<AU>Campbell SE, Glazener CMA, Hunter KF, Cody JD, Moore KN</AU>
<TI>Conservative management for postprostatectomy urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-02-26 16:39:32 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2014-02-26 16:39:25 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001843.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2004" MODIFIED="2011-12-02 14:11:13 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 2004" NOTES="&lt;p&gt;Hunter KF, Moore KN, Cody DJ, Glazener CMA. Conservative management for postprostatectomy urinary incontinence. &lt;i&gt;Cochrane Database of Systematic Reviews&lt;/i&gt; 2004, Issue 2. Art. No.: CD001843. DOI: 10.1002/14651858.CD001843.pub2&lt;/p&gt;" NOTES_MODIFIED="2011-12-02 14:11:13 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Hunter KF, Moore KN, Cody DJ, Glazener CMA</AU>
<TI>Conservative management for postprostatectomy urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-12-02 14:11:13 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 14:11:13 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001843.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hunter-2007" MODIFIED="2011-12-02 14:11:24 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 2007" TYPE="COCHRANE_REVIEW">
<AU>Hunter KF, Moore KN, Glazener CMA</AU>
<TI>Conservative management for postprostatectomy urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-12-02 14:11:24 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 14:11:24 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001843.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-1999b" MODIFIED="2011-12-02 14:12:59 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 1999b" NOTES="&lt;p&gt;this will be preWiley - there is no doi for this on the Wiley website.&lt;/p&gt;" NOTES_MODIFIED="2011-12-02 14:12:59 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Moore KN, Cody DJ, Glazener CM</AU>
<TI>Conservative management for post prostatectomy urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-12-02 14:12:59 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 14:12:59 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001843"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2001" MODIFIED="2011-12-02 14:12:45 +0000" MODIFIED_BY="[Empty name]" NAME="Moore 2001" NOTES="&lt;p&gt;the wiley website doesnt have the citation for this 2001 version (?possibly because this was pre Wiley??) they have the doi for the 2004 issue 1 version so have used the doi here .&lt;/p&gt;&lt;p&gt;Moore KN, Cody DJ, Glazener CMA. Conservative management for post prostatectomy urinary incontinence. &lt;i&gt;The Cochrane Database of Systematic Reviews (Complete Reviews)&lt;/i&gt; 2004, Issue 1. Art. No.: CD001843. DOI: 10.1002/14651858.CD001843&lt;/p&gt;" NOTES_MODIFIED="2011-12-02 14:12:45 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="COCHRANE_REVIEW">
<AU>Moore KN, Cody DJ, Glazener CM</AU>
<TI>Conservative management for post prostatectomy urinary incontinence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-12-02 14:12:45 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-12-02 14:12:45 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001843"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-05-27 11:06:02 +0100" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmed-2012">
<CHAR_METHODS MODIFIED="2014-02-19 09:09:34 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> Pre-operatively</P>
<P>
<B>Population:</B> 95 men after radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included:</B> men who underwent RP for clinically localized prostate cancer. Patients were not taking anticholinergic drugs or any drug that may affect continence for the duration of the study</P>
<P>
<B>Excluded: </B>previous urethral, bladder or prostate surgery, prior urinary or faecal incontinence, neurogenic and psychiatric disorders, pre-operative urinary tract complications, radiotherapy</P>
<P>
<B>Age</B> (mean, SD): A 57.2 (3.25); B 58.8 (5.4); C 56.3 (6.8)</P>
<P>
<B>Dropouts: </B>10 A: 4 (2 received radiotherapy, 2 had post-operative complications); B: 4 (2 received radiotherapy, 2 refused follow up); C: 2 (2 received radiotherapy) No differential dropout</P>
<P>
<B>Baseline characteristics:</B> Comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> Post-operative treatment</P>
<P>A (26): PFMT alone. At catheter removal men received standard care of verbal and written instructions, active instructions from physiotherapist to perform 3 sets of 15 to 20 contractions daily, for a duration of 3 to 5 seconds with a 6 to 10 second rest period, encouraged to perform exercises before functional activities such as sneezing, coughing, or lifting weight, also in the supine position, sitting, squatting and going up and down stairs.</P>
<P>B (26): ES: treatment started one week after catheter removal, patients received 15 minutes of twice weekly electrical stimulation for 12 weeks</P>
<P>C (28): PFMT + BFB + ES: treatment started one week after catheter removal, patients received twice weekly treatment with 15 minutes of electrical stimulation and 15 minutes of biofeedback for 12 weeks, instructed to perform 3 series of 10 rapid contractions, 3 sustained contractions of 5, 7 or 10 seconds and then 10 contractions during prolonged expiration in the supine position</P>
<P>All patients were given a logbook to complete daily regarding self-report of exercises</P>
<P>
<B>Duration of treatment:  </B>12 weeks</P>
<P>
<B>Follow up:</B> 6, 12 and 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (defined as some pads required and weight gain of the pad &gt; 1 g during the test)</P>
<P>Baseline: A 22/26; B 22/26; C 23/28</P>
<P>2 months: A 21/26; B 19/26; C 18/28</P>
<P>3 months: A 17/26; B 12/26; C 20/28</P>
<P>6 months: A 9/26; B 6/26; C 1/28</P>
<P>
<B>Other outcomes</B>
</P>
<P>Leakage weight in grams on 24 hour pad test (mean (SD) N)</P>
<P>Baseline: A 791 (380.3) 26; B 790 (399.46) 26; C 785 (311.98) 28</P>
<P>2 months: A 533 (316.53) 26;  B 383 (145.87) 26; C 263 (145.87) 28</P>
<P>3 months : A 260 (216.53) 26; B 132 (145.87) 26; C 83 (145.87) 28</P>
<P>6 months : A 123 (116.53) 26; B 98 (105.87) 26; C 36 (95.87) 28</P>
<P>
<B>Quality of life</B>
</P>
<P>(Higher score = worse)</P>
<P>Mean scores of IIQ-7 (mean (SD) N)</P>
<P>2 months: 40 (23) 26; B 36 (25) 26; C 26 (25) 28</P>
<P>3 months: 32 (26) 26; B 29 (28) 26; C 20 (24) 28</P>
<P>6 months: 25 (26) 26; B 23 (24) 26; C 15 (25) 28</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 09:09:35 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bales-2000">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: not stated<BR/>Blinding: Outcome assessment nurse not involved in intervention<BR/>Dropouts: None mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>N = 100 consecutive patients with stage T1c to T2c prostate cancer undergoing radical retropubic prostatectomy by a single surgeon randomised into 2 groups<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-operative intervention</P>
<P>Group A (50) intervention: 2 to 4 weeks prior to surgery, participants underwent a 45 minute session with nurse trained in biofeedback. Patients were instructed to perform graded PFMT. Contractions of 5 to 10 seconds, 10 to 15 repetitions were performed with biofeedback (surface electrodes used to measure muscle strength). Advised to practice the exercises 4 times per day until surgery</P>
<P>Group B (50) control: no biofeedback training. Written and brief verbal instructions from a nurse on how to perform PFMT (isolate muscle that stops urine flow, practice 4 times per day, 10 to 15 repetitions)</P>
<P>Both groups: Encouraged to perform PME 4 times per day after catheter removal 2 weeks post-operatively</P>
<P>Length of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: time to return of continence measured by number of pads used</P>
<P>Continence definition: use of 1 pad or less per day</P>
<P>Data collection: at 1, 2, 3, 4, and 6 months post-operatively</P>
<P>There was no significant difference in incontinence between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-16 11:47:05 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burgio-2006">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: stratified by age and tumour differentiation, then randomised using computer generated random numbers, block size of 4 to ensure equity of number in each group<BR/>Blinding: intervention providers and bladder diary scorers were blinded<BR/>Dropouts: 6 participants in the intervention group, and 7 in the control were excluded after randomisation as surgery was cancelled. At 6 months, 6 in the intervention and 4 in the control were lost to follow-up</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>N = 125 volunteer patients randomised, 13 excluded after randomisation</P>
<P>Analysis on N = 112 men aged 53 to 68 years who underwent radical prostatectomy for prostate cancer. To be eligible, the men had to be ambulatory, continent and identified at least 1 week prior to their surgery<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-operative intervention</P>
<P>Group A (57) intervention: single session of biofeedback (rectal probe to measure intra-abdominal rectal pressure and external anal sphincter contraction) assisted behavioural training. Feedback and verbal instruction used to teach control of pelvic muscles. Taught to contract sphincter during 2 to 10 seconds periods separated by 2 to 10 seconds of relaxation, dependent on ability. Written instructions for daily at home practice of 45 PFM exercises daily (3 sessions of 15 exercises each time). Additionally instructed to slow or interrupt voiding once daily. Encouraged to exercise daily preoperatively, then resume when catheter removed post-operatively</P>
<P>Group B (55) control: usual care of brief verbal instructions post operatively to interrupt the voiding stream plus any instruction from physician</P>
<P>Length of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome:<BR/>Continual or episodic urine loss using bladder diaries, incontinent pads or other products<BR/>Secondary outcomes:<BR/>Impact of incontinence and quality of life pre-operatively and at follow-up contacts by IIQ, SCL-90-R and SF-36</P>
<P>Continence definition: 3 consecutive weekly 1 day diaries showing no leakage or a 7 day diary showing no leakage</P>
<P>Data collection: 1 day bladder diaries mailed in each week. Questionaire on bladder control, lifestyle and 7 day bladder diary at 6 weeks, 3 months and 6 months post-surgery</P>
<P>Time to continence was significantly reduced in the intervention group. The intervention group had a significantly smaller proportion of those with severe or continual leakage at 6 months, and stress type urine loss. No differences on quality of life, return to work or activities between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]">
<P>Analysis by "intention to treat". Additional data supplied to KFH by author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Centemero-2009">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
<P>Method of allocation: 100 consecutive patients</P>
<P>Blinding: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>Number of men 100</P>
<P>Recruitment: pre-operative</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>Excluded: impaired mental status, BMI.27, diabetes mellitus, neurological-rheumatic-immune disease, neck-urethral surgery, prior catheterisation, post-operative catheterisation time longer than 6 days.</P>
<P>Aged: 48-68 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (50) intervention: PFMT both pre and post-operatively. A structured PFMT program 30 and 15 days before surgery, previous physiotherapist evaluation to provide the patients with feedback about the quality of pelvic floor muscle function, PC test (endurance and contraction quality), breathing co-ordination, typify muscle contraction as tonic and modify incorrect physical attitudes. This was also repeated after the procedure</P>
<P>Group B (50) intervention: PFMT post-operatively only (no details as to whether this is the same as the treatment pre-operatively above)</P>
<P>Duration of treatment: not stated</P>
<P>Length of follow-up: at one and three months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>UI at </P>
<P>1 month: A 33/59; B 47/59</P>
<P>3 month: A 24/59; B 37/59</P>
<P>24 hour pad test, number of subjects with pad test weight of &gt; 150 g</P>
<P>1 month: A 15/59; B 20/59</P>
<P>3 month: A 10/59; B 19/59</P>
<P>Quality of life measured by the ICS male sf questionnaire, mean score</P>
<P>1 month: A 14.6 (6.36) 59; B 18.3 (6.36) 59</P>
<P>3month: A 8.1 (7.04) 59; B 12.2 (6.36) 59</P>
<P>Satisfaction scale (PGI-I) used only for Group A and 75% reported extreme satisfaction for pre-operative PFMT</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-01-07 13:44:25 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<CHAR_METHODS MODIFIED="2014-02-04 12:16:53 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population:</B> men having a laparoscopic radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included:</B> patients with prostate cancer, undergoing laparoscopic radical prostatectomy</P>
<P>
<B>Excluded:  </B>neurological disorders, a medical history with invasive perineal and/or rectal surgery, preoperatively existing stress urinary incontinence, radiation, &#8805; 75 years</P>
<P>
<B>Age</B> (mean, SD): A 63.7 (5.3); B 63.7 (5.3)</P>
<P>
<B>Dropouts: </B>9 from A (1 unable to understand Dutch, 3 post-operative radiotherapy, 1 oesophageal cancer, 3 discontinued intervention at own request, 1 excluded due to poor compliance) 8 from B (2 post operative radiotherapy, 1 pelvic lymph node dissection, 1 died of cause unrelated to prostate cancer, 5 discontinued intervention at own request, 1 prolonged catheter) Not differential dropout</P>
<P>
<B>Baseline characteristics:</B>  comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative (+ postoperative treatment for all men)</P>
<P>A (56): 30 mins of guided PFMT + biofeedback weekly for 4 weeks before surgery, received written instructions to: carry out two sets of 30 contractions during abdominal breathing, one breath between each contraction; restart PFMT after catheter removal (7 to 10 days after surgery)</P>
<P>B (46): received written instructions on PFMT after catheter removal (7 to 10 days after surgery)</P>
<P>All men were seen before surgery by a physiotherapist, who explained relevant anatomy, anal visual inspection and digital palpation, biofeedback registration with rectal probe</P>
<P>All patients received PFMT + biofeedback and/or electrical stimulation if still incontinent after 6 weeks</P>
<P>
<B>Duration of treatment</B>
</P>
<P>
<B>Follow up:</B> 6 weeks, 3 months, 6 months, 9 months and 12 months after surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (leakage on 24 hour pad test)</P>
<P>12 months: A 20/58; B 9/45</P>
<P>
<B>Other outcomes</B>
</P>
<P>Number of continent men after 1 year (no leakage at all on 24 hour pad test)</P>
<P>12 months: 38/58; B 36/45</P>
<P>Adverse effects:</P>
<P>A 0/56; B 0/46</P>
<P>
<B>Quality of life</B>
</P>
<P>King&#8217;s Health Questionnaire (KHQ) (mean (SD) N):</P>
<P>General health</P>
<P>12 months: A 24.48 (50.7) 56; B 29.64 (50.7) 46</P>
<P>Role limitations</P>
<P>12 months: A 21.36 (22.2) 56; B 17.73 (22.2) 46</P>
<P>Physical limitations</P>
<P>12 months: A 16.49 (15.45) 56; B 13.48 (15.45) 46</P>
<P>Social limitations</P>
<P>12 months: A 7.98 (24.8) 56; B 4.15 (24.8) 46</P>
<P>Personal</P>
<P>12 months: A 18.72 (4.4) 56; B 19.62 (4.4) 46</P>
<P>Emotional</P>
<P>12 months: A 5.08 (7.0) 56; B 4.24 (7.0) 46</P>
<P>Sleep or energy disturbance: A 9.13 (39.0) 56; B 6.13 (39.0) 46</P>
<P>Symptom severity: A 14.62 (86.1) 56; B 10.93 (86.1) 46 </P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>Trial was stopped early because interim analysis found no benefit for group A</P>
<P>Additional information supplied by author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dubbelman-2004">
<CHAR_METHODS MODIFIED="2011-11-25 15:28:24 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy (&#8805; 1 g urine loss on 1 hour pad test), one week after catheter removal</P>
<P>Excluded: pre-operative UI</P>
<P>N = 66 men completing the trial, 33 in intervention group, 33 in control</P>
<P>All participants had a radical retropubic prostatectomy and lived within 75 km of hospital</P>
<P>Age range 61 to 67 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>A (35) intervention: 9 or less sessions of physiotherapy guided pelvic floor exercises after surgery plus information folder</P>
<P>B (44) control: exercise instruction through information folder only</P>
<P>Length of follow-up: 6.5 months</P>
<P>Dropouts: A 1, B 2 due to stricture; + A 1, B 3 refused further measurements; + B 5 withdrew consent or 1 did not understand</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]">
<P>Continence definition: incontinence defined as loss of at least 1 gram of urine on 1 hour pad test and 4 grams on the 24 hour pad test</P>
<P>Main outcome: urinary incontinence on both 1 hour (&gt; 1 g) and 24 hour (&gt; 4 g) pad tests</P>
<P>Secondary outcome: urodynamic study (urethral pressure profilometry)</P>
<P>Data collection: 1 and 26 weeks after catheter removal</P>
<P>Number of wet men at 6 months: A: 17/33, B: 20/33</P>
<P>No significance difference in continence rates between the groups</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-11-24 13:00:45 +0000" MODIFIED_BY="[Empty name]">
<P>Sample size required 96 men in each arm</P>
<P>Other data presented as median (IQR) </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fader-2013">
<CHAR_METHODS MODIFIED="2014-03-20 09:04:25 +0000" MODIFIED_BY="[Empty name]">
<P>RCT Cross-over design</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> post-operative</P>
<P>
<B>Population:</B> 74 men with incontinence after prostate surgery</P>
<P>
<B>Included:</B> men who were experiencing incontinence more than a year after prostate cancer treatment and using absorbent pads</P>
<P>
<B>Excluded:  </B>no description </P>
<P>
<B>Age</B> (mean, SD): no description</P>
<P>
<B>Dropouts: </B>no information</P>
<P>
<B>Baseline characteristics:</B> no information</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> post-operative</P>
<P>A: penile compression device (clamp)  </P>
<P>B: sheath drainage system (sheath)</P>
<P>C: body-worn urinals (BWU)</P>
<P>D: pads alone</P>
<P>All men tested each device for three weeks and asked to state which device was preferred</P>
<P>
<B>Duration of treatment: </B>3 weeks with each device</P>
<P>
<B>Follow-up:</B> 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Not reported</P>
<P>
<B>Other outcomes</B>
</P>
<P>Overall opinion: patient satisfaction questionnaire related to device performance</P>
<P>Asked to state which device they preferred:</P>
<P>Pads were most highly rated compared with sheaths (P = 0.31), clamps (P &lt; 0.01) and BWUs (P &lt; 0.001)</P>
<P>The clamp was rated as more secure, less leaky and less restrictive of clothing choice than the others (P &lt; 0.05) but was more painful than the rest (P&lt;0.002)</P>
<P>Three months later asked which products they were actually using and for what activities and circumstances:</P>
<P>30/56 using a combination of devices and pads</P>
<P>
<B>Quality of life</B>
</P>
<P>EORTC QLC C30</P>
<P>IIQ-7</P>
<P>ICIQ-UI</P>
<P>King's Health Questionnaire</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]">
<P>Awaiting further information from author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filocamo-2005">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: block randomisation, block size of 4 for 2 groups (A and B) with only one permutation code (ABBA)</P>
<P>Blinding: not described<BR/>Dropouts: at 12 months, 2 participants dropped out of the control group<BR/>Intention to treat: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: all men undergoing RRP</P>
<P>N = 300 consecutive men post RRP, randomised after catheter removal to 2 groups<BR/>Intervention group: N = 150<BR/>Control group: N = 150</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (150) intervention: formal instruction (3 treatment sessions plus at home exercises) in PFMT using verbal explanation, palpation and visualization of the base of the penis with a mirror, in different positions and prior to sneezing, coughing or lifting</P>
<P>Group B (150) control: no formal instruction</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss on 1 hour and 24 hour pad tests plus number of pads used daily</P>
<P>Continence definition: 0 to 1 pads per day</P>
<P>Data collection: 1, 3, 6, and 12 months</P>
<P>Wet (leakage or use of pads)</P>
<P>1 month: A 145/150, B 147/150</P>
<P>3 months: A 115/150, B 129/150</P>
<P>6 months: A 35/150, B 102/150</P>
<P>12 months: A 16/150, B 49/148</P>
<P>Surgical implantation of artificial urinary sphincter: A 2/150, B 3/148</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>74% of the intervention group achieved continence at 3 months compared to only 30% of the control (a significant difference favouring intervention)</P>
<P>Differences between the groups declined between 6 to 12 months, with most participants achieving continence in 1 year</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Floratos-2002">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: randomised 2:1 to intervention: control groups<BR/>Blinding: not mentioned<BR/>Dropouts: 1 participant randomised to intervention unable to follow intervention protocol (unable to attend clinic, provided with control invention)</P>
<P>Intention to treat: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy one week after catheter removal</P>
<P>N = 42 consecutive patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (28) intervention: initiated after catheter removal. Intervention group received 15 treatment sessions (3 times per week for 30 minutes) of PFMT with EMG (surface) biofeedback in clinic</P>
<P>Group B (14) control: instruction with verbal feedback and an information pamphlet with instructions to perform PME 50 to 100 times daily at home</P>
<P>Length of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: incontinence episodes measured by 1 hour pad test and continence questionnaire (pads used, number of incontinence episodes)</P>
<P>Continence definition: incontinence defined as a urine loss of &gt; 1 g on the 1 hour pad test; 2 or more pads/day a not deemed a "socially acceptable continence rate"</P>
<P>Data collection: baseline, 1, 2, 3 and 6 months</P>
<P>Level of incontinence in both groups declined over the 6 months of the study. Control group had less urine loss and appeared to regain continence sooner, but the difference was not significant</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]">
<P>Additional data supplied to KFH by author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fode-2014">
<CHAR_METHODS MODIFIED="2014-02-04 09:28:54 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population:</B> 83 men undergoing nerve sparing radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included: </B>sexually active men with an IIEF score of at least 18 without aids, continent pre-operatively</P>
<P>
<B>Excluded: </B>condition that may prevent patient being able to have post-operative treatment with PDE5-inhibitor</P>
<P>
<B>Age</B> (mean, range): A 62 (46-73); B 65 (49 to 76)</P>
<P>
<B>Dropouts:</B> 12 from group A (3 excluded because underwent non-nerve sparing surgery, 2 withdrew consent, 1 lost a partner, 6 non-compliance), 3 from group B (2 excluded because underwent non-nerve sparing surgery, 1 withdrew consent). Differential dropout</P>
<P>
<B>Baseline characteristics:</B> comparable except Group A significantly more LUTS pre-operatively</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative + post-operative</P>
<P>A (30): pre-operative session guided PFMT + instruction on how to use penile vibratory stimulation device, instructed to stimulate frenulum once daily, 10 seconds of stimulation then 10 second pause, repeated 10 times for 1 week pre-operatively, Instructed to restart stimulation after catheter removal for 6 weeks</P>
<P>B (38): pre-operative session guided PFMT </P>
<P>All men were offered a PDE5 inhibitor after 1 month post-operatively and also received telephone contact to ensure compliance with treatment </P>
<P>
<B>Duration of treatment:  </B>6 weeks</P>
<P>
<B>Follow up:</B> 3, 6 and 12 months post-operatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (men reporting use of more than one pad daily)</P>
<P>3 months: A 14/42; B 15/41</P>
<P>6 months: A 7/42; B 3/41</P>
<P>12 months: A 3/30; B 2/38</P>
<P>(dropout figures added to 3 and 6 months) </P>
<P>
<B>Other outcomes</B>
</P>
<P>Continence rate (patients reporting use of up to one pad daily for security reasons only)</P>
<P>3 months: A 65.5%; B 62.9%, P = 0.83</P>
<P>6 months : A 83.3%; B 91.9%, P = 0.28</P>
<P>12 months : A 90%; B 94.7%, P = 0.46</P>
<P>Median (range) pad use</P>
<P>3 months: A 1 (0 to 6); B 5 (0 to -34), P = 0.09</P>
<P>6 months: A 0 (0 to 3); B 1/3 (0 to 6), P = 0.14</P>
<P>12 months: A 0 (0 to 2); B 0 (0 to 3),  P = 0.56</P>
<P>Median (range) IIEF-5</P>
<P>3 months : A 5 (0 to 25); B 5 (0-25), P = 0.25</P>
<P>6 months : A 10.5 (0 to 25); B 5 (0-25), P = 0.08</P>
<P>12 months : 18 (0 to 25); B 7.5 (0-25), P = 0.09</P>
<P>IIEF &#8805; 18, n/N (%)</P>
<P>3 months: 5/30 (17); B 4/38 (11), P = 0.46</P>
<P>6 months: 13/30 (43); B 9/38 (24), P = 0.09</P>
<P>12 months: 16/30 (53); B 12/38 (32), P = 0.07</P>
<P>Adverse effects: A: 5/30 reported side effects as a result of penile vibratory stimulation (1 red spots on glans penis, 1 small laceration + some bleeding, 2 complained of soreness, 1 frank pain post-operatively)</P>
<P>B: 0/38</P>
<P>
<B>Quality of life</B>
</P>
<P>Median (range) DAN-PSS post-operatively</P>
<P>3 months: A 1 (0 to 34); B 5 (0-34), P = 0.74</P>
<P>6 months: A 2 (0 to 41); B 1 (0-48), P = 0.74</P>
<P>12 months: A 3 (0 to 36); B 0.5 (0-21), P = 0.13</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]">
<P>Further information provided by authors</P>
<P>PDE5 (phosphodiesterase yype 5) inhibitor is used for erectile dysfunction</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Franke-1998">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: not stated<BR/>Blinding: none<BR/>Dropouts: 2 with gravitational incontinence consistent with intrinsic sphincter deficiency<BR/>Intention to treat: not clear</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinence post-radical prostatectomy at 6 weeks post surgery</P>
<P>N = 30 men: 6 weeks post-radical prostatectomy with post-void residual of &lt; 50 ml; no previous TURP, no urinary tract infection, no neurological conditions<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention.</P>
<P>Group A (13): intervention, biofeedback (perineal patch EMG) enhanced PFMT; exercise treatment sessions at 6, 7, 9, 11, and 16 weeks post-operatively</P>
<P>Group B (10): control, completed bladder diary but did not have any other intervention</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measured by voiding diary, 48 hour pad test (reported as mean grams of urine lost in 24 hours), and incontinence questionnaire</P>
<P>Continence definition: not clear. Participants described as "completely dry" or with "significant incontinence"</P>
<P>Data collection: 6, 12 and 24 weeks</P>
<P>There were no significant differences between treatment or control groups on any of the outcome measures at any of the measurement intervals</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]">
<P>Numbers in the groups unclear as 5 withdrew from the study after initial randomisation. Not clear how many were in each group prior to follow-up at 6 weeks</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geraerts-2013">
<CHAR_METHODS MODIFIED="2014-01-20 12:08:17 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population:</B> men having a radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included:</B> men planning to undergo open radical prostatectomy (ORP) or robot-assisted laparoscopic radical prostatectomy (RARP)</P>
<P>Willing to accept ambulatory visits once a week until total continence was achieved; willing to perform measurements pre-operatively and at 1 month, 3 months, 6 months and 12 months after surgery</P>
<P>
<B>Excluded:  </B>cognitive problems; non-Dutch speaking; simultaneous other surgery; transport problems; lack of time; psychosocial/other medical problems; refused participation; insisted on preoperative PFMT; not approachable; not enough time between diagnosis and date of planned surgery</P>
<P>
<B>Age</B> (mean, SD): A 62 (5.90); B 62 (6.33)</P>
<P>
<B>Dropouts:</B> 6 from A; (1 died, 1 cerebrovascular accident, 3 transport problems, 1 refused further participation) 4 from B: (2 transport problems, 2 refused further participation). Not differential dropout</P>
<P>
<B>Baseline characteristics: </B>Comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative</P>
<P>A (85): 30 mins of guided PFMT + biofeedback weekly for 3 weeks before surgery instructed to: carry out 60 contractions a day at home; contract their pelvic floor while coughing, and sitting down or getting up from a chair; restart PFMT on day 4 after surgery while catheter was in situ</P>
<P> </P>
<P>B (85): instructed to start PFMT on the day after catheter removal (e.g. 2 to 3 weeks after surgery)</P>
<P>All men performed an individual guided exercise programme with digital or EMG biofeedback postoperatively weekly, delivered by a therapist (blinded to group allocation) different from the pre-operative Group A therapist. This  included advice on using PF muscles to prevent leakage during functional activities</P>
<P>
<B>Duration of treatment: </B>as long as any degree of UI persisted</P>
<P>
<B>Follow up:</B> 1 month, 3 months, 6 months and 12 months after surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (1 hour pad test defined as &#8804; 1 g)</P>
<P>1 month: A 37/85; B 35/86, P = 0.758</P>
<P>3 months: A 15/86; B 15/86, P = 1.000</P>
<P>6 months: A 8/86; B 5/85, P = 0.566</P>
<P>12 months: A 7/81; B 7/83, P = 1.000</P>
<P>
<B>Other outcomes</B>
</P>
<P>Cumulative incidence of number of continent men</P>
<P>1 month: A 44/85; B 44/85</P>
<P>3 months: A 67/85; B 71/85</P>
<P>6 months: A 80/85; B 80/85</P>
<P>12 months: A 83/85; B 81/85</P>
<P>Point prevalence of continence, 1 hour pad test, defined as 0 g</P>
<P>1 month: A 42/85; B 41/86</P>
<P>3 months: A 63/86; B 61/86</P>
<P>6 months: A 76/86; B 73/85</P>
<P>12 months: A 68/81; B 73/83</P>
<P>Point prevalence of continence, VAS scale, defined as &#8804; 1/10</P>
<P>1 month: A 35/89; B 38/88</P>
<P>3 months: A 64/88; B 52/87</P>
<P>6 months: A 73/88; B 65/86</P>
<P>12 months: A 72/84; B 62/84</P>
<P>Urine loss on 24 hour pad test in grams (mean (SD) N):</P>
<P>1 month: A 90 (?) 85; B 85 (?) 85</P>
<P>3 months: A 17 (?) 85; B 13 (?) 85</P>
<P>6 months: A 12 (?) 85; B 3 (?) 85 </P>
<P>12 months: A 2 (?) 85; B 3 (?) 85</P>
<P>
<B>Quality of life</B>
</P>
<P>International prostate Symptom Score (IPSS), King&#8217;s Health Questionnaire (KHQ): data not given</P>
<P>Only one aspect of the King&#8217;s Health Questionnaire, incontinence impact, favoured A at 3 (P = 0.008) and 6 months (P = 0.024) after surgery</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-19 16:17:43 +0000" MODIFIED_BY="[Empty name]">
<P>Some men had pre-operative incontinence</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ghanem-2013">
<CHAR_METHODS MODIFIED="2014-02-19 09:45:03 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population: </B>100 men undergoing a radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included:</B> men undergoing RP for clinically localized prostate cancer.</P>
<P>
<B>Excluded: p</B>atients who had previous pelvic organ surgeries, patients with central or peripheral neurologic diseases  </P>
<P>
<B>Age</B> (mean, SD): not reported  </P>
<P>
<B>Dropouts:</B> not reported</P>
<P>
<B>Baseline characteristics:</B> not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative (post-operative treatment for all men)</P>
<P>A (50): pre-operative PFMT for 2 weeks + post-operative PFMT programme      </P>
<P>B (50): post-operative PFMT programme only</P>
<P>
<B>Duration of treatment</B>
</P>
<P>
<B>Follow-up:</B> 3.5, 4.5, 12, 13 and 13.5 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (defined as using &gt; 1 pad on pad test)</P>
<P>12 months: A 2/50; B 3/50</P>
<P>13 months: A 2/50; B2/50</P>
<P>
<B>Other outcomes</B>
</P>
<P>
<B>Quality of life</B>
</P>
<P>ICS male SF questionnaire, results not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 09:45:03 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glazener-RP-2011">
<CHAR_METHODS MODIFIED="2011-11-15 12:04:44 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-15 12:13:41 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men with persistent urinary incontinence at 6 weeks after radical prostatectomy</P>
<P>Excluded: radiotherapy planned; unable to comply with study or intervention; previous formal PFMT</P>
<P>Age (mean, SD): A 62.4 (5.8); B 62.3 (5.6)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]">
<P>A (205): one-to-one therapy sessions including PFMT and BT if OAB or urgency symptoms + PFMT and lifestyle leaflet</P>
<P>Duration of treatment: 4 sessions in 3 months starting 6 weeks after surgery</P>
<P>B (206): control group with standard care + lifestyle leaflet only, no individual PFMT instruction or sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]">
<P>UI defined as positive response to ICIQ-SF questionnaire</P>
<P>UI at 3 months: A 172/200, B 176/198</P>
<P>UI at 6 months: A 158/197, B 158/197</P>
<P>UI at 9 months: A 144/191, B 157/194</P>
<P>UI at 12 months: A 148/196, B 151/195</P>
<P>Severe UI at 12 months: A 74/196, B 78/195</P>
<P>UI episodes at 12 months from diaries (mean (SD N): A 3 (3.8) 105, B 2.9 (3) 106</P>
<P>ICI-Q score at 12 months (mean (SD N): A 4.9 (4.1) 196, B 5.4 (4.5) 195</P>
<P>QoL due to UI at 12 months (mean (SD N): A 1.4 (2) 193, B 1.7 (2.3) 193</P>
<P>Use of pads at 12 months: A 63/159, B 68/161</P>
<P>Men not doing PFMT at 12 months: A 63/191, B 91/189</P>
<P>Erectile dysfunction (no erection): A 105/189, B 105/190</P>
<P>QALYs virtually identical</P>
<P>Cost: NHS intervention cost was GBP 181 higher in intervention group (95% CI 107 to 255)</P>
<P>Other outcomes: use of other protection, catheters, sheath catheters, urinary frequency, nocturia, faecal incontinence, urgency, constipation, EQ5D, SF-12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Low dropout rates</P>
<P>ICI-Q score: 0 = no UI, no effect on QoL; 21 = maximum amount, frequency and effect on QoL</P>
<P>QoL due to UI measured using ICIQ-SF: 0 = no effect, 10 = maximum effect</P>
<P>Compliance with therapy high</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Glazener-TURP-2011">
<CHAR_METHODS MODIFIED="2011-11-15 17:09:19 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-15 17:12:24 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men with persistent urinary incontinence at 6 weeks after transurethral resection of the prostate (TURP)</P>
<P>Excluded: radiotherapy planned; channel TURP for palliation for prostate cancer; unable to comply with study or intervention; previous formal PFMT</P>
<P>Age (mean, SD): A 68.2 (7.7); B 67.9 (8.1)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>A (220): one-to-one therapy sessions including PFMT and BT if OAB or urgency symptoms + PFMT and lifestyle leaflet</P>
<P>Duration of treatment: 4 sessions in 3 months starting 6 weeks after surgery</P>
<P>B (222): control group with standard care + lifestyle leaflet only, no individual PFMT instruction or sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>UI defined as positive response to ICIQ-short form questionnaire</P>
<P>UI at 3 months: A 142/205, B 132/208</P>
<P>UI at 6 months: A 140/199, B 129/201</P>
<P>UI at 9 months: A 133/197, B 131/202</P>
<P>UI at 12 months: A 126/194, B 125/203</P>
<P>Severe UI at 12 months: A 48/194, B 49/203</P>
<P>UI episodes at 12 months from diaries (mean (SD N): A 1.4 (2.3) 175, B 1.2 (2.2) 179</P>
<P>ICI-Q score at 12 months (mean (SD N): A 3.9 (3.7) 194, B 4 (4.3) 203</P>
<P>QoL due to UI at 12 months (mean (SD N): A 1.2 (1.9) 190, B 1.3 (2.2) 199</P>
<P>Use of pads at 12 months: A 24/146, B 24/136</P>
<P>Men not doing PFMT at 12 months: A 66/188, B 154/193</P>
<P>Erectile dysfunction (no erection): A 52/177, B 43/178</P>
<P>QALYs virtually identical</P>
<P>Cost: NHS intervention cost was GBP 209 higher in intervention group (95% CI 147 to 271)</P>
<P>Other outcomes: use of other protection, catheters, sheath catheters, urinary frequency, nocturia, faecal incontinence, urgency, constipation, EQ5D, SF-12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Low dropout rates</P>
<P>ICI-Q score: 0= no UI, no effect on QoL; 21 = maximum amount, frequency and effect on QoL</P>
<P>QoL due to UI measured using ICIQ-SF: 0 = no effect, 10 = maximum effect</P>
<P>Compliance with therapy high</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goode-2009">
<CHAR_METHODS MODIFIED="2011-11-23 13:09:21 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent 1 to 16 years after radical prostatectomy (mean years since operation: A 5.1, B 3.9, C 5.1)</P>
<P>N = 208 (prior to dropout). Analysis of 172 men at 8 weeks</P>
<P>Age between 51 to 84 years</P>
<P>% of men with prior PFMT instruction: A 36%, B 56%, C 47%</P>
<P>% of men using antimuscarinics: A 16%, B 20%, C 28%</P>
<P>% of men with urgency UI: A 1%, B 3%, C 2%</P>
<P>% of men with stress UI: A 44%, B 47%, C 44%</P>
<P>% of men with mixed UI: A 54%, B 50%, C 54%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>A (70): behavioural therapy with PFMT alone for 8 weeks</P>
<P>B (70): behavioural therapy with biofeedback and electrical stimulation for 8 weeks</P>
<P>C (68): control, no treatment for 8 weeks, then offered choice of intervention A or B</P>
<P>Behavioural therapy consisted of pelvic floor muscle exercises and bladder control strategies in both groups</P>
<P>Dropouts: A 19 at 6 months, 23 at 12 months; B 22 at 6 months, 36 at 12 months; C 3 at 8 weeks</P>
<P>Length of follow-up: 12 months for groups A and B C transferred to treatment at 8 weeks so no further follow up possible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Frequency of UI, mean accidents in a week</P>
<P>Number of continent men at 8 weeks: A 11/70, B 12/70, C 4/68</P>
<P>Incontinence episodes per day at 8 weeks (mean, SD, N): A 1.86 (0.56) 58; B 1.71 (0.54) 54; C: 3 (1.17) 64</P>
<P>Change in quality of life at 8 weeks using EPIC UI subscale (bigger change is better, mean, SD, N): A 13.1 (15.5) 58; B 12.3 (14.6) 54; C 2.9 (12.4) 64</P>
<P>Adverse events: A 0/70, B 2/70 (haemorrhoidal irritation), C 0/68</P>
<P>Patient's Global Perceptions of Improvement (much better): A 90%, B 91%, C 10%</P>
<P>Completely satisfied with treatment progress: A 47%, B 47%, C not reported</P>
<P>Compliance with PFMT and bladder control strategies at 8 weeks: A 100%, B 93%</P>
<P>Compliance at 6 months: A 82%, B 84%</P>
<P>Compliance at 12 months: A 91%, B 81%</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Some baseline differences between groups, did not quite reach statistical significance</P>
<P>High dropout rates</P>
<P>No data available for control group after eight weeks as all received treatment</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hoffman-2005">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: computerised randomisation<BR/>Blinding: unclear<BR/>Dropouts: 1 participant from each intervention group had dropped out by discharge; 15 dropouts from the perineal group, 31 from the anal group and 5 from the control group dropped out by 3 months<BR/>Intention to treat: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy in an inpatient rehabilitation program</P>
<P>N= 180 men (prior to dropouts). Randomly assigned to 3 groups (60 in each group)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention<BR/>Group A (60) intervention: perineal ES plus physiotherapy (PFMT)</P>
<P>Group B (60) intervention: anal ES plus physiotherapy (PFMT)</P>
<P>Group C (60) control: PFMT alone.</P>
<P>Length of follow-up: 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measure on 1 hour pad test</P>
<P>Secondary outcomes: quality of life (QLQ-C30)</P>
<P>Continence definition: self-reports of incontinence</P>
<P>Data collection: admission and discharge from the rehabilitation program and at 3 months after discharge</P>
<P>All groups improved on continence and quality of life. Use of ES was only of additional value in a compliant subgroup. Perineal ES was better accepted than anal<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>Additional data supplied to KFH by author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hou-2013">
<CHAR_METHODS MODIFIED="2014-02-03 09:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population:</B> 66 men who underwent TURP (whole population, with or without UI)</P>
<P>
<B>Included:</B> patients with benign prostatic hyperplasia and underwent TURP, aged 60 to 90 years, remarkable lower urinary tract symptoms (LUTS) with poor response to medication, ambulatory, able to communicate verbally</P>
<P>
<B>Excluded: </B>indwelling catheter-dependent postdischarge, neurogenic bladder, dementia or disability affecting verbal communication</P>
<P>
<B>Age</B> (mean, SD): A  69.67 (6.09); B 71.41 (6.67)</P>
<P>
<B>Dropouts:</B> 5 (2 catheter still in situ after discharge from hospital, 3 lost to follow-up). Not differential dropout</P>
<P>
<B>Baseline characteristics:</B> comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> post-operative treatment</P>
<P>A (32): guided PFMT + EMG biofeedback after catheter removal (2 days postoperatively), instructed to: contract pelvic muscles for 5 seconds and relax for 10 seconds. After discharge, patients were instructed to carry out 5 mins of each PFE three times daily. Patients also received motivational telephone interviews once weekly</P>
<P>B (29): no description</P>
<P>
<B>Duration of treatment: </B>12 weeks</P>
<P>
<B>Follow up:</B> 1 week, 1 month, 2 months and 3 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Not reported</P>
<P>
<B>Other outcomes</B>
</P>
<P>
<B>Quality of life</B>
</P>
<P>SF-36 scores (mean (SD) N)</P>
<P>Physical component</P>
<P>3 months: A 54.86 (8.62) 32; B 49.86 (11.23) 29</P>
<P>Physical functioning</P>
<P>3 months: A 89.69 (17.13) 32; B 85.82 (21.60) 29</P>
<P>Body pain</P>
<P>3 months: A 93.66 (15.16) 32; B 89.48 (22.71) 29</P>
<P>General health</P>
<P>3 months: A 82.03 (14.05) 32; B 64.93 (27.16) 29</P>
<P>Physical role limitation</P>
<P>3 months: A 68.75 (36.48) 32; B 51.72 (38.92) 29</P>
<P>Mental health component</P>
<P>3 months: A 56.21 (6.20) 32; B 48.52 (11.94) 29</P>
<P>Mental role limitation</P>
<P>3 months: A 93.75 (21.48) 32; B 73.81 (37.80) 29</P>
<P>Vitality</P>
<P>3 months: A 80.47 (13.16) 32; B 64.14 (24.02) 29</P>
<P>Mental health</P>
<P>3 months: A 88.00 (10.51) 32; B 77.38 (18.68) 29</P>
<P>Social functioning</P>
<P>3 months: A 90.63 (14.20) 32; B 76.29 (29.57) 29</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-03 09:42:08 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Joseph-2000">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: yes<BR/>Method of allocation: not described<BR/>Blinding: none<BR/>Dropouts: 3 did not return to clinic for all appointments, one had other health problems<BR/>Intention to treat: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy or post-TURP. UI of at least 6 months duration</P>
<P>N = 11 patients at least 6 months post-surgery (4 radical retropubic, 6 radical peritoneal, 1 TURP)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (6): intervention: Instruction in PFMT including biofeedback with visual feedback as well as verbal to assist in identifying and discriminating muscles</P>
<P>Group B (5): comparator: Instruction in PFMT, squeezing of finger during digital rectal examination</P>
<P>Both: weekly visit for a total of 4 clinic visits</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measure by standardised pad test, bladder diary, subjective estimation of degree of incontinence</P>
<P>Secondary outcomes: leak point pressure measured by video-urodynamics, Joseph Continence Assessment Tool</P>
<P>Continence definition: subjective evaluation by participants</P>
<P>Data collection: baseline, 3, 6, and 12 months</P>
<P>No differences between the groups. Improvement seen in all patients at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]">
<P>Data not published in article. Raw data supplied to review author (KFH) who calculated means and standard deviations. These were reviewed by a second review author (KNM)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Koo-2009">
<CHAR_METHODS MODIFIED="2010-01-08 14:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men with UI after radical prostatectomy</P>
<P>Randomised: N = 32</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]">
<P>A (16) intervention: extra-corporeal magnetic innervation (ExMI), treatment sessions were for 20 minutes twice weekly for 8 weeks</P>
<P>B (16) control: PFMT alone. Duration of treatment not specified</P>
<P>Length of follow-up: six months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>24 hour pad test, g of urine</P>
<P>Baseline: A 655, B 646</P>
<P>1 month: A 147, B 187</P>
<P>2 months: A 33, B 81, P = 0.001</P>
<P>3 months: A 9 (SD 28), B 45 (28), P = 0.001</P>
<P>6 months: Less than 10 g in both groups</P>
<P>Number of pads used daily</P>
<P>Baseline: A 4.2, B 4.1</P>
<P>I month: A 1.5, B 1.8</P>
<P>2months: A 0.6, B 0.9, P = 0.033</P>
<P>3 months: A 0.1 (0.42), B 0.6 (0.42), P = 0.002</P>
<P>6 months: A 0, B 0.1</P>
<P>Quality of life measured by I-QoL</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>Awaiting further translation - information from abstract only</P>
<P>SDs calculated using P values</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laurienzo-2013">
<CHAR_METHODS MODIFIED="2014-03-19 09:20:54 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population:</B> men having a radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included: </B>patients with prostate cancer (stage T2) and candidates for RPP who were referred for treatment</P>
<P>
<B>Excluded: </B>radiotherapy (previous or after RPP), previous transurethral resection, pre-existing neurological disease, urinary fistula after RPP, prolonged indwelling urethral catheterization (more than 15 days), clinical situations that rendered the patient unsuitable for surgical procedure, failure to attend all PFMR or electrical stimulation sessions, loss of follow-up and desistance  </P>
<P>
<B>Age</B> (mean, SD): A 64 (8); B 62 (7); C 60 (8)</P>
<P>
<B>Dropouts:</B> 9 (2 failed to attend all sessions, 2 desistance, 1 adjuvant radiotherapy, 1 postoperative urethral stenosis, 1 urinary fistula, 1 unsuitable for surgery due to cardiovascular risk, 1 inadequate follow up) Unclear from which group</P>
<P>
<B>Baseline characteristics:</B> Comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative only</P>
<P>A (15): standard treatment with verbal instructions for PFMT</P>
<P>B (17): pre-operative guided PFMT, with 10 physiotherapy sessions: contractions of the pelvic floor muscles for 5 seconds in &#8220;dorsal decubitus&#8221; position for 10 times, in the same position with the waist elevated (10 times), lying down with legs adducted against a plastic ball performed 10 times and standing and flexing the hips to 60&#778; (10 times) </P>
<P>C (17): pre-operative PFMT + electrical stimulation during 10 physiotherapy sessions, electrical stimulation was with an anal probe lasting 15 minutes in total, and men also received guided PFMT and followed the same training regime as above</P>
<P>Men did not receive PFMT post-operatively</P>
<P>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           </P>
<P>
<B>Duration of treatment: </B>10 pre-operative sessions  </P>
<P>
<B>Follow up:</B> 1, 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Not reported</P>
<P>
<B>Other outcomes</B>
</P>
<P>1 hour pad test score (mean (SD) N)</P>
<P>1 month: A 17.6 (38.5) 15; B 29.5 (35.8) 17; C 25.5 (35.4) 17</P>
<P>3 months:14.3 (34.4) 15; B 11.8 (28.4) 17; C 9.6 (18.8) 17</P>
<P>6 months: A 5.5 (14.16) 15; B 25.3 (59) 17; 4.35 (7.3) 17</P>
<P>
<B>Quality of life</B>
</P>
<P>ICIQ-SF score (mean (SD) N)</P>
<P>1 month: A 7.5 (5) 15; B 14 (3.6) 17; C 9.6 (6.3) 17</P>
<P>3 months: A 5.4 (5.2) 15; B 6.9 (5.8) 17; C 7.2 (6.4) 17</P>
<P>6 months: A 3.7 (5.3) 15; B 4.8 (5.3) 17; C 5.3 (5.5) 17</P>
<P>SF-36</P>
<P>Results not reported: &#8220;There were no differences between groups on the various domains of the SF-36 (p &gt; 0.05)&#8221;</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-03-19 09:20:54 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:13:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu--2008">
<CHAR_METHODS MODIFIED="2015-01-19 10:13:59 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled clinical trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:13:59 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men with UI after radical prostatectomy</P>
<P>Randomised: N = 24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:13:59 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (12) intervention: extra-corporeal magnetic innervation (ExMI), the frequency of the pulse field was 10 Hz for 10 minutes, followed by a 3 minute rest and a second treatment of 50 Hz for 20 minutes. This was done twice a week</P>
<P>Group B (12) control: PFMT alone, instructions given to carry out 20 mins x 3 a day</P>
<P>Duration of treatment: six weeks</P>
<P>Length of follow up: 1, 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:13:59 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome measures: quality of life scale and the ICI-Q-SF</P>
<P>1 month: both scores were decreased with no significant differences between the groups</P>
<P>At 3 and 6 months: both scores decreased with group A having a significantly lower (better) score than group B (P &lt; 0.05)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:13:59 +0000" MODIFIED_BY="[Empty name]">
<P>Information from abstract, awaiting translation of paper</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manassero--2007">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: prospective randomised controlled trial</P>
<P>Method of allocation: computer generated random numbers</P>
<P>Blinding: blinded outcome assessors, not instructors</P>
<P>Dropouts: 12 excluded as the couldn't attend regularly for PFMT; 33 continent after surgery and were not randomised; 13 lost to follow-up in the control group (5 social reasons and 8 non-responders)</P>
<P>Intention to treat: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent (UI &gt; 2g/24 hour pad test), post-radical prostatectomy who were able to attend hospital</P>
<P>Excluded: those with a history of preoperative incontinence, significant perioperative complications, rectal lesion, infection, psychiatric neurological disorders, inability to contract PF muscles or weak contraction with increased detrusor activity</P>
<P>Mean age: A 66.8 (6.3 years), B 67.9 (5.5 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (54) intervention: PFMT re-education program, verbal feedback</P>
<P>The training program involved active PFE. Verbal feedback of the contraction was used to instruct the patients to correctly and selectively contract their pelvic muscles while relaxing the abdominal muscles. The strength of the pelvic floor muscles was measured by digital anal control using a score of 0 to 5 ( 0 = no contraction, 5 = good contraction against strong resistance)</P>
<P>Initially home practice comprised 45 contractions (3 sessions of 15) per day at home, progressively increasing the number until 90 per day. This was taught by two experienced urologists</P>
<P>Group B (53) control: no treatment</P>
<P>Duration of treatment: up to a year or until incontinence ceased</P>
<P>Length of follow-up: 1, 3, 6 and 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>UI at -</P>
<P>1 month: A 83.3% (45/54), B 97.5% (39/40), P = 0.04</P>
<P>3 months: A 53.7% (29/54), B 77.5% (31/40), P = 0.03</P>
<P>6 months: A 33.3% (18/54), B 60% (24/40), P = 0.01</P>
<P>12 months: A 16.6% (9/54), B 52.5% (21/40), P &lt; 0.01</P>
<P>Subjective assessment of continence using VAS: P = 0.01 at 12 months</P>
<P>Quality of lIfe (single question): P = 0.03 at 12 months</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>ITT analysis used for data entry, assuming that all 13 men who dropped out of the control group were dry, because of differential dropout of 13 men from B versus none from A with no explanation for difference between groups</P>
<P>If unable to contract anal sphincter or strength 2 or less, not randomised. These men were given ES treatment at home with anal probe</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marchiori-2010">
<CHAR_METHODS MODIFIED="2014-02-04 10:33:56 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> post-operative</P>
<P>
<B>Population: </B>men with incontinence after retropubic radical prostatectomy, open or laparoscopic</P>
<P>
<B>Included:</B> moderate to severe incontinence at 30 days after catheter removal</P>
<P>
<B>Excluded: </B>lack of cooperation, pre-operative incontinence, early recovery of continence</P>
<P>
<B>Age</B> (mean): A 67; B 66.5</P>
<P>
<B>Dropouts:</B> &#8220;Survey questionnaire were correctly filled in and returned by fewer than 10% of the patients&#8221;</P>
<P>
<B>Baseline characteristics:</B> comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> post-operative treatment</P>
<P>A (166): one-to-one guided PFMT + biofeedback during first session, second session involved 10 sets of pelvic floor electrical stimulation lasting 15 mins each, instructed to: carry out three sets of 30 contractions a day at home for the first month after catheter removal (16 days after surgery)</P>
<P>B (166): received oral and written information on pelvic floor anatomy and on PFME, instructed to: perform three sets of 30 contractions a day at home for the first month after catheter removal (16 days after surgery) and continue for duration of</P>
<P>All men received oral and written information on pelvic floor anatomy and on PFME, pelvic floor muscle endurance assessed by digital anal control + PFMT consisting of 3 sets of 30 contractions daily for the first month after catheter removal</P>
<P>
<B>Duration of treatment</B>
</P>
<P>
<B>Follow up:</B> 3 months, 6 months and 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (defined as 0 or 2 minipads daily)</P>
<P>3 months: A 36/166; B 81/166</P>
<P>6.5 months: A 1/166; B 28/166</P>
<P>12 months: A 0/166; B 0/166</P>
<P>
<B>Other outcomes</B>
</P>
<P>Median time of continence recovery, days:</P>
<P>A 44 ± 2, B 76 ± 4, P &#8804; 0.01</P>
<P>
<B>Quality of life</B>
</P>
<P>ICIQ-male: Results not reported</P>
<P>RAND 36-Item Health Survey questionnaire: results not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mariotti-2009">
<CHAR_METHODS MODIFIED="2009-11-06 11:12:29 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised post-operatively</P>
<P>Included: radical prostatectomy, all men after catheter removal</P>
<P>Age: Group A mean 61.86 years, Group B, 61.43 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention post-operative</P>
<P>Group A (30) intervention: PFMT plus ES and biofeedback twice a week for 6 weeks</P>
<P>ES - a surface electrode was inserted into the anus and pulsed, the intensity was adequate to induce visual lifting of the levator ani and pubococcygeus muscle, considering the level of comfort to the patient</P>
<P>Biofeedback - via surface electrodes both perineal and abdominally</P>
<P>Group B (30) control: instructions to conduct PFMT - verbal and written instructions at catheter removal and follow-up visits</P>
<P>Duration of treatment: 6 weeks</P>
<P>Length of follow up: 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]">
<P>24 hour pad test: g/24hrs, mean (SD)</P>
<P>3 months: A 16.67 (30.55), B 136.67 (152.62), P = 0.000</P>
<P>6 months: A 3.47 (14.67), B 27.83 (55.98), P = 0.0004</P>
<P>ICS-male questionnaire, number of men incontinent, n/N</P>
<P>3 months: A 6/30, B 20/30</P>
<P>6 months: A 1/30, B 10/30</P>
<P>Time to regain continence: A 8 (6.49) weeks, B 13.88 (8.32) weeks, P = 0.003</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-06 11:11:31 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martini-2011">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]">
<P>RCT (abstract only)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population: </B>70 consecutive men undergoing a laparoscopic radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included:</B> men undergoing RP for clinically localized prostate cancer T1 to T3</P>
<P>
<B>Excluded: </B>history of incontinence or overactive bladder, central or peripheral neurologic disease and cognitive impairment</P>
<P>
<B>Age</B> (mean, SD): not reported  </P>
<P>
<B>Dropouts:</B> 5 lost to follow up, unclear from which group</P>
<P>
<B>Baseline characteristics:</B> not reported</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative (post-operative treatment for all men)</P>
<P>A (24): PFMT:  5 sessions of guided PFMT for 2 to 3 weeks pre-operatively and continued post-operatively</P>
<P>B (25): post-operative standard care, written instructions for PFMT</P>
<P>All men underwent clinical examination of pelvic muscles function using digital perineal testing according to &#8220;AIPDA score&#8221; and evaluation of voiding symptoms</P>
<P>
<B>Duration of treatment: </B>
</P>
<P>
<B>Follow up:</B> 1, 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (need to wear a pad)</P>
<P>No useable data</P>
<P>
<B>Other outcomes</B>
</P>
<P>24 hour pad test</P>
<P>Pad use</P>
<P>Bladder diary</P>
<P>
<B>Quality of life</B>
</P>
<P>Instrument unspecified</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-19 09:43:06 +0000" MODIFIED_BY="[Empty name]">
<P>No useable data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes, block procedure<BR/>Method of allocation: not reported<BR/>Blinding: none<BR/>Dropouts: 2, not accounted for<BR/>Intention to treat: not clear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>N = 53 men<BR/>Randomised pre-operatively<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>Pre and post-operative intervention</P>
<P>Group A (27) intervention: pre-operatively received further instruction and practice with PME protocol home exercises and biofeedback (anal probe) (Incare 8900); practiced at home 3 times a week, starting with daily 15 PFMT and increasing by 10 every 4 weeks to a maximum of 35 PFMT</P>
<P>Group B (24) control: post-operatively no further interventions until week 5 when pelvic muscle strength was assessed</P>
<P>Both: pre-operatively, both groups received 30 minutes' prostate education programme and baseline 'perineal muscle evaluation' (not defined); as well all were taught to contract the perineal muscle and hold for a few seconds prior to standing, lifting or coughing and limit the amount of tea, chocolate, alcohol and over-the-counter medications</P>
<P>Length of follow-up: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measured by 24 hour pad test, frequency of micturitions (self-recorded bladder diary), number of pads used; days to achieve continence from baseline</P>
<P>Secondary outcomes: perineal muscle strength (method not described)</P>
<P>Continence definition: self-report of return of continence</P>
<P>Data collection: 3 day bladder diaries at weeks 2, 5, 9 and 12. 24 hour pad test at weeks 5 and 12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion of other modalities such as caffeine limitation and using perineal muscles during any event which increased abdominal stress may have masked any treatment benefit</P>
<P>Extra information obtained from thesis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-1999">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: sealed envelopes</P>
<P>Blinding: physiotherapist blinded to results of control group<BR/>Dropouts: 5<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy. Median duration of UI 8 weeks post-surgery, range 4 to 200 weeks</P>
<P>N = 63 men (53 completed study)<BR/>Randomised to 3 groups<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Intervention<BR/>Group A (18) intervention: PFMT alone<BR/>Group B (19) intervention: PFMT plus rectal electrical stimulation treated by one physiotherapist 30 minutes twice a week for 12 weeks<BR/>Intervention groups also did home exercises 3 times/day gradually working up to 30 minutes per session lying, standing, sitting; strength, endurance, speed and control with maximum contractions of 5 to 10 seconds, 10 to 20 second relaxation and 12 to 20 repetitions; submaximum contractions at 65% to 75% of maximum strength with hold 20 to 30 seconds and equal rest time, 8 to 10 repetitions; speed was sets of quick repetitive contractions in a 10 second time span; control involved gradual recruitment to maximum contraction in 3 stages with 5 second hold at each stage and a slow release with rest 15 to 30 seconds</P>
<P>Group C (21) control: oral and written information about PFMT pre and post-operatively (standard treatment)</P>
<P>Length of follow-up: 24 weeks<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measured by 24 hour pad test</P>
<P>Secondary outcomes: quality of life measures (Incontinence Impact Questionnaire, European Organization for the research and treatment of Cancer-EORTC QLQ C-30, version 2), physical symptom inventory (adapted from Herr 1994)</P>
<P>Continence definition: &#8804; 2 g urine/24 hours</P>
<P>Data collection: baseline, 12, 16, 24 weeks after baseline</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Intervention perhaps administered too early - all subjects improved at the same rate; wide range of severity of urinary incontinence at study entry and size of SD of pad test results also may have resulted in Type II error</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2004">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes (order of product testing: in threes to treatment block of 4 periods (1 no device, 3 with devices)<BR/>Block, multiple period cross-over design using Latin square configuration<BR/>Method of allocation: sealed envelopes. Blinding: research assistant not involved in study chose envelope; but research assistant and participants could not be blinded to intervention</P>
<P>Dropouts: none<BR/>Intention to treat: not discussed</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy who required continuous pad protection for stress incontinence</P>
<P>Inclusion criteria: normal perineal and penile sensation, intact penile skin, sufficient manual dexterity<BR/>Exclusion criteria: overactive bladder, neurological disorders affecting sensation or circulation, cognitive impairment.</P>
<P>N = 12 men</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Each participant had 4 periods (each lasted 1 day)<BR/>Group A: no device<BR/>Group B: C3 device<BR/>Group C: U-Tex device<BR/>Group D: Cunningham clamp</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: 4 hour pad test</P>
<P>Secondary outcomes: resistive index, cavernosal flow</P>
<P>None of the devices completely eliminated urine loss when applied at a comfortable pressure. Each device showed improvement in terms of urine lost, with Cunningham clamp having the lowest mean loss<BR/>Cunningham clamp significantly lowered flow, but ranked positively by participants</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Unable to blind participants and research assistant to intervention<BR/>Sample size calculation given and required size achieved</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Moore-2008">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: computer generated list of numbers; group allocation placed in sealed opaque envelopes; opened by subject after initial post-operation instruction session with therapist<BR/>Blinding: data entry by clerk blinded to group; therapist blinded to outcome of non-intervention group; pads weighed by third party<BR/>Dropouts: control = 7; treatment = 12<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative (but approached before surgery)</P>
<P>Included: men incontinent after radical prostatectomy (&gt; 8 grams urine lost on 24 hour pad test) at 4 weeks post-surgery</P>
<P>N = 217 men from 3 centres with early stage prostate cancer<BR/>Inclusion criteria: English speaking, living within 1 hour drive of research centre</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (106) intervention: maximum 24 weekly, 30 minute treatment protocol (30 min biofeedback-assisted PFMT) and home exercise protocol of 2 to 3 times a day</P>
<P>Group B (99) control: verbal and written information on PFME and weekly telephone contact by a urology nurse</P>
<P>Both: at 4 weeks post-surgery, both groups received standardised verbal and written instruction about PFMT and recovery after radical prostatectomy by one dedicated physiotherapist or registered nurse at each site</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: grams of urine loss on 24 hour pad test (&gt; 8 g defined as incontinence)</P>
<P>Definition of continence: &lt; 8 g of urine loss on 24 hour pad test; subjective continence defined as yes or no</P>
<P>Secondary outcome: IPSS, IIQ-7 (Incontinence Impact Questionnaire), voiding diary, and subjective continence</P>
<P>All measures obtained at baseline (pre-operatively) and at 4, 8, 12, 28 weeks and 1 year post-operatively</P>
<P>24 hour pad test, mean (SD) N</P>
<P>12 weeks: A 115 (300) 93, B 72 (144) 82</P>
<P>16 weeks: A 76 (259) 94, B 61 (194) 80</P>
<P>28 weeks: A 45 (142) 87, B 35 (101) 74</P>
<P>12 months: A 47 (215) 89, B 8 (10) 78</P>
<P>Dry at 8 weeks: A 20/101 (20%), B 20/88 (23%)</P>
<P>Dry at 12 weeks: A 30/93 (32%), B 23/82 (28%)</P>
<P>Dry at 16 weeks: A 41/94 (44%), B 32/80 (40%)</P>
<P>Dry at 28 weeks: A 41/87 (47%). B 37/74 (50%)</P>
<P>Dry at 12 months: A 53/89 60%, B 47/78 60% (&lt; 8 g on pad test)</P>
<P>No significant differences between groups on continence or on symptom and quality of life measures or diary at any time point post-operatively</P>
<P>Cost: A: CAD 400; B 240</P>
<P>Adverse events: none in either group</P>
<P>The majority of men reported a low impact of incontinence as per the IIQ-7 and fewer LUTS at 12 months than at baseline on the IPSS. The majority were very satisfied with treatment and support from the continence nurse</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]">
<P>Groups comparable at pre-operation baseline on PSA, Gleason score, IPPS, IIQ, pad test and voiding diary</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morihiro-2011">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>RCT abstract only</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> not reported</P>
<P>
<B>Population:</B> men having laparoscopic radical prostatectomy</P>
<P>
<B>Included:</B> patients who underwent laparoscopic radical prostatectomy performed by a single surgeon</P>
<P>
<B>Excluded: </B>not reported</P>
<P>
<B>Age</B> (mean, SD): not reported</P>
<P>
<B>Dropouts:</B> not reported</P>
<P>
<B>Baseline characteristics:</B> comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> post-operative treatment for all men</P>
<P>A (20): PFMT + sacral surface therapeutic ES (ssTES), ssTES 2 times a day for 15 minutes each, lasting 1 month after catheter removal (day 5)</P>
<P>B (14): PFMT only, carried out alone</P>
<P>
<B>Duration of treatment: </B>1 month  </P>
<P>
<B>Follow-up: </B>1 month, 3 months, 6 months and 12 months post-operatively</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (defined as requirement for a pad to keep clothing dry)</P>
<P>6 months: A 3/20; B 6/14</P>
<P>12 months: A 0/20; B 5/14</P>
<P>
<B>Other outcomes</B>
</P>
<P>Recovery rate of urinary continence (defined as no requirement for a pad to keep clothing dry)</P>
<P>6 months: A 17/20, B 8/14</P>
<P>12 months: A 20/20, B 9/14, P = 0.007</P>
<P>
<B>Quality of life</B>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nowak--2007">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: men undergoing radical prostatectomy</P>
<P>Aged: 59 to 72 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>Group A intervention: extra-corporeal magnetic innervation (ExMI) based pelvic floor device</P>
<P>Group B control: PFMT alone</P>
<P>Treatment initiated one week after catheter removal</P>
<P>Duration of treatment: 10 weeks</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]">
<P>On first day following catheter removal 16.8% of patients were continent</P>
<P>Subsequent follow-up data unclear if N = 105 or 88 subjects. Group numbers not stated</P>
<P>UI at -</P>
<P>4 weeks: A 49%, B 56%</P>
<P>3 months: A 36%, B 50%</P>
<P>6 months; A 18%, B 32%</P>
<P>Twenty minute pad test at 12 months, significantly better in Group A at 12 months, P =0.004</P>
<P>QoL score and urinary symptom inventory also carried out, numbers not given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]">
<P>No useable data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opsomer-1994">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: method not described<BR/>Blinding: none<BR/>Dropouts: 4<BR/>Intention to treat: not specified</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy 6 weeks after six week after surgery</P>
<P>N = 43 (39 completed study)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (21) intervention: PFMT plus biofeedback plus ES directed by physiotherapist</P>
<P>Group B (22) control: PFME on their own without medical supervision</P>
<P>Length of follow-up: 12 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measured by pad test</P>
<P>No statistical difference between groups as to recovery of continence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]">
<P>Abstract only - unable to contact author for further data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Overgard-2008">
<CHAR_METHODS MODIFIED="2009-11-05 10:38:57 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: Pre-operative</P>
<P>Included: radical prostatectomy, all men</P>
<P>Age: Group A 48 to 68 years, Group B 49 to 72 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: post operative</P>
<P>Group A (38) intervention: instructions on PFMT and physiotherapy, 45 minutes weekly. Patients were instructed to perform 3 sets of contractions daily at home, in either a supine, sitting or standing position. Digital anal palpation to teach correct contractions, as well as oral and written instructions</P>
<P>DVD of instructions given to those living too far from hospital</P>
<P>Group B (42) control: instructions on PFMT alone</P>
<P>Duration of treatment: up to 1 year</P>
<P>Length of follow-up: 3, 6 and 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]">
<P>Self-reported continence (not using pads)</P>
<P>3 months: A 16/35 (46%), B 17/40 (43%), P = 0.73</P>
<P>6 months: A 27/34 (79%), B 22/38 (58%), P = 0.061</P>
<P>12 months: A 33/36 (92%), B 28/39 (72%), P = 0.028</P>
<P>24 hour pad test: g/24hrs, mean (range)</P>
<P>3 months: A 17 (0-282), B 7 (0-46), P = 0.53</P>
<P>6 months: A 9 (0-203), B 2 (0-12), P = 0.73</P>
<P>12 months: A 2 (0-55), B 1 (0-14), P = 0.95</P>
<P>PFM strength (anal squeeze pressure, cm H<SUB>2</SUB>O), mean (SD)</P>
<P>3 months: A 50.7 (23.9), B 55.7 (25.6), P = 0.398</P>
<P>6 months: A 56.1 (21.7), B 65.8 (27.0), P = 0.117</P>
<P>12 months: A 64.0 (24.0), B 71.5 (26.2), P = 0.237.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-06 16:49:12 +0000" MODIFIED_BY="[Empty name]">
<P>No SDs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Parekh-2003">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: not described<BR/>Blinding: none<BR/>Dropouts: 1 from each of the control and treatment groups. Reasons not described<BR/>Intention to treat: yes, dropouts categorised as incontinent</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men scheduled for radical prostatectomy</P>
<P>N = 38 patients with localized carcinoma of the prostate<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]">
<P>Pre and post-operative interventions</P>
<P>Group A (19) intervention: 2 treatment sessions pre-operatively. Session 1 consisted of PFMT in a hook lying position<BR/>Session 2 was on an exercise ball. Teaching methods varied and included verbal cues, visualization with an anatomical model, palpation or biofeedback with rectal probe. Post-operatively, PFMT was reviewed and participants were seen every 3 weeks for 3 months by a physiotherapist<BR/>Home exercise for 6 months or more for those requiring further physical therapy guidance</P>
<P>Group B (19) control: no formal education on PFMT pre-operatively, telephone or face to face follow-up at least monthly</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measured by number of pads used daily</P>
<P>Continence definition: 0 pads or 1 precautionary pad used</P>
<P>Data collection: UI questionnaires at 6, 12, 16, 20, 28, and 52 weeks</P>
<P>Greater number of the intervention group gained continence earlier than the control group at 3 months (only point of statistical difference). Minimal long-term effect as continence rates the same at 1 year</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-16 11:32:30 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Park-2012">
<CHAR_METHODS MODIFIED="2014-02-13 10:32:05 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> post-operative</P>
<P>
<B>Population:</B> 121 men who underwent radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included: </B>elderly male patients aged &#8805; 65 years, clinically localized prostate cancer (cT1 to T2), Eastern Cooperative Oncology Group performance status of 0 or 1, and written informed consent</P>
<P>
<B>Excluded:</B> adjuvant or neoadjuvant therapy, severe postoperative complications, a history of intrapelvic surgery, diseases that can affect voiding function, and limitations for exercise intervention, such as patients with serious cardiovascular events or spinal or articular disease</P>
<P>
<B>Age</B> (mean, SD): A 69.1 (5.7); B 69.4 (7.2)</P>
<P>
<B>Dropouts:</B> A: 7 (1 orthopaedic surgery for a pre-existing ankle problem, 1 transurethral surgery for urethral stricture, 4 non-compliance with follow-up due to a long distance from the centre to the home or personal affairs, 1 new employment after surgery)</P>
<P>B: 8 (1 ophthalmologic surgery for a cataract, 2 adjuvant radiotherapy, 4 non-compliance with follow-up due to a long distance from the center to the home or personal affairs, 1 new employment after surgery)</P>
<P>Not differential dropout</P>
<P>
<B>Baseline characteristics:</B> comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> post-operative treatment for all men</P>
<P>A (26): patients performed Kegel exercises twice weekly, together with other types of exercises which included resistance training and pelvic flexibility. The intervention started 3 weeks after surgery and lasted 12 weeks</P>
<P>B (23): &#8216;In the control group, only kegel exercises were performed&#8217;</P>
<P>
<B>Duration of treatment: </B>15 weeks</P>
<P>
<B>Follow-up:</B> 1 week before surgery, 3 weeks and 15 weeks after surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Cumulative number of incontinent men [defined as &gt; 1 g on 24 hour pad test)</P>
<P>15 weeks: A 7/26; B 13/23</P>
<P>
<B>Other outcomes</B>
</P>
<P>Cumulative number of continent men [defined as &lt; 1 g on 24 hour pad test)</P>
<P>15 weeks: A 19/26; B 10/23, P = 0.035</P>
<P>Urine loss in grams using 24 hour pad test (mean (SD) N)</P>
<P>1 week before surgery: A 0 (NR) 26; B 0 (NR) 23</P>
<P>3 weeks post-operatively: A 60 (NR) 26; B 83 (NR) 23</P>
<P>15 weeks: A 12 (NR) 26; B 46 (NR) 23</P>
<P>
<B>Quality of life</B>
</P>
<P>ICIQ score (mean (SD) N)</P>
<P>1 week before surgery: A 4 (NR) 26; B 3 (NR) 23</P>
<P>3 weeks post-operatively: A 10 (NR) 26; B 10 (NR) 23</P>
<P>15 weeks: A 6 (NR) 26; B 10 (NR) 23</P>
<P> </P>
<P>SF-36 physical composite score (mean (SD) N)</P>
<P>1 week before surgery: A 57 (NR) 26; B 54 (NR) 23</P>
<P>3 weeks post-operatively: A 45 (NR) 26; B 44 (NR) 23</P>
<P>15 weeks: A 57 (NR) 26; B 48 (NR) 23</P>
<P> </P>
<P>SF-36 mental composite score (mean (SD) N)</P>
<P>1 week before surgery: A 45 (NR) 26; B 44.6 (NR) 23</P>
<P>3 weeks post-operatively: A 44 (NR) 26; B 43 (NR) 23</P>
<P>15 weeks: A 49 (NR) 26; B 46 (NR) 23</P>
<P> </P>
<P>Beck Depression Inventory (mean (SD) N)</P>
<P>1 week before surgery: A 9 (NR) 26; B 7.4 (NR) 23</P>
<P>3 weeks post-operatively: A 8 (NR) 26; B 9 (NR) 23</P>
<P>15 weeks: A 6 (NR) 26; B 9 (NR) 23 </P>
<P>NR = Not reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>Details of the combined exercise regime</P>
<P>Post-operative weeks 1 to 4</P>
<P>1)    Education about post-operative symptoms</P>
<P>2)    Performing Kegel exercises, recognizing the parapelvic muscles</P>
<P>3)    Pelvic floor flexibility fitness: performing pelvic exercises while sitting on a ball</P>
<P>Post-operative weeks 5 to 8 (ball exercises)</P>
<P>1)    Performing pelvic exercises while sitting on a ball</P>
<P>2)    Performing lower extremity exercises while placing a ball on the wall</P>
<P>3)    Lifting a heel on the ball while standing face-to-face with the wall</P>
<P>4)    Lifting up and down on the ball while spreading and bending legs</P>
<P>5)    Performing flank exercises while having a ball in the hand</P>
<P>6)    Squeezing the ball with the adductor muscles while lying on a table</P>
<P>Post-operative weeks 9-12 (elastic band exercises)</P>
<P>1)    Lifting the object with an elastic band lateral, anterior, and posterior to the patient&#8217;s arms</P>
<P>2)    Lifting the legs and then spreading them while attaching an elastic band to the foot</P>
<P>Further information provided by author</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perissinotto-2008">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes.</P>
<P>Method of allocation: consecutive patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-operative randomisation</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>Pre-operative intervention</P>
<P>Age: not given</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (N not given) intervention: early pelvic floor rehabilitation program at home twice dally, Kegel exercises</P>
<P>Group B (N not given) control: no formal PFMT</P>
<P>Duration of treatment: for six months or until continence was achieved</P>
<P>Length of follow-up: at 3 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>PFM strength: P = 0.002</P>
<P>Quality of life using ICIQ-SF not significant</P>
<P>24 hour pad test not significant</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-06 11:06:07 +0000" MODIFIED_BY="[Empty name]">
<P>No useable data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Porru-2001">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: not described<BR/>Blinding: report stated that urologist performing digital evaluation of pelvic floor muscle contraction was blinded to the study group<BR/>Dropouts: intervention 2, control 1. Reason reported was non-attendance at all clinic appointments<BR/>Intention to treat: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men undergoing TURP</P>
<P>N = 58 men (55 completed study) with benign prostatic hypertrophy randomised to 2 groups<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Pre and post-operative intervention</P>
<P>Group A (30) intervention: initial visit before surgery, digital evaluation of pelvic muscle contraction strength. Verbal instruction, feedback and reinforcement on contraction was given to teach selective contraction of anal sphincter and relaxation of abdominal muscles. Verbal and written instruction given for home PFMT. Weekly digital anal reassessment and grading of pelvic muscle contraction by the therapist. Instructed to practice contractions 45 times per day (3 groups of 15 contractions)</P>
<P>Group B (28) control: not specified</P>
<P>Both A and B: voiding diaries initiated after catheter removal</P>
<P>Length of follow-up: 4 weeks. Data collection at catheter removal and weekly for 4 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss (incontinence episodes) measured by 48 hour bladder diaries completed weekly</P>
<P>Secondary outcomes<BR/>Muscle contraction strength by digital evaluation Scale 0 to 4 (0 = none, 4 = strong)<BR/>Pressure flow: urine flowmetry pre-operatively and 1 month post-operatively<BR/>Symptoms: AUA (American Urological Association) symptom score preoperatively and 30 days after surgery<BR/>Quality of life: ICS male questionnaire</P>
<P>Significant increase in muscle strength in intervention group by week 4<BR/>Both groups showed improvement in symptom score and quality of life post-operatively, no significant difference between groups<BR/>Significantly better satisfaction with life in intervention group A compared to control B at 4 weeks<BR/>Significant difference in voiding intervals between the groups at weeks 2 and 3, but not week 4<BR/>No difference in uroflowmetry<BR/>Significantly less incontinence in the intervention group A at weeks 1, 2 and 3. No difference at week 4<BR/>Concluded that PFMT quickens the return to normal voiding post-TURP</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-16 11:34:45 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ribeiro-2008">
<CHAR_METHODS MODIFIED="2009-10-19 09:42:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised: yes </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Included: radical prostatectomy, all men after catheter removal</P>
<P>Age: 51 to 76 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (36) intervention: PFMT plus BF weekly for 3 months</P>
<P>Group B (37) control: PFMT oral instructions only</P>
<P>Duration of treatment: weekly until continent or to a maximum of 3 months</P>
<P>Length of follow-up: 3 months after treatment finished</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>UI severity (24 hour pad test weights)</P>
<P>1 month (N, mean, SD): A 96 g (160) 36, B 355 (423) 37, P = 0.007</P>
<P>3 months: A 51 (119), 36, B 197 (269) 37</P>
<P>6 months: A 40 (77), 36, B 80 (176) 37</P>
<P>ICI-SF score: 3 months:A 3.4 (3.7), 36, B 6.8 (5.6) 37, P = 0.022</P>
<P>6 months: A 2.7 (3.5), 36, B 4.3 (5.5) 37, P = 0.339</P>
<P>PFM Strength, A versus B: 1 month, P = 0.006; 3 months P &lt; 0.001; 6 months P = 0.799</P>
<P>Quality of life (IIQ): 3 months: A 1.6 (2.7), 36, B 4.3 (6.2) 37</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-19 10:05:11 +0100" MODIFIED_BY="[Empty name]">
<P>Groups comparable at baseline before operation on age, BMI, voiding symptoms and PFMT strength</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-2008">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operatively</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>Groups comparable at baseline</P>
<P>Age range 39 to 74 years</P>
<P>Pre-operative UI 9%</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (62) intervention: brief verbal instruction in PFMT before operation and offer of one biofeedback session at 2 months after surgery (uptake 33%) plus PFMT for four weeks with biofeedback</P>
<P>Group B (64) control: brief verbal instruction in PFMT before operation and offer of one biofeedback session at 2 months after surgery (uptake 46%)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>No urinary outcomes provided</P>
<P>No between group differences in intensity and distress of lower urinary tract symptoms nor in impact on health-related quality of life</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]">
<P>No useable data</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-2009">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: randomly assigned via sealed envelopes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>Number of men 54 but no numbers in groups</P>
<P>Recuitment: post-operatively</P>
<P>Included: radical prostatectomy, all with UI who were 50 + years, English speaking and were within a 50 mile radius of treatment centre</P>
<P>Age: mean 59.5 (6.3) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>Group A intervention: routine brief verbal and written PFMT plus one PFMT session and 3 weekly nurse phone calls</P>
<P>Group B intervention: routine brief verbal and written PFMT plus four BF enhanced PFMT sessions and 4 weekly nurse phone calls</P>
<P>Group C control: routine brief verbal and written PFMT</P>
<P>Duration of treatment: 3 months</P>
<P>Length of follow-up: 9 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>Urine stream interruption test (PFM strength)</P>
<P>Mishell Uncertainty in Illness Scale</P>
<P>Broome Pelvic Muscle self-Efficacy Scale</P>
<P>UI frequency (3 day bladder diary)</P>
<P>24 hour pad test (volume of urine lost)</P>
<P>Male Urogenital Distress Inventory (UI distress)</P>
<P>Male Urinary Symptom Impact Questionnaire (QoL)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>No useable data in abstract</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seleme-2008">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: yes, single blind</P>
<P>Method of allocation: using coloured cards</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Included: men with UI eight weeks after radical prostatectomy</P>
<P>Exclusion: previous radiotherapy, anterior transurethral resection, diabetes mellitus and urethral obstruction after surgery</P>
<P>Age: median 63.7 years, range 46 to 83 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>A (44) intervention: verbal instruction and information on PFMT plus information on life style changes. Additional 15 physiotherapy sessions consisting of intensive PFMT with BF and ES</P>
<P>B (32) control: verbal instruction and information on PFMT plus information on life style changes</P>
<P>Duration of treatment: no description</P>
<P>Length of follow-up: 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Incontinence Quality of life (I-QoL, higher score better), mean (SD)</P>
<P>Directly after treatment: A 44.23 (14.61), B 37.53 (9.94)</P>
<P>At 6 months: A 80.32 (7.01), B 51.69 (16.17), P = 0.001</P>
<P>At 6 months for Group A (44) intervention only:</P>
<P>1 hour pad test: mean urine loss before treatment 54.2 g and after treatment 8.8 g (P &gt; 0.001)</P>
<P>VAS severity of UI: before treatment 9.3, after treatment 1.3 (P &gt; 0.001)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Unexplained disparity between numbers in randomised groups</P>
<P>No results for Group B control for pad test or VAS</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tibaek-2007">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: yes, mathematical table, grouped in blocks of 10</P>
<P>Method of allocation: sealed envelopes by independent third party</P>
<P>Blinding: Slingle blind. Independent physiotherapist undertook initial assessment and 4 week outcome assessment</P>
<P>Dropouts: 9 before intervention (4, training too time consuming; 1, didn't have TURP; 4, operated elsewhere)</P>
<P>Setting: Hospital, Denmark</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Pre-operative intervention</P>
<P>Included: TURP, all men</P>
<P>Exclusion: prostate cancer, previous lower urinary tract surgery, neurological disease</P>
<P>Age: A 70 (58 to 77) years, B 68 (52 to 79) years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (26) intervention: 1 hour individual session with physiotherapist to teach correct contraction for PFMT, three 1 hour group lessons and home training programme</P>
<P>Group B (23) control: no pre-operative physiotherapy. Information about anatomy and physiology and verbal instructions for 2 to 3 days after TURP in the ward</P>
<P>Duration of treatment: 4 weeks after surgery</P>
<P>Length of follow-up: 2 and 4 weeks and 3 months after operation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]">
<P>Compliance: A 24/26 attended all 4 training sessions</P>
<P>Use of urinary pads per 24 hours, at 4 weeks: A 4/26, B 4/21. At 3 months: A 3/26, B 5/22</P>
<P>UI (pad test weight g/24hrs): </P>
<P>4 weeks (N, Median, range): A 26, 12 (0 to 374), B 23, 4 (0 to 56), P = 0.755</P>
<P>Danish Prostatic Symptom Scale: 3 months (N, median, range): A 26, 3 (0 to 24), B 23, 4.5 (0 to 51), P = 0.754</P>
<P>Also data on muscle function, muscle strength, static endurance and dynamic endurance</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-05 10:16:48 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tienforti-2012">
<CHAR_METHODS MODIFIED="2014-01-28 15:45:23 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P>
<B>Population:</B> men undergoing radical prostatectomy (whole population, with or without UI)</P>
<P>
<B>Included:</B> men who underwent open retropubic radical prostatectomy for clinically localized prostate cancer (cT1a to cT2b), able to regularly attend an ambulatory schedule</P>
<P>
<B>Excluded: </B>prior diseases with a possible impact on urinary continence, preoperative radiotherapy and any medical condition that could limit participation in the training programme </P>
<P>
<B>Age</B> (mean, range): A 67 (60 to 74); B 64 (52 to 74)</P>
<P>
<B>Dropouts:</B> 1 from A (intolerance to procedure using rectal probe), 1 from B (surgical complication)</P>
<P>Not differential dropout</P>
<P>
<B>Baseline characteristics:</B> comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> pre-operative</P>
<P>A (16): on the day before RP + the day after catheter removal, patients received guided PFMT + biofeedback + information about the anatomy of pelvic floor muscles and wrong execution was corrected, also given oral and written instructions on Kegel exercises to be performed at home, instructed to: perform three sets daily for 10 mins, each contraction lasting 5 seconds with 5 seconds of relaxation, contract their pelvic floor while lying, sitting and standing, frequency recorded in training diary, After RP visits at monthly intervals after catheter removal involving assisted biofeedback and motivation for 20 min</P>
<P>B (16): after catheter removal, men received standard care, oral and written instructions from urologist on PFMT, Instructed to: start PFMT (e.g. 2 to 3 weeks after surgery), control visits at 3 + 6 months after catheter removal  </P>
<P>All men were given oral and written instructions post-operatively to perform PFMT at home, 3 sets daily of 10 min each</P>
<P>
<B>Duration of treatment: </B>monthly visits as long as patient required pads, including safety pads </P>
<P>
<B>Follow up: </B>at least 6 months after catheter removal</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI)</B>
</P>
<P>Number of incontinent men (defined as ICIQ-UI &gt; 0)</P>
<P>1 month: A 10/16; B 16/16, P = 0.02</P>
<P>3 months: A 8/16; B 15/16, P = 0.01</P>
<P>6 months: A 6/16; B 15/16, P = 0.002</P>
<P>Other outcomes</P>
<P>Number of continent men (efined as ICIQ-UI = 0)</P>
<P>1 month: A 6/16; B 0/16, P = 0.02</P>
<P>3 months: A 8/16; B 1/16, P = 0.01</P>
<P>6 months : A 10/16; B 1/16, P = 0.002</P>
<P> </P>
<P>Mean number of incontinence episodes per week/24 hours (mean (SD) N)</P>
<P>1 month: A 1.43 (0.82) 16; B 14 (0.82) 16, P = N.S</P>
<P>3 months: A 0.57 (1.47) 16; B 2 (1.47) 16, P = 0.01</P>
<P>6 months: A 0.43 (1.33) 16; B 1.86 (1.33) 16, P = 0.005</P>
<P> </P>
<P>Mean number of pads used per week/24 hours (mean (SD) N)</P>
<P>1 month: A 0.46 (0.67) 16; B 0.94 (0.67) 16 P = NS</P>
<P>3 months: A 0.23 (0.63) 16; B 0.91 (0.63) 16 P = 0.005</P>
<P>6 months: A 0.2 (0.57) 16; B 0.66 (0.57) 16 P = 0.03</P>
<P> </P>
<P>
<B>Quality of life</B>
</P>
<P>Mean ICIQ-OAB score (mean (SD) N)</P>
<P>1 month: A 11.5 (3.6) 16; B 14 (3.6) 16, P = NS</P>
<P>3 months: A 11 (0.92) 16; B 11.7 (0.92) 16, P = 0.04</P>
<P>6 months: A 9 (4.1) 16; B 13 (4.1) 16, P = 0.01</P>
<P> </P>
<P>Mean UCLA-PCI score (mean (SD) N)</P>
<P>1 month: A 330 (?) 16; B 260 (?) 16, P = NS</P>
<P>3 months: A 400 (500) 16; B 270 (338) 16, P = 0.006</P>
<P>6 months: A 430 (487) 26; B 275 (311) 16, P = 0.003</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-28 15:45:23 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tobia-2008">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men, radical prostatectomy</P>
<P>Age: 45 to 75 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (19) intervention: PFMT</P>
<P>Group B (19) control: no PFMT</P>
<P>length of follow-up: 2, 4 and 8 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]">
<P>Dry at 2 weeks: A 9/19, B 9/19</P>
<P>Dry at 4 weeks: A 9/19, B 9/19</P>
<P>Dry at 8 weeks: A 15/19, B 17/19, P = 0.374</P>
<P>No significant differences for age (P = 0.674), PSA (P = 0.208), Gleason score pre (P = 0.762) and post-operation (P = 0.824)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-04-19 14:56:10 +0100" MODIFIED_BY="[Empty name]">
<P>Awaiting translation for more information.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Kampen-1998">
<CHAR_METHODS MODIFIED="2011-12-06 18:42:08 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: stratified randomisation with sealed envelopes. Stratified by grams of urine loss (&lt; 50 , &gt; 50, &lt; 250, &gt; 250 g)</P>
<P>Blinding: yes (outcome assessor not involved with the study)<BR/>Dropouts: 5</P>
<P>Intention to treat: yes<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: men incontinent post-radical prostatectomy 15 days after surgery after catheter removal</P>
<P>N = 102 eligible, 98 completed<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (50) intervention: 1 session of PFMT in hospital before discharge and then saw the physiotherapist for 1 to 2 weeks for as long as UI persisted; 90 daily home exercises sitting, standing and lying; 7 men unable to contract PFM or with weak contraction received electrical stimulation by anal probe</P>
<P>Group B (52) control: No formal PFMT instruction but saw the therapist at 1 to 2 weeks and received placebo stimulation and information about aetiology of UI</P>
<P>Both A and B: received bladder training to increase bladder capacity</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measured by 24 and 1 hour pad tests; 24 hour pad test done daily until continence achieved; 1 hour pad test when loss of &lt; 2 g of urine to confirm continence</P>
<P>Secondary outcomes:<BR/>Subjective UI by visual analogue scale<BR/>Fluid Volume Chart<BR/>Quality of Life - questionnaire designed for study</P>
<P>Continence definition:<BR/>Numbers cured defined as &lt; 2 g urine loss on 24 and 1 hour pad tests</P>
<P>Data collection: subject assessment of continence preoperatively (during screening), and at 1, 6 and 12 months. Daily weighing of pads by participants (24 hour pad test)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Pragmatic study; policy of management left to clinical judgment as to which protocols to add to PFMT regime. 63 of the eligible subjects were unable to participate because of geographical reasons; demographics and post-operative variables did not differ from the 102 subjects who were in the treatment groups</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wille-2003">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes<BR/>Method of allocation: not described<BR/>Blinding: not mentioned<BR/>Dropouts: numbers participating at 3 and 12 months identified (for pad test, N = 116 at baseline, 79 at 3 months and 124 at 12 months), reason for dropouts not described</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-07 10:33:36 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: pre-operative</P>
<P>Included: all men undergoing radical prostatectomy</P>
<P>N = 139 randomised (number in each group at various data collection points varied)<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative intervention</P>
<P>Group A (47): PFMT alone</P>
<P>Group B (46): PFMT + ES; PFMT as above plus instructed by dedicated in ES via surface anal electrode and bio-impulser (biphasic pulse with 1 second bursts, 5 second pulse width, 2 second pulse trains</P>
<P>Group C (46): PFMT + ES + biofeedback. As above plus biofeedback (anal probe) 15 minutes twice daily for 3 months</P>
<P>All groups A and B and C: PFMT by physiotherapist, 20-30 minute sessions for 3 days, instructed to perform exercises twice daily for 3 months plus 3 week rehabilitation program after discharge. Regular interaction with health professional for 6 weeks after surgery, encouraged to performed treatment for 3 months post-surgery</P>
<P>Length of follow-up: 12 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]">
<P>Main outcome: urine loss measure by continence questionnaire and 20 minute provocative pad test</P>
<P>Continence definition: reported use of 0 to 1 pads on questionnaire (subjective) or loss of less than 1 gram of urine on pad test</P>
<P>Data collection: baseline (after catheter removal), 3 months and 12 months post-operatively</P>
<P>Willingness to undergo surgery again: A 73%, B 83%, C 73%</P>
<P>Quality of life EORCT QLQ-C30: scores for physical; role; emotional; social; and global quality of life were not significantly different between the groups at 3 or 12 months (no SDs provided)</P>
<P>No significant differences in continence rates between the three groups at baseline, 3 months or 12 months (objective)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-10-16 11:38:29 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yamanishi-2006">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes.</P>
<P>Blinding: double blind</P>
<P>Dropouts: 1 due to pain in the intervention group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation: postoperative</P>
<P>Included: radical prostatectomy, all with severe post-operative UI of &gt; 100 g after catheter removal</P>
<P>Age: mean 65.7 (7.0) years</P>
<P>Pre-operative intervention</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>All patients instructed pre-operatively PFMT by nurses and continued after catheter removal</P>
<P>A (26) intervention: oral PFMT plus electrical stimulation for 15 minutes twice daily (50 Hz square waves, 300 µsec pulse duration, maximum output 70 mA (5 sec on, 5 sec off duty cycle)</P>
<P>B (30) control: oral PFMT plus sham stimulation (output 3 mA, 2 sec on, 13 sec off duty cycle)</P>
<P>Duration of treatment: until continent or 12 months</P>
<P>Length of follow-up: 1, 3, 6 and 12 months after treatment</P>
<P>Dropouts: A 4/26, B 5/30 (including 2+4 with adverse effects)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Number of incontinent men</P>
<P>1 month: A 18/26, B 29/30</P>
<P>3 months: A 10/24, B 25/29</P>
<P>6 months: A 5/23, B 15/26</P>
<P>12 months: A 3/22, B 8/25</P>
<P>24 hour pad test weights (mean ml, SD, N)</P>
<P>1 month: A 210 (261) 26, B 423 (357) 30</P>
<P>3 months: A 81 (140) 24, B 232 (339) 29</P>
<P>6 months: A 20 (49) 23, B 132 (293) 26</P>
<P>12 months: A 18 (49) 22, B 98 (277) 25</P>
<P>Time until continent in months (mean, SD, N): A 2.71 (2.6) 22, B 6.82 (3.9) 25, P = 0.0006</P>
<P>ICIQ-SF (mean score SD N; 0 to 21, higher = worse)</P>
<P>1 month: A 10.6 (6) 26, B 14.9 (4.9) 30</P>
<P>3 months: A 5.8 (5.7) 24, B 11.2 (5.7) 29</P>
<P>6 months: A 4.3 (6.2) 23, B 8.2 (5.3) 26</P>
<P>12 months: A 4.2 (6.2) 22, B 5.6 (6.5) 25</P>
<P>ICIQ-QoL score (mean score SD N; 0 to 21; 0 to 10, higher = worse)</P>
<P>1 month: A 4.2 (3.5) 26, B 6 (3) 30</P>
<P>3 months: A 2.2 (2.3) 24, B 3.7 (2.9) 29</P>
<P>6 months: A 1.6 (3.1) 23, B 2.5 (2.2) 26</P>
<P>12 months: A 1.5 (3.1) 22, B 1.9 (2.5) 25</P>
<P>Adverse effects: A 2/26, B 4/30 (discomfort or anal pain)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-05 13:57:19 +0000" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yokoyama-2004">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
<P>Method of allocation: not stated</P>
<P>Blinding: not mentioned</P>
<P>Dropouts: it appears that there are no dropouts but this is not specifically mentioned</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>Recruitment: post-operative</P>
<P>Included: 36 men with urinary incontinence, &gt;100g on 24hour pad test, one day after catheter removal</P>
<P>Mean age: Group A 67.2 years, Group B 68.2 years, Group C 66.2 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>A (12) intervention: anal electrode for 15 minutes twice a day for 1 month</P>
<P>B (12) intervention: extra-corporeal magnetic innervation, neocontrol system, treatment sessions 20 minutes, twice a week for 2 weeks</P>
<P>C (12) control: PFMT, digital anal teaching of correct contractions, then verbal and written instructions for home practice</P>
<P>Length of follow-up: 2, 3, 4, 5 and 6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]">
<P>24 hour pad test weight (grams)</P>
<P>3 months: A 34 g, B 7.3 g, C 50 g.</P>
<P>6 months: for all groups less than 10 g</P>
<P>Quality of life measured by I-QOL: improvement in all groups over time, no statistically significant difference between the groups</P>
<P>Remaining UI at 6 months: A 2/12, B 1/12, C 2/12</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-12-01 11:24:49 +0000" MODIFIED_BY="[Empty name]">
<P>Adverse effects: None in any of the groups, no discomfort or irritation from anal probe</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_METHODS MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]">
<P>Randomised: yes</P>
<P>Method of allocation: not stated</P>
<P>Blinding: none</P>
<P>Dropouts: two did not complete the control follow-up assessment because they believed the control group was not helpful</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]">
<P>58 men approached, 33 consented, 3 dropouts</P>
<P>Recruitment: post-operative</P>
<P>Included: all incontinent men 6 months after radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]">
<P>Group A (14) intervention: PFMT plus BF using rectal electrical sensor, initial 45 minute session with physical therapist then written instructions to carry out at home three times a day for 10 minutes. Plus support group, 6 meetings in 3 months with a health psychologist</P>
<P>Group B (15) control: PFMT plus BF using rectal electrical sensor, initial 45 minute session with physical therapist then written instructions to carry out at home three times a day for 10 minutes</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]">
<P>Length of follow-up: 3 months</P>
<P>Frequency of PFMT: 4 to 7 times per week A 12/14, B 6/13, P = 0.077</P>
<P>Use of pad or brief: A 7/14 (50%), B 11/13 (85%), P = 0.057</P>
<P>Not able to control urge to urinate and prevent leakage: A 4/14, B 8/13, P = 0.085</P>
<P>Nocturia per week (mean): A 13, B 15.08, P = 0.484</P>
<P>VAS for severity of UI: A 3.21, B 4.65, P = 0.057 (t = -1.902)</P>
<P>QoL measured by Illness Intrusiveness Questionnaires (IIRS): A 10.96, B 17.27, P = 0.037 Mann Whitney U = 48.5</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ExMI = extra-corporeal magnetic innervation; g = gram(s); PFMT = pelvic floor muscle training; TURP = transurethral resection of the prostate; UI = urinary incontinence</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bennett-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient information to assess study for inclusion. Abstract only, no data included. Attempts to contact the author for data unsuccessful</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bocker-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Data from study that included male postprostatectomy and female post-polio patients. Translation obtained as reported in German. Data from the two groups were not separated and therefore not in a usable form</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burkert-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not measuring incontinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ceresoli-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient information to assess study for inclusion. Attempts to contact the author for data unsuccessful</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chang-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Data from study which involved post-TURP patients. Two groups, treatment and control. Not randomly assigned to groups, first 25 consecutively assigned to control, next 25 to intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornel-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cornu-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT. PFMT + Duloxetine (drug) versus PFMT + placebo</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crevenna-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive pilot study. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dieperink-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention after radiotherapy only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eren-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, 58 men after RP. Pharmacological intervention: Duloxetine + PFMT versus PFMT alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Filocamo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT, 112 men after RP. Pharmacological intervention: Duloxetine + PFMT versus PFMT alone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Griebling-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient information to assess study for inclusion. Data reported in paper presentation and in later published report did not contain sufficient detail of analysis to include in tables of comparison. Attempts to contact authors not successful in providing further data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hotston-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Pharmacological intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ip-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Education intervention (refrigerator magnet) not an intervention included in review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kahihara-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>A comparative study. Early versus delayed PFMT no randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Measuring erectile dysfunction only</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-McGlynn-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study of change in education delivery approach. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mishel-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Data not separated for men who received radiotherapy and those who underwent prostate surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nehra-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Insufficient information to assess study for inclusion. Abstract only. Attempts to contact authors for further data unsuccessful. Possibly ongoing trial but no further data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ottenbacher-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>RCT but of written information about diet and general exercise</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pemberton-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Comparative study of different types of urinary sheath</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prota-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Measuring erectile dysfunction, no useable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pulker-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study. No control group<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ribeiro-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not prostatectomy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ricci-2004-NEWa">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Measuring "sensory urgency" only, not incontinence</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Robinson-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Measuring the validity of a specific test, no useable data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salinas-Casado-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study. No control group. Article in Spanish with English abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salinas-Casado-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study. No control group. Article in Spanish with English abstract</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Seki-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shen-2012-NEWa">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not looking at incontinence. Translation obtained as reported in Chinese</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Traeger-2013">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Data for men who received radiotherapy not separated from those who underwent prostate surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yang-2010-NEWa">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised. Translation obtained as reported in Chinese</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yao-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not RCT. Physiotherapist-guided PFMT versus control (retrospective analysis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zahariou-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zermann-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Descriptive study. No control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Data for men who received radiotherapy not separated from those who underwent surgery</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Estim = Electrical stimulation</P>
<P>ExMI = Extra-corporeal magnetic innervation</P>
<P>TURP = Transurethral resection of the prostate</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Crivellaro-2011">
<CHAR_METHODS MODIFIED="2014-05-26 11:33:36 +0100" MODIFIED_BY="[Empty name]">
<P>Not enough information</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-17 10:35:00 +0000" MODIFIED_BY="[Empty name]">
<P>73 men after retropubic radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Ultrasound-guided biofeedback versus biofeedback using verbal instructions and digital biofeedback</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Authors to be contacted regarding whether assignment was randomised</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-05-15 12:04:19 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Delmastro-2010">
<CHAR_METHODS MODIFIED="2011-11-24 11:44:59 +0000" MODIFIED_BY="[Empty name]">
<P>Open label RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-11-24 11:45:22 +0000" MODIFIED_BY="[Empty name]">
<P>Men scheduled for radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-11-24 11:44:10 +0000" MODIFIED_BY="[Empty name]">
<P>Preoperative intensive PFMT with or without proprioceptive training</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-11-24 11:50:38 +0000" MODIFIED_BY="[Empty name]">
<P>Anal examination to assess pelvic floor muscle function; subjective and objective voiding and incontinence parameters; four tests of pelvic floor muscle function; PGI-I; ICIQ-male score</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-15 12:04:19 +0100" MODIFIED_BY="[Empty name]">
<P>Further information needed from authors</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lilli-2006-NEW">
<CHAR_METHODS MODIFIED="2014-05-26 11:34:17 +0100" MODIFIED_BY="[Empty name]">
<P>Unclear if randomised, further information from authors required</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of recruitment:</B> pre-operative</P>
<P> </P>
<P>
<B>Population:</B> Men having a radical prostatectomy (whole population, with or without UI)</P>
<P> </P>
<P>
<B>Included:</B> Men who were candidates for retropubic radical prostatectomy</P>
<P> </P>
<P>
<B>Excluded: </B>Acquired or congenital disability, cardiovascular diseases requiring the administration of drugs that interfere with voiding, e.g. diuretics and/or alphalytics, problems relating to vesico-sphincteral innervations, episodes of unstable or transitory continence during their lifetime, any type of neuropathy, other cancers, and psychoaffective disturbances such as depression or insomnia</P>
<P>
<B>Age</B> (mean, SD): A 68 (?); B 68 (?)</P>
<P> </P>
<P>
<B>Dropouts:</B> Not reported</P>
<P>
<B>Baseline characteristics:</B>  Comparable at baseline</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Time of intervention:</B> Pre-operative</P>
<P> </P>
<P>A (45): 20 mins of PFMT + biofeedback daily for 15 weeks before surgery, instructed to: carry out exercises during increased abdominal pressure (coughing, extending the abdomen, raising the head and keeping it raised), instructed how to carry out rapid, brief contractions without increasing abdominal activity and how to perform slow contractions</P>
<P> </P>
<P>B (45): Instructed to start PFMT at home 15 weeks before surgery</P>
<P> </P>
<P>After surgery and removal of catheter, all men were instructed to carry out four series of PF contractions at home on a daily basis for six months</P>
<P> </P>
<P>
<B>Duration of treatment: </B>6 months</P>
<P>
<B>Follow up:</B> 1 month, 3 months and 6 months after surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Primary outcome (number of men with UI):</B>
</P>
<P>Number of incontinent men (defined as use of pads):</P>
<P>Pre-operative: A 0/45; B 0/45</P>
<P>1 month: A 42/45; B 42/45</P>
<P>3 months: A 30/45; B 33/45</P>
<P>6 months: A 13/45; B 15/45</P>
<P>
<B>Other outcomes:</B>
</P>
<P>Number of continent men (defined as completely dry without the use of pads):</P>
<P>Pre-operative: A 45/45; B 45/45</P>
<P>1 month: A 3/45; B 3/45</P>
<P>3 months: A 15/45; B 12/45</P>
<P>6 months: A 32/45; B 30/45</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Unclear if randomised</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-04-02 11:38:31 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Simeit-2010-NEW">
<CHAR_METHODS MODIFIED="2014-04-02 11:36:01 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-02 11:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Men with urinary incontinence after radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-02 11:37:33 +0100" MODIFIED_BY="[Empty name]">
<P>A: PFMT </P>
<P>B: PFMT with additional 'BBS trainer'</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-02 11:38:31 +0100" MODIFIED_BY="[Empty name]">
<P>Quality of life (EORTC questionnaire), impact of incontinence</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-02 11:27:07 +0100" MODIFIED_BY="[Empty name]">
<P>Awaiting German translation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2014-04-02 11:37:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zellner-2011-NEW">
<CHAR_METHODS MODIFIED="2014-04-02 11:31:17 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-04-02 11:32:11 +0100" MODIFIED_BY="[Empty name]">
<P>Men after radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-04-02 11:37:00 +0100" MODIFIED_BY="[Empty name]">
<P>A: PFMT + biofeedback + electrical stimulation</P>
<P>B: Whole body vibration</P>
<P>C: Guided PFMT </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-04-02 11:34:58 +0100" MODIFIED_BY="[Empty name]">
<P>International Prostate Symptom Score (IPSS), the enclosed question about quality of life (IPSS-QL), pad test, pelvic floor strength, maximum uroflow, micturition volume, serum testosterone and blood glucose</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-04-02 11:27:19 +0100" MODIFIED_BY="[Empty name]">
<P>Awaiting German translation</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2013">
<CHAR_METHODS MODIFIED="2014-05-08 10:54:58 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 10:55:39 +0100" MODIFIED_BY="[Empty name]">
<P>127 Men with incontinence after &#8220;cancer treatment&#8221; Radical prostatectomy?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>A: Biofeedback + PFMT + 6 biweekly sessions of problem-solving therapy delivered through a support group, B: Biofeedback + PFMT + 6 biweekly sessions of Problem-solving therapy delivered through telephone contact, C (?): Standard care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 10:57:44 +0100" MODIFIED_BY="[Empty name]">
<P>Number of incontinent men [need for wearing a pad]</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-08 12:02:19 +0100" MODIFIED_BY="[Empty name]">
<P>Further information required about participants + no useable data</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2014-05-08 11:45:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burnett-2012">
<CHAR_STUDY_NAME MODIFIED="2014-05-08 11:39:39 +0100" MODIFIED_BY="[Empty name]">
<P>Health Interventions in Men Undergoing Radical Prostatectomy- A Randomized Controlled Clinical Trial</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-05-08 11:39:56 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 11:40:46 +0100" MODIFIED_BY="[Empty name]">
<P>Men undergoing radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-08 11:42:13 +0100" MODIFIED_BY="[Empty name]">
<P>Intensive fitness intervention</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 11:44:06 +0100" MODIFIED_BY="[Empty name]">
<P>Expanded Prostate Cancer Index (EPIC)-26, RAND-12 Questionnaire, body weight change, body mass index (BMI) change, blood pressure (BP) change, International Index of Erectile Function (IIEF), Quality of Erection Questionnaire (QEQ)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-05-08 11:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>December 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-05-08 11:45:45 +0100" MODIFIED_BY="[Empty name]">
<P>Arthur L Burnett, Johns Hopkins Hospital, Baltimore, United States</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Burnett-2013">
<CHAR_STUDY_NAME MODIFIED="2014-05-08 11:38:49 +0100" MODIFIED_BY="[Empty name]">
<P>Study of Non-Invasive Viberect Penile Vibratory Stimulation Regimen to Enhance Recovery of Erectile Function/Rigidity and Urinary Control/Continence After Nerve Sparing Radical Prostatectomy (RP) for Clinically Localized Prostate Cancer</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-11 13:47:02 +0000" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 13:51:10 +0000" MODIFIED_BY="[Empty name]">
<P>Men with Urinary Incontinence </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Post-operative use of Viberect device 3 days after catheter removal, daily usage for 7-10 minutes versus no treatment</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Recovery of erectile function following radical prostatectomy, IIEF, recovery of continence, EPIC urinary and and sexual domain, AUA, EHS EDITS and TSS questionnaires</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-11 13:58:30 +0000" MODIFIED_BY="[Empty name]">
<P>April 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-11 13:59:12 +0000" MODIFIED_BY="[Empty name]">
<P>Arthur L. Burnett, M.D., Johns Hopkins University </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fode-2012-NEW">
<CHAR_STUDY_NAME MODIFIED="2014-03-11 14:02:00 +0000" MODIFIED_BY="[Empty name]">
<P>Mechanical Nerve Stimulation in the Treatment of Post Prostatectomy Incontinence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-11 14:02:08 +0000" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Men with urinary incontinence more than 1 year after radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 14:04:25 +0000" MODIFIED_BY="[Empty name]">
<P>Medical vibrator used daily for 6 weeks </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 14:06:02 +0000" MODIFIED_BY="[Empty name]">
<P>24 hour pad test, Micturition diary, Validated symptom score ICI-Q, IPSS</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-11 14:06:14 +0000" MODIFIED_BY="[Empty name]">
<P>June 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-11 14:06:51 +0000" MODIFIED_BY="[Empty name]">
<P>Copenhagen University Hospital at Herlev</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-12 12:16:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goode-2014">
<CHAR_STUDY_NAME MODIFIED="2014-03-12 12:08:10 +0000" MODIFIED_BY="[Empty name]">
<P>Perioperative Post-Prostatectomy Incontinence Home Telehealth Program (ProsTel)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-12 12:08:17 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-12 12:11:12 +0000" MODIFIED_BY="[Empty name]">
<P>Men undergoing radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-12 12:13:14 +0000" MODIFIED_BY="[Empty name]">
<P>Guided PFMT using a telehealth device (home messaging unit)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-12 12:15:31 +0000" MODIFIED_BY="[Empty name]">
<P>Time to continence using ICIQ-SF, EPIC-UI, HRQOL, IIQ-SF, IPSS, patient satisfaction questionnaire, Estimated Percent improvement, Global perception of Improvement</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-12 12:15:44 +0000" MODIFIED_BY="[Empty name]">
<P>January 2012</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-12 12:16:17 +0000" MODIFIED_BY="[Empty name]">
<P>Department of Veterans Affairs</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mina-2013">
<CHAR_STUDY_NAME MODIFIED="2014-05-08 11:56:54 +0100" MODIFIED_BY="[Empty name]">
<P>A Multicentre, Pilot Randomized Controlled Trial to Examine the Effects of Prehabilitation on Functional Outcomes After Radical Prostatectomy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-05-08 11:56:59 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 11:57:20 +0100" MODIFIED_BY="[Empty name]">
<P>Men undergoing radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-08 11:57:33 +0100" MODIFIED_BY="[Empty name]">
<P>Behavioral: Prehabilitation (PREHAB)<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Adherence to Prehabilitation Program, Recruitment, Contamination, Study Retention, Physical Fitness, Quality of Life, Psychosocial Wellbeing, Physical Activity, Treatment Complications, Post-operative length of stay</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-05-08 12:00:15 +0100" MODIFIED_BY="[Empty name]">
<P>November 2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-05-08 12:01:48 +0100" MODIFIED_BY="[Empty name]">
<P>Daniel Santa Mina, University Health Network, Toronto, Ontario, Canada</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2014-05-08 12:01:25 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ng-2011">
<CHAR_STUDY_NAME MODIFIED="2014-03-11 14:08:08 +0000" MODIFIED_BY="[Empty name]">
<P>Trial study of the efficacy of intensive preoperative pelvic floor muscle training to decrease post-prostatectomy urinary incontinence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-11 14:08:12 +0000" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 14:08:57 +0000" MODIFIED_BY="[Empty name]">
<P>Men with urinary incontinence after radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Preoperative guided PFMT 3 weeks before surgery versus PFMT on the day of admission for surgery</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 14:12:38 +0000" MODIFIED_BY="[Empty name]">
<P>Pad test, IIQ-7, SF 12</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-03-11 14:12:46 +0000" MODIFIED_BY="[Empty name]">
<P>February 2011</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-11 14:13:21 +0000" MODIFIED_BY="[Empty name]">
<P>Sau-loi NG, Queen Mary Hospital, Hong Kong</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-05-08 12:29:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terrone-2007">
<CHAR_STUDY_NAME MODIFIED="2014-05-08 12:26:06 +0100" MODIFIED_BY="[Empty name]">
<P>Prevention of Urinary Incontinence After Prostatectomy</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-05-08 12:26:31 +0100" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 12:27:17 +0100" MODIFIED_BY="[Empty name]">
<P>Men undergoing radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-08 12:27:34 +0100" MODIFIED_BY="[Empty name]">
<P>BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 12:28:24 +0100" MODIFIED_BY="[Empty name]">
<P>24-hour PAD test: Complete continence</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2014-05-08 12:28:33 +0100" MODIFIED_BY="[Empty name]">
<P>February 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-05-08 12:29:12 +0100" MODIFIED_BY="[Empty name]">
<P>Carlo Cisari, Azienda Ospedaliero Universitaria Maggiore della Carita</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2014-03-11 14:20:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zopf-2012">
<CHAR_STUDY_NAME MODIFIED="2014-03-11 14:14:15 +0000" MODIFIED_BY="[Empty name]">
<P>Implementation and scientific evaluation of rehabilitative sports groups for prostate cancer patients: study protocol of the ProRehab Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2014-03-11 14:15:01 +0000" MODIFIED_BY="[Empty name]">
<P>"Patient preference RCT"?</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-03-11 14:16:37 +0000" MODIFIED_BY="[Empty name]">
<P>Men after radical prostatectomy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-03-11 14:17:47 +0000" MODIFIED_BY="[Empty name]">
<P>exercise intervention - rehabilitative sports group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-03-11 14:19:31 +0000" MODIFIED_BY="[Empty name]">
<P>"quality of life using EORTC-QLQ-C30/PR 25, incontinence using pad test and erectile dysfunction using IIEF"</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION MODIFIED="2014-03-11 14:20:20 +0000" MODIFIED_BY="[Empty name]">
<P>German Sport University Cologne</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Estim = Electrical stimulation</P>
<P>ExMI = Extra-corporeal magnetic innervation</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>Randomised using &#8220;a computer-generated random-number list&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 11:07:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-13 17:00:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>Stratified by age and tumour differentiation, then randomised using computer generated random numbers, block size of 4 to ensure equity of number in each group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>"Individuals were randomised by a computer-generated list that was centrally maintained". "Permuted block randomisation was used, with a block size of every 10 consecutively enrolled participants"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:42:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>&#8220;Computer-generated random numbers with block randomization and variable block size&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 15:24:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>Random number generator to achieve 1:1 ratio</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>&#8220;random order&#8221; cross-over design</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Block randomisation, block size of 4 for 2 groups (A and B) with only one permutation code (ABBA)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 12:42:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>"randomized prospective trial" and &#8220;randomized by a draw&#8221; </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Sequence of randomisation was carried out using a &#8220;computer program&#8221; and was &#8220;determined by the patients&#8217; presence at the outpatient urology clinic&#8221;. It is unclear what influence the patients&#8217; presence had on randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:47:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>&#8220;Patients were divided randomly&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-15 12:16:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>Computer generated, minimised on centre, age and pre-existing urinary incontinence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-15 17:10:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>Computer generated, minimised on centre, age and pre-existing urinary incontinence</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 09:11:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Stratified by site, type and frequency of UI, generated by computer programme</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Computerised randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:21:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>"randomly classified"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>No description, Chinese language</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 09:22:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>&#8220;The patients were randomized (computer generated list using Randomizer, v4)&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Quote "randomly assigned". No additional information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Computer generated random numbers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 10:35:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>&#8220;Prospectively randomized&#8221; Sequence generation not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 13:40:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Consecutive patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:42:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>&#8220;randomised&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-13 17:29:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>Block procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:10:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"Participants were assigned using a computer-generated random-number list placed in sealed envelopes at the end of the assessment visit, with patient and researcher opening the sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:08:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>"A computer-generated randomized list of device assignments was prepared by one of the investigators" Block, multiple period crossover design using Latin square configuration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-28 10:15:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Computer generated list of random numbers, random blocked allocation to groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:12:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>&#8220;randomly assigned&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 14:36:28 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>"randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Norwegian University performed the computerised randomisation procedure immediately after pre-operative test</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:52:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>"Patients were enrolled in prospective, randomized fashion into a treatment or a control group"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:37:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>&#8220;A random number generator was used to determine the randomization allocation in a 1:1 ratio&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>Consecutive patients. No additional information provided. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 13:59:40 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-12 14:31:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>Computer-generated randomisation list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 14:01:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>Via sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-28 10:20:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Coloured cards</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-09 09:23:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Mathematical table, grouped in blocks of 10</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-28 15:49:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>&#8220;Generated by computer and was stratified with a 1:1 allocation&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 09:43:27 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>"Prospective randomized trial" Method of sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-24 12:00:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>By computer</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-06 18:42:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>Stratified by grams of urine loss (&lt; 50 , &gt; 50, &lt; 250, &gt; 250 g)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:18:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>&#8220;sealed envelopes&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 13:39:15 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>"Randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>Computer allocated. "The randomization schedule was implemented by the research nurse, so that interventionists would be blinded to the next group assignment."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>"Individuals were randomised by a computer-generated list that was centrally maintained". "Permuted block randomisation was used, with a block size of every 10 consecutively enrolled participants"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:43:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>"central computer system"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-25 15:24:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>Sealed envelopes, sequentially numbered, opened by trial nurse after result of pad test was known</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:05:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>&#8220;random order&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Not stated. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Randomised 2:1 to intervention: control groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>Used opaque sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 14:00:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>"Randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-20 12:07:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>&#8220;Allocation to the treatment groups was concealed&#8221;. Method not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-15 12:17:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>Remote computer allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-15 17:10:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>Remote computer allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-11-23 09:11:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Sealed envelopes, opened sequentially</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:27:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Method of allocation concealment not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:21:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>"randomly classified"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Reported as "Randomised". No additional information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:26:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>"Randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 09:21:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>&#8220;The patients were randomized (computer generated list using Randomizer, v4)&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-28 10:29:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Stratified on volume of urine lost on pad test </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 11:12:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>"Prospectively randomized"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 13:48:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Quote - "Randomized fashion"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 09:55:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"Participants were assigned using a computer-generated random-number list placed in sealed envelopes at the end of the assessment visit, with patient and researcher opening the sealed envelope"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-07 13:55:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>Sealed envelopes, research assistant not involved in study chose envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Group allocation placed in sealed opaque envelopes; opened by participant after initial post-operation instruction session with therapist</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:10:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>"randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 14:06:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>"Randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Norwegian University performed the computerised randomisation procedure immediately after pre-operative test. Urologist no prior knowledge of randomisation procedure</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:49:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>"Randomly assigned"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:37:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>&#8220;Sealed envelope, sequentially numbered, and opened by the trial nurse&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>Randomised controlled trial. No additional information provided. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-08 15:20:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>B - 'randomised'</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 14:07:11 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>"Randomised controlled trial"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>The co-project director who supervised the intervention was responsible for recruitment, but did not have access to the randomisation list</P>
<P>The co-project director who supervised data collection was responsible for concealment of the randomisation list and allocation to the next available assignment on the list to participants sequentially as they enrolled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-28 10:20:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Method of selection unknown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-11-05 10:35:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Sealed envelopes by independent third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-28 15:49:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 09:43:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>"Prospective randomized trial" Method of sequence generation not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 09:46:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>"None of the patients, doctors or medical staff knew which type of stimulation had been assigned until the key code was opened"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 14:31:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Randomly assigned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-04-13 14:31:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>"Randomised"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-16 11:18:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>A - stratified randomisation with sealed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-05-08 14:10:15 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-01-20 11:48:53 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-14" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Blinding of participants (performance bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:18:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>Blinding to treatment not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:11:38 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:12:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:24:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 14:08:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>&#8220;participants were also blinded until their first visit to the pelvic floor physiotherapist&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-20 09:39:02 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:13:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>Blinding was not possible for participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:17:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:17:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 09:29:35 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>&#8220;It was not possible to create a believable sham device, which could maintain blinding of the study subjects&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>Blinding not possible. Therefore judged to be at high risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 11:42:05 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Blinding was not possible for participants</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-17 04:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Blinding to treatment not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:18:54 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>Blinding to intervention not possible for men</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:19:23 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>Blinding to intervention not possible for men</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:19:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:28:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:21:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Blinding to intervention was not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 09:22:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:20:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 15:47:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Blinding of intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 11:13:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:21:45 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:46:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Blinding to treatment not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:19:37 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-01 12:53:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:10:28 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 14:07:56 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:22:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:23:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:23:06 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:00:55 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:25:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:36:10 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>Blinding of participants was not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:43:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:26:48 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:27:36 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>Participants were advised by the research assistant of their group assignment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:27:49 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:41:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:28:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Not possible to blind to intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-28 15:50:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>&#8220;Participants were unblinded to treatment assignment&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>No description, Spanish language</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:30:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:10:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>Men were blinded to the intervention (sham, low energy stimulation in control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 11:52:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Group therapy (unable to blind to intervention)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-17 06:10:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>The control group "received placebo electrotherapy that could not affect the pelvic-floor muscle function."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Blinding of personnel (performance bias)</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:18:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>&#8220;One experienced physiotherapist delivered all therapy&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:11:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:12:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>Intervention providers and bladder diary scorers were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:26:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>"The surgeon who performed the procedures was blinded to randomisation allocation throughout the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:43:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>&#8220;The pelvic floor physiotherapists were blinded to randomization&#8221; (to pre-operative randomisation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-20 09:39:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>"The physiotherapist who guided men in the PGPFME group was unaware of the outcome data of both treatment groups"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:17:31 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:18:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Post-operative treatment was delivered by a therapist who was blinded to group allocation and treatment delivered by the pre-operative Group A therapist </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:18:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>Blinding to intervention not possible for therapists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:19:25 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>Blinding to intervention not possible for therapists</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Data entry staff blinded to group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:28:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:21:46 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:13:51 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 11:08:32 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>&#8220;PFMR was performed in the preoperative period by the same physiotherapist.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:20:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:21:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Blinidng of intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 09:38:24 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 09:55:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Physiotherapist blinded </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:10:29 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Therapist blinded to outcome of non-intervention group; pads weighed by third party</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:00:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:25:30 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Blinding to intervention not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:36:08 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:17:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>Urologist performing digital evaluation of pelvic floor muscle contraction was blinded to the study group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:27:01 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:27:39 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>Questionnaires were filled in by research assistants either in person or by telephone interview</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:28:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Blinding not possible</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:27:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Independent physiotherapist undertook initial assessment and 4 week outcome assessment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-28 15:49:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>&#8220;Surgeons and person scoring the evaluation questionnaires were blinded throughout the duration of the study&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-10 11:30:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>Blinding of doctors, nurses and medical staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>A research assistant, who was a doctoral candidate in medical anthropology, collected data under supervision</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-17 06:10:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>"The patients in both groups were treated by the same therapist (MVK) until they became continent, within a period of 1 year"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>No information provided. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-06 13:21:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Outcome assessment nurse not involved in intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-18 10:12:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>Bladder diary scorers were blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-19 10:25:35 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>"Only the statistician and the data monitoring committee saw unblinded data"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-24 09:35:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>Outcome assessor blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-17 03:33:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>"The data for outcome assessment (e.g. pad-tests, voiding diaries) were collected and entered in a data base by a trial nurse who was not involved in the treatment or intervention"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-19 11:51:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>No description of blinding of pad test or data entry from questionnaires</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-11 12:43:04 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>Outcome assessor not blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-20 12:07:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>&#8220;One blinded and well-trained assessor performed the measurements&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-01-20 11:40:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>Outcomes from questionnaires completed by men, data entry clerks blinded to group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-19 11:01:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>Outcomes from questionnaires completed by men, data entry clerks blinded to group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-18 16:17:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Outcomes from questionnaires completed by men, data entry staff blinded to group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-07 15:28:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Insufficient information to permit judgement </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk.\</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>No information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-02 15:47:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Blinded outcome assessors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-18 10:10:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>"A research assistant not directly involved with recruitment or data collection entered the data"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-18 14:08:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Data entry by clerk blinded to group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>No information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-15 12:04:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>An independent assessor performed serial measurements</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-07 10:42:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>"One urologist, who was blinded to the study group of the patients, performed only the digital evaluation of the pelvic floor muscle contraction and established and reported the grading during all the visits"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>No information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>No information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-13 11:52:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>&#8220;nurse scoring the evaluation questionnaires was blinded&#8221; to randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>No information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-02 13:18:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-03-10 11:30:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>Blinding of assessors, medical staff</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-02-05 13:45:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>Outcome assessor not involved with the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>4 (2 received radiotherapy, 2 had post-operative complications); B: 4 (2 received radiotherapy, 2 refused follow-up); C: 2 (2 received radiotherapy). No differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Three patients dropped out of the biofeedback arm of the study because they never completed their biofeedback session</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>6 and 4 lost to follow-up at 6 months; 6 and 7 excluded after randomisation as surgery cancelled</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>No description. It appears that there were was no loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>9 from A (1 unable to understand Dutch, 3 post-operative radiotherapy, 1 oesophageal cancer, 3 discontinued intervention at own request, 1 excluded due to poor compliance) 8 from B (2 post-operative radiotherapy, 1 pelvic lymph node dissection, 1 died of cause unrelated to prostate cancer, 5 discontinued intervention at own request, 1 prolonged catheter á demeure). Not differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-24 12:55:19 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>13 dropped out (of which 2 from intervention group)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>No information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-15 15:55:44 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>2 dropped out of control group but none from intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-17 11:18:57 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>1 dropped out of intervention group but followed control intervention - unclear if analysed as control</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>12 from group A (3 excluded because underwent non-nerve sparing surgery, 2 withdrew consent, 1 lost a partner, 6 non-compliance), 3 from group B (2 excluded because underwent non-nerve sparing surgery, 1 withdrew consent). Differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>Five men withdrew after initial randomisation. Dropouts from 25 left at 6 weeks appears to be 10</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-17 04:10:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Dropouts: Group A: 6 (1 died, 1 cerebrovascular accident, 3 transport problems, 1 refused further participation); Group B: 4 (2 transport problems, 2 refused further participation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-15 16:24:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>No differential dropout from the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-11-15 17:10:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>No differential dropout from the groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:53 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Analysis and reported tables on 172 men</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-07 15:51:18 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Dropouts: 22 out of 60 in anal ES group, 4 out of 60 in perineal ES group. No reasons for dropouts given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>5 (2 catheter still in situ after discharge from hospital, 3 lost to follow-up). Not differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Three dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>No description Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>9 (2 failed to attend all sessions, 2 desistance, 1 adjuvant radiotherapy, 1 post-operative urethral stenosis, 1 urinary fistula, 1 unsuitable for surgery due to cardiovascular risk, 1 inadequate follow-up). Unclear from which group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-02-12 09:22:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>All 24 patients included in the final analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Differential dropout of 13 from control group, ITT analysis used for data entry by review authors</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-13 11:14:26 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Not reported for primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-11-17 11:34:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>&#8220;Five patients lost at follow up&#8221;. Not clear why there were dropouts or from which group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>Two dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>5 (3 from group B, 2 from group A), 3 bladder neck contractures, 1 rectal pain when performing exercises, 1 vacation for 4 months). No differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-16 11:04:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>No dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Dropouts: control = 7; treatment = 12; no differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>Not enough information. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-18 14:37:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>One patient withdrew from Group A for non-medical reasons</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>Four dropouts</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Drop out rate was 6% Four lost to follow up in physiotherapy group, one lost in instructions only group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-16 11:13:15 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>1 dropout from each arm. Categorised as incontinent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>A: 7 (1 orthopaedic surgery for a pre-existing ankle problem, 1 transurethral surgery for urethral stricture, 4 non-compliance with follow-up due to a long distance from the centre to the home or personal affairs, 1 new employment after surgery)</P>
<P>B: 8 (1 ophthalmologic surgery for a cataract, 2 adjuvant radiotherapy, 4 non-compliance with follow up due to a long distance from the center to the home or personal affairs, 1 new employment after surgery)</P>
<P>No differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-10-16 11:16:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>Dropouts due to non-attendance at all clinic appointments (A 2, B 1) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>19: A:10 (2 refused further follow-up, 7 post-operative complications, 1 radiotherapy); B: 9 (6 refused further follow-up, 2 post-operative complications, 1 radiotherapy). No differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>No significant difference between groups in the number of participants who either withdrew prematurely or were dropped from the study. Questionnaires with &gt; 20% data missing were excluded from analysis. In remainder mean substitution was inputted for missing data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>No information for Group B control for both the one hour pad test and the VAS severity of UI</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-01-06 14:17:32 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Nine dropped out before intervention</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>1 from A (intolerance to procedure) 1 from B (surgical complication). Not differential dropout</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>No dropouts. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-07 16:01:43 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>"Results at baseline after catheter removal, at 3 and 12 months postoperatively were available for 139, 120 and 128 (questionnaires at three different time points) and 116, 79 and 124 (pad test at three different time points) patients, respectively". However, no information about individual groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-07 15:58:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>It is reported that "In the active ES group 2 patients discontinued after 2 and 3 months, respectively, due to urethral stricture at the bladder neck. In the sham group 1 patient discontinued treatment at 7 months because of an increase in prostate specific antigen and he then underwent radiation therapy". However, there is no evidence that dropout was related to trial interventions</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2009-12-01 10:51:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Numbers not given</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Two dropouts in the control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-04-13 14:18:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>Dropouts: 5</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>All outcomes in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:48:17 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:48:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>Protocol not available. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 12:12:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>All outcomes in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-20 09:47:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>All outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:13:13 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>Quality of life outcome not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:51:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:52:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:51:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>Outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:56:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:49:52 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Results not reported for quality of life outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Protocol not available. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:58:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>Outcomes in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:02:03 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>Outcomes in methods were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:22:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Results of outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:52:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:58:22 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Protocol not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:58:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 20:59:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 09:36:44 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>Results of SF-36 not reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:48:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-21 15:09:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 11:15:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>No reporting of primary outcome</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:49:33 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:23:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:44:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>Outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 09:48:47 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:26:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>Outcomes reported </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Protocol not available. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>Protocol not available. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:24:25 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:51:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-26 11:48:16 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:51:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:56:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>Results of outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:25:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:46:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>Results reported for outcomes stated in methods</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 13:53:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>Outcomes in methods reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:56:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:25:42 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:26:12 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:56:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:26:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:55:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>Spanish language</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 16:01:53 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Protocol not available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:58:50 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:57:17 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 13:57:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Outcomes reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:28:24 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>Protocol not available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-01-20 11:51:53 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Financial support</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-05 16:06:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-17 14:34:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:31:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>"Supported by Grant RO1 DK50283 from the National Institute for Diabetes and Digestive and Kidney Diseases, National Institutes of Health"</P>
<P>"The funding organization did not participate in the design or conduct of the study; collection, management, analysis or interpretation of the data; or the preparation, review or approval of the manuscript."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:28:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 14:08:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-06 13:43:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>No description</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-20 09:13:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>Prostate Cancer UK</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 09:29:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>&#8220;This study was funded by unrestricted grants from the Velux Foundation and Grosserer L.F. Foghts Foundation&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:46:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-20 12:06:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Unconditional funding from the &#8220;Agency for innovation by Science and Technology (Applied Biomedical Research): governmental grant&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:47:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:01:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>"The trial was funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme (project number 03-14-03) and will be published in full in Health Technology Assessment. HSRU, HERU, and NMAHP RU are funded by the Chief Scientist Office of the Scottish Government Health Directorates"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:02:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>"The trial was funded by the National Institute of Health Research Health Technology Assessment (NIHR HTA) Programme (project number 03-14-03) and will be published in full in Health Technology Assessment. HSRU, HERU, and NMAHP RU are funded by the Chief Scientist Office of the Scottish Government Health Directorates"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 16:16:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>National Institutes of Health - National Institute of Diabetes and Digestive and Kidney Diseases, grant R01 DK60044-01A2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>Not reported, Chinese language</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 11:09:30 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>&#8220;Sao Paulo State Foundation for Research Support &#8211; FAPESP (number 08/54585-1)&#8221; </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:31:40 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-01 12:34:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"Funding for the research project was received from the Oncology Nurses' Society, Canadian Nurses' Foundation, Caritas Health, Alberta Physiotherapy Association, Edna Minton Foundation, and the University of Alberta" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:24:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>"This study was supported by the University of Alberta Internal Allocations Fund and Department of Radiology, University of Alberta Hospital."</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 14:24:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>"Funded by the Alberta Heritage Foundation for Medical Research, the Northern Alberta Urology Foundation, and Pfizer Corporation (unrestricted)"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:12:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-26 11:48:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>"The work was funded by The Norwegian Fund for Postgraduate Training in Physiotherapy and The Norwegian Cancer Society"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:37:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>Unconditional funding from the &#8220;Medical Research Institute, Pusan National University Hospital, Busan, Korea.&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>"FAPESP" (Sao Paulo Research Foundation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>Grant FAPESP 2003/07656-7 (Sao Paulo Research Foundation)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-17 05:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>"This study was supported by the American Cancer Society (TPRB-98-118-01-PBP) and a Rutgers College of Nursing Faculty Research Development Award"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 14:27:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>"NIH/NINR"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:39:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>"None"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:30:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-28 15:49:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:27:39 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>Unable to be determined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:13:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>"None"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 15:45:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:36:21 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>"This study was supported by an American Cancer Society pilot research grant and the Frances Payne Bolton School of Nursing at Case Western Reserve University"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-24 09:34:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>"supported by a grant from the Fund of Scientific Research, Flanders, Belgium"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Approved by medical ethics committee</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:19:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>&#8220;At the time of this study, there was no Human Research Ethics Committee established in the faculty, but the study was approved by the postgraduate affairs and departmental committee&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-17 14:33:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:12:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>"This study was reviewed and approved by the University and VA Medical center Institutional Review Boards for Human use"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:27:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>"The study was approved by the university institutional review board"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 14:08:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>&#8220;Medical ethical approval was obtained from the Medical Ethics committee of our university hospital&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-06 13:37:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>"approved by our institutional review board"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>Southampton and South West Hampshire Research Ethics Committee (REC)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 16:13:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>"Approved by the Ethics Committee of our Institution"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 09:29:51 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>&#8220;The study was approved by the Danish ethical counsel and the Danish Data protection Agency&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:51 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-20 12:06:40 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>&#8220;Ethical approval from the commission on medical ethics of the University Hospitals Leuven&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>&#8220;Faculty of Physical Therapy Ethical committee, Cairo University&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:56:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>"Our trials were approved by the Multicentre Research Ethics Committee, Edinburgh, Scotland and overseen by an independent trial steering committee and a separate independent data monitoring committee"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:01:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>"Our trials were approved by the Multicentre Research Ethics Committee, Edinburgh, Scotland and overseen by an independent trial steering committee and a separate independent data monitoring committee"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 16:16:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Approved by "University of Alabama at Birmingham Institutional Review Board"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 11:09:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>&#8220;After approval by the ethical committee and internal review board, 58 consecutive males were included in this analysis&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Hospital board, local military university hospital</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 15:49:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>"The study was approved by the Medical Centre Institutional Review Board"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:39:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>"Permission to conduct this study was obtained from the Univerisity of Florida Health Center Institutional Review Board (IRB)." </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-01 12:36:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"approved by the University of Alberta and Caritas Health Group ethics review boards"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:10:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>"The Institutional review Board at the University of Alberta approved the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 14:15:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>"Healthcare ethics approval was obtained at all sites" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:11:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>&#8220;ethics committee of Kitasato university of medicine&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-17 05:31:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>"The study was approved by the Regional Committee for Medical and Health Research Ethics"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:38:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>&#8220;Our institutional review board approved this prospective, randomized, controlled trial&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-24 09:34:08 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>"COMITE DE ESTICA E PESQUISA - UNICAMP"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 13:51:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>"institutional review board approval"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 13:34:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>"Recruitment was initiated in January 1998 after approval of the parent study was obtained from the institutional review boards of both medical centres and the university"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 14:27:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>"Yes"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:39:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>"Medical Ethical Committee of Nossa Senhora das Gracas Hospital in Curitiba, Brazil"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-17 05:59:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>"This study was approved by the ethical committee in Copenhagen County and followed the Declaration of Helsinki"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>&#8220;Work was carried out in accordance with the ethical standards of the appropriate institutional committee on human experimentation and with the last revision of the Helsinki Declaration</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:27:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>Unable to be determined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:18 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>"Local ethical committee approval" was obtained</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 15:43:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>"The local ethics committee approved the protocol procedure"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:33:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Informed consent</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:19:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>&#8220;All patients signed an informed consent form&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-17 14:33:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:32:31 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>"All participants provided informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:27:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>Patients were "provided written informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 14:08:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>&#8220;Informed consent was obtained&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-06 13:37:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>"informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-24 09:32:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 16:01:01 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>"All patients signed an informed consent form"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-01 21:58:02 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>"Patients were informed about the aims and perspectives of the study. Eligible patients consented"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>Assumed as they acquired ethical approval</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:46:38 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>"Informed consent was obtained"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-20 12:07:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>Patients &#8220;signed written informed consent&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:47:34 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:56:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>"All men gave signed informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:01:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>"All men gave signed informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 16:19:06 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:56 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 11:10:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>&#8220;All subjects received and signed an informed consent form&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 15:49:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>"All men provided informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:40:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>"All patients signed an informed consent before randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-07 10:58:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>"The informed consent was explained to each subject, and his signature was obtained to confirm consent to participate in the study"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-01 12:36:54 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>"All patients signed informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:24:53 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>"the study was explained and informed consent obtained"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-24 09:35:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>"After the consent form was signed, baseline data were collected"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-04 11:12:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:02:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>"Eighty-five men provided written informed consent" </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:38:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>Patients signed &#8220;written informed consent&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:09:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:17:18 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>"Informed consent was given by all patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 13:51:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>"All patients signed an informed consent before randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 14:02:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>"Written informed consent was obtained by a research assistant"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 14:25:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>"Following informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:39:56 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>"after signing informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:30:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>"Informed consent was obtained from the patients"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-28 15:51:44 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>&#8220;All eligible patients gave informed signed consent&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:27:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>Unable to be determined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:13:36 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>"Informed consent was obtained"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:13:59 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>"written informed consent from each subject was obtained"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 15:43:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>"Each patient provided written informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-02 16:36:57 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>"33 patients consented to participate"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-24 09:34:39 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>"All patients included in the study gave written informed consent"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="STUDY" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>ITT analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 09:19:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ahmed-2012">
<DESCRIPTION>
<P>Assumed from flow diagram of patients</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:29:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bales-2000">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Burgio-2006">
<DESCRIPTION>
<P>"intention to treat". Patient flow diagram</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:28:09 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Centemero-2009">
<DESCRIPTION>
<P>Assumed from patient flow chart</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:44:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013">
<DESCRIPTION>
<P>Assumed from flow diagram</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dubbelman-2004">
<DESCRIPTION>
<P>"the concept of an intent to treat analysis was not applied". Authors also state, "Participants were analysed in the group to which they were allocated at randomization"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:29:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fader-2013">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:29:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Filocamo-2005">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:49 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Floratos-2002">
<DESCRIPTION>
<P>"Analysed using the intention-to-treat approach". Authors also state "One of the patients initially randomized to group A could not follow the programme but performed PMEs under verbal instruction"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 10:52:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fode-2014">
<DESCRIPTION>
<P>Assumed from patient flow diagram</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:29:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Franke-1998">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-20 12:07:43 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Geraerts-2013">
<DESCRIPTION>
<P>&#8220;Data were analyzed according to the intention-to-treat principle&#8221;</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:29:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ghanem-2013">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 10:56:35 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-RP-2011">
<DESCRIPTION>
<P>"We used intention-to-treat analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 11:01:55 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Glazener-TURP-2011">
<DESCRIPTION>
<P>"We used intention-to-treat analysis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:30:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Goode-2009">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-07 15:53:14 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hoffman-2005">
<DESCRIPTION>
<P>No intention-to-treat analysis; insufficient information on methods of statistical analysis; interventions unclear and insufficiently specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:55 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hou-2013">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 15:05:21 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Joseph-2000">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Koo-2009">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:13:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Laurienzo-2013">
<DESCRIPTION>
<P>Data presented for all men randomised and not excluded. No differential dropout apparent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:00 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Liu--2008">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-21 15:09:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manassero--2007">
<DESCRIPTION>
<P>Assumed from patient flow chart</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:01 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Marchiori-2010">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mariotti-2009">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:04 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martini-2011">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mathewson_x002d_Chapman-97">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-18 10:11:22 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Moore-1999">
<DESCRIPTION>
<P>Intention-to-treat-analysis not performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:06 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Moore-2004">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Moore-2008">
<DESCRIPTION>
<P>Patient flow chart give details of patient dropouts and withdrawals</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:08 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morihiro-2011">
<DESCRIPTION>
<P>No description. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:09 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nowak--2007">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Opsomer-1994">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 12:02:11 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Overgard-2008">
<DESCRIPTION>
<P>Assumed from patient flow chart</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:11 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Parekh-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-11 12:46:42 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Park-2012">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:13 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Perissinotto-2008">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:32:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Porru-2001">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-19 13:51:15 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ribeiro-2008">
<DESCRIPTION>
<P>Assumed from patient flow chart</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-08 14:02:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Robinson-2008">
<DESCRIPTION>
<P>"Data analysis was by intention-to-treat"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:15 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Robinson-2009">
<DESCRIPTION>
<P>Not specified. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Seleme-2008">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-26 11:33:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tibaek-2007">
<DESCRIPTION>
<P>Not specified</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-13 11:52:33 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tienforti-2012">
<DESCRIPTION>
<P>Assumed from patient flow diagram</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:28:03 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tobia-2008">
<DESCRIPTION>
<P>Unable to be determined</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wille-2003">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:19 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yamanishi-2006">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Yokoyama-2004">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zhang-2007">
<DESCRIPTION>
<P>Not reported. Therefore judged to be unclear risk</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-03-19 21:35:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-van-Kampen-1998">
<DESCRIPTION>
<P>"The groups were analysed on an intention-to-treat basis"</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-01-17 08:25:53 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-01-17 08:03:30 +0000" MODIFIED_BY="[Empty name]" NO="1" READONLY="YES">
<TITLE MODIFIED="2015-01-17 07:50:47 +0000" MODIFIED_BY="[Empty name]">Treatment of UI after radical: PFMT ± biofeedback versus no treatment; for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Treatment of UI after radical: PFMT </B>±<B> biofeedback versus no treatment; for postprostatectomy urinary incontinence</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with postprostatectomy urinary incontinence<BR/>
<B>Intervention:</B> treatment of UI after radical: PFMT ± biofeedback versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment of UI after radical: PFMT </B>±<B> biofeedback versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men - after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>623 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>529 per 1000</B>
<BR/>(374 to 760)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.85 </B>
<BR/>(0.6 to 1.22)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>665<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Urinary Incontinence Score (ICI-SF) - after first year</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean urinary incontinence score (ici-short form) - after first year in the intervention groups was<BR/>
<B>0.5 lower</B>
<BR/>(1.35 lower to 0.35 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>391<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>138<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>2,3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Wide CI (0.60 to 1.22)<BR/>
<SUP>2</SUP> Funnel plot could not be used as there are fewer than 10 trials<BR/>
<SUP>3</SUP> Not applicable (only one trial)<BR/>
<SUP>4</SUP> 95% CI is very wide (-1.35 to 0.35)<BR/>
<SUP>5</SUP> Not estimable as the event rate is zero in each arm<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2015-01-17 08:17:09 +0000" MODIFIED_BY="[Empty name]" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-05-07 11:38:50 +0100" MODIFIED_BY="Grade Profiler">Treatment of UI after radical: electric or magnetic energy versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="12">
<TR>
<TD COLSPAN="7">
<P>
<B>Treatment of UI after radical: electric or magnetic energy versus no treatment for postprostatectomy UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Patients with postprostatectomy UI<BR/>
<B>Intervention:</B> Treatment of UI after radical: electric or magnetic energy versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment of UI after radical: electric or magnetic energy versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men - after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>63 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>16 per 1000</B>
<BR/>(6 to 47)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.26 </B>
<BR/>(0.09 to 0.74)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>413<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Urinary Incontinence Score (ICIQ-SF UI score) - after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean urinary incontinence score (iciq-short form ui score) - after 12 months in the intervention groups was<BR/>
<B>1.4 lower</B>
<BR/>(5.03 lower to 2.23 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>47<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Urinary Incontinence Quality of Life Score (ICIQ-SF) - after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>47<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>133 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>77 per 1000</B>
<BR/>(15 to 387)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.58 </B>
<BR/>(0.11 to 2.9)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>56<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY </B>- not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Random sequence generation and allocation concealment unclear is 1/2 trials taking part in the meta-analysis<BR/>
<SUP>2</SUP> Funnel plot could not be used as there are fewer than 10 trials<BR/>
<SUP>3</SUP> Not applicable. Only one trial<BR/>
<SUP>4</SUP> 95% CI very wide (-5.03 to 2.23)<BR/>
<SUP>5</SUP> 95% CI very wide (-2.02 to 1.22)<BR/>
<SUP>6</SUP> 95% CI very wide (0.11 to 2.90)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2015-01-17 08:19:53 +0000" MODIFIED_BY="[Empty name]" NO="3" READONLY="YES">
<TITLE MODIFIED="2014-05-07 11:39:02 +0100" MODIFIED_BY="Grade Profiler">Treatment of UI after radical: combinations of treatments versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Treatment of UI after radical: combinations of treatments versus no treatment for postprostatectomy UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with postprostatectomy UI<BR/>
<B>Intervention:</B> Treatment of UI after radical: combinations of treatments versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment of UI after radical: combinations of treatments versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men with 3 to 6 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>150 per 1000</B>
<BR/>(17 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2.85 </B>
<BR/>(0.32 to 25.07)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Urinary Incontinence Quality of Life Score (ICIQ-SF) after 12 months</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events - PFMT + anal EStim + BFB</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 4.86 </B>
<BR/>(0.24 to 99.39)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>138<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic Analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Random sequence generation and allocation concealment unclear<BR/>
<SUP>2</SUP> Not applicable, only one trial<BR/>
<SUP>3</SUP> No explanation was provided<BR/>
<SUP>4</SUP> Funnel plot cannot be used as there is only one trial<BR/>
<SUP>5</SUP> 95% CI is very wide (0.24 to 99.39)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-04" MODIFIED="2015-01-17 08:22:28 +0000" MODIFIED_BY="[Empty name]" NO="4" READONLY="YES">
<TITLE MODIFIED="2014-05-07 11:39:12 +0100" MODIFIED_BY="Grade Profiler">Treatment of UI after radical: one active treatment versus another active treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Treatment of UI after radical: one active treatment versus another active treatment for postprostatectomy UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> Patients with postprostatectomy UI<BR/>
<B>Intervention:</B> Treatment of UI after radical: one active treatment versus another active treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment of UI after radical: one active treatment versus another active treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men within 6 to 12 months - FES versus ExMI</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>83 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>167 per 1000</B>
<BR/>(17 to 1000)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 2 </B>
<BR/>(0.21 to 19.23)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of Life Score (ICI-Q-SF) within 6 to 12 months - PFMT + ExMI versus PFMT</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life score (ICI-Q-SF) within 6 to 12 months - PFMT + ExMI versus PFMT in the intervention groups was<BR/>
<B>1.6 lower</B>
<BR/>(2.73 to 0.47 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>24<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,5,6</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events PFMT + Anal EStim versus PFMT alone</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>0 per 1000</B>
<BR/>(0 to 0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 5 </B>
<BR/>(0.24 to 102.3)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>140<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,5,7</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Random sequence generation and allocation concealment is unclear<BR/>
<SUP>2</SUP> Not applicable, only one trial<BR/>
<SUP>3</SUP> GRADE-specific outcome was number of incontinent men after 12 months<BR/>
<SUP>4</SUP> 95% CI is very wide (0.21 to 19.23)<BR/>
<SUP>5</SUP> Funnel plot cannot be used as there was only one trial<BR/>
<SUP>6</SUP> GRADE-specific outcome was ICI-Q-SF after 12 months<BR/>
<SUP>7</SUP> 95% CI very wide (0.24 to 102.30)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-05" MODIFIED="2015-01-17 08:23:22 +0000" MODIFIED_BY="[Empty name]" NO="5" READONLY="YES">
<TITLE MODIFIED="2015-01-17 07:53:36 +0000" MODIFIED_BY="[Empty name]">Prevention of UI after radical: PFMT ± biofeedback versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after radical: PFMT </B>±<B> biofeedback versus no treatment compared to for UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> All men after radical prostatectomy<BR/>
<B>Intervention:</B> Prevention of UI after radical: PFMT ± biofeedback versus no treatment<BR/>
<B>Comparison: </B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after radical: PFMT </B>±<B> biofeedback versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men - after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>321 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>103 per 1000</B>
<BR/>(64 to 164)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.32 </B>
<BR/>(0.2 to 0.51)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>373<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life score assessed using (ICI-SF UI score) - within 6 to 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean quality of life score assessed using (ICI-SF UI score) - within 6 to 12 months in the intervention groups was<BR/>
<B>0.69 lower</B>
<BR/>(3.19 lower to 1.81 higher)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>105<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment is unclear for Filocamo 2005 which contributes 84.2% weightage<BR/>
<SUP>2</SUP> Funnel plot cannot be used as there are fewer than 10 trials<BR/>
<SUP>3</SUP> Sequence generation is unclear in Ribeiro 2008. Allocation concealment is unclear in both the trials taking part in the meta-analysis<BR/>
<SUP>4</SUP> 95% CI is very wide (-3.19 to 1.81)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-06" MODIFIED="2015-01-17 08:24:57 +0000" MODIFIED_BY="[Empty name]" NO="6" READONLY="YES">
<TITLE MODIFIED="2014-05-07 14:10:08 +0100" MODIFIED_BY="[Empty name]">Prevention of UI after radical: electric or magnetic energy versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after radical: electric or magnetic energy versus no treatment for UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>All men after radical prostatectomy<BR/>
<B>Intervention:</B> Prevention of UI after radical: electric or magnetic energy versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after radical: electric or magnetic energy versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men after 12 months</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life score assessed using (ICIQ-SF score) - within 6 to 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>32<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment is unclear<BR/>
<SUP>2</SUP> 95% CI is very wide (-2.15 to 5.35)<BR/>
<SUP>3</SUP> Funnel plot cannot be used as there are fewer than 10 trials</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-07" MODIFIED="2015-01-17 08:25:53 +0000" MODIFIED_BY="[Empty name]" NO="7" READONLY="YES">
<TITLE MODIFIED="2014-05-07 14:10:25 +0100" MODIFIED_BY="[Empty name]">Prevention of UI after radical: combinations of treatments versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after radical: combinations of treatments versus no treatment compared to for postprostatectomy UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> All men after radical prostatectomy<BR/>
<B>Intervention:</B> Prevention of UI after radical: combinations of treatments versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after radical: combinations of treatments versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men within 6 to 12 months - PFMT + anal EStim + biofeedback versus no treatment</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>60<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life Score assessed using (ICIQ-SF) or (ICIQ- SF UI score)</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval;</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Sequence generation and allocation concealment are both unclear<BR/>
<SUP>2</SUP> Funnel plot cannot be used as there are fewer than 10 trials</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-08" MODIFIED="2015-01-17 08:04:36 +0000" MODIFIED_BY="[Empty name]" NO="8" READONLY="YES">
<TITLE MODIFIED="2015-01-17 07:57:07 +0000" MODIFIED_BY="[Empty name]">Prevention of UI after radical: one active treatment versus another active treatment (PFMT pre and post-operation versus PFMT post-operation) for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after radical: one active treatment versus another active treatment compared to (PFMT pre and post-operation versus PFMT post-operation) for UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>All men after radical prostatectomy<BR/>
<B>Intervention:</B> Prevention of UI after radical: one active treatment versus another active treatment<BR/>
<B>Comparison: </B>(PFMT pre and post-operation versus PFMT post-operation)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>(PFMT pre and post-operation versus PFMT post-operation)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after radical: one active treatment versus another active treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men after 12 months </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>367<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of Life Score assessed using (ICIQ-SF) or (ICIQ-SF UI score) after 12 months</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>102<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
<SUP>3,4,5</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic Analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Sequence generation is unclear 2/3 trials and allocation concealment is unclear in 1/3 trials<BR/>
<SUP>2</SUP> Due to clinical heterogeneity we decided not to pool the results<BR/>
<SUP>3</SUP> Not applicable<BR/>
<SUP>4</SUP> RR is not estimable as there is zero event in both arms of the trial<BR/>
<SUP>5</SUP> Funnel plot cannot be used as there were fewer than 10 trials</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-09" MODIFIED="2015-01-17 08:13:54 +0000" MODIFIED_BY="[Empty name]" NO="9" READONLY="YES">
<TITLE MODIFIED="2015-01-17 07:59:21 +0000" MODIFIED_BY="[Empty name]">Prevention of UI after radical: one active treatment versus another active treatment (PFMT + penile vibration pre and post-operation versus PFMT pre and post-operation) for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after radical: one active treatment versus another active treatment compared to (PFMT + penile vibration pre and post-operation versus PFMT pre and post-operation) for </B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>All men after radical prostatectomy<BR/>
<B>Intervention:</B> Prevention of UI after radical: one active treatment versus another active treatment<BR/>
<B>Comparison: </B>PFMT + penile vibration pre and post-operation versus PFMT pre and post-operation)</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>(PFMT + penile vibration pre and post-operation versus PFMT pre and post-operation)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after radical: one active treatment versus another active treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men after 12 months </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>71 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>100 per 1000</B>
<BR/>(18 to 555)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 1.4 </B>
<BR/>(0.25 to 7.77)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>58<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Quality of life Score assessed using (ICIQ-SF) or (ICIQ-SF UI score)</B>
</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>0<BR/>(0)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>68<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Not applicable<BR/>
<SUP>2</SUP> 95% CI very wide (0.25 to 7.77)<BR/>
<SUP>3</SUP> Funnel plot cannot be used as there were fewer than 10 trials<BR/>
<SUP>4</SUP> 95% CI is very wide (0.80 to 240.77)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-10" MODIFIED="2015-01-17 08:07:55 +0000" MODIFIED_BY="[Empty name]" NO="10" READONLY="YES">
<TITLE MODIFIED="2015-01-17 08:06:11 +0000" MODIFIED_BY="[Empty name]">Prevention of UI after radical: one active treatment versus another active treatment (pre-operative PFMT + electrical stimulation versus pre-operative PFMT) for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after radical: one active treatment versus another active treatment compared to (pre-operative PFMT + electrical stimulation versus pre-operative PFMT) for UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>All men after radical prostatectomy<BR/>
<B>Intervention:</B> Prevention of UI after radical: one active treatment versus another active treatment<BR/>
<B>Comparison: </B>Pre-operative PFMT + electrical stimulation versus pre-operative PFMT</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>(pre-operative PFMT + electrical stimulation versus pre-operative PFMT)</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after radical: one active treatment versus another active treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men after 12 months</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of Life Score assessed using (ICIQ-SF) within 6 to 12 months </B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>34<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Allocation concealment is unclear<BR/>
<SUP>2</SUP> Not applicable<BR/>
<SUP>3</SUP> 95% CI very wide (-3.13 to 4.13)<BR/>
<SUP>4</SUP> Funnel plot cannot be used as there were fewer than 10 trials</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-11" MODIFIED="2015-01-17 08:10:14 +0000" MODIFIED_BY="[Empty name]" NO="11" READONLY="YES">
<TITLE MODIFIED="2015-01-17 08:08:20 +0000" MODIFIED_BY="[Empty name]">Treatment of UI after TURP: PFMT ± biofeedback versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Treatment of UI after TURP: PFMT </B>±<B> biofeedback versus no treatment compared to for UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>Men with UI after TURP<BR/>
<B>Intervention:</B> Treatment of UI after TURP: PFMT ± biofeedback versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P/>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Treatment of UI after TURP: PFMT </B>±<B> biofeedback versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men- after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1609<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
<SUP>1,2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Quality of life Score assessed using Score (ICIQ-SF UI score) - after 12 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>397<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Not applicable<BR/>
<SUP>2</SUP> 95% CI is wide (0.91 to 1.23)<BR/>
<SUP>3</SUP> Funnel plot cannot be used at there are fewer than 10 trials<BR/>
<SUP>4</SUP> 95% CI is very wide (-0.89 to 0.69)<BR/>
<SUP>5</SUP> GRADE specific outcome is IIEF score<BR/>
<SUP>6</SUP> 95% CI is very wide (0.86 to 1.72)</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-12" MODIFIED="2015-01-17 08:13:07 +0000" MODIFIED_BY="[Empty name]" NO="12" READONLY="YES">
<TITLE MODIFIED="2015-01-17 08:10:46 +0000" MODIFIED_BY="[Empty name]">Prevention of UI after TURP:  pre or post-operative PFMT ± biofeedback versus no treatment for postprostatectomy urinary incontinence</TITLE>
<TABLE COLS="7" ROWS="11">
<TR>
<TD COLSPAN="7">
<P>
<B>Prevention of UI after TURP:  pre or post-operative PFMT </B>±<B> biofeedback versus no treatment for UI</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>All men after TURP<BR/>
<B>Intervention:</B> Prevention of UI after TURP: pre or post-operative PFMT ± biofeedback versus no treatment<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Prevention of UI after TURP:  pre or post-operative PFMT </B>±<B> biofeedback versus no treatment</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Number of incontinent men - within 3 to 6 months</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>227 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
<BR/>(32 to 430)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.51 </B>
<BR/>(0.14 to 1.89)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>48<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
<SUP>1,2,3,4</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Urinary Incontinence Score assessed using (ICIQ-SF) or (ICIQ-SF UI score) at 12 months</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Economic analysis using QALY</B> - not reported</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>Not estimable</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-<BR/>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>See comment</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP> Not applicable<BR/>
<SUP>2</SUP> GRADE specific outcome was number of incontinent men after 12 months<BR/>
<SUP>3</SUP> 95% CI is very wide (0.14 to 1.89)<BR/>
<SUP>4</SUP> Funnel plot cannot be used as there are fewer than 10 trials</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2011-12-06 15:27:33 +0000" MODIFIED_BY="[Empty name]">Details of interventions</TITLE>
<TABLE COLS="3" ROWS="48">
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Study ID</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Control</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ahmed-2012" TYPE="STUDY">Ahmed 2012</LINK>
</P>
</TD>
<TD>
<P>A: At catheter removal received standard care of verbal and written instructions, instructed by physiotherapist to perform 3 sets of 15-20 contractions daily, for a duration of 3-5 seconds with a 6-10 second rest period, encouraged to perform exercises before functional activities such as sneezing, coughing, or lifting weight, also in the supine position, sitting, squatting and going up and down stairs</P>
<P> </P>
<P>B: ES, treatment started one week after catheter removal, patients received 15 minutes of twice weekly electrical stimulation for 12 weeks</P>
<P> </P>
<P>C: PFMT + BFB + ES: Treatment started one week after catheter removal, patients received twice weekly treatment with 15 minutes of electrical stimulation and 15 minutes of biofeedback for 12 weeks, instructed to perform 3 series of 10 rapid contractions, 3 sustained contractions of 5, 7 or 10 seconds and then 10 contractions during prolonged expiration in the supine position</P>
<P> </P>
<P>All patients were given a logbook to complete daily regarding self-report of exercises   </P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Bales-2000" TYPE="STUDY">Bales 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT + biofeedback</P>
<P>45 minute session with nurse trained in biofeedback. Patients were instructed to perform graded PFMT. Contractions of 5-10 seconds, 10-15 repetitions were performed with biofeedback (surface electrodes used to measure muscle strength). Advised to practice the exercises 4 times per day until surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No biofeedback training</P>
<P>Written and brief verbal instructions from a nurse on how to perform PFMT (isolate muscle that stops urine flow, practice 4 times per day, 10-15 repetitions).</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Burgio-2006" TYPE="STUDY">Burgio 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT + biofeedback</P>
<P>Single session of biofeedback (rectal probe to measure intra-abdominal rectal pressure and external anal sphincter contraction) assisted behavioural training. Feedback and verbal instruction used to teach control of pelvic muscles. Taught to contract sphincter during 2-10 seconds periods separated by 2-10 seconds of relaxation, dependent on ability.</P>
<P>Written instructions for daily at home practice of 45 PFM exercises daily (3 sessions of 15 exercises each time). Additionally instructed to slow or interrupt voiding once daily. Encouraged to exercise daily preoperatively, then resume when catheter removed post-operatively</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Usual care of brief verbal instructions post operatively to interrupt the voiding stream plus any instruction from physician.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Centemero-2009" TYPE="STUDY">Centemero 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: PFMT both pre and post-operatively. A structured PFMT program 30 and 15 days before surgery, previous physiotherapist evaluation to provide the patients with feedback about the quality of pelvic floor muscle function, PC teste (endurance and contraction quality), breathing coordination, typify muscle contraction as tonic and modify incorrect physical attitudes. This was also repeated after the procedure</P>
<P>Intervention B: PFMT post-operatively only</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Dijkstra_x002d_Eshuis-2013" TYPE="STUDY">Dijkstra-Eshuis 2013</LINK>
</P>
</TD>
<TD>
<P>30 mins of guided PFMT + biofeedback weekly for 4 weeks before surgery, received written instructions to: carry out two sets of 30 contractions during abdominal breathing, one breath between each contraction; restart PFMT after catheter removal (7-10 days after surgery)</P>
<P/>
<P>All men were seen before surgery by a physiotherapist, who explained relevant anatomy, anal visual inspection and digital palpation, biofeedback registration with rectal probe, All patients received PFMT + biofeedback or electrical stimulation, or both, if still incontinent after 6 weeks</P>
</TD>
<TD>
<P>Received written instructions on PFMT after catheter removal (7-10 days after surgery)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Dubbelman-2004" TYPE="STUDY">Dubbelman 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Nine or less sessions of physiotherapy guided pelvic floor exercises after surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Exercise instruction through information folder</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Filocamo-2005" TYPE="STUDY">Filocamo 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Formal instruction (3 treatment sessions plus at home exercises) in PFMT using verbal explanation, palpation and visualization of the base of the penis with a mirror, in different positions and prior to sneezing, coughing or lifting</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No formal instruction</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Floratos-2002" TYPE="STUDY">Floratos 2002</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Initiated after catheter removal, 15 treatment sessions (3 times per week for 30 minutes) of PFMT with EMG (surface) biofeedback in clinic</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Instruction with verbal feedback and an information pamphlet with instructions to perform PFMT 50-100 times daily at home</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Fode-2014" TYPE="STUDY">Fode 2014</LINK>
</P>
</TD>
<TD>
<P>Pre-operative session guided PFMT + instruction on how to use penile vibratory stimulation device. Instructed to stimulate frenulum once daily, 10 seconds of stimulation then 10 second pause, repeated 10 times for 1 week pre-operatively, instructed to restart stimulation after catheter removal for 6 weeks</P>
<P/>
<P>All men were offered a PDE5 inhibitor after 1 month post-operatively and also received telephone contact to ensure compliance with treatment </P>
</TD>
<TD>
<P>Preoperative session guided PFMT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Franke-1998" TYPE="STUDY">Franke 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Biofeedback (perineal patch EMG) enhanced PFMT; exercise treatment sessions at 6, 7, 9, 11, and 16 weeks post-operatively</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No treatment.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Geraerts-2013" TYPE="STUDY">Geraerts 2013</LINK>
</P>
</TD>
<TD>
<P>Intervention A: PFMT + biofeedback</P>
<P>30 mins of guided PFMT + biofeedback weekly for 3 weeks before surgery. Patients were instructed to carry out 60 contractions a day at home; contract their pelvic floor while coughing, and sitting down or getting up from a chair. Patients were also instructed to restart PFMT on day 4 after surgery while catheter was in situ</P>
<P>Intervention B: Instructed to start PFMT on the day after catheter removal (e.g. 2-3 weeks after surgery)</P>
<P>All men: Received weekly individual guided exercise programme with digital or EMG biofeedback after surgery. Advice was given on how to contract pelvic floor muscles to prevent leakage during functional activities. When patients carried out the instructed 60 contractions, they were asked to colour in three squares in their diary to assess compliance</P>
</TD>
<TD>
<P/>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Ghanem-2013" TYPE="STUDY">Ghanem 2013</LINK>
</P>
</TD>
<TD>
<P>Pre-operative PFMT for 2 weeks + postoperative PFMT programme      </P>
</TD>
<TD>
<P>Postoperative PFMT programme only</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Goode-2009" TYPE="STUDY">Goode 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: Behavioural therapy with PFMT for 8 weeks</P>
<P>Intervention B: Behavioural therapy with biofeedback and electrical stimulation for 8 weeks</P>
<P>Behavioural therapy consisted of pelvic floor muscle exercises and bladder control strategies in both groups</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No treatment</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Hoffman-2005" TYPE="STUDY">Hoffman 2005</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: perineal EStim plus physiotherapy (PFMT)</P>
<P>Intervention B: anal EStim plus physiotherapy (PFMT)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT alone</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hou-2013" TYPE="STUDY">Hou 2013</LINK>
</P>
</TD>
<TD>
<P>Guided PFMT + biofeedback after catheter removal (2 days post-operatively), instructed to: contract pelvic muscles for 5 seconds and relax for 10 seconds. After discharge, patients were instructed to carry out 5 mins of each PFE three times daily. Patients also received motivational telephone interviews once weekly</P>
</TD>
<TD>
<P>No description</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Joseph-2000" TYPE="STUDY">Joseph 2000</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: Instruction in PFMT including biofeedback with visual feedback as well as verbal to assist in identifying and discriminating muscles</P>
<P>Intervention B: Instruction in PFMT, squeezing of finger during digital rectal examination</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Koo-2009" TYPE="STUDY">Koo 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>ExMI, treatment sessions were for 20 minutes twice weekly for 8 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT alone</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Laurienzo-2013" TYPE="STUDY">Laurienzo 2013</LINK>
</P>
</TD>
<TD>
<P>A (15): Standard treatment with verbal instructions for PFMT</P>
<P>B (17): Pre-operative guided PFMT, with 10 physiotherapy sessions: contractions of the pelvic floor muscles for 5 seconds in &#8220;dorsal decubitus&#8221; position for 10 times, in the same position with the waist elevated (10 times), lying down with legs adducted against a plastic ball performed 10 times and standing and flexing the hips to 60&#778; (10 times)</P>
<P>C (17): Pre-operative PFMT + ES during 10 physiotherapy sessions, ES was with an anal probe lasting 15 minutes in total, and men also received guided PFMT and followed the same training regime as above</P>
<P/>
<P>Men did not receive treatment post-operatively</P>
</TD>
<TD>
<P>Instructed to start PFMT at home 15 weeks before surgery.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Liu--2008" TYPE="STUDY">Liu 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Extra-corporeal magnetic innervation (ExMI), the frequency of the pulse field was 10Hz for 10 minutes, followed by a 3 minute rest and a second treatment of 50 Hz for 20 minutes. This was done twice a week</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT alone, instructions given to carry out 20mins x 3 a day.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Manassero--2007" TYPE="STUDY">Manassero 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT re-education program, verbal feedback</P>
<P>The training program involved active PFE. verbal feedback of the contraction was used to instruct the patients to correctly and selectively contract their pelvic muscles while relaxing the abdominal muscles. the strength of the pelvic floor muscles was measured by digital anal control using a score of 0 to 5 ( 0 = no contraction, 5 = good contraction against strong resistance)</P>
<P>Initially home practice comprised 45 contractions (3 sessions of 15) per day at home, progressively increasing the number until 90 per day. This was taught by two experienced urologists</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No treatment.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Marchiori-2010" TYPE="STUDY">Marchiori 2010</LINK>
</P>
</TD>
<TD>
<P>Guided PFMT + biofeedback during first session, second session involved 10 sets of pelvic floor electrical stimulation lasting 15 mins each, instructed to: carry out three sets of 30 contractions a day at home for the first month after catheter removal (16 days after surgery)</P>
<P/>
<P>All men received oral and written information on pelvic floor anatomy and on PFME, pelvic floor muscle endurance assessed by digital anal control</P>
</TD>
<TD>
<P>Received oral and written information on pelvic floor anatomy and on PFME, instructed to: perform 30 contractions a day at home for the first month after catheter removal (16 days after surgery)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mariotti-2009" TYPE="STUDY">Mariotti 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT plus ES and biofeedback twice a week for 6 weeks</P>
<P>ES - a surface electrodes was inserted into the anus and pulsed, the intensity was adequate to induce visual lifting of the levator ani and pubococcygeus muscle, considering the level of comfort to the patient</P>
<P>Biofeedback - via surface electrodes both perineal and abdominally</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Instructions to conduct PFMT - verbal and written instructions at catheter removal and follow up visits.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Martini-2011" TYPE="STUDY">Martini 2011</LINK>
</P>
</TD>
<TD>
<P>PFMT: 5 sessions of guided PFMT for 2-3 weeks pre-operatively and continued post-operatively</P>
<P/>
<P>All men underwent clinical examination of pelvic muscles function using digital perineal testing according to &#8220;AIPDA score&#8221; and evaluation of voiding symptoms</P>
</TD>
<TD>
<P>Postoperative standard care, written instructions for PFMT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Mathewson_x002d_Chapman-97" TYPE="STUDY">Mathewson-Chapman 97</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Pre-operatively received further instruction and practice with PME protocol Home exercises and biofeedback (anal probe) (Incare 8900); practiced at home 3 times a week, starting with daily 15 PFMT and increasing by 10 every 4 weeks to a maximum of 35 PFMT.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Post-operatively no further interventions until week 5 when pelvic muscle strength was assessed.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Moore-1999" TYPE="STUDY">Moore 1999</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: PFMT alone</P>
<P>Intervention B: PFMT plus rectal ES treated by one physiotherapist 30 minutes twice a week for 12 weeks</P>
<P>Both included home exercises 3x/day gradually working up to 30 minutes per session lying, standing, sitting; strength, endurance, speed and control with maximum contractions of 5-10 seconds, 10-20 second relaxation and 12-20 repetitions; submaximum contractions at 65-75% of maximum strength with hold 20-30 seconds and equal rest time, 8-10 repetitions; speed was sets of quick repetitive contractions in a 10 second time span; control involved gradual recruitment to maximum contraction in 3 stages with 5 second hold at each stage and a slow release with rest 15-30 seconds<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>oral and written information about PFMT pre and post- operatively (standard treatment)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Moore-2004" TYPE="STUDY">Moore 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Each participant had 4 periods (each lasted 1 day)<BR/>Group A: No device<BR/>Group B: C3 device<BR/>Group C: U-Tex device<BR/>Group D: Cunningham clamp</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Moore-2008" TYPE="STUDY">Moore 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Maximum 24 weekly, 30-minute treatment protocol (30 min biofeedback-assisted PFMT) and home exercise protocol of 2-3 times a day</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Verbal and written information on PFME and weekly telephone contact by a urology nurse</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Morihiro-2011" TYPE="STUDY">Morihiro 2011</LINK>
</P>
</TD>
<TD>
<P> PFMT + sacral surface therapeutic electrical stimulation (ssTES), ssTES 2x a day for 15 minutes each, lasting 1 month after catheter removal (day 5)</P>
</TD>
<TD>
<P>PFME only, carried out alone</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Nowak--2007" TYPE="STUDY">Nowak 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Extra-corporeal magnetic innervation (EXMI) based pelvic floor device</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT alone</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Opsomer-1994" TYPE="STUDY">Opsomer 1994</LINK>;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT plus biofeedback plus electrical stimulation directed by physiotherapist</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT on their own without medical supervision.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Overgard-2008" TYPE="STUDY">Overgard 2008</LINK>;</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Instructions on PFMT and physiotherapy, 45 minutes weekly</P>
<P>Patients were instructed to perform 3 sets of contractions daily at home, in either a supine, sitting or standing position. Digital anal palpation to teach correct contractions, as well as oral and written instructions</P>
<P>DVD of instructions given to those living too far from hospital</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Instructions on PFMT alone.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Parekh-2003" TYPE="STUDY">Parekh 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Two treatment sessions preoperatively. Session 1 consisted of PFMT in a hook lying position<BR/>Session 2 was on an exercise ball. Teaching methods varied and included verbal cues, visualization with an anatomical model, palpation or biofeedback with rectal probe. Post-operatively, PFMT was reviewed and participants were seen every 3 weeks for 3 months by a physiotherapist<BR/>Home exercise for 6 months or more for those requiring further physical therapy guidance</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No formal education on PFMT pre-operatively, telephone or face to face follow-up at least monthly.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Park-2012" TYPE="STUDY">Park 2012</LINK>
</P>
</TD>
<TD>
<P>Patients performed Kegel exercises together with other types of exercises which included resistance training and pelvic flexibility. The intervention started 3 weeks after surgery and lasted 12 weeks</P>
<P>Details of the combined exercise regime:</P>
<P>Post-operative weeks 1-4</P>
<P>1) Education about postoperative symptoms</P>
<P>2) Performing Kegel exercises, recognizing the parapelvic muscles</P>
<P>3) Pelvic floor flexibility fitness: performing pelvic exercises while sitting on a ball</P>
<P>Post-operative weeks 5-8 (ball exercises)</P>
<P>1) Performing pelvic exercises while sitting on a ball</P>
<P>2) Performing lower extremity exercises while placing a ball on the wall</P>
<P>3) Lifting a heel on the ball while standing face-to-face with the wall</P>
<P>4) Lifting up and down on the ball while spreading and bending legs</P>
<P>5) Performing flank exercises while having a ball in the hand</P>
<P>6) Squeezing the ball with the adductor muscles while lying on a table</P>
<P>Post-operative weeks 9-12 (elastic band exercises)</P>
<P>1)  Lifting the object with an elastic band lateral, anterior, and posterior to the patient&#8217;s arms</P>
<P>2) Lifting the legs and then spreading them while attaching an elastic band to the foot</P>
</TD>
<TD>
<P>In the control group, only Kegel exercises were performed</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Perissinotto-2008" TYPE="STUDY">Perissinotto 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Early pelvic floor rehabilitation program at home twice dally, Kegel exercises</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No formal PFMT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Porru-2001" TYPE="STUDY">Porru 2001</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Initial visit before surgery, digital evaluation of pelvic muscle contraction strength. Verbal instruction, feedback and reinforcement on contraction was given to teach selective contraction of anal sphincter and relaxation of abdominal muscles. Verbal and written instruction given for home PFMT. Weekly digital anal reassessment and grading of pelvic muscle contraction by the therapist. Instructed to practice contractions 45 times per day (3 groups of 15 contractions)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Not specified</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Ribeiro-2008" TYPE="STUDY">Ribeiro 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT plus BF weekly for 3 months</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT oral instructions only</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Robinson-2008" TYPE="STUDY">Robinson 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: Brief verbal instruction in PFMT before operation and offer of one biofeedback session at 2 months after surgery (uptake 33%) plus PFMT for four weeks with biofeedback</P>
<P>Intervention B: Brief verbal instruction in PFMT before operation and offer of one biofeedback session at 2 months after surgery (uptake 46%)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Robinson-2009" TYPE="STUDY">Robinson 2009</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: routine brief verbal and written PFMT plus one PFMT session and 3 weekly nurse phone calls</P>
<P>Intervention B: routine brief verbal and written PFMT plus four BF enhanced PFMT sessions and 4 weekly nurse phone calls</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Routine brief verbal and written PFMT.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Seleme-2008" TYPE="STUDY">Seleme 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Verbal instruction and information on PFMT plus information on life style changes. Additional 15 physiotherapy sessions consisting of intensive PFMT with BF and ES</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Verbal instruction and information on PFMT plus information on life style changes.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tibaek-2007" TYPE="STUDY">Tibaek 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>One hour individual session with physiotherapist to teach correct contraction for PFMT, three 1 hour group lessons and home training programme</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No pre operative physiotherapy. Information about anatomy and physiology and verbal instructions for 2 to 3 days after TURP in the ward.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Tienforti-2012" TYPE="STUDY">Tienforti 2012</LINK>
</P>
</TD>
<TD>
<P>PFMT + biofeedback</P>
<P>Patients received guided PFMT + biofeedback + information about the anatomy of pelvic floor muscles the day before surgery and after catheter removal. They were also given oral and written instructions on Kegel exercises to be performed at home which involved three sets of contractions daily for 10 mins, contracting their pelvic floor while lying, sitting and standing. The frequency of contractions was recorded in a training diary and visits at monthly intervals after catheter removal involved assisted biofeedback and motivation for 20 min</P>
</TD>
<TD>
<P>No biofeedback training</P>
<P>Received standard care, oral and written instructions from urologist on PFMT, Instructed to: start PFMT after catheter removal (e.g. 2-3 weeks after surgery)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Tobia-2008" TYPE="STUDY">Tobia 2008</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT</P>
<P/>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No PFMT</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-van-Kampen-1998" TYPE="STUDY">van Kampen 1998</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1 session of PFMT in hospital before discharge and then saw the physiotherapist for 1-2 weeks for as long as UI persisted. 90 daily home exercises sitting, standing and lying. 7 men unable to contract PFM or with weak contraction received electrical stimulation by anal probe</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>No formal PFMT instruction but saw the therapist at 1-2 weeks and received placebo stimulation and information about aetiology of UI.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Wille-2003" TYPE="STUDY">Wille 2003</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: PFMT alone</P>
<P>Intervention B: PFMT + ES; PFMT as above plus instructed by dedicated in ES via surface anal electrode and bio-impulser (biphasic pulse with 1 second bursts, 5 second pulse width, 2 second pulse trains</P>
<P>Intervention C: PFMT + ES + biofeedback. As above plus biofeedback (anal probe) 15 minutes twice daily for 3 months</P>
<P>All groups: PFMT by physiotherapist, 20-30 minute sessions for 3 days, instructed to perform exercises twice daily for 3 months plus 3 week rehabilitation program after dischargeRegular interaction with health professional for 6 weeks after surgery, encouraged to performed treatment for 3 months post-surgery</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yamanishi-2006" TYPE="STUDY">Yamanishi 2006</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Oral PFMT plus ES for 15 minutes twice daily</P>
<P>Instructed pre-operatively PFMT by nurses and continued after catheter removal</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Oral PFMT plus sham device.</P>
<P>Instructed pre-operatively PFMT by nurses and continued after catheter removal.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Yokoyama-2004" TYPE="STUDY">Yokoyama 2004</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Intervention A: anal electrode for 15 minutes twice a day for 1 month</P>
<P>Intervention B: extra-corporeal magnetic innervation, neocontrol system, treatment sessions 20 minutes, twice a week for 2 weeks</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT, digital anal teaching of correct contractions, then verbal and written instructions for home practice.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>
<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT plus BF using rectal electrical sensor, initial 45 minute session with physical therapist then written instructions to carry out at home three times a day for 10 minutes. Plus support group, 6 meetings in 3 months with a health psychologist</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>PFMT plus BF using rectal electrical sensor, initial 45 minute session with physical therapist then written instructions to carry out at home three times a day for 10 minutes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-01-19 10:21:37 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2015-01-19 10:20:51 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Treatment of UI after radical: PFMT ± biofeedback versus no treatment</NAME>
<DICH_OUTCOME CHI2="35.81311723701226" CI_END="1.0238802292522717" CI_START="0.8664544098702545" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9418840373499267" ESTIMABLE="YES" EVENTS_1="1037" EVENTS_2="1085" I2="41.362267179867686" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.010249157013790745" LOG_CI_START="-0.0622542835705647" LOG_EFFECT_SIZE="-0.02600256327838696" METHOD="MH" MODIFIED="2014-08-30 22:26:28 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.022945655160512723" P_Q="0.9252576595395436" P_Z="0.15977189463402408" Q="0.47080203507967333" RANDOM="YES" SCALE="79.50737202205846" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.007101487366159513" TOTALS="SUB" TOTAL_1="1694" TOTAL_2="1638" WEIGHT="400.0" Z="1.4058391469592968">
<NAME>Number of incontinent men</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.228781587838581" CI_END="1.0808837496697463" CI_START="0.8390657432347302" DF="6" EFFECT_SIZE="0.9523300513829162" ESTIMABLE="YES" EVENTS_1="362" EVENTS_2="378" I2="60.60091895472789" ID="CMP-001.01.01" LOG_CI_END="0.033778987577905116" LOG_CI_START="-0.07620400960577704" LOG_EFFECT_SIZE="-0.02121251101393596" MODIFIED="2011-11-24 08:50:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.018550067599954034" P_Z="0.4496253832052438" STUDIES="7" TAU2="0.01294623359893973" TOTAL_1="496" TOTAL_2="484" WEIGHT="100.0" Z="0.7560397274778434">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="4.68714484802803" CI_START="0.5049692258435812" EFFECT_SIZE="1.5384615384615385" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.6709083748403013" LOG_CI_START="-0.29673508812601235" LOG_EFFECT_SIZE="0.18708664335714445" ORDER="103866" O_E="0.0" SE="0.5683985600588051" STUDY_ID="STD-Franke-1998" TOTAL_1="13" TOTAL_2="10" VAR="0.32307692307692304" WEIGHT="1.242101533304836"/>
<DICH_DATA CI_END="1.0423433869177907" CI_START="0.8980305931310394" EFFECT_SIZE="0.9675" ESTIMABLE="YES" EVENTS_1="172" EVENTS_2="176" LOG_CI_END="0.018010815389785023" LOG_CI_START="-0.04670886800788697" LOG_EFFECT_SIZE="-0.014349026309050977" MODIFIED="2011-11-10 10:10:41 +0000" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.038016662395392156" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="200" TOTAL_2="198" VAR="0.0014452666196852239" WEIGHT="29.001485028841458"/>
<DICH_DATA CI_END="1.0070038145448126" CI_START="0.7964063333004738" EFFECT_SIZE="0.8955357142857143" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="64" LOG_CI_END="0.0030311156704257458" LOG_CI_START="-0.0988652949699527" LOG_EFFECT_SIZE="-0.047917089649763475" MODIFIED="2011-11-24 08:50:46 +0000" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.059854456005525754" STUDY_ID="STD-Goode-2009" TOTAL_1="70" TOTAL_2="68" VAR="0.003582555903717418" WEIGHT="25.251388074482016"/>
<DICH_DATA CI_END="1.3840628970510738" CI_START="0.9266254125829277" EFFECT_SIZE="1.1324786324786325" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="39" LOG_CI_END="0.14115582655248202" LOG_CI_START="-0.033095793499152024" LOG_EFFECT_SIZE="0.054030016526665" MODIFIED="2010-04-14 16:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="0.1023562641777603" STUDY_ID="STD-Manassero--2007" TOTAL_1="54" TOTAL_2="53" VAR="0.010476804816427456" WEIGHT="17.81898960893103"/>
<DICH_DATA CI_END="1.5607452744230437" CI_START="0.6407195436613878" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="14" LOG_CI_END="0.19333202866172655" LOG_CI_START="-0.19333202866172652" LOG_EFFECT_SIZE="0.0" ORDER="103867" O_E="0.0" SE="0.227128381289749" STUDY_ID="STD-Moore-1999" TOTAL_1="18" TOTAL_2="21" VAR="0.0515873015873016" WEIGHT="6.467565691674757"/>
<DICH_DATA CI_END="1.1439398089180137" CI_START="0.7748822444660949" EFFECT_SIZE="0.9414980863860033" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="59" LOG_CI_END="0.058403173633158924" LOG_CI_START="-0.1107642903507207" LOG_EFFECT_SIZE="-0.026180558358780904" MODIFIED="2010-04-15 10:01:40 +0100" MODIFIED_BY="[Empty name]" ORDER="103868" O_E="0.0" SE="0.09936980573658291" STUDY_ID="STD-Moore-2008" TOTAL_1="93" TOTAL_2="82" VAR="0.009874358292126226" WEIGHT="18.28939758115645"/>
<DICH_DATA CI_END="0.5700442740175377" CI_START="0.09729711466987187" EFFECT_SIZE="0.23550724637681159" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="23" LOG_CI_END="-0.2440914123717308" LOG_CI_START="-1.0119000384729937" LOG_EFFECT_SIZE="-0.6279957254223621" ORDER="103869" O_E="0.0" SE="0.45101458768587815" STUDY_ID="STD-van-Kampen-1998" TOTAL_1="48" TOTAL_2="52" VAR="0.20341415830546267" WEIGHT="1.929072481609457"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.384672158756292" CI_END="1.0953121328129085" CI_START="0.8337694649866787" DF="6" EFFECT_SIZE="0.9556347686061012" ESTIMABLE="YES" EVENTS_1="268" EVENTS_2="277" I2="18.750624658596823" ID="CMP-001.01.02" LOG_CI_END="0.03953789839203424" LOG_CI_START="-0.07895401401977006" LOG_EFFECT_SIZE="-0.019708057813867943" MODIFIED="2011-11-24 16:49:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.28673246054725643" P_Z="0.5144151130903034" STUDIES="7" TAU2="0.00665740458083055" TOTAL_1="451" TOTAL_2="444" WEIGHT="100.0" Z="0.6519783964017829">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="1.3071632098645352" CI_START="0.5527236343156219" EFFECT_SIZE="0.85" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="20" LOG_CI_END="0.11632981613321035" LOG_CI_START="-0.257491964704625" LOG_EFFECT_SIZE="-0.07058107428570728" MODIFIED="2011-11-24 16:49:29 +0000" MODIFIED_BY="[Empty name]" ORDER="103870" O_E="0.0" SE="0.21958476451180328" STUDY_ID="STD-Dubbelman-2004" TOTAL_1="33" TOTAL_2="33" VAR="0.0482174688057041" WEIGHT="8.828340814494856"/>
<DICH_DATA CI_END="15.075299361074784" CI_START="0.08663990131778537" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.17826594499607" LOG_CI_START="-1.0622820510406963" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="103871" O_E="0.0" SE="1.3161089837634485" STUDY_ID="STD-Franke-1998" TOTAL_1="7" TOTAL_2="8" VAR="1.7321428571428572" WEIGHT="0.2786139932647226"/>
<DICH_DATA CI_END="1.1030892163528296" CI_START="0.9065449876360172" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="158" LOG_CI_END="0.04261063900666249" LOG_CI_START="-0.04261063900666255" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-10 10:10:52 +0000" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.05005940055715685" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="197" TOTAL_2="197" VAR="0.0025059435841418756" WEIGHT="52.868675912636704"/>
<DICH_DATA CI_END="1.2845641448170866" CI_START="0.6562677033419033" EFFECT_SIZE="0.9181600955794504" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="31" LOG_CI_END="0.10875579567480759" LOG_CI_START="-0.1829189679897997" LOG_EFFECT_SIZE="-0.037081586157496044" MODIFIED="2010-04-14 16:49:02 +0100" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="0.17133119998995594" STUDY_ID="STD-Manassero--2007" TOTAL_1="54" TOTAL_2="53" VAR="0.029354380089998282" WEIGHT="13.452654147435549"/>
<DICH_DATA CI_END="2.9536950600333323" CI_START="0.6018826390824906" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.47036565665607927" LOG_CI_START="-0.22048818343947937" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="103872" O_E="0.0" SE="0.40581096545379314" STUDY_ID="STD-Moore-1999" TOTAL_1="18" TOTAL_2="21" VAR="0.16468253968253968" WEIGHT="2.8274439243654523"/>
<DICH_DATA CI_END="1.2093276707272504" CI_START="0.7302129675197692" EFFECT_SIZE="0.9397163120567376" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="48" LOG_CI_END="0.08254399011464719" LOG_CI_START="-0.13655045887975367" LOG_EFFECT_SIZE="-0.02700323438255326" MODIFIED="2010-04-15 10:02:08 +0100" MODIFIED_BY="[Empty name]" ORDER="103873" O_E="0.0" SE="0.12869716387432473" STUDY_ID="STD-Moore-2008" TOTAL_1="94" TOTAL_2="80" VAR="0.01656295998929479" WEIGHT="20.86332809054455"/>
<DICH_DATA CI_END="0.7656041370544443" CI_START="0.04258115527875864" EFFECT_SIZE="0.18055555555555555" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="12" LOG_CI_END="-0.11599572845082869" LOG_CI_START="-1.3707825597980348" LOG_EFFECT_SIZE="-0.7433891441244317" ORDER="103874" O_E="0.0" SE="0.7370679960283384" STUDY_ID="STD-van-Kampen-1998" TOTAL_1="48" TOTAL_2="52" VAR="0.5432692307692307" WEIGHT="0.8809431172581728"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.42563720334509" CI_END="1.1408898105662115" CI_START="0.7260148405758275" DF="4" EFFECT_SIZE="0.9101114953305525" ESTIMABLE="YES" EVENTS_1="214" EVENTS_2="227" I2="37.74936440672903" ID="CMP-001.01.03" LOG_CI_END="0.05724370140863198" LOG_CI_START="-0.13905450173197753" LOG_EFFECT_SIZE="-0.04090540016167275" MODIFIED="2011-11-17 09:51:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.16953661787368357" P_Z="0.41401406034235044" STUDIES="5" TAU2="0.022517725098275872" TOTAL_1="408" TOTAL_2="384" WEIGHT="100.0" Z="0.8168501780186859">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="80.83835513154432" CI_START="0.2680736163777298" EFFECT_SIZE="4.655172413793103" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="1.907617468072343" LOG_CI_START="-0.5717459268802432" LOG_EFFECT_SIZE="0.66793577059605" ORDER="103875" O_E="0.0" SE="1.4563903312418913" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" VAR="2.121072796934866" WEIGHT="0.6202489308290476"/>
<DICH_DATA CI_END="1.0357529565198063" CI_START="0.83792707416613" EFFECT_SIZE="0.9316036949344716" ESTIMABLE="YES" EVENTS_1="144" EVENTS_2="157" LOG_CI_END="0.01525618165018161" LOG_CI_START="-0.07679377691315271" LOG_EFFECT_SIZE="-0.030768797631485576" MODIFIED="2011-11-10 10:11:02 +0000" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.054070601314746176" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="191" TOTAL_2="194" VAR="0.002923629926538231" WEIGHT="52.259784438743786"/>
<DICH_DATA CI_END="1.1889368493982906" CI_START="0.45575134472067586" EFFECT_SIZE="0.7361111111111112" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.0751587875991745" LOG_CI_START="-0.34127204126013333" LOG_EFFECT_SIZE="-0.1330566268304794" MODIFIED="2010-04-14 16:49:15 +0100" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="0.24461353023780555" STUDY_ID="STD-Manassero--2007" TOTAL_1="54" TOTAL_2="53" VAR="0.05983577917540181" WEIGHT="16.144543467245"/>
<DICH_DATA CI_END="1.4304435171033334" CI_START="0.781747382258147" EFFECT_SIZE="1.0574712643678161" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="37" LOG_CI_END="0.15547071380528615" LOG_CI_START="-0.1069335643514126" LOG_EFFECT_SIZE="0.024268574726936762" MODIFIED="2010-04-15 10:02:30 +0100" MODIFIED_BY="[Empty name]" ORDER="103876" O_E="0.0" SE="0.15413757191137048" STUDY_ID="STD-Moore-2008" TOTAL_1="87" TOTAL_2="74" VAR="0.023758391074732904" WEIGHT="28.731013736235308"/>
<DICH_DATA CI_END="0.9961205409132071" CI_START="0.05166218401784614" EFFECT_SIZE="0.22685185185185186" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="-0.0016881042611808456" LOG_CI_START="-1.2868272379836536" LOG_EFFECT_SIZE="-0.6442576711224173" ORDER="103877" O_E="0.0" SE="0.75489708868989" STUDY_ID="STD-van-Kampen-1998" TOTAL_1="48" TOTAL_2="49" VAR="0.5698696145124716" WEIGHT="2.244409426946866"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.26099328907959" CI_END="1.216436337960697" CI_START="0.5953851259234445" DF="2" EFFECT_SIZE="0.8510276742001892" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="203" I2="68.05618681162947" ID="CMP-001.01.04" LOG_CI_END="0.08508938511571314" LOG_CI_START="-0.225202019219123" LOG_EFFECT_SIZE="-0.07005631705170491" MODIFIED="2014-02-21 10:08:31 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.04369612995727401" P_Z="0.3761430419273344" STUDIES="3" TAU2="0.06454051349975026" TOTAL_1="339" TOTAL_2="326" WEIGHT="100.0" Z="0.8850252143155843">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="1.0885026735933754" CI_START="0.8735688031206474" EFFECT_SIZE="0.9751317745641302" ESTIMABLE="YES" EVENTS_1="148" EVENTS_2="151" LOG_CI_END="0.03682950009775971" LOG_CI_START="-0.058702883882099946" LOG_EFFECT_SIZE="-0.010936691892170107" MODIFIED="2011-11-10 10:11:15 +0000" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.056116195242697" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="196" TOTAL_2="195" VAR="0.0031490273685164894" WEIGHT="49.07870848048078"/>
<DICH_DATA CI_END="0.8325618117812722" CI_START="0.2125172377039429" EFFECT_SIZE="0.42063492063492064" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" LOG_CI_END="-0.07958351335438549" LOG_CI_START="-0.6726058376791622" LOG_EFFECT_SIZE="-0.37609467551677384" MODIFIED="2011-11-10 10:34:55 +0000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="0.3483442488162225" STUDY_ID="STD-Manassero--2007" TOTAL_1="54" TOTAL_2="53" VAR="0.12134371568333832" WEIGHT="17.871958573629726"/>
<DICH_DATA CI_END="1.4760574744757284" CI_START="0.7017582672462291" EFFECT_SIZE="1.017760057992026" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="31" LOG_CI_END="0.16910326830117736" LOG_CI_START="-0.153812462344013" LOG_EFFECT_SIZE="0.00764540297858219" MODIFIED="2010-04-15 10:02:51 +0100" MODIFIED_BY="[Empty name]" ORDER="104" O_E="0.0" SE="0.18968229863963115" STUDY_ID="STD-Moore-2008" TOTAL_1="89" TOTAL_2="78" VAR="0.035979374417214216" WEIGHT="33.049332945889496"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="9.77809290362266" CI_END="-0.6129880611673716" CI_START="-1.1592199040819957" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.8861039826246836" ESTIMABLE="YES" I2="59.09222749849257" I2_Q="65.60801990054047" ID="CMP-001.02" MODIFIED="2014-03-13 11:42:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.04433631915566272" P_Q="0.033210358019293174" P_Z="2.031307145069951E-10" Q="8.72296387507838" RANDOM="NO" SCALE="5.78" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="526" TOTAL_2="529" UNITS="" WEIGHT="400.0" Z="6.358955139762282">
<NAME>Number of incontinence episodes per day</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0551290285442785" CI_END="-0.7827569090050941" CI_START="-1.3925275567609872" DF="1" EFFECT_SIZE="-1.0876422328830406" ESTIMABLE="YES" I2="5.224861325286246" ID="CMP-001.02.01" MODIFIED="2011-11-24 08:51:43 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.30432914581607917" P_Z="2.7111265148508368E-12" STUDIES="2" TAU2="0.0" TOTAL_1="197" TOTAL_2="203" WEIGHT="100.0" Z="6.991939058925896">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.3791355991434089" CI_START="-1.579135599143409" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.9" MODIFIED="2011-11-17 09:56:09 +0000" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="3.8" SD_2="4.5" SE="0.4995681588369509" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="139" TOTAL_2="139" WEIGHT="9.695882799436891"/>
<CONT_DATA CI_END="-0.8191642581347827" CI_START="-1.4608357418652171" EFFECT_SIZE="-1.14" ESTIMABLE="YES" MEAN_1="1.86" MEAN_2="3.0" MODIFIED="2011-11-24 08:51:43 +0000" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="0.56" SD_2="1.17" SE="0.16369471296203839" STUDY_ID="STD-Goode-2009" TOTAL_1="58" TOTAL_2="64" WEIGHT="90.30411720056311"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.0457839538018924E-33" CI_END="1.0027308356338986" CI_START="-1.402730835633899" DF="0" EFFECT_SIZE="-0.2000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.02" MODIFIED="2011-11-17 09:56:27 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.7444856621122771" STUDIES="1" TAU2="0.0" TOTAL_1="117" TOTAL_2="110" WEIGHT="100.0" Z="0.32591897147245885">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="1.0027308356338986" CI_START="-1.402730835633899" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.3" MEAN_2="3.5" MODIFIED="2011-11-17 09:56:27 +0000" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="5.2" SD_2="4.0" SE="0.6136494573986492" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="117" TOTAL_2="110" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.3280890275256832E-33" CI_END="0.9274532361572692" CI_START="-1.3274532361572686" DF="0" EFFECT_SIZE="-0.19999999999999976" ESTIMABLE="YES" I2="100.0" ID="CMP-001.02.03" MODIFIED="2011-11-17 09:56:56 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.7280806151103104" STUDIES="1" TAU2="0.0" TOTAL_1="107" TOTAL_2="110" WEIGHT="99.99999999999999" Z="0.3476798720664022">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.9274532361572692" CI_START="-1.3274532361572686" EFFECT_SIZE="-0.19999999999999973" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="3.3" MODIFIED="2011-11-17 09:56:56 +0000" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="4.7" SD_2="3.7" SE="0.5752418131406883" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="107" TOTAL_2="110" WEIGHT="99.99999999999999"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0243666205214037" CI_START="-0.8243666205214034" DF="0" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.04" MODIFIED="2011-11-17 09:57:13 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8320811452992849" STUDIES="1" TAU2="0.0" TOTAL_1="105" TOTAL_2="106" WEIGHT="100.0" Z="0.21203318478056982">
<NAME>after first year</NAME>
<CONT_DATA CI_END="1.0243666205214037" CI_START="-0.8243666205214035" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.0" MEAN_2="2.9" MODIFIED="2011-11-17 09:57:13 +0000" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="3.8" SD_2="3.0" SE="0.47162428892198505" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="105" TOTAL_2="106" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="305" EVENTS_2="330" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-18 11:15:14 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="651" TOTAL_2="658" WEIGHT="0.0" Z="0.0">
<NAME>Number of men using pads</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="101" EVENTS_2="108" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:00:32 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="177" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="1.1126695347664164" CI_START="0.7860117521537504" EFFECT_SIZE="0.9351851851851852" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="108" LOG_CI_END="0.04636619709476632" LOG_CI_START="-0.1045709605033805" LOG_EFFECT_SIZE="-0.029102381704307106" MODIFIED="2011-11-17 10:00:32 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.08866123352413147" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="177" TOTAL_2="177" VAR="0.007860814330020574" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="74" EVENTS_2="83" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:00:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="161" TOTAL_2="164" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="1.138054912725622" CI_START="0.7247362439565134" EFFECT_SIZE="0.9081793010551523" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="83" LOG_CI_END="0.05616321787483276" LOG_CI_START="-0.1398200191333318" LOG_EFFECT_SIZE="-0.04182840062924952" MODIFIED="2011-11-17 10:00:43 +0000" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.11512152355126513" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="161" TOTAL_2="164" VAR="0.013252965184764492" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="67" EVENTS_2="71" I2="0.0" ID="CMP-001.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:00:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="154" TOTAL_2="156" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="1.2258750780756378" CI_START="0.7454086823863024" EFFECT_SIZE="0.9559173221145052" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="71" LOG_CI_END="0.08844621596818172" LOG_CI_START="-0.12760555296868234" LOG_EFFECT_SIZE="-0.01957966850025033" MODIFIED="2011-11-17 10:00:54 +0000" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.12690987854701846" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="154" TOTAL_2="156" VAR="0.01610611727281898" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="68" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 09:59:27 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="159" TOTAL_2="161" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="1.2209827382954068" CI_START="0.7207941492677201" EFFECT_SIZE="0.9381243063263041" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="68" LOG_CI_END="0.08670952412830177" LOG_CI_START="-0.14218874721081462" LOG_EFFECT_SIZE="-0.02773961154125641" MODIFIED="2011-11-17 09:59:27 +0000" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.13445597764931397" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="159" TOTAL_2="161" VAR="0.018078409925632817" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2011-11-18 11:15:11 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.175068815691695" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pad changes over 24 hours</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.9636232476345333" CI_START="-0.36362324763453346" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="0.9" ORDER="103878" SD_1="1.1" SD_2="1.0" SE="0.3385895112711809" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.8536435129293701" CI_START="-0.053643512929370085" EFFECT_SIZE="0.4" ESTIMABLE="YES" MEAN_1="0.8" MEAN_2="0.4" ORDER="103879" SD_1="1.0" SD_2="0.5" SE="0.23145502494313785" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.5333585395401861" CI_START="-0.13335853954018606" EFFECT_SIZE="0.2" ESTIMABLE="YES" MEAN_1="0.4" MEAN_2="0.2" ORDER="103880" SD_1="0.7" SD_2="0.4" SE="0.17008401285415226" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.04.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2015-01-05 16:06:33 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.39" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="777" TOTAL_2="784" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence Score (ICIQ-SF)</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.01" MODIFIED="2011-11-17 09:44:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="198" TOTAL_2="198" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="-0.0010759521249686932" CI_START="-1.798924047875032" EFFECT_SIZE="-0.9000000000000004" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="7.2" MODIFIED="2011-11-17 09:44:30 +0000" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="4.2" SD_2="4.9" SE="0.458643145979023" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="198" TOTAL_2="198" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.02" MODIFIED="2011-11-17 09:44:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="197" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.6698229070092555" CI_START="-1.0698229070092542" EFFECT_SIZE="-0.1999999999999993" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="5.6" MODIFIED="2011-11-17 09:44:52 +0000" MODIFIED_BY="[Empty name]" ORDER="211" SD_1="4.2" SD_2="4.6" SE="0.44379535229744366" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="197" TOTAL_2="197" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.03" MODIFIED="2011-11-17 09:45:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="186" TOTAL_2="194" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.38505097478451134" CI_START="-1.3850509747845114" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="5.1" MEAN_2="5.6" MODIFIED="2011-11-17 09:45:11 +0000" MODIFIED_BY="[Empty name]" ORDER="212" SD_1="4.2" SD_2="4.6" SE="0.45156491739934024" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="186" TOTAL_2="194" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.05.04" MODIFIED="2011-11-16 17:17:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="196" TOTAL_2="195" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="0.3534545186482292" CI_START="-1.3534545186482292" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="4.9" MEAN_2="5.4" MODIFIED="2011-11-16 17:17:43 +0000" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="4.1" SD_2="4.5" SE="0.4354439802874795" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="196" TOTAL_2="195" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2011-11-18 11:15:08 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0155839612125535" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="771" TOTAL_2="781" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life related to urinary incontinence</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.01" MODIFIED="2011-11-17 09:47:03 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="198" TOTAL_2="198" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.004716913933618949" CI_START="-1.004716913933619" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="2.5" MODIFIED="2011-11-17 09:47:03 +0000" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="2.3" SD_2="2.8" SE="0.25751336142641473" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="198" TOTAL_2="198" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.02" MODIFIED="2011-11-17 09:47:23 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="196" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.15806045628302673" CI_START="-0.7580604562830269" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.8" MODIFIED="2011-11-17 09:47:23 +0000" MODIFIED_BY="[Empty name]" ORDER="214" SD_1="2.1" SD_2="2.5" SE="0.2337086088806474" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="194" TOTAL_2="196" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.03" MODIFIED="2011-11-17 09:47:41 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="186" TOTAL_2="194" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.04532649171600367" CI_START="-0.8453264917160039" EFFECT_SIZE="-0.40000000000000013" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.8" MODIFIED="2011-11-17 09:47:41 +0000" MODIFIED_BY="[Empty name]" ORDER="215" SD_1="1.9" SD_2="2.5" SE="0.22721156879855053" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="186" TOTAL_2="194" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.06.04" MODIFIED="2011-11-17 09:27:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="193" TOTAL_2="193" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="0.13000875062941153" CI_START="-0.7300087506294116" EFFECT_SIZE="-0.30000000000000004" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.7" MODIFIED="2011-11-17 09:27:08 +0000" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="2.0" SD_2="2.3" SE="0.21939625116648354" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="193" TOTAL_2="193" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-24 08:53:20 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2011-11-24 08:53:07 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-Goode-2009" TOTAL_1="70" TOTAL_2="68" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.1119237865819582" CI_END="41.7418428145525" CI_START="-2.184229548874594" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="19.77880663283895" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2015-01-07 13:35:41 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.9091224240583735" P_Q="0.7884964019957306" P_Z="0.07755619191147835" Q="1.052727275552656" RANDOM="NO" SCALE="351.58293412057884" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="416" TOTAL_2="372" UNITS="" WEIGHT="400.0" Z="1.765045066484146">
<NAME>24 hour pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.0180512927691088" CI_END="77.70045867782326" CI_START="-33.12225044316125" DF="1" EFFECT_SIZE="22.289104117331004" ESTIMABLE="YES" I2="1.773122130222839" ID="CMP-001.08.01" MODIFIED="2010-01-28 11:07:18 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.31298198202692606" P_Z="0.43046774409948274" STUDIES="2" TAU2="0.0" TOTAL_1="111" TOTAL_2="103" WEIGHT="100.0" Z="0.7883915068335069">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="77.31373614658555" CI_START="-111.31373614658555" EFFECT_SIZE="-17.0" ESTIMABLE="YES" MEAN_1="87.0" MEAN_2="104.0" ORDER="103882" SD_1="123.0" SD_2="176.0" SE="48.120137354829104" STUDY_ID="STD-Moore-1999" TOTAL_1="18" TOTAL_2="21" WEIGHT="34.51815980444832"/>
<CONT_DATA CI_END="111.4759914515142" CI_START="-25.475991451514204" EFFECT_SIZE="43.0" ESTIMABLE="YES" MEAN_1="115.0" MEAN_2="72.0" MODIFIED="2009-11-06 16:41:10 +0000" MODIFIED_BY="[Empty name]" ORDER="103883" SD_1="300.0" SD_2="144.0" SE="34.93737231482011" STUDY_ID="STD-Moore-2008" TOTAL_1="93" TOTAL_2="82" WEIGHT="65.48184019555168"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.02111355214150991" CI_END="64.52276479206103" CI_START="-40.772786143316665" DF="1" EFFECT_SIZE="11.874989324372182" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.02" MODIFIED="2010-04-15 10:08:51 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.8844700527354473" P_Z="0.6584310041941857" STUDIES="2" TAU2="0.0" TOTAL_1="112" TOTAL_2="101" WEIGHT="100.0" Z="0.44208043332906316">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="91.23629686436837" CI_START="-77.23629686436837" EFFECT_SIZE="7.0" ESTIMABLE="YES" MEAN_1="74.0" MEAN_2="67.0" ORDER="103885" SD_1="131.0" SD_2="137.0" SE="42.97849222170077" STUDY_ID="STD-Moore-1999" TOTAL_1="18" TOTAL_2="21" WEIGHT="39.062633445347736"/>
<CONT_DATA CI_END="82.44320254672962" CI_START="-52.44320254672962" EFFECT_SIZE="15.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="61.0" MODIFIED="2010-04-15 10:08:51 +0100" MODIFIED_BY="[Empty name]" ORDER="103886" SD_1="259.0" SD_2="194.0" SE="34.41042951743654" STUDY_ID="STD-Moore-2008" TOTAL_1="94" TOTAL_2="80" WEIGHT="60.93736655465226"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.020031666118683615" CI_END="44.817607838813785" CI_START="-22.349563237781364" DF="1" EFFECT_SIZE="11.234022300516212" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.03" MODIFIED="2010-04-15 10:08:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8874486885999634" P_Z="0.512064657380132" STUDIES="2" TAU2="0.0" TOTAL_1="104" TOTAL_2="90" WEIGHT="100.0" Z="0.6556262161293851">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="90.05274858932785" CI_START="-58.05274858932785" EFFECT_SIZE="16.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="54.0" ORDER="103888" SD_1="114.0" SD_2="103.0" SE="37.78270885253325" STUDY_ID="STD-Moore-1999" TOTAL_1="17" TOTAL_2="16" WEIGHT="20.567038341936875"/>
<CONT_DATA CI_END="47.6813699593383" CI_START="-27.681369959338298" EFFECT_SIZE="10.0" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="35.0" MODIFIED="2010-04-15 10:08:03 +0100" MODIFIED_BY="[Empty name]" ORDER="103889" SD_1="142.0" SD_2="101.0" SE="19.225542028610796" STUDY_ID="STD-Moore-2008" TOTAL_1="87" TOTAL_2="74" WEIGHT="79.43296165806312"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="83.72258488438132" CI_START="-5.7225848843813125" DF="0" EFFECT_SIZE="39.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.04" MODIFIED="2009-11-06 16:43:48 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.08741907083989263" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="78" WEIGHT="100.0" Z="1.7091721239877873">
<NAME>after first year</NAME>
<CONT_DATA CI_END="83.72258488438132" CI_START="-5.7225848843813125" EFFECT_SIZE="39.0" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="8.0" MODIFIED="2009-11-06 16:43:48 +0000" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="215.0" SD_2="10.0" SE="22.818064636466463" STUDY_ID="STD-Moore-2008" TOTAL_1="89" TOTAL_2="78" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2015-01-07 13:35:41 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="84" TOTAL_2="42" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="8.237335876874956" CI_START="-1.2373358768749565" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="6.5" MEAN_2="3.0" ORDER="103890" SD_1="11.4" SD_2="4.1" SE="2.417052514353558" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.02" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="6.2764627867178255" CI_START="-1.4764627867178253" EFFECT_SIZE="2.4000000000000004" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="1.3" ORDER="103891" SD_1="9.9" SD_2="2.4" SE="1.9778234790510791" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.03" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="3.1" MEAN_2="0.0" ORDER="103892" SD_1="8.1" SD_2="0.0" SE="0.0" STUDY_ID="STD-Floratos-2002" TOTAL_1="28" TOTAL_2="14" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.09.04" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="63" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-07 13:35:41 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.14" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="191" TOTAL_2="189" WEIGHT="0.0" Z="0.0">
<NAME>Number of men not carrying out pelvic floor muscle contractions at 12 months</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.880075115168154" CI_START="0.5332556271039871" EFFECT_SIZE="0.6850583971002819" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="91" LOG_CI_END="-0.05548025886024659" LOG_CI_START="-0.27306455302374394" LOG_EFFECT_SIZE="-0.16427240594199527" MODIFIED="2011-11-17 09:34:12 +0000" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="0.12781009145126507" STUDY_ID="STD-Glazener-RP-2011" TOTAL_1="191" TOTAL_2="189" VAR="0.016335419476780737" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-06-11 13:43:31 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Treatment of UI after radical: electric or magnetic energy versus no treatment</NAME>
<DICH_OUTCOME CHI2="11.537959346004886" CI_END="0.681145646898984" CI_START="0.4327953621150851" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5429518182148023" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="102" I2="47.99773668748842" I2_Q="65.35814788400374" ID="CMP-002.01" LOG_CI_END="-0.16676001454623904" LOG_CI_START="-0.3637174018262061" LOG_EFFECT_SIZE="-0.2652387081862225" METHOD="MH" MODIFIED="2014-05-12 13:46:07 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07310670274653763" P_Q="0.03416956256779691" P_Z="1.299678991933393E-7" Q="8.660045051733006" RANDOM="NO" SCALE="237.40679455647393" SORT_BY="EFFECT_SIZE" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="320" TOTAL_2="325" WEIGHT="400.0" Z="5.2788912620166695">
<NAME>Number of incontinent men</NAME>
<GROUP_LABEL_1>PFMT + extra stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5038197956206583" CI_END="0.9770074371281288" CI_START="0.6013688594857072" DF="1" EFFECT_SIZE="0.7665127840909091" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="43" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="-0.010102130353474379" LOG_CI_START="-0.220859064602102" LOG_EFFECT_SIZE="-0.11548059747778819" MODIFIED="2014-03-04 09:39:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.47782658343508855" P_Z="0.0317251672298947" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="51" WEIGHT="100.0" Z="2.1478563709094733">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="0.9332387192851022" CI_START="0.549606776606875" EFFECT_SIZE="0.7161803713527851" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="29" LOG_CI_END="-0.030007250993773243" LOG_CI_START="-0.25994792109983783" LOG_EFFECT_SIZE="-0.14497758604680555" MODIFIED="2011-11-25 15:45:26 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.13506828784497643" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="26" TOTAL_2="30" VAR="0.01824344238137341" WEIGHT="66.93892045454545"/>
<DICH_DATA CI_END="1.4152283907546668" CI_START="0.532885808100266" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.15082653232705753" LOG_CI_START="-0.2733658458049029" LOG_EFFECT_SIZE="-0.06126965673892266" ORDER="103893" O_E="0.0" SE="0.24917270270085023" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" VAR="0.0620870357712463" WEIGHT="33.06107954545455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9304370711697796E-31" CI_END="0.7931111714304633" CI_START="0.2945502717983001" DF="0" EFFECT_SIZE="0.4833333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" I2="100.0" ID="CMP-002.01.02" LOG_CI_END="-0.10066593278980833" LOG_CI_START="-0.5308405721795667" LOG_EFFECT_SIZE="-0.3157532524846875" MODIFIED="2011-11-24 16:57:07 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.004011280121466217" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="100.0" Z="2.877273303462454">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="0.7931111714304633" CI_START="0.29455027179830007" EFFECT_SIZE="0.48333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="25" LOG_CI_END="-0.10066593278980833" LOG_CI_START="-0.5308405721795667" LOG_EFFECT_SIZE="-0.31575325248468755" MODIFIED="2011-11-24 16:57:07 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.25268671257635156" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="24" TOTAL_2="29" VAR="0.0638505747126437" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.009672231971340152" CI_END="0.7337662493131969" CI_START="0.18441890692129403" DF="1" EFFECT_SIZE="0.36785917092561043" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="21" I2="0.0" ID="CMP-002.01.03" LOG_CI_END="-0.13444226815125684" LOG_CI_START="-0.7341945564349808" LOG_EFFECT_SIZE="-0.4343184122931188" MODIFIED="2014-02-21 11:24:54 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9216563571907346" P_Z="0.0045302439163323535" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="40" WEIGHT="100.0" Z="2.838666771420245">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="1.168952001300874" CI_START="0.10479472199343962" EFFECT_SIZE="0.35" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.06779667882810507" LOG_CI_START="-0.9796605901275539" LOG_EFFECT_SIZE="-0.4559319556497244" MODIFIED="2014-02-21 11:24:54 +0000" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="0.615281584781658" STUDY_ID="STD-Morihiro-2011" TOTAL_1="20" TOTAL_2="14" VAR="0.37857142857142856" WEIGHT="33.3901192504259"/>
<DICH_DATA CI_END="0.8749223671627098" CI_START="0.16228522992980532" EFFECT_SIZE="0.37681159420289856" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="15" LOG_CI_END="-0.058030480701815816" LOG_CI_START="-0.7897210048310588" LOG_EFFECT_SIZE="-0.42387574276643736" MODIFIED="2011-11-24 16:57:23 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="0.42979863580002553" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="23" TOTAL_2="26" VAR="0.18472686733556298" WEIGHT="66.6098807495741"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.58822869939711" CI_END="0.7425511489237028" CI_START="0.09066465696443435" DF="1" EFFECT_SIZE="0.25946704067321175" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="37.036775599156535" ID="CMP-002.01.04" LOG_CI_END="-0.12927362560639685" LOG_CI_START="-1.0425619772913068" LOG_EFFECT_SIZE="-0.5859178014488519" MODIFIED="2014-02-21 11:26:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.2075794341544105" P_Z="0.01190932570388858" STUDIES="3" TAU2="0.0" TOTAL_1="208" TOTAL_2="205" WEIGHT="100.0" Z="2.514819742575316">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-21 10:08:31 +0000" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.0" STUDY_ID="STD-Marchiori-2010" TOTAL_1="166" TOTAL_2="166" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.087464006788309" CI_START="0.0038774273279850416" EFFECT_SIZE="0.06493506493506493" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.03641489145480266" LOG_CI_START="-2.411456333127729" LOG_EFFECT_SIZE="-1.187520720836463" MODIFIED="2014-02-21 11:26:08 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.4378916744777637" STUDY_ID="STD-Morihiro-2011" TOTAL_1="20" TOTAL_2="14" VAR="2.0675324675324673" WEIGHT="46.14305750350631"/>
<DICH_DATA CI_END="1.4103425801529417" CI_START="0.1287575110960138" EFFECT_SIZE="0.42613636363636365" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.14932461804455557" LOG_CI_START="-0.8902274268894552" LOG_EFFECT_SIZE="-0.3704514044224498" MODIFIED="2011-11-24 16:57:31 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.6106380170598518" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="22" TOTAL_2="25" VAR="0.37287878787878787" WEIGHT="53.85694249649369"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-04 09:57:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="146.5253845360764" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT + BF + Estim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.8980755964159766" CI_START="0.11484870756926112" EFFECT_SIZE="0.5769230769230769" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.46210970987156236" LOG_CI_START="-0.9398738877018358" LOG_EFFECT_SIZE="-0.23888208891513676" MODIFIED="2011-11-24 17:07:56 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.8235321051453478" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="26" TOTAL_2="30" VAR="0.6782051282051282" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="23.283610002886114" CI_END="24.332099553415006" CI_START="-58.20767868880719" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="MD" EFFECT_SIZE="-16.937789567696093" ESTIMABLE="YES" I2="74.23080012396586" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2014-06-11 13:43:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="7.068497026770926E-4" P_Q="0.6244295671354886" P_Z="0.421166585980306" Q="1.7565774001031869" RANDOM="NO" SCALE="399.9" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="152" TOTAL_2="173" UNITS="" WEIGHT="100.0" Z="0.8043989997884644">
<NAME>24 hour pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>PFMT + extra stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.1447758621524295" CI_END="61.32709085613334" CI_START="-116.96679762524161" DF="1" EFFECT_SIZE="-27.819853384554136" ESTIMABLE="YES" I2="86.0037596798909" ID="CMP-002.03.01" MODIFIED="2011-11-24 16:59:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.007518288013731" P_Z="0.5407754232756063" STUDIES="2" TAU2="0.0" TOTAL_1="45" TOTAL_2="51" WEIGHT="21.43155494112451" Z="0.6116408268767637">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="158.64295885924147" CI_START="-54.642958859241475" EFFECT_SIZE="52.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="104.0" ORDER="103894" SD_1="168.0" SD_2="176.0" SE="54.41067269624724" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" WEIGHT="14.976220702620452"/>
<CONT_DATA CI_END="-50.5671235045391" CI_START="-375.4328764954609" EFFECT_SIZE="-213.0" ESTIMABLE="YES" MEAN_1="210.0" MEAN_2="423.0" MODIFIED="2011-11-24 16:59:02 +0000" MODIFIED_BY="[Empty name]" ORDER="216" SD_1="261.0" SD_2="357.0" SE="82.87543943496446" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="26" TOTAL_2="30" WEIGHT="6.455334238504056"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="9.342202044482653" CI_END="96.43234358805849" CI_START="-86.18983424616754" DF="1" EFFECT_SIZE="5.121254670945472" ESTIMABLE="YES" I2="89.29588553920664" ID="CMP-002.03.02" MODIFIED="2011-11-24 17:00:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0022393750451218386" P_Z="0.912467958695617" STUDIES="2" TAU2="0.0" TOTAL_1="43" TOTAL_2="50" WEIGHT="20.427704189905747" Z="0.10992613087575921">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="258.5877774308061" CI_START="11.4122225691939" EFFECT_SIZE="135.0" ESTIMABLE="YES" MEAN_1="202.0" MEAN_2="67.0" ORDER="103895" SD_1="242.0" SD_2="137.0" SE="63.0561471566063" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" WEIGHT="11.151044783828725"/>
<CONT_DATA CI_END="-15.500561285071143" CI_START="-286.49943871492883" EFFECT_SIZE="-151.0" ESTIMABLE="YES" MEAN_1="81.0" MEAN_2="232.0" MODIFIED="2011-11-24 17:00:42 +0000" MODIFIED_BY="[Empty name]" ORDER="217" SD_1="140.0" SD_2="339.0" SE="69.13363703809414" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="24" TOTAL_2="29" WEIGHT="9.276659406077023"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="5.040054696147845" CI_END="60.13243012977632" CI_START="-64.03221287820182" DF="1" EFFECT_SIZE="-1.9498913742127486" ESTIMABLE="YES" I2="80.15894548199431" ID="CMP-002.03.03" MODIFIED="2011-11-24 17:01:03 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0247677384170355" P_Z="0.9509141406433055" STUDIES="2" TAU2="0.0" TOTAL_1="42" TOTAL_2="47" WEIGHT="44.190682296811914" Z="0.06155885886091967">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="117.91541335548547" CI_START="-29.91541335548547" EFFECT_SIZE="44.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="54.0" ORDER="103896" SD_1="132.0" SD_2="103.0" SE="37.71263856811697" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="21" WEIGHT="31.174290942383365"/>
<CONT_DATA CI_END="2.389985040536587" CI_START="-226.3899850405366" EFFECT_SIZE="-112.0" ESTIMABLE="YES" MEAN_1="20.0" MEAN_2="132.0" MODIFIED="2011-11-24 17:01:03 +0000" MODIFIED_BY="[Empty name]" ORDER="218" SD_1="49.0" SD_2="293.0" SE="58.363309705091616" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="23" TOTAL_2="26" WEIGHT="13.016391354428551"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="30.495676842449242" CI_START="-190.49567684244926" DF="0" EFFECT_SIZE="-80.0" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.04" MODIFIED="2011-11-24 17:01:17 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.15588911319442647" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="13.950058572157829" Z="1.4190339680598927">
<NAME>after first year</NAME>
<CONT_DATA CI_END="30.495676842449242" CI_START="-190.49567684244926" EFFECT_SIZE="-80.0" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="98.0" MODIFIED="2011-11-24 17:01:17 +0000" MODIFIED_BY="[Empty name]" ORDER="219" SD_1="49.0" SD_2="277.0" SE="56.37638125701545" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="22" TOTAL_2="25" WEIGHT="13.950058572157829"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2014-03-04 09:49:36 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="11.044521081175382" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="110" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence Score (ICIQ-short form UI score)</NAME>
<GROUP_LABEL_1>PFMT + extra stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT + Estim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.01" MODIFIED="2011-11-24 17:02:48 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="-1.4028651178572265" CI_START="-7.197134882142775" EFFECT_SIZE="-4.300000000000001" ESTIMABLE="YES" MEAN_1="10.6" MEAN_2="14.9" MODIFIED="2011-11-24 17:02:48 +0000" MODIFIED_BY="[Empty name]" ORDER="220" SD_1="6.0" SD_2="4.9" SE="1.4781572033950645" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.02" MODIFIED="2011-11-24 17:03:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="-2.317122545629692" CI_START="-8.482877454370307" EFFECT_SIZE="-5.3999999999999995" ESTIMABLE="YES" MEAN_1="5.8" MEAN_2="11.2" MODIFIED="2011-11-24 17:03:08 +0000" MODIFIED_BY="[Empty name]" ORDER="85" SD_1="5.7" SD_2="5.7" SE="1.5729255632693515" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.03" MODIFIED="2011-11-24 17:03:25 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="-0.6487694884040551" CI_START="-7.151230511595944" EFFECT_SIZE="-3.8999999999999995" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="8.2" MODIFIED="2011-11-24 17:03:25 +0000" MODIFIED_BY="[Empty name]" ORDER="86" SD_1="6.2" SD_2="5.3" SE="1.658821558580278" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.04.04" MODIFIED="2011-11-24 17:03:41 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="2.2337503542914416" CI_START="-5.03375035429144" EFFECT_SIZE="-1.3999999999999995" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="5.6" MODIFIED="2011-11-24 17:03:41 +0000" MODIFIED_BY="[Empty name]" ORDER="221" SD_1="6.2" SD_2="6.5" SE="1.8539883298642221" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2014-03-04 09:49:36 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.255407750888907" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="95" TOTAL_2="110" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence Quality of Life Score (ICIQ-short form)</NAME>
<GROUP_LABEL_1>PFMT + extra stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT + Estim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.01" MODIFIED="2011-11-24 17:05:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="-0.0788504584377645" CI_START="-3.5211495415622354" EFFECT_SIZE="-1.7999999999999998" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="6.0" MODIFIED="2011-11-24 17:05:38 +0000" MODIFIED_BY="[Empty name]" ORDER="222" SD_1="3.5" SD_2="3.0" SE="0.8781536574847514" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="26" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.02" MODIFIED="2011-11-24 17:05:51 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="-0.09973409439636782" CI_START="-2.900265905603632" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="3.7" MODIFIED="2011-11-24 17:05:51 +0000" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="2.3" SD_2="2.9" SE="0.7144345083117603" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="24" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.03" MODIFIED="2011-11-24 17:06:05 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.623208469504116" CI_START="-2.423208469504116" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="2.5" MODIFIED="2011-11-24 17:06:05 +0000" MODIFIED_BY="[Empty name]" ORDER="224" SD_1="3.1" SD_2="2.2" SE="0.7771614588426062" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="23" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-002.05.04" MODIFIED="2011-11-24 17:06:19 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="1.2243102421515901" CI_START="-2.02431024215159" EFFECT_SIZE="-0.3999999999999999" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.9" MODIFIED="2011-11-24 17:06:19 +0000" MODIFIED_BY="[Empty name]" ORDER="225" SD_1="3.1" SD_2="2.5" SE="0.8287449437662844" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2014-03-04 09:49:36 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.652667178725868" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="22" TOTAL_2="25" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Time until continent (months)</NAME>
<GROUP_LABEL_1>PFMT + extra stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT + Estim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.2344949813314647" CI_START="-5.985505018668536" EFFECT_SIZE="-4.11" ESTIMABLE="YES" MEAN_1="2.71" MEAN_2="6.82" MODIFIED="2011-11-24 17:01:55 +0000" MODIFIED_BY="[Empty name]" ORDER="87" SD_1="2.6" SD_2="3.9" SE="0.9569078990544112" STUDY_ID="STD-Yamanishi-2006" TOTAL_1="22" TOTAL_2="25" WEIGHT="0.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-02-27 10:23:07 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Treatment of UI after radical: lifestyle interventions versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2014-03-19 12:21:30 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Treatment of UI after radical: combinations of treatments versus no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="58" EVENTS_2="64" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 12:21:30 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0971563276315384" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men at &lt; 3 months</NAME>
<GROUP_LABEL_1>PFMT + anal Estim + BFB</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="58" EVENTS_2="64" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 09:39:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + Biofeedback vs no treatment</NAME>
<DICH_DATA CI_END="0.9945904277419515" CI_START="0.7792440761159976" EFFECT_SIZE="0.8803571428571428" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="64" LOG_CI_END="-0.002355724873404526" LOG_CI_START="-0.10832649058453629" LOG_EFFECT_SIZE="-0.05534110772897041" MODIFIED="2014-03-04 09:39:27 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.062247752342469105" STUDY_ID="STD-Goode-2009" TOTAL_1="70" TOTAL_2="68" VAR="0.0038747826716893675" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 09:43:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men within 3-6 months</NAME>
<GROUP_LABEL_1>PFMT + anal Estim + BFB</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="1" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 09:36:57 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="19" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + Biofeedback vs no treatment</NAME>
<DICH_DATA CI_END="25.069305322031088" CI_START="0.3240017980419221" EFFECT_SIZE="2.85" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3991422996946112" LOG_CI_START="-0.4894525796775908" LOG_EFFECT_SIZE="0.4548448600085102" MODIFIED="2014-03-04 09:36:29 +0000" MODIFIED_BY="[Empty name]" ORDER="103897" O_E="0.0" SE="1.1093699808386581" STUDY_ID="STD-Opsomer-1994" TOTAL_1="20" TOTAL_2="19" VAR="1.2307017543859649" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.03" MODIFIED="2014-03-19 12:15:59 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="54" TOTAL_2="64" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinence episodes per day at &gt; 3 months</NAME>
<GROUP_LABEL_1>PFMT + anal Estim + BFB</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.03.01" MODIFIED="2014-03-04 09:45:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="64" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + BFB</NAME>
<CONT_DATA CI_END="-0.9692055479925639" CI_START="-1.6107944520074362" EFFECT_SIZE="-1.29" ESTIMABLE="YES" MEAN_1="1.71" MEAN_2="3.0" MODIFIED="2014-03-04 09:45:01 +0000" MODIFIED_BY="[Empty name]" ORDER="213" SD_1="0.54" SD_2="1.17" SE="0.16367364632096396" STUDY_ID="STD-Goode-2009" TOTAL_1="54" TOTAL_2="64" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 12:15:59 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="143.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-04 09:57:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="68" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + BFB</NAME>
<DICH_DATA CI_END="99.39444968306866" CI_START="0.2375523653979146" EFFECT_SIZE="4.859154929577465" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.997362133498754" LOG_CI_START="-0.6242406407903565" LOG_EFFECT_SIZE="0.6865607463541988" MODIFIED="2014-03-04 09:57:26 +0000" MODIFIED_BY="[Empty name]" ORDER="622" O_E="0.0" SE="1.5399424467604488" STUDY_ID="STD-Goode-2009" TOTAL_1="70" TOTAL_2="68" VAR="2.371422739334558" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2014-05-15 10:53:01 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Treatment of UI after radical: one active treatment versus another active treatment</NAME>
<DICH_OUTCOME CHI2="0.23630898922731833" CI_END="1.1168955291497171" CI_START="0.830729742070172" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9632436528988254" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.048012552492810334" LOG_CI_START="-0.0805402404969309" LOG_EFFECT_SIZE="-0.016263844002060275" METHOD="MH" MODIFIED="2014-04-07 13:46:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6268847851096162" P_Q="1.0" P_Z="0.619944293032743" Q="0.0" RANDOM="NO" SCALE="2.2" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="89" TOTAL_2="88" WEIGHT="100.0" Z="0.4959293027069388">
<NAME>Number of incontinent men at &lt; 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.23630898922731833" CI_END="1.1168955291497171" CI_START="0.830729742070172" DF="1" EFFECT_SIZE="0.9632436528988254" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="71" I2="0.0" ID="CMP-005.01.01" LOG_CI_END="0.048012552492810334" LOG_CI_START="-0.0805402404969309" LOG_EFFECT_SIZE="-0.016263844002060275" MODIFIED="2011-11-24 09:01:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6268847851096162" P_Z="0.619944293032743" STUDIES="2" TAU2="0.0" TOTAL_1="89" TOTAL_2="88" WEIGHT="100.0" Z="0.4959293027069388">
<NAME>PFMT + Anal EStim vs PFMT alone</NAME>
<DICH_DATA CI_END="1.1386300124125377" CI_START="0.8487295769058175" EFFECT_SIZE="0.9830508474576272" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="59" LOG_CI_END="0.056382626913937216" LOG_CI_START="-0.07123066307235103" LOG_EFFECT_SIZE="-0.007424018079206888" MODIFIED="2011-11-24 09:01:53 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.07496067823391904" STUDY_ID="STD-Goode-2009" TOTAL_1="70" TOTAL_2="70" VAR="0.005619103281289143" WEIGHT="82.72072754831376"/>
<DICH_DATA CI_END="1.437141582914502" CI_START="0.5247604923686948" EFFECT_SIZE="0.868421052631579" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.15749955564261792" LOG_CI_START="-0.28003886912046333" LOG_EFFECT_SIZE="-0.06126965673892266" MODIFIED="2010-01-21 11:44:40 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.2570122365559669" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" VAR="0.06605528973950028" WEIGHT="17.279272451686246"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-05-15 10:53:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-05-15 10:53:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + BF + support group vs PFMT + BF</NAME>
<DICH_DATA CI_END="1.0478301946501036" CI_START="0.3332348652499043" EFFECT_SIZE="0.5909090909090909" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.020290909077551968" LOG_CI_START="-0.4772495661082909" LOG_EFFECT_SIZE="-0.22847932851536945" MODIFIED="2010-01-21 11:51:06 +0000" MODIFIED_BY="[Empty name]" ORDER="132" O_E="0.0" SE="0.2922577379892368" STUDY_ID="STD-Zhang-2007" TOTAL_1="14" TOTAL_2="13" VAR="0.08541458541458541" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 12:08:15 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men within 6 to 12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="1" I2="0.0" ID="CMP-005.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-04-29 11:22:27 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>FES vs ExMI</NAME>
<DICH_DATA CI_END="19.227059748420054" CI_START="0.20804012950179201" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.2839128758834253" LOG_CI_START="-0.6818528845554628" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2010-04-29 11:22:15 +0100" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="1.1547005383792517" STUDY_ID="STD-Yokoyama-2004" TOTAL_1="12" TOTAL_2="12" VAR="1.3333333333333335" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.04" MODIFIED="2011-11-24 09:07:36 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.6341200895512489" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="54" TOTAL_2="58" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinence episodes at &lt; 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.04.01" MODIFIED="2011-11-24 09:05:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="54" TOTAL_2="58" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="0.05375045541777218" CI_START="-0.35375045541777245" EFFECT_SIZE="-0.15000000000000013" ESTIMABLE="YES" MEAN_1="1.71" MEAN_2="1.86" MODIFIED="2011-11-24 09:05:46 +0000" MODIFIED_BY="[Empty name]" ORDER="210" SD_1="0.54" SD_2="0.56" SE="0.10395622420867419" STUDY_ID="STD-Goode-2009" TOTAL_1="54" TOTAL_2="58" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2014-03-03 12:08:29 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.173376197852419" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="15" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life Score (severity of UI) within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.05.01" MODIFIED="2010-02-09 15:42:46 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + BF + support group vs PFMT + BF</NAME>
<CONT_DATA CI_END="0.04582482435052948" CI_START="-2.9258248243505305" EFFECT_SIZE="-1.4400000000000004" ESTIMABLE="YES" MEAN_1="3.21" MEAN_2="4.65" MODIFIED="2009-11-20 11:24:12 +0000" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="2.04" SD_2="2.04" SE="0.7580878200163506" STUDY_ID="STD-Zhang-2007" TOTAL_1="14" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.06" MODIFIED="2014-03-03 12:08:51 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="57.45342863799044" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="44" TOTAL_2="32" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life Score (I-QoL) within 6-12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.06.01" MODIFIED="2010-02-12 09:54:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="32" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + BF + EStim vs PFMT</NAME>
<CONT_DATA CI_END="-22.656859480238744" CI_START="-34.60314051976125" EFFECT_SIZE="-28.629999999999995" ESTIMABLE="YES" MEAN_1="-80.32" MEAN_2="-51.69" MODIFIED="2010-01-28 10:18:33 +0000" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="7.01" SD_2="16.17" SE="3.0475766732841123" STUDY_ID="STD-Seleme-2008" TOTAL_1="44" TOTAL_2="32" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.07" MODIFIED="2014-03-13 11:35:15 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.724066078802442" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="12" TOTAL_2="12" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life Score (ICI-Q-SF) within 6-12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.07.01" MODIFIED="2010-02-12 09:55:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + ExMI vs PFMT</NAME>
<CONT_DATA CI_END="-0.4684142659238286" CI_START="-2.7315857340761722" EFFECT_SIZE="-1.6000000000000005" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="8.3" MODIFIED="2010-02-12 09:55:11 +0000" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="1.2" SD_2="1.6" SE="0.5773502691896258" STUDY_ID="STD-Liu--2008" TOTAL_1="12" TOTAL_2="12" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-24 09:10:40 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="238.0176020898689" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-24 09:09:35 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="70" TOTAL_2="70" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + Anal EStim vs PFMT alone</NAME>
<DICH_DATA CI_END="102.30202151149861" CI_START="0.24437444764656996" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0098842155559025" LOG_CI_START="-0.611944206883865" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2011-11-24 09:09:04 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="1.540074993601121" STUDY_ID="STD-Goode-2009" TOTAL_1="70" TOTAL_2="70" VAR="2.371830985915493" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.09" MODIFIED="2014-03-03 12:09:36 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="46.48081045898199" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="177" TOTAL_2="179" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test (grams of urine lost): at &lt; 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.09.01" MODIFIED="2010-01-21 12:00:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="35.956545585084285" CI_START="-36.7565455850843" EFFECT_SIZE="-0.4000000000000057" ESTIMABLE="YES" MEAN_1="89.6" MEAN_2="90.0" ORDER="103899" SD_1="89.5" SD_2="111.8" SE="18.54959880480462" STUDY_ID="STD-Hoffman-2005" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.09.02" MODIFIED="2010-01-21 12:01:08 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + perineal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="33.49930043686204" CI_START="-42.89930043686205" EFFECT_SIZE="-4.700000000000003" ESTIMABLE="YES" MEAN_1="85.3" MEAN_2="90.0" MODIFIED="2010-01-21 12:01:08 +0000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="100.6" SD_2="111.8" SE="19.489797127994827" STUDY_ID="STD-Hoffman-2005" TOTAL_1="59" TOTAL_2="60" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.09.03" MODIFIED="2010-01-21 12:24:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + perineal EStim vs PFMT + anal EStim</NAME>
<CONT_DATA CI_END="30.058033059924526" CI_START="-38.65803305992452" EFFECT_SIZE="-4.299999999999997" ESTIMABLE="YES" MEAN_1="85.3" MEAN_2="89.6" MODIFIED="2010-01-21 12:24:08 +0000" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="100.6" SD_2="89.5" SE="17.529930820635634" STUDY_ID="STD-Hoffman-2005" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.10" MODIFIED="2014-03-03 12:09:42 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="289.65" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="25" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost): at &lt; 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.10.01" MODIFIED="2010-01-21 12:05:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="163.52582782453132" CI_START="-25.52582782453132" EFFECT_SIZE="69.0" ESTIMABLE="YES" MEAN_1="156.0" MEAN_2="87.0" MODIFIED="2010-01-21 12:02:32 +0000" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="168.0" SD_2="123.0" SE="48.22834938301876" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.10.02" MODIFIED="2010-01-28 11:07:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="6" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + visual BF vs PFMT + oral BF</NAME>
<CONT_DATA CI_END="113.89622755557926" CI_START="-57.89622755557926" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="59.0" MEAN_2="31.0" MODIFIED="2010-01-28 11:07:18 +0000" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="98.0" SD_2="40.0" SE="43.825411197918804" STUDY_ID="STD-Joseph-2000" TOTAL_1="6" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.11" MODIFIED="2014-03-03 12:09:28 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="289.65" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="24" TOTAL_2="23" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost): within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.11.01" MODIFIED="2010-01-21 12:08:15 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="252.5110169198391" CI_START="3.4889830801609065" EFFECT_SIZE="128.0" ESTIMABLE="YES" MEAN_1="202.0" MEAN_2="74.0" MODIFIED="2010-01-21 12:08:15 +0000" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="242.0" SD_2="131.0" SE="63.52719636787518" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="18" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.11.02" MODIFIED="2010-01-28 11:09:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + visual BF vs PFMT + oral BF</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="4.0" MEAN_2="0.0" MODIFIED="2010-01-28 11:09:35 +0000" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="6.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Joseph-2000" TOTAL_1="5" TOTAL_2="5" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.12" MODIFIED="2014-03-03 12:10:01 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="289.65" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="39" TOTAL_2="36" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost): within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.12.01" MODIFIED="2010-01-21 12:09:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="108.37102839305595" CI_START="-52.37102839305595" EFFECT_SIZE="28.0" ESTIMABLE="YES" MEAN_1="98.0" MEAN_2="70.0" MODIFIED="2010-01-21 12:09:51 +0000" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="132.0" SD_2="114.0" SE="41.00638023301059" STUDY_ID="STD-Moore-1999" TOTAL_1="19" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.12.02" MODIFIED="2010-01-28 11:09:52 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="4" TOTAL_2="3" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + visual BF vs PFMT + oral BF</NAME>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="6.0" MEAN_2="0.0" MODIFIED="2010-01-28 11:09:52 +0000" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="10.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Joseph-2000" TOTAL_1="4" TOTAL_2="3" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.12.03" MODIFIED="2010-01-28 11:10:10 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ExMI vs PFMT alone</NAME>
<CONT_DATA CI_END="-16.597346459104507" CI_START="-55.40265354089549" EFFECT_SIZE="-36.0" ESTIMABLE="YES" MEAN_1="9.0" MEAN_2="45.0" MODIFIED="2010-01-28 11:10:10 +0000" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="28.0" SD_2="28.0" SE="9.899494936611665" STUDY_ID="STD-Koo-2009" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.13" MODIFIED="2014-03-03 12:10:09 +0000" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.8870482054118094" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="16" TOTAL_2="16" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pad changes over 24 hours within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-005.13.01" MODIFIED="2010-02-09 15:42:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>ExMI vs PFMT alone</NAME>
<CONT_DATA CI_END="-0.20896019688656764" CI_START="-0.7910398031134324" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="0.6" MODIFIED="2010-01-21 10:24:59 +0000" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="0.42" SD_2="0.42" SE="0.14849242404917498" STUDY_ID="STD-Koo-2009" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-005.14" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-03 12:10:21 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="243.84" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>Number of men not carrying out sufficient PFMT within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="7" I2="0.0" ID="CMP-005.14.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2010-02-09 15:42:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="14" TOTAL_2="13" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + BF + support group vs PFMT + BF</NAME>
<DICH_DATA CI_END="1.0527407398286648" CI_START="0.06686103799912656" EFFECT_SIZE="0.2653061224489796" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.02232142994601915" LOG_CI_START="-1.1748268853893729" LOG_EFFECT_SIZE="-0.5762527277216769" MODIFIED="2009-11-09 09:52:11 +0000" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="0.7032108464077431" STUDY_ID="STD-Zhang-2007" TOTAL_1="14" TOTAL_2="13" VAR="0.49450549450549447" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2015-01-19 10:21:04 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Prevention of UI after radical: PFMT ± biofeedback versus no treatment</NAME>
<DICH_OUTCOME CHI2="283.2361161744115" CI_END="0.9177125225970807" CI_START="0.773471598168286" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8425108732308523" ESTIMABLE="YES" EVENTS_1="555" EVENTS_2="738" I2="92.5856913010809" I2_Q="88.19266564960486" ID="CMP-006.01" LOG_CI_END="-0.03729334211313113" LOG_CI_START="-0.11155562893972984" LOG_EFFECT_SIZE="-0.07442448552643051" METHOD="MH" MODIFIED="2014-05-19 11:23:52 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.220446049250313E-16" P_Q="1.2686675487261212E-5" P_Z="8.548104227475256E-5" Q="25.407936380658217" RANDOM="YES" SCALE="3.4843899704450187" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.1510907132910946" TOTALS="SUB" TOTAL_1="1182" TOTAL_2="1191" WEIGHT="400.0" Z="3.928489612508941">
<NAME>Number of incontinent men</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="14.834521306097363" CI_END="1.0550983566436032" CI_START="0.8272457550937329" DF="6" EFFECT_SIZE="0.9342513777029147" ESTIMABLE="YES" EVENTS_1="261" EVENTS_2="276" I2="59.5538010550172" ID="CMP-006.01.01" LOG_CI_END="0.02329294660672089" LOG_CI_START="-0.08236545268923107" LOG_EFFECT_SIZE="-0.029536253041255112" MODIFIED="2014-03-24 14:09:41 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.02158358340592781" P_Z="0.27316835375542947" STUDIES="7" TAU2="0.009898679458359684" TOTAL_1="332" TOTAL_2="331" WEIGHT="100.0" Z="1.0957953666697204">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="1.310919372896349" CI_START="0.8633130607460413" EFFECT_SIZE="1.0638297872340425" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="38" LOG_CI_END="0.11757598155812489" LOG_CI_START="-0.06383168875752222" LOG_EFFECT_SIZE="0.026872146400301333" ORDER="103904" O_E="0.0" SE="0.10655976352586169" STUDY_ID="STD-Bales-2000" TOTAL_1="47" TOTAL_2="50" VAR="0.011354983202687564" WEIGHT="18.123808918859638"/>
<DICH_DATA CI_END="1.0426943157895274" CI_START="0.8528232296968008" EFFECT_SIZE="0.9429920116194626" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="51" LOG_CI_END="0.018157006006652047" LOG_CI_START="-0.06914097858985638" LOG_EFFECT_SIZE="-0.025491986291602185" ORDER="103905" O_E="0.0" SE="0.05127926828398213" STUDY_ID="STD-Burgio-2006" TOTAL_1="54" TOTAL_2="53" VAR="0.0026295633557406155" WEIGHT="30.746316671096917"/>
<DICH_DATA CI_END="1.0240797190619626" CI_START="0.950096174733655" EFFECT_SIZE="0.9863945578231292" ESTIMABLE="YES" EVENTS_1="145" EVENTS_2="147" LOG_CI_END="0.010333765429975845" LOG_CI_START="-0.02223243045637821" LOG_EFFECT_SIZE="-0.005949332513201213" MODIFIED="2010-04-16 13:56:42 +0100" MODIFIED_BY="[Empty name]" ORDER="103906" O_E="0.0" SE="0.01912954466891388" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="150" VAR="3.659394792399715E-4" WEIGHT="37.52670442384676"/>
<DICH_DATA CI_END="1.50491156375714" CI_START="0.33601908877835196" EFFECT_SIZE="0.7111111111111111" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.17751097933135163" LOG_CI_START="-0.47363605024222716" LOG_EFFECT_SIZE="-0.14806253545543768" ORDER="103907" O_E="0.0" SE="0.38248698840130013" STUDY_ID="STD-Mathewson_x002d_Chapman-97" TOTAL_1="27" TOTAL_2="24" VAR="0.1462962962962963" WEIGHT="2.4661313146190613"/>
<DICH_DATA CI_END="1.0539102657757484" CI_START="0.23721184631974646" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="12" LOG_CI_END="0.022803634844780523" LOG_CI_START="-0.6248636261727429" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="103908" O_E="0.0" SE="0.3804429551263411" STUDY_ID="STD-Parekh-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.14473684210526316" WEIGHT="2.4910015305651334"/>
<DICH_DATA CI_END="0.9333936568974635" CI_START="0.43385625635383607" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="-0.029935154794113496" LOG_CI_START="-0.3626541354938229" LOG_EFFECT_SIZE="-0.19629464514396822" MODIFIED="2014-01-27 11:00:43 +0000" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.19544077624852607" STUDY_ID="STD-Tienforti-2012" TOTAL_1="16" TOTAL_2="16" VAR="0.03819709702062643" WEIGHT="8.00896355344261"/>
<DICH_DATA CI_END="11.333908087048945" CI_START="0.551442622615033" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0543796863847683" LOG_CI_START="-0.25849966904069305" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2009-11-06 09:02:00 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="0.7711918322345376" STUDY_ID="STD-Tobia-2008" TOTAL_1="19" TOTAL_2="19" VAR="0.5947368421052632" WEIGHT="0.6370735875698791"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.923472190008555" CI_END="0.971417264403695" CI_START="0.747368089128499" DF="6" EFFECT_SIZE="0.8520600123487918" ESTIMABLE="YES" EVENTS_1="199" EVENTS_2="233" I2="13.338281207242256" ID="CMP-006.01.02" LOG_CI_END="-0.01259418234473012" LOG_CI_START="-0.12646544945034807" LOG_EFFECT_SIZE="-0.06952981589753912" MODIFIED="2014-03-24 14:10:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3279826725722549" P_Z="0.01668808494037826" STUDIES="7" TAU2="0.004863239378789142" TOTAL_1="347" TOTAL_2="350" WEIGHT="99.99999999999997" Z="2.393508713387345">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="1.819661624655628" CI_START="0.6891383932739099" EFFECT_SIZE="1.1198208286674132" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="0.25999063622271273" LOG_CI_START="-0.1616935539998056" LOG_EFFECT_SIZE="0.04914854111145356" ORDER="103909" O_E="0.0" SE="0.24769938070711353" STUDY_ID="STD-Bales-2000" TOTAL_1="47" TOTAL_2="50" VAR="0.06135498320268756" WEIGHT="6.756565500434619"/>
<DICH_DATA CI_END="0.9996926865314429" CI_START="0.592791642417885" EFFECT_SIZE="0.769811320754717" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="40" LOG_CI_END="-1.334850555372938E-4" LOG_CI_START="-0.2270979279662808" LOG_EFFECT_SIZE="-0.11361570651090906" ORDER="103910" O_E="0.0" SE="0.13332003725788263" STUDY_ID="STD-Burgio-2006" TOTAL_1="53" TOTAL_2="51" VAR="0.01777423233444321" WEIGHT="19.764033893086282"/>
<DICH_DATA CI_END="0.9945116629876527" CI_START="0.7991096578794052" EFFECT_SIZE="0.8914728682170543" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="129" LOG_CI_END="-0.0023901193857201464" LOG_CI_START="-0.09739362050555435" LOG_EFFECT_SIZE="-0.04989186994563727" MODIFIED="2010-04-16 13:56:48 +0100" MODIFIED_BY="[Empty name]" ORDER="103911" O_E="0.0" SE="0.055805526832705656" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="150" VAR="0.0031142568250758307" WEIGHT="56.08373188286121"/>
<DICH_DATA CI_END="62.810798118010894" CI_START="0.11422788935875403" EFFECT_SIZE="2.6785714285714284" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7980343118891207" LOG_CI_START="-0.9422278477901591" LOG_EFFECT_SIZE="0.4279032320494808" ORDER="103912" O_E="0.0" SE="1.6096435571120649" STUDY_ID="STD-Mathewson_x002d_Chapman-97" TOTAL_1="27" TOTAL_2="24" VAR="2.590952380952381" WEIGHT="0.1723572948286006"/>
<DICH_DATA CI_END="1.4144144557671443" CI_START="0.6301714703007063" EFFECT_SIZE="0.9440993788819876" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="23" LOG_CI_END="0.15057668631988902" LOG_CI_START="-0.2005412624940434" LOG_EFFECT_SIZE="-0.02498228808707716" MODIFIED="2009-11-06 11:37:20 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.20624842119518166" STUDY_ID="STD-Overgard-2008" TOTAL_1="35" TOTAL_2="40" VAR="0.042538411245505066" WEIGHT="9.438653555342682"/>
<DICH_DATA CI_END="1.634716802426043" CI_START="0.19974751085955794" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.21344252653972576" LOG_CI_START="-0.6995186239123148" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="103913" O_E="0.0" SE="0.5362778990061086" STUDY_ID="STD-Parekh-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.287593984962406" WEIGHT="1.5298228970132675"/>
<DICH_DATA CI_END="0.8846633209418502" CI_START="0.32152847044863664" EFFECT_SIZE="0.5333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="15" LOG_CI_END="-0.053221978654591676" LOG_CI_START="-0.4927805654728837" LOG_EFFECT_SIZE="-0.27300127206373764" MODIFIED="2014-01-27 11:01:29 +0000" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.2581988897471611" STUDY_ID="STD-Tienforti-2012" TOTAL_1="16" TOTAL_2="16" VAR="0.06666666666666665" WEIGHT="6.2548349764333215"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.24173905129909" CI_END="0.7533804356842061" CI_START="0.3456589285154433" DF="5" EFFECT_SIZE="0.510306451226222" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="169" I2="55.52289572650948" ID="CMP-006.01.03" LOG_CI_END="-0.12298566205246762" LOG_CI_START="-0.4613522206276115" LOG_EFFECT_SIZE="-0.2921689413400396" MODIFIED="2014-03-24 14:10:57 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.04679223579797598" P_Z="7.124694769171733E-4" STUDIES="6" TAU2="0.1102573378263745" TOTAL_1="317" TOTAL_2="323" WEIGHT="99.99999999999999" Z="3.38473521047147">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="9.130868545551916" CI_START="0.2788782987906378" EFFECT_SIZE="1.5957446808510638" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9605120904148798" LOG_CI_START="-0.5545852795029147" LOG_EFFECT_SIZE="0.20296340545598257" ORDER="103914" O_E="0.0" SE="0.8899756949426497" STUDY_ID="STD-Bales-2000" TOTAL_1="47" TOTAL_2="50" VAR="0.7920567375886524" WEIGHT="4.378167175294812"/>
<DICH_DATA CI_END="1.0597114837793011" CI_START="0.48776975540560347" EFFECT_SIZE="0.7189542483660131" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="0.025187640681545848" LOG_CI_START="-0.31178513200029334" LOG_EFFECT_SIZE="-0.14329874565937376" ORDER="103915" O_E="0.0" SE="0.19793947471543893" STUDY_ID="STD-Burgio-2006" TOTAL_1="51" TOTAL_2="50" VAR="0.03918003565062389" WEIGHT="26.43570195909942"/>
<DICH_DATA CI_END="0.4679157938664099" CI_START="0.2516332580457178" EFFECT_SIZE="0.3431372549019608" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="102" LOG_CI_END="-0.3298322955360371" LOG_CI_START="-0.5992319592872467" LOG_EFFECT_SIZE="-0.4645321274116419" MODIFIED="2010-04-16 13:56:57 +0100" MODIFIED_BY="[Empty name]" ORDER="103916" O_E="0.0" SE="0.15824669603730337" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="150" VAR="0.02504201680672269" WEIGHT="29.198083593978826"/>
<DICH_DATA CI_END="1.0436247781787364" CI_START="0.22909789146288492" EFFECT_SIZE="0.4889705882352941" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="0.01854438175297181" LOG_CI_START="-0.6399789078871977" LOG_EFFECT_SIZE="-0.31071726306711295" MODIFIED="2009-11-06 11:37:35 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.38681984007749176" STUDY_ID="STD-Overgard-2008" TOTAL_1="34" TOTAL_2="38" VAR="0.14962958867757628" WEIGHT="15.200771812307774"/>
<DICH_DATA CI_END="2.9080662948391867" CI_START="0.1934275023228471" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.4636043028591656" LOG_CI_START="-0.7134817760757654" LOG_EFFECT_SIZE="-0.12493873660829995" ORDER="103917" O_E="0.0" SE="0.6914261894364405" STUDY_ID="STD-Parekh-2003" TOTAL_1="19" TOTAL_2="19" VAR="0.4780701754385965" WEIGHT="6.714766482473409"/>
<DICH_DATA CI_END="0.7624734359689447" CI_START="0.2098433761127342" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="15" LOG_CI_END="-0.11777528222782019" LOG_CI_START="-0.678104735116255" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2014-01-27 11:02:01 +0000" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.32914029430219166" STUDY_ID="STD-Tienforti-2012" TOTAL_1="16" TOTAL_2="16" VAR="0.10833333333333334" WEIGHT="18.07250897684575"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.017046414875986213" CI_END="0.5105902031140732" CI_START="0.19780980780235782" DF="1" EFFECT_SIZE="0.31780457822970654" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="60" I2="0.0" ID="CMP-006.01.04" LOG_CI_END="-0.2919275224231045" LOG_CI_START="-0.7037521790237471" LOG_EFFECT_SIZE="-0.4978398507234258" MODIFIED="2014-02-21 11:05:24 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.896121873351031" P_Z="2.1513785740957573E-6" STUDIES="2" TAU2="0.0" TOTAL_1="186" TOTAL_2="187" WEIGHT="100.0" Z="4.738658367572783">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="0.5400957132571904" CI_START="0.19218433603034057" EFFECT_SIZE="0.3221768707482993" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="49" LOG_CI_END="-0.26752926970294966" LOG_CI_START="-0.7162820123636758" LOG_EFFECT_SIZE="-0.49190564103331275" MODIFIED="2011-11-29 14:38:25 +0000" MODIFIED_BY="[Empty name]" ORDER="103918" O_E="0.0" SE="0.26359958240081244" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="148" VAR="0.06948473984188269" WEIGHT="84.21907325655592"/>
<DICH_DATA CI_END="0.9746132571054409" CI_START="0.08956720811392374" EFFECT_SIZE="0.29545454545454547" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.01116768545566725" LOG_CI_START="-1.047850962903034" LOG_EFFECT_SIZE="-0.5295093241793506" MODIFIED="2009-11-06 11:38:07 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="0.608952888837569" STUDY_ID="STD-Overgard-2008" TOTAL_1="36" TOTAL_2="39" VAR="0.37082362082362075" WEIGHT="15.780926743444091"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2014-03-20 09:59:05 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="6.530797343076039" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="81" TOTAL_2="72" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pad changes over 24 hours</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.39950789129162967" CI_START="-2.2795078912916296" EFFECT_SIZE="-0.94" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="2.04" ORDER="103919" SD_1="2.1" SD_2="2.7" SE="0.6834349517937558" STUDY_ID="STD-Mathewson_x002d_Chapman-97" TOTAL_1="27" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.02" MODIFIED="2014-03-20 09:58:45 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.03736426467257048" CI_START="-2.4373642646725706" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.8" ORDER="103920" SD_1="1.6" SD_2="2.7" SE="0.6313198989536247" STUDY_ID="STD-Mathewson_x002d_Chapman-97" TOTAL_1="27" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.02.03" MODIFIED="2014-03-20 09:58:50 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="27" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>within 6 - 12 months</NAME>
<CONT_DATA CI_END="0.03736426467257048" CI_START="-2.4373642646725706" EFFECT_SIZE="-1.2000000000000002" ESTIMABLE="YES" MEAN_1="0.6" MEAN_2="1.8" MODIFIED="2009-11-06 09:51:25 +0000" MODIFIED_BY="[Empty name]" ORDER="88" SD_1="1.6" SD_2="2.7" SE="0.6313198989536247" STUDY_ID="STD-Mathewson_x002d_Chapman-97" TOTAL_1="27" TOTAL_2="24" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.03" MODIFIED="2014-03-19 12:11:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="45" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>Favours [experimental]</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.03.01" MODIFIED="2014-03-19 10:52:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Less than 3 months</NAME>
<CONT_DATA CI_END="37.769093450912564" CI_START="-13.969093450912563" EFFECT_SIZE="11.899999999999999" ESTIMABLE="YES" MEAN_1="29.5" MEAN_2="17.6" MODIFIED="2014-03-19 10:52:12 +0000" MODIFIED_BY="[Empty name]" ORDER="255" SD_1="35.8" SD_2="38.5" SE="13.198759597097023" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.03.02" MODIFIED="2014-03-19 10:53:26 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Within 3-6 months</NAME>
<CONT_DATA CI_END="19.52980098058332" CI_START="-24.52980098058332" EFFECT_SIZE="-2.5" ESTIMABLE="YES" MEAN_1="11.8" MEAN_2="14.3" MODIFIED="2014-03-19 10:53:26 +0000" MODIFIED_BY="[Empty name]" ORDER="256" SD_1="28.4" SD_2="34.4" SE="11.239900913665547" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.03.03" MODIFIED="2014-03-19 10:54:20 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Within 6-12 months</NAME>
<CONT_DATA CI_END="48.747264452676255" CI_START="-9.147264452676254" EFFECT_SIZE="19.8" ESTIMABLE="YES" MEAN_1="25.3" MEAN_2="5.5" MODIFIED="2014-03-19 10:54:20 +0000" MODIFIED_BY="[Empty name]" ORDER="257" SD_1="59.0" SD_2="14.16" SE="14.7692838649121" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="111.4013004676629" CI_END="-0.7829960534156946" CI_START="-2.3741930855652553" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5785945694904748" ESTIMABLE="YES" I2="93.71641087616214" I2_Q="93.68547537460441" ID="CMP-006.04" MODIFIED="2014-03-19 10:47:19 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="2.707958302039515E-10" P_Z="1.0070719224470366E-4" Q="47.509514618640935" RANDOM="YES" SCALE="462.05407700592303" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="123.03193018956866" TOTALS="SUB" TOTAL_1="773" TOTAL_2="775" UNITS="" WEIGHT="400.0" Z="3.888881690801232">
<NAME>24 hour pad test (gm/24hrs)</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="11.124718749033262" CI_END="55.074741409084254" CI_START="-211.45720928499446" DF="2" EFFECT_SIZE="-78.1912339379551" ESTIMABLE="YES" I2="82.02201740899022" ID="CMP-006.04.01" MODIFIED="2009-10-23 10:11:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.003839733050878591" P_Z="0.2501558492282776" STUDIES="3" TAU2="11030.984599577121" TOTAL_1="213" TOTAL_2="211" WEIGHT="100.0" Z="1.1499709661528597">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="-1.2431432908284759" CI_START="-19.156856709171514" EFFECT_SIZE="-10.199999999999996" ESTIMABLE="YES" MEAN_1="53.6" MEAN_2="63.8" ORDER="103921" SD_1="41.0" SD_2="38.1" SE="4.5699088247651805" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="150" WEIGHT="41.83181102421"/>
<CONT_DATA CI_END="121.97589661861689" CI_START="-133.1758966186169" EFFECT_SIZE="-5.599999999999994" ESTIMABLE="YES" MEAN_1="120.4" MEAN_2="126.0" ORDER="103922" SD_1="249.2" SD_2="215.6" SE="65.09093923404679" STUDY_ID="STD-Mathewson_x002d_Chapman-97" TOTAL_1="27" TOTAL_2="24" WEIGHT="30.280670968354546"/>
<CONT_DATA CI_END="-113.0250451703647" CI_START="-404.9749548296353" EFFECT_SIZE="-259.0" ESTIMABLE="YES" MEAN_1="96.0" MEAN_2="355.0" MODIFIED="2009-10-23 10:11:33 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SD_1="160.0" SD_2="423.0" SE="74.47838632804843" STUDY_ID="STD-Ribeiro-2008" TOTAL_1="36" TOTAL_2="37" WEIGHT="27.887518007435464"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="6.84547915798151" CI_END="49.85907196287586" CI_START="-196.41833117169148" DF="1" EFFECT_SIZE="-73.2796296044078" ESTIMABLE="YES" I2="85.39181879132526" ID="CMP-006.04.02" MODIFIED="2010-04-14 10:51:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0088866460044984" P_Z="0.24346441868060553" STUDIES="2" TAU2="6886.423226426629" TOTAL_1="186" TOTAL_2="187" WEIGHT="100.0" Z="1.166371197657925">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="-13.781291476840035" CI_START="-24.21870852315997" EFFECT_SIZE="-19.000000000000004" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="32.2" ORDER="103923" SD_1="13.9" SD_2="29.5" SE="2.662655316283603" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="150" WEIGHT="57.26013416975765"/>
<CONT_DATA CI_END="-51.006148051842544" CI_START="-240.99385194815744" EFFECT_SIZE="-146.0" ESTIMABLE="YES" MEAN_1="51.0" MEAN_2="197.0" MODIFIED="2009-10-23 10:14:08 +0100" MODIFIED_BY="[Empty name]" ORDER="73" SD_1="119.0" SD_2="269.0" SE="48.46714158905819" STUDY_ID="STD-Ribeiro-2008" TOTAL_1="36" TOTAL_2="37" WEIGHT="42.73986583024235"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.6515925999899513" CI_END="-10.63700123518122" CI_START="-18.361439254918846" DF="1" EFFECT_SIZE="-14.499220245050033" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.03" MODIFIED="2010-04-14 10:51:14 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.41954413362918064" P_Z="1.867794633815201E-13" STUDIES="2" TAU2="0.0" TOTAL_1="186" TOTAL_2="187" WEIGHT="100.00000000000001" Z="7.357933201508773">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="-10.53027458663669" CI_START="-18.26972541336331" EFFECT_SIZE="-14.4" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="17.8" ORDER="103924" SD_1="4.8" SD_2="23.7" SE="1.9743859805012798" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="150" WEIGHT="99.61242091777332"/>
<CONT_DATA CI_END="22.03784910625935" CI_START="-102.03784910625936" EFFECT_SIZE="-40.0" ESTIMABLE="YES" MEAN_1="40.0" MEAN_2="80.0" MODIFIED="2009-10-23 10:14:52 +0100" MODIFIED_BY="[Empty name]" ORDER="74" SD_1="77.0" SD_2="176.0" SE="31.652545452674634" STUDY_ID="STD-Ribeiro-2008" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.38757908222668885"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1869314571917472" CI_START="-1.813068542808253" DF="0" EFFECT_SIZE="-1.0" ESTIMABLE="YES" I2="0.0" ID="CMP-006.04.04" MODIFIED="2010-02-04 11:36:42 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.015927327367729966" STUDIES="2" TAU2="0.0" TOTAL_1="188" TOTAL_2="190" WEIGHT="100.0" Z="2.4105765766937015">
<NAME>after first year</NAME>
<CONT_DATA CI_END="-0.1869314571917472" CI_START="-1.813068542808253" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="2.4" ORDER="103925" SD_1="2.3" SD_2="4.5" SE="0.4148385119428896" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="148" WEIGHT="100.0"/>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="2.0" MEAN_2="1.0" MODIFIED="2010-02-04 11:36:42 +0000" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Overgard-2008" TOTAL_1="38" TOTAL_2="42" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.05" MODIFIED="2014-03-19 10:47:15 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.563706974442443" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="48" TOTAL_2="48" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinence episodes per day</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.01" MODIFIED="2014-01-27 11:20:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="-0.0017794320166321098" CI_START="-1.138220567983368" EFFECT_SIZE="-0.5700000000000001" ESTIMABLE="YES" MEAN_1="1.43" MEAN_2="2.0" MODIFIED="2014-01-27 11:20:31 +0000" MODIFIED_BY="[Empty name]" ORDER="204" SD_1="0.82" SD_2="0.82" SE="0.28991378028648446" STUDY_ID="STD-Tienforti-2012" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.02" MODIFIED="2014-01-27 11:20:59 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="-0.41136068910298684" CI_START="-2.4486393108970135" EFFECT_SIZE="-1.4300000000000002" ESTIMABLE="YES" MEAN_1="0.57" MEAN_2="2.0" MODIFIED="2014-01-27 11:20:59 +0000" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="1.47" SD_2="1.47" SE="0.5197234841721124" STUDY_ID="STD-Tienforti-2012" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.03" MODIFIED="2014-01-27 11:21:06 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="-0.5083739568074642" CI_START="-2.351626043192536" EFFECT_SIZE="-1.4300000000000002" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="1.86" MODIFIED="2014-01-27 11:21:06 +0000" MODIFIED_BY="[Empty name]" ORDER="205" SD_1="1.33" SD_2="1.33" SE="0.47022600948905413" STUDY_ID="STD-Tienforti-2012" TOTAL_1="16" TOTAL_2="16" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.05.04" MODIFIED="2014-01-27 11:04:26 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="29.735404305713374" CI_END="3.5113645495481958" CI_START="-0.07666046914900582" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="1.717352040199595" ESTIMABLE="YES" I2="86.54802215273246" I2_Q="86.12196425992951" ID="CMP-006.06" MODIFIED="2014-03-19 11:00:38 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="5.540576285989474E-6" P_Q="7.423971820555986E-4" P_Z="0.06062614822221542" Q="14.411261344610448" RANDOM="YES" SCALE="10.18" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="12.98167849410587" TOTALS="SUB" TOTAL_1="123" TOTAL_2="119" UNITS="" WEIGHT="300.0" Z="1.8762121947464863">
<NAME>Urinary Incontinence Score (ICI-short form)</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="9.554665087728605" CI_START="3.4453349122713948" DF="0" EFFECT_SIZE="6.5" ESTIMABLE="YES" I2="0.0" ID="CMP-006.06.01" MODIFIED="2014-03-19 10:55:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="3.038075723375191E-5" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0" Z="4.17059334939511">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="9.554665087728605" CI_START="3.4453349122713948" EFFECT_SIZE="6.5" ESTIMABLE="YES" MEAN_1="14.0" MEAN_2="7.5" MODIFIED="2014-03-19 10:55:51 +0000" MODIFIED_BY="[Empty name]" ORDER="258" SD_1="3.6" SD_2="5.0" SE="1.5585312341570627" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="100.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="4.793050855039302" CI_END="3.564099070294133" CI_START="-5.985251080647823" DF="1" EFFECT_SIZE="-1.2105760051768453" ESTIMABLE="YES" I2="79.13646171835161" ID="CMP-006.06.02" MODIFIED="2014-03-19 10:56:30 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.02857487331965991" P_Z="0.6192375181238943" STUDIES="2" TAU2="9.50033222928811" TOTAL_1="53" TOTAL_2="52" WEIGHT="100.0" Z="0.49693127452467484">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="5.311356565462467" CI_START="-2.311356565462467" EFFECT_SIZE="1.5" ESTIMABLE="YES" MEAN_1="6.9" MEAN_2="5.4" MODIFIED="2014-03-19 10:56:30 +0000" MODIFIED_BY="[Empty name]" ORDER="259" SD_1="5.8" SD_2="5.2" SE="1.9446054088370812" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="44.68212234332968"/>
<CONT_DATA CI_END="-1.2281995182970644" CI_START="-5.571800481702935" EFFECT_SIZE="-3.4" ESTIMABLE="YES" MEAN_1="3.4" MEAN_2="6.8" MODIFIED="2009-10-23 10:22:05 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="3.7" SD_2="5.6" SE="1.1080818315202832" STUDY_ID="STD-Ribeiro-2008" TOTAL_1="36" TOTAL_2="37" WEIGHT="55.31787765667031"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5567393193853178" CI_END="1.8142064847274404" CI_START="-3.1909376930599556" DF="1" EFFECT_SIZE="-0.6883656041662577" ESTIMABLE="YES" I2="35.76316936641311" ID="CMP-006.06.03" MODIFIED="2014-03-19 10:57:21 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.21214332643324751" P_Z="0.5898081588727709" STUDIES="2" TAU2="1.303567523405757" TOTAL_1="53" TOTAL_2="52" WEIGHT="99.99999999999999" Z="0.5391140572331897">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="4.779839353242036" CI_START="-2.5798393532420363" EFFECT_SIZE="1.0999999999999996" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="3.7" MODIFIED="2014-03-19 10:57:21 +0000" MODIFIED_BY="[Empty name]" ORDER="260" SD_1="5.3" SD_2="5.3" SE="1.8775035573450019" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="33.76423688273118"/>
<CONT_DATA CI_END="0.5089844036589066" CI_START="-3.708984403658906" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="2.7" MEAN_2="4.3" MODIFIED="2009-10-23 10:24:09 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="3.5" SD_2="5.5" SE="1.0760322231909902" STUDY_ID="STD-Ribeiro-2008" TOTAL_1="36" TOTAL_2="37" WEIGHT="66.2357631172688"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.07" MODIFIED="2014-03-19 10:47:12 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.089886424687238" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="36" TOTAL_2="37" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life Score (IIQ)</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.07.01" MODIFIED="2009-10-23 10:18:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.07.02" MODIFIED="2009-10-23 10:25:01 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="-0.5162281125864703" CI_START="-4.883771887413529" EFFECT_SIZE="-2.6999999999999997" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="4.3" MODIFIED="2009-10-23 10:25:01 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="2.7" SD_2="6.2" SE="1.114189803812133" STUDY_ID="STD-Ribeiro-2008" TOTAL_1="36" TOTAL_2="37" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.07.03" MODIFIED="2009-10-23 10:19:02 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.07.04" MODIFIED="2009-10-23 10:19:05 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-006.08" MODIFIED="2014-03-19 10:47:09 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="44.54344639951161" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="105" TOTAL_2="117" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Pelvic floor muscle strength (anal squeeze pressure, cm H<SUB>2</SUB>O)</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.08.01" MODIFIED="2009-11-06 11:46:31 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.08.02" MODIFIED="2009-11-06 11:50:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="16.208575593341187" CI_START="-6.2085755933411875" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="-50.7" MEAN_2="-55.7" MODIFIED="2009-11-06 11:50:17 +0000" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="23.9" SD_2="25.6" SE="5.718766100679911" STUDY_ID="STD-Overgard-2008" TOTAL_1="35" TOTAL_2="40" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.08.03" MODIFIED="2009-11-06 11:50:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="20.9649203090902" CI_START="-1.5649203090902084" EFFECT_SIZE="9.699999999999996" ESTIMABLE="YES" MEAN_1="-56.1" MEAN_2="-65.8" MODIFIED="2009-11-06 11:50:18 +0000" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="21.7" SD_2="27.0" SE="5.747513932881653" STUDY_ID="STD-Overgard-2008" TOTAL_1="34" TOTAL_2="38" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-006.08.04" MODIFIED="2009-11-06 11:50:20 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="39" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="18.861204000152775" CI_START="-3.8612040001527763" EFFECT_SIZE="7.5" ESTIMABLE="YES" MEAN_1="-64.0" MEAN_2="-71.5" MODIFIED="2009-11-06 11:50:20 +0000" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="24.0" SD_2="26.2" SE="5.796639167744154" STUDY_ID="STD-Overgard-2008" TOTAL_1="36" TOTAL_2="39" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-006.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 10:47:06 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="56.95616371715406" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="105" TOTAL_2="112" WEIGHT="0.0" Z="0.0">
<NAME>Number of men not carrying out sufficient PFMT</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-006.09.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-06 11:52:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="3" EVENTS_2="18" I2="0.0" ID="CMP-006.09.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-06 11:53:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="35" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="0.5925739968270336" CI_START="0.061226411102396204" EFFECT_SIZE="0.19047619047619047" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.22725741003164543" LOG_CI_START="-1.2130611967802685" LOG_EFFECT_SIZE="-0.7201593034059569" MODIFIED="2009-11-06 11:53:44 +0000" MODIFIED_BY="[Empty name]" ORDER="142" O_E="0.0" SE="0.5790660241435861" STUDY_ID="STD-Overgard-2008" TOTAL_1="35" TOTAL_2="40" VAR="0.33531746031746024" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="21" I2="0.0" ID="CMP-006.09.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-06 11:53:55 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="34" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="1.0303055574618991" CI_START="0.35530803405870603" EFFECT_SIZE="0.6050420168067226" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="21" LOG_CI_END="0.012966042413884837" LOG_CI_START="-0.44939497233640935" LOG_EFFECT_SIZE="-0.21821446496126232" MODIFIED="2009-11-06 11:53:55 +0000" MODIFIED_BY="[Empty name]" ORDER="143" O_E="0.0" SE="0.2715931487882579" STUDY_ID="STD-Overgard-2008" TOTAL_1="34" TOTAL_2="36" VAR="0.0737628384687208" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="30" EVENTS_2="26" I2="0.0" ID="CMP-006.09.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2009-11-06 11:54:06 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="1.4812199853120596" CI_START="0.8988272909814097" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="26" LOG_CI_END="0.17061956312098606" LOG_CI_START="-0.04632374962329719" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2009-11-06 11:54:06 +0000" MODIFIED_BY="[Empty name]" ORDER="144" O_E="0.0" SE="0.1274335757927095" STUDY_ID="STD-Overgard-2008" TOTAL_1="36" TOTAL_2="36" VAR="0.016239316239316237" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-006.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 10:47:04 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="50.39284854774434" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="150" TOTAL_2="148" WEIGHT="0.0" Z="0.0">
<NAME>Number of men having surgery for incontinence</NAME>
<GROUP_LABEL_1>PFMT +/- BF</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.8800081193849314" CI_START="0.11151306688679295" EFFECT_SIZE="0.6577777777777778" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5888326344087389" LOG_CI_START="-0.9526742398415491" LOG_EFFECT_SIZE="-0.1819208027164051" MODIFIED="2010-04-16 13:59:39 +0100" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="0.905488768516711" STUDY_ID="STD-Filocamo-2005" TOTAL_1="150" TOTAL_2="148" VAR="0.8199099099099098" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-007" MODIFIED="2014-03-19 12:15:01 +0000" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Prevention of UI after radical: electric or magnetic energy versus no treatment</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.01" MODIFIED="2014-03-19 12:15:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="45" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test (grams of urine lost)</NAME>
<GROUP_LABEL_1>EStim</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.01" MODIFIED="2014-03-19 11:18:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Less than 3 months</NAME>
<CONT_DATA CI_END="33.64440565650244" CI_START="-17.844405656502445" EFFECT_SIZE="7.899999999999999" ESTIMABLE="YES" MEAN_1="25.5" MEAN_2="17.6" MODIFIED="2014-03-19 11:18:49 +0000" MODIFIED_BY="[Empty name]" ORDER="520" SD_1="35.4" SD_2="38.5" SE="13.135142206474725" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.02" MODIFIED="2014-03-19 11:19:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Within 3-6 months</NAME>
<CONT_DATA CI_END="14.868378468871581" CI_START="-24.268378468871582" EFFECT_SIZE="-4.700000000000001" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="14.3" MODIFIED="2014-03-19 11:19:46 +0000" MODIFIED_BY="[Empty name]" ORDER="521" SD_1="18.8" SD_2="34.4" SE="9.984050025012936" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.01.03" MODIFIED="2014-03-19 11:20:37 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Within 6-12 months</NAME>
<CONT_DATA CI_END="6.811832532565457" CI_START="-9.111832532565458" EFFECT_SIZE="-1.1500000000000004" ESTIMABLE="YES" MEAN_1="4.35" MEAN_2="5.5" MODIFIED="2014-03-19 11:20:37 +0000" MODIFIED_BY="[Empty name]" ORDER="522" SD_1="7.3" SD_2="14.16" SE="4.062234099895394" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-007.02" MODIFIED="2014-03-19 12:15:01 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="16.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="51" TOTAL_2="45" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>ICIQ-SF score</NAME>
<GROUP_LABEL_1>EStim</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.01" MODIFIED="2014-03-19 11:23:38 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Less than 3 months</NAME>
<CONT_DATA CI_END="6.0206004480582695" CI_START="-1.8206004480582707" EFFECT_SIZE="2.0999999999999996" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="7.5" MODIFIED="2014-03-19 11:23:38 +0000" MODIFIED_BY="[Empty name]" ORDER="523" SD_1="6.3" SD_2="5.0" SE="2.000343107824157" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.02" MODIFIED="2014-03-19 11:24:03 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Within 3-6 months</NAME>
<CONT_DATA CI_END="5.8225024355059825" CI_START="-2.222502435505983" EFFECT_SIZE="1.7999999999999998" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="5.4" MODIFIED="2014-03-19 11:24:03 +0000" MODIFIED_BY="[Empty name]" ORDER="524" SD_1="6.4" SD_2="5.2" SE="2.052334873107347" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-007.02.03" MODIFIED="2014-03-19 11:24:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0" Z="0.0">
<NAME>Within 6-12 months</NAME>
<CONT_DATA CI_END="5.34557190613968" CI_START="-2.1455719061396814" EFFECT_SIZE="1.5999999999999996" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="3.7" MODIFIED="2014-03-19 11:24:29 +0000" MODIFIED_BY="[Empty name]" ORDER="525" SD_1="5.5" SD_2="5.3" SE="1.911041190391392" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="15" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-008" MODIFIED="2014-02-27 10:25:08 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Prevention of UI after radical: lifestyle interventions versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-009" MODIFIED="2014-03-19 12:15:29 +0000" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Prevention of UI after radical: combinations of treatments versus no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-009.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 12:15:29 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men within 3 to 6 months</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="20" I2="0.0" ID="CMP-009.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-19 12:11:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + Biofeedback versus no treatment/sham treatment</NAME>
<DICH_DATA CI_END="0.6408998867369677" CI_START="0.14042754861171783" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="20" LOG_CI_END="-0.1932098051666186" LOG_CI_START="-0.8525476853940566" LOG_EFFECT_SIZE="-0.5228787452803376" MODIFIED="2014-03-03 11:09:28 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.3872983346207417" STUDY_ID="STD-Mariotti-2009" TOTAL_1="30" TOTAL_2="30" VAR="0.15000000000000002" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-009.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 12:15:29 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="551.89" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men within 6 to 12 months</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="10" I2="0.0" ID="CMP-009.02.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-19 12:11:50 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + biofeedback versus no treatment</NAME>
<DICH_DATA CI_END="0.7332835516809254" CI_START="0.013637289391091267" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.13472805657581619" LOG_CI_START="-1.8652719434241833" LOG_EFFECT_SIZE="-1.0" MODIFIED="2014-03-03 11:17:25 +0000" MODIFIED_BY="[Empty name]" ORDER="156" O_E="0.0" SE="1.016530045465127" STUDY_ID="STD-Mariotti-2009" TOTAL_1="30" TOTAL_2="30" VAR="1.0333333333333332" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.03" MODIFIED="2014-03-19 12:15:29 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="447.4711647396696" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost) within 3 to 6 months</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.03.01" MODIFIED="2014-03-19 12:11:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + Biofeedback versus no treatment/sham treatment</NAME>
<CONT_DATA CI_END="-74.3067574449909" CI_START="-185.6932425550091" EFFECT_SIZE="-130.0" ESTIMABLE="YES" MEAN_1="6.7" MEAN_2="136.7" MODIFIED="2014-03-03 11:41:07 +0000" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="30.6" SD_2="152.6" SE="28.415441811334436" STUDY_ID="STD-Mariotti-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.04" MODIFIED="2014-03-19 12:15:29 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="166.51093468103153" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost) 6 to 12 months</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.04.01" MODIFIED="2014-03-19 12:12:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + Biofeedback versus no treatment/sham treatment</NAME>
<CONT_DATA CI_END="-3.582120685858012" CI_START="-45.01787931414199" EFFECT_SIZE="-24.3" ESTIMABLE="YES" MEAN_1="3.5" MEAN_2="27.8" MODIFIED="2014-03-03 11:42:22 +0000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="14.7" SD_2="56.0" SE="10.570540825016161" STUDY_ID="STD-Mariotti-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-009.05" MODIFIED="2014-03-19 12:15:29 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.59645083531858" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="30" TOTAL_2="30" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Time until continent (months)</NAME>
<GROUP_LABEL_1>Intervention</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours intervention</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-009.05.01" MODIFIED="2014-03-03 11:00:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal Estim + Biofeedback versus no treatment/sham treatment</NAME>
<CONT_DATA CI_END="-0.5552783835041128" CI_START="-2.444721616495887" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="2.0" MEAN_2="3.5" MODIFIED="2014-02-25 10:57:45 +0000" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="1.6" SD_2="2.1" SE="0.4820096817838137" STUDY_ID="STD-Mariotti-2009" TOTAL_1="30" TOTAL_2="30" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-010" MODIFIED="2014-08-28 13:22:46 +0100" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Prevention of UI after radical: one active treatment versus another active treatment</NAME>
<DICH_OUTCOME CHI2="4.121746578598522" CI_END="0.9949507945268746" CI_START="0.7410185677037561" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8586483638230604" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="143" I2="2.953761864707321" I2_Q="0.0" ID="CMP-010.01" LOG_CI_END="-0.0021983968360528667" LOG_CI_START="-0.13017090976661777" LOG_EFFECT_SIZE="-0.06618465330133531" METHOD="MH" MODIFIED="2014-06-02 14:09:42 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.3897802022950353" P_Q="0.9538059796670367" P_Z="0.042631423551123836" Q="0.3324928357643255" RANDOM="NO" SCALE="2.69" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="226" TOTAL_2="223" WEIGHT="400.0" Z="2.0273031111027757">
<NAME>Number of incontinent men at &lt; 3months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.786515567975346" CI_END="1.0643764913322438" CI_START="0.6923482482294487" DF="1" EFFECT_SIZE="0.8584399799814114" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="82" I2="73.59049548197946" ID="CMP-010.01.01" LOG_CI_END="0.027095273811113513" LOG_CI_START="-0.15967540230496244" LOG_EFFECT_SIZE="-0.06629006424692445" MODIFIED="2014-03-20 10:06:24 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.05166714139451045" P_Z="0.16413733792765384" STUDIES="2" TAU2="0.0" TOTAL_1="144" TOTAL_2="145" WEIGHT="100.00000000000001" Z="1.3912905511577265">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="0.9111739847630194" CI_START="0.541041841166851" EFFECT_SIZE="0.7021276595744681" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="47" LOG_CI_END="-0.040398688440759147" LOG_CI_START="-0.2667691476749008" LOG_EFFECT_SIZE="-0.15358391805782998" MODIFIED="2014-03-10 16:32:49 +0000" MODIFIED_BY="[Empty name]" ORDER="151" O_E="0.0" SE="0.13297112830598" STUDY_ID="STD-Centemero-2009" TOTAL_1="59" TOTAL_2="59" VAR="0.0176813209629654" WEIGHT="57.46049903481805"/>
<DICH_DATA CI_END="1.520441511494304" CI_START="0.7524136957777511" EFFECT_SIZE="1.0695798319327732" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="35" LOG_CI_END="0.18196971831517825" LOG_CI_START="-0.12354330782318954" LOG_EFFECT_SIZE="0.029213205245994377" MODIFIED="2014-03-20 10:06:24 +0000" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.17945986386754692" STUDY_ID="STD-Geraerts-2013" TOTAL_1="85" TOTAL_2="86" VAR="0.03220584273935847" WEIGHT="42.539500965181965"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2627405698106766" CI_START="0.6128501654615004" DF="0" EFFECT_SIZE="0.8796992481203008" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" I2="0.0" ID="CMP-010.01.02" LOG_CI_END="0.10131413387060455" LOG_CI_START="-0.21264569231245284" LOG_EFFECT_SIZE="-0.055665779220924146" MODIFIED="2014-06-02 14:09:09 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.48704778979342833" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.6950119941826944">
<NAME>PFMT + Biofeedback + transcutaneous Estim versus Estim only</NAME>
<DICH_DATA CI_END="1.2627405698106766" CI_START="0.6128501654615004" EFFECT_SIZE="0.8796992481203008" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="19" LOG_CI_END="0.10131413387060455" LOG_CI_START="-0.21264569231245284" LOG_EFFECT_SIZE="-0.055665779220924146" MODIFIED="2014-02-24 10:18:48 +0000" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.18442155602613214" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" VAR="0.034011310327099795" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.641417366118512E-31" CI_END="1.1112707285860508" CI_START="0.5700555509873332" DF="0" EFFECT_SIZE="0.7959183673469387" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" I2="99.99999999999999" ID="CMP-010.01.03" LOG_CI_END="0.045819874969567055" LOG_CI_START="-0.2440828209735961" LOG_EFFECT_SIZE="-0.09913147300201451" MODIFIED="2014-06-02 14:09:31 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.18011235431846537" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="1.3404091754734526">
<NAME>PFMT + Biofeedback + transcutaneous Estim versus post-op PFMT</NAME>
<DICH_DATA CI_END="1.111270728586051" CI_START="0.5700555509873333" EFFECT_SIZE="0.7959183673469388" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="21" LOG_CI_END="0.045819874969567145" LOG_CI_START="-0.24408282097359602" LOG_EFFECT_SIZE="-0.09913147300201446" MODIFIED="2014-03-17 11:41:36 +0000" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="0.17029027863850302" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" VAR="0.028998778998778993" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.220510089975835" CI_START="0.6706983506581231" DF="0" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" I2="0.0" ID="CMP-010.01.04" LOG_CI_END="0.08654137408726273" LOG_CI_START="-0.17347276164944336" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2014-06-02 14:09:42 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5122866924658291" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="0.655281253325776">
<NAME>Post-op transcutaneous Estim versus post-op PFMT</NAME>
<DICH_DATA CI_END="1.220510089975835" CI_START="0.6706983506581232" EFFECT_SIZE="0.9047619047619048" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="21" LOG_CI_END="0.08654137408726273" LOG_CI_START="-0.1734727616494433" LOG_EFFECT_SIZE="-0.0434656937810903" MODIFIED="2014-03-17 11:50:25 +0000" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.15273359042247095" STUDY_ID="STD-Ahmed-2012" TOTAL_1="26" TOTAL_2="26" VAR="0.023327549643339107" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.177584540972946" CI_END="1.0346864715061939" CI_START="0.7004709773290141" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8513329806398039" ESTIMABLE="YES" EVENTS_1="98" EVENTS_2="111" I2="62.05677918852621" I2_Q="63.97488971358218" ID="CMP-010.02" LOG_CI_END="0.0148087707371756" LOG_CI_START="-0.15460985416403805" LOG_EFFECT_SIZE="-0.06990054171343123" METHOD="MH" MODIFIED="2014-06-02 12:58:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.021770260116413587" P_Q="0.025426579792961923" P_Z="0.10580800423375197" Q="11.103366424690945" RANDOM="NO" SCALE="6.08" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="253" TOTAL_2="246" WEIGHT="500.0" Z="1.6173256551698474">
<NAME>Number of incontinent men within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.3576072964210408" CI_END="1.037731678768211" CI_START="0.5420476328405898" DF="1" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="52" I2="26.340996940998647" ID="CMP-010.02.01" LOG_CI_END="0.016085074616101452" LOG_CI_START="-0.26596254783270135" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-20 10:07:01 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.24395275874868616" P_Z="0.0824910295886171" STUDIES="2" TAU2="0.0" TOTAL_1="145" TOTAL_2="145" WEIGHT="100.0" Z="1.7364119002325829">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="0.9349504295459335" CI_START="0.4500185850473981" EFFECT_SIZE="0.6486486486486487" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="37" LOG_CI_END="-0.029211414523590475" LOG_CI_START="-0.3467695501871874" LOG_EFFECT_SIZE="-0.18799048235538895" MODIFIED="2014-03-10 16:33:34 +0000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.1865352208269203" STUDY_ID="STD-Centemero-2009" TOTAL_1="59" TOTAL_2="59" VAR="0.03479538860894793" WEIGHT="71.15384615384616"/>
<DICH_DATA CI_END="1.9160686801843043" CI_START="0.5219019601655465" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.28241107201313165" LOG_CI_START="-0.28241107201313165" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-03-20 10:07:01 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.3317793233157319" STUDY_ID="STD-Geraerts-2013" TOTAL_1="86" TOTAL_2="86" VAR="0.11007751937984497" WEIGHT="28.846153846153847"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.4928491665210473" CI_START="0.96079808947922" DF="0" EFFECT_SIZE="1.5476190476190477" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" I2="0.0" ID="CMP-010.02.02" LOG_CI_END="0.39669600167692703" LOG_CI_START="-0.017367869187016806" LOG_EFFECT_SIZE="0.18966406624495513" MODIFIED="2014-03-24 09:37:43 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07256723080231325" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="99.99999999999999" Z="1.7955429833851808">
<NAME>post-op PFMT + biofeedback + transcutaneous Estim vs post-op Estim</NAME>
<DICH_DATA CI_END="2.4928491665210473" CI_START="0.96079808947922" EFFECT_SIZE="1.5476190476190477" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="12" LOG_CI_END="0.39669600167692703" LOG_CI_START="-0.017367869187016806" LOG_EFFECT_SIZE="0.18966406624495513" MODIFIED="2014-02-24 10:22:04 +0000" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="0.24322316739469774" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" VAR="0.059157509157509156" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.9861287827729484" CI_START="0.23008309805476948" DF="0" EFFECT_SIZE="0.47633136094674555" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" I2="0.0" ID="CMP-010.02.03" LOG_CI_END="-0.006066364982266679" LOG_CI_START="-0.6381152835093434" LOG_EFFECT_SIZE="-0.32209082424580504" MODIFIED="2014-03-24 09:37:43 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.04576143190023367" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="100.0" Z="1.9975872017746497">
<NAME>PFMT + general exercise versus PFMT alone</NAME>
<DICH_DATA CI_END="0.9861287827729484" CI_START="0.23008309805476948" EFFECT_SIZE="0.47633136094674555" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="13" LOG_CI_END="-0.006066364982266679" LOG_CI_START="-0.6381152835093434" LOG_EFFECT_SIZE="-0.32209082424580504" MODIFIED="2014-02-24 12:07:30 +0000" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.3712686634354105" STUDY_ID="STD-Park-2012" TOTAL_1="26" TOTAL_2="23" VAR="0.1378404204491161" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5733963721783863" CI_START="0.7584983447215153" DF="0" EFFECT_SIZE="1.0924369747899159" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" I2="0.0" ID="CMP-010.02.04" LOG_CI_END="0.19683814446999756" LOG_CI_START="-0.12004536264138559" LOG_EFFECT_SIZE="0.03839639091430597" MODIFIED="2014-03-24 09:37:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.6348062722188099" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="100.0" Z="0.4749729262615657">
<NAME>Post-op PFMT + transcutaneous Estim + Biofeedback versus post-op PFMT</NAME>
<DICH_DATA CI_END="1.5733963721783863" CI_START="0.7584983447215153" EFFECT_SIZE="1.0924369747899159" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="17" LOG_CI_END="0.19683814446999756" LOG_CI_START="-0.12004536264138559" LOG_EFFECT_SIZE="0.03839639091430597" MODIFIED="2014-03-17 11:42:56 +0000" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="0.1861389406758847" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" VAR="0.03464770523594053" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1644930668511724" CI_START="0.4278856700633778" DF="0" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" I2="0.0" ID="CMP-010.02.05" LOG_CI_END="0.06613690717963763" LOG_CI_START="-0.36867225784093577" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2014-03-24 09:37:43 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Z="0.17265539066605276" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="100.0" Z="1.3637210046349506">
<NAME>Post-op transcutaneous electrical stimulation versus post-op PFMT</NAME>
<DICH_DATA CI_END="1.1644930668511724" CI_START="0.4278856700633778" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.06613690717963763" LOG_CI_START="-0.36867225784093577" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2014-03-17 11:51:19 +0000" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.2554090558731642" STUDY_ID="STD-Ahmed-2012" TOTAL_1="26" TOTAL_2="26" VAR="0.0652337858220211" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="16" EVENTS_2="29" I2="0.0" I2_Q="0.0" ID="CMP-010.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-19 12:03:08 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="202.54901269172493" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="168" TOTAL_2="163" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men within 6 to 12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="5" I2="0.0" ID="CMP-010.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-01-20 12:37:06 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="85" WEIGHT="0.0" Z="0.0">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="4.639915530243135" CI_START="0.5389777535870173" EFFECT_SIZE="1.5813953488372092" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6665100742869465" LOG_CI_START="-0.2684291600336469" LOG_EFFECT_SIZE="0.19904045712664978" MODIFIED="2014-01-20 12:37:06 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.5491879342637662" STUDY_ID="STD-Geraerts-2013" TOTAL_1="86" TOTAL_2="85" VAR="0.30160738714090285" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="6" I2="0.0" ID="CMP-010.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-19 12:02:33 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>post-op PFMT + Biofeedback + transcutaneous Estim vs post-op Estim</NAME>
<DICH_DATA CI_END="1.200492314205727" CI_START="0.019951187427117826" EFFECT_SIZE="0.15476190476190477" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.07935938396095393" LOG_CI_START="-1.7000312514710436" LOG_EFFECT_SIZE="-0.8103359337550449" MODIFIED="2014-02-24 10:24:22 +0000" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.0452228673784565" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" VAR="1.0924908424908424" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="1" EVENTS_2="9" I2="0.0" ID="CMP-010.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-19 12:02:47 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-op PFMT + transcutaneous Estim + Biofeedback versus post-op PFMT</NAME>
<DICH_DATA CI_END="0.7591917928284879" CI_START="0.014021488167801743" EFFECT_SIZE="0.10317460317460317" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="9" LOG_CI_END="-0.11964849545505982" LOG_CI_START="-1.8532058901663924" LOG_EFFECT_SIZE="-0.9864271928107261" MODIFIED="2014-03-17 11:43:46 +0000" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="1.0183001949009372" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" VAR="1.0369352869352868" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="6" EVENTS_2="9" I2="0.0" ID="CMP-010.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-19 12:03:08 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-op transcutaneous Estim versus post-op PFMT</NAME>
<DICH_DATA CI_END="1.6046863985357112" CI_START="0.27696654302672685" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.205390171511719" LOG_CI_START="-0.5575726896230815" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-03-17 11:52:15 +0000" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="0.44816816135765475" STUDY_ID="STD-Ahmed-2012" TOTAL_1="26" TOTAL_2="26" VAR="0.20085470085470086" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4178716718181241" CI_END="2.2122641251900617" CI_START="0.8016921257335782" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3317487485286987" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-010.04" LOG_CI_END="0.34483697673063757" LOG_CI_START="-0.09599238204718016" LOG_EFFECT_SIZE="0.12442229734172872" METHOD="MH" MODIFIED="2014-03-19 12:04:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.7013509289421785" P_Q="0.9518378239644314" P_Z="0.2685604693919065" Q="0.0036480503984866013" RANDOM="NO" SCALE="20.68" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="219" TOTAL_2="206" WEIGHT="200.0" Z="1.1063837596462418">
<NAME>Number of incontinent men after 12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.4176032281506414" CI_END="2.2531524907900895" CI_START="0.7788404012928504" DF="2" EFFECT_SIZE="1.3247060768717485" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="19" I2="0.0" ID="CMP-010.04.01" LOG_CI_END="0.3527905852735776" LOG_CI_START="-0.10855152812857274" LOG_EFFECT_SIZE="0.12211952857250243" MODIFIED="2014-02-24 10:56:39 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.49223379601276795" P_Z="0.29944504722200793" STUDIES="3" TAU2="0.0" TOTAL_1="189" TOTAL_2="178" WEIGHT="100.0" Z="1.0376242309466963">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="3.415498559636266" CI_START="0.8703419290999317" EFFECT_SIZE="1.7241379310344827" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.5334541065227774" LOG_CI_START="-0.060310093648652044" LOG_EFFECT_SIZE="0.2365720064370627" MODIFIED="2014-02-21 11:05:24 +0000" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="0.348780030360891" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="58" TOTAL_2="45" VAR="0.12164750957854403" WEIGHT="50.55182554163936"/>
<DICH_DATA CI_END="2.790764037433789" CI_START="0.37623832223952314" EFFECT_SIZE="1.0246913580246915" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.44572311790296" LOG_CI_START="-0.4245369709081115" LOG_EFFECT_SIZE="0.0105930734974242" MODIFIED="2014-01-20 12:37:41 +0000" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.5111950840245392" STUDY_ID="STD-Geraerts-2013" TOTAL_1="81" TOTAL_2="83" VAR="0.2613204139308557" WEIGHT="34.485996208967386"/>
<DICH_DATA CI_END="3.820037874641474" CI_START="0.1163455596591846" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.5820676688452829" LOG_CI_START="-0.9342501869566455" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2014-02-24 10:56:39 +0000" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="0.8906926143924925" STUDY_ID="STD-Ghanem-2013" TOTAL_1="50" TOTAL_2="50" VAR="0.7933333333333332" WEIGHT="14.962178249393258"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.767435777274962" CI_START="0.2523355269617207" DF="0" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" I2="0.0" ID="CMP-010.04.02" LOG_CI_END="0.8902776711075202" LOG_CI_START="-0.5980215997510442" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-03-19 12:04:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.7003289384318327" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="100.0" Z="0.3848764729901534">
<NAME>PFMT + Penile vibration pre and post op versus PFMT pre and post op</NAME>
<DICH_DATA CI_END="7.767435777274962" CI_START="0.2523355269617207" EFFECT_SIZE="1.4" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.8902776711075202" LOG_CI_START="-0.5980215997510442" LOG_EFFECT_SIZE="0.146128035678238" MODIFIED="2014-02-04 09:57:23 +0000" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.8742343589025281" STUDY_ID="STD-Fode-2014" TOTAL_1="30" TOTAL_2="28" VAR="0.7642857142857142" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-010.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-10 16:34:49 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.306147019475041" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>No. with severe incontinence (e.g. pad test weight &gt;150g) at &lt; 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="15" EVENTS_2="20" I2="0.0" ID="CMP-010.05.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-10 16:34:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="1.3180977396086386" CI_START="0.4267513577308873" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.11994761526471505" LOG_CI_START="-0.3698250884813149" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2014-03-10 16:34:49 +0000" MODIFIED_BY="[Empty name]" ORDER="155" O_E="0.0" SE="0.28769491059440194" STUDY_ID="STD-Centemero-2009" TOTAL_1="59" TOTAL_2="59" VAR="0.08276836158192091" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-010.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-03-10 16:35:23 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="8.092923526092896" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>No. with severe incontinence (e.g. pad test weight &gt;150g) at 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="10" EVENTS_2="19" I2="0.0" ID="CMP-010.06.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-10 16:35:23 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="1.0340721218571174" CI_START="0.26788103498218385" EFFECT_SIZE="0.5263157894736842" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="19" LOG_CI_END="0.014550829891634517" LOG_CI_START="-0.5720580317972923" LOG_EFFECT_SIZE="-0.278753600952829" MODIFIED="2014-03-10 16:35:23 +0000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.3445769491167723" STUDY_ID="STD-Centemero-2009" TOTAL_1="59" TOTAL_2="59" VAR="0.11873327386262265" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.07" MODIFIED="2014-03-03 12:11:17 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="18.073540871342168" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="78" TOTAL_2="80" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>20 minute pad test (grams of urine lost): within 3 to 6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.07.01" MODIFIED="2010-02-04 11:07:20 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="4.139541718373457" CI_START="-14.219541718373456" EFFECT_SIZE="-5.04" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="9.74" ORDER="103926" SD_1="10.0" SD_2="22.1" SE="4.683525713115399" STUDY_ID="STD-Wille-2003" TOTAL_1="26" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.07.02" MODIFIED="2010-02-04 11:12:35 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="27" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim + BF vs PFMT alone</NAME>
<CONT_DATA CI_END="4.3124445332021955" CI_START="-14.892444533202195" EFFECT_SIZE="-5.29" ESTIMABLE="YES" MEAN_1="4.45" MEAN_2="9.74" MODIFIED="2010-02-04 11:11:31 +0000" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="12.4" SD_2="22.1" SE="4.899296420212337" STUDY_ID="STD-Wille-2003" TOTAL_1="26" TOTAL_2="27" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.07.03" MODIFIED="2010-02-04 11:15:53 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT + anal EStim + BF</NAME>
<CONT_DATA CI_END="6.37312323001707" CI_START="-5.87312323001707" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="4.7" MEAN_2="4.45" MODIFIED="2010-02-04 11:14:59 +0000" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="10.0" SD_2="12.4" SE="3.124099870362662" STUDY_ID="STD-Wille-2003" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.08" MODIFIED="2014-03-19 11:30:49 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="122" TOTAL_2="126" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>20 minute pad test (grams of urine lost): within 6 to 12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.08.01" MODIFIED="2010-02-04 11:08:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT alone</NAME>
<CONT_DATA CI_END="-0.5506797467781244" CI_START="-6.069320253221876" EFFECT_SIZE="-3.31" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="3.7" MODIFIED="2010-02-04 11:07:57 +0000" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="0.5" SD_2="9.0" SE="1.4078423251585446" STUDY_ID="STD-Wille-2003" TOTAL_1="39" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.08.02" MODIFIED="2010-02-04 11:17:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="44" TOTAL_2="41" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim + BF vs PFMT alone</NAME>
<CONT_DATA CI_END="-0.5082516468484646" CI_START="-6.031748353151535" EFFECT_SIZE="-3.27" ESTIMABLE="YES" MEAN_1="0.43" MEAN_2="3.7" MODIFIED="2010-02-04 11:12:52 +0000" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="0.66" SD_2="9.0" SE="1.4090811744174148" STUDY_ID="STD-Wille-2003" TOTAL_1="44" TOTAL_2="41" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.08.03" MODIFIED="2010-02-04 11:17:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="39" TOTAL_2="44" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + anal EStim vs PFMT + anal EStim + BF</NAME>
<CONT_DATA CI_END="0.2103101643061312" CI_START="-0.29031016430613116" EFFECT_SIZE="-0.03999999999999998" ESTIMABLE="YES" MEAN_1="0.39" MEAN_2="0.43" MODIFIED="2010-02-04 11:16:35 +0000" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="0.5" SD_2="0.66" SE="0.1277116142340093" STUDY_ID="STD-Wille-2003" TOTAL_1="39" TOTAL_2="44" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.09" MODIFIED="2014-03-19 12:12:29 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test (grams of urine lost) at less than 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.09.01" MODIFIED="2014-03-19 12:04:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Pre-op PFMT + Estim versus pre-op PFMT</NAME>
<CONT_DATA CI_END="19.932908452214626" CI_START="-27.932908452214626" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="25.5" MEAN_2="29.5" MODIFIED="2014-03-19 11:36:38 +0000" MODIFIED_BY="[Empty name]" ORDER="527" SD_1="35.4" SD_2="35.8" SE="12.210891955665693" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.10" MODIFIED="2014-03-19 12:12:48 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test (grams of urine lost) within 3-6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.10.01" MODIFIED="2014-03-19 11:37:28 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Pre-op PFMT + electrical stimulation versus pre-op PFMT</NAME>
<CONT_DATA CI_END="13.990215331208331" CI_START="-18.39021533120833" EFFECT_SIZE="-2.200000000000001" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="11.8" MODIFIED="2014-03-19 11:37:28 +0000" MODIFIED_BY="[Empty name]" ORDER="528" SD_1="18.8" SD_2="28.4" SE="8.260465732490333" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.11" MODIFIED="2014-03-19 12:13:11 +0000" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>1 hour pad test within 6-12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.11.01" MODIFIED="2014-03-19 11:38:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Pre-op PFMT + electrical stimulation versus pre-op PFMT</NAME>
<CONT_DATA CI_END="7.310166827898403" CI_START="-49.210166827898405" EFFECT_SIZE="-20.950000000000003" ESTIMABLE="YES" MEAN_1="4.35" MEAN_2="25.3" MODIFIED="2014-03-19 11:38:52 +0000" MODIFIED_BY="[Empty name]" ORDER="529" SD_1="7.3" SD_2="59.0" SE="14.418717410529476" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.12" MODIFIED="2014-03-19 12:20:20 +0000" MODIFIED_BY="[Empty name]" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="465.77" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="82" TOTAL_2="78" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost) at less than 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.12.01" MODIFIED="2014-03-19 12:05:16 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + Biofeedback + transcutaneous Estim versus Estim only</NAME>
<CONT_DATA CI_END="-42.13446637581325" CI_START="-197.86553362418675" EFFECT_SIZE="-120.0" ESTIMABLE="YES" MEAN_1="263.0" MEAN_2="383.0" MODIFIED="2014-02-24 14:11:45 +0000" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="145.87" SD_2="145.87" SE="39.7280430856792" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.12.02" MODIFIED="2014-03-17 12:24:13 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-operative PFMT + transcutaneous Estim + Biofeedback versus post-operative PFMT</NAME>
<CONT_DATA CI_END="-136.8747233680127" CI_START="-403.1252766319873" EFFECT_SIZE="-270.0" ESTIMABLE="YES" MEAN_1="263.0" MEAN_2="533.0" MODIFIED="2014-03-17 11:45:03 +0000" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="145.87" SD_2="316.53" SE="67.9223075944571" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.12.03" MODIFIED="2014-03-17 12:24:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-operative transcutaneous electrical stimulation versus post-operative PFMT</NAME>
<CONT_DATA CI_END="-16.033973095740578" CI_START="-283.9660269042594" EFFECT_SIZE="-150.0" ESTIMABLE="YES" MEAN_1="383.0" MEAN_2="533.0" MODIFIED="2014-03-17 11:53:38 +0000" MODIFIED_BY="[Empty name]" ORDER="231" SD_1="145.87" SD_2="316.53" SE="68.35126969728339" STUDY_ID="STD-Ahmed-2012" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.13" MODIFIED="2014-06-02 14:06:22 +0100" MODIFIED_BY="[Empty name]" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="321.7336186582656" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="108" TOTAL_2="101" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost) within 3-6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.13.01" MODIFIED="2014-03-19 12:05:42 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + Biofeedback + transcutaneous Estim versus Estim only</NAME>
<CONT_DATA CI_END="28.865533624186753" CI_START="-126.86553362418675" EFFECT_SIZE="-49.0" ESTIMABLE="YES" MEAN_1="83.0" MEAN_2="132.0" MODIFIED="2014-02-25 09:45:25 +0000" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="145.87" SD_2="145.87" SE="39.7280430856792" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.13.02" MODIFIED="2014-06-02 14:05:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Postoperative PFMT + biofeedback + transcutaneous Estim versus postoperative PFMT</NAME>
<CONT_DATA CI_END="-77.77065854585598" CI_START="-276.229341454144" EFFECT_SIZE="-177.0" ESTIMABLE="YES" MEAN_1="83.0" MEAN_2="260.0" MODIFIED="2014-03-17 11:45:56 +0000" MODIFIED_BY="[Empty name]" ORDER="229" SD_1="145.87" SD_2="216.53" SE="50.62814533167568" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.13.03" MODIFIED="2014-06-02 14:06:22 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-operative transcutaneous Estim only versus post-operative PFMT only</NAME>
<CONT_DATA CI_END="-27.64553178062917" CI_START="-228.35446821937083" EFFECT_SIZE="-128.0" ESTIMABLE="YES" MEAN_1="132.0" MEAN_2="260.0" MODIFIED="2014-03-17 11:54:40 +0000" MODIFIED_BY="[Empty name]" ORDER="232" SD_1="145.87" SD_2="216.53" SE="51.20220014804051" STUDY_ID="STD-Ahmed-2012" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.13.04" MODIFIED="2014-06-02 13:54:44 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + general exercise versus PFMT alone</NAME>
<CONT_DATA CI_END="-20.259108582627942" CI_START="-47.94089141737204" EFFECT_SIZE="-34.099999999999994" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="46.3" MODIFIED="2014-02-17 10:58:55 +0000" MODIFIED_BY="[Empty name]" ORDER="402" SD_1="14.5" SD_2="31.0" SE="7.061809056976168" STUDY_ID="STD-Park-2012" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.14" MODIFIED="2014-03-19 12:23:05 +0000" MODIFIED_BY="[Empty name]" NO="14" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="183.69" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="82" TOTAL_2="78" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>24 hour pad test (grams of urine lost) within 6-12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.14.01" MODIFIED="2014-03-19 12:06:08 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + transcutaneous Estim + biofeedback versus Estim only</NAME>
<CONT_DATA CI_END="-7.990756169995933" CI_START="-116.00924383000407" EFFECT_SIZE="-62.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="98.0" MODIFIED="2014-02-25 09:50:29 +0000" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="95.87" SD_2="105.87" SE="27.55624300039291" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.14.02" MODIFIED="2014-03-19 12:06:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-op PFMT + transcutaneous Estim + Biofeedback versus post-op PFMT</NAME>
<CONT_DATA CI_END="-29.839891530937365" CI_START="-144.16010846906264" EFFECT_SIZE="-87.0" ESTIMABLE="YES" MEAN_1="36.0" MEAN_2="123.0" MODIFIED="2014-03-17 11:46:37 +0000" MODIFIED_BY="[Empty name]" ORDER="230" SD_1="95.87" SD_2="116.53" SE="29.163856540188632" STUDY_ID="STD-Ahmed-2012" TOTAL_1="28" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.14.03" MODIFIED="2014-03-19 12:06:42 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0" Z="0.0">
<NAME>Post-op transcutaneous Estim versus post-op PFMT</NAME>
<CONT_DATA CI_END="35.31729579807691" CI_START="-85.71729579807692" EFFECT_SIZE="-25.200000000000003" ESTIMABLE="YES" MEAN_1="97.8" MEAN_2="123.0" MODIFIED="2014-03-17 11:55:26 +0000" MODIFIED_BY="[Empty name]" ORDER="312" SD_1="105.87" SD_2="116.53" SE="30.876738692868656" STUDY_ID="STD-Ahmed-2012" TOTAL_1="26" TOTAL_2="26" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.15" MODIFIED="2014-06-12 14:26:29 +0100" MODIFIED_BY="[Empty name]" NO="15" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="7.038092663391631" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="76" TOTAL_2="76" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of Life Score (ICS male short form) at &lt; 3 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="1" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.15.01" MODIFIED="2014-06-12 14:26:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="2" TAU2="0.0" TOTAL_1="76" TOTAL_2="76" WEIGHT="0.0" Z="0.0">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<CONT_DATA CI_END="-1.4049391816813825" CI_START="-5.99506081831862" EFFECT_SIZE="-3.700000000000001" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="18.3" MODIFIED="2014-03-10 16:36:35 +0000" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="6.36" SD_2="6.36" SE="1.1709709139666673" STUDY_ID="STD-Centemero-2009" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.9507647317331878" CI_START="-7.849235268266813" EFFECT_SIZE="-4.4" ESTIMABLE="YES" MEAN_1="9.6" MEAN_2="14.0" MODIFIED="2014-06-12 14:26:29 +0100" MODIFIED_BY="[Empty name]" ORDER="530" SD_1="6.3" SD_2="3.6" SE="1.7598462499688463" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.16" MODIFIED="2014-08-28 13:22:45 +0100" MODIFIED_BY="[Empty name]" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="21.180097883625308" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="102" TOTAL_2="99" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence Quality of Life Score (ICIQ - short form) within 3-6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.16.01" MODIFIED="2014-03-19 11:49:11 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Pre-op PFMT + electrical stimulation versus pre-op PFMT</NAME>
<CONT_DATA CI_END="4.405755128824601" CI_START="-3.805755128824601" EFFECT_SIZE="0.2999999999999998" ESTIMABLE="YES" MEAN_1="7.2" MEAN_2="6.9" MODIFIED="2014-03-19 11:49:11 +0000" MODIFIED_BY="[Empty name]" ORDER="531" SD_1="6.4" SD_2="5.8" SE="2.0948115175637274" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.16.02" MODIFIED="2014-03-19 11:42:46 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + general exercise versus PFMT alone</NAME>
<CONT_DATA CI_END="-2.591429418340381" CI_START="-5.408570581659619" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="10.0" MODIFIED="2014-02-24 12:02:23 +0000" MODIFIED_BY="[Empty name]" ORDER="223" SD_1="2.5" SD_2="2.52" SE="0.7186716657909246" STUDY_ID="STD-Park-2012" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.16.03" MODIFIED="2014-06-12 14:27:09 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0" Z="0.0">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<CONT_DATA CI_END="-1.5595553206032902" CI_START="-6.640444679396709" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="8.1" MEAN_2="12.2" MODIFIED="2014-06-12 14:27:09 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="7.04" SD_2="7.04" SE="1.2961690620008393" STUDY_ID="STD-Centemero-2009" TOTAL_1="59" TOTAL_2="59" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.17" MODIFIED="2014-08-28 13:22:45 +0100" MODIFIED_BY="[Empty name]" NO="17" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="13.59" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence Quality of Life Score (ICIQ-short form) within 6-12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.17.01" MODIFIED="2014-03-19 11:49:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0" Z="0.0">
<NAME>Pre-op PFMT + electrical stimulation versus pre-op PFMT</NAME>
<CONT_DATA CI_END="4.130837754562788" CI_START="-3.130837754562788" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="5.3" MEAN_2="4.8" MODIFIED="2014-03-19 11:49:56 +0000" MODIFIED_BY="[Empty name]" ORDER="532" SD_1="5.5" SD_2="5.3" SE="1.8525022822880282" STUDY_ID="STD-Laurienzo-2013" TOTAL_1="17" TOTAL_2="17" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.18" MODIFIED="2014-08-28 13:22:45 +0100" MODIFIED_BY="[Empty name]" NO="18" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="65.19741153589283" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="448" TOTAL_2="368" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>King's health Questionnaire after 12 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.01" MODIFIED="2014-02-26 09:51:12 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>General Health</NAME>
<CONT_DATA CI_END="14.613484458817481" CI_START="-24.93348445881748" EFFECT_SIZE="-5.16" ESTIMABLE="YES" MEAN_1="24.48" MEAN_2="29.64" MODIFIED="2014-02-26 09:51:12 +0000" MODIFIED_BY="[Empty name]" ORDER="243" SD_1="50.7" SD_2="50.7" SE="10.088697861179186" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.02" MODIFIED="2014-02-26 09:52:10 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Role limitations</NAME>
<CONT_DATA CI_END="12.288212129896412" CI_START="-5.0282121298964135" EFFECT_SIZE="3.629999999999999" ESTIMABLE="YES" MEAN_1="21.36" MEAN_2="17.73" MODIFIED="2014-02-26 09:52:10 +0000" MODIFIED_BY="[Empty name]" ORDER="244" SD_1="22.2" SD_2="22.2" SE="4.417536341581419" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.03" MODIFIED="2014-02-26 09:53:07 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Physical limitations</NAME>
<CONT_DATA CI_END="9.03564763094142" CI_START="-3.015647630941425" EFFECT_SIZE="3.009999999999998" ESTIMABLE="YES" MEAN_1="16.49" MEAN_2="13.48" MODIFIED="2014-02-26 09:53:07 +0000" MODIFIED_BY="[Empty name]" ORDER="245" SD_1="15.45" SD_2="15.45" SE="3.0743665079924742" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.04" MODIFIED="2014-02-26 09:53:56 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Social limitations</NAME>
<CONT_DATA CI_END="13.502236973938334" CI_START="-5.842236973938334" EFFECT_SIZE="3.83" ESTIMABLE="YES" MEAN_1="7.98" MEAN_2="4.15" MODIFIED="2014-02-26 09:53:56 +0000" MODIFIED_BY="[Empty name]" ORDER="246" SD_1="24.8" SD_2="24.8" SE="4.9349054626675315" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.05" MODIFIED="2014-02-26 09:54:35 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Personal</NAME>
<CONT_DATA CI_END="0.816042043763251" CI_START="-2.6160420437632554" EFFECT_SIZE="-0.9000000000000021" ESTIMABLE="YES" MEAN_1="18.72" MEAN_2="19.62" MODIFIED="2014-02-26 09:54:35 +0000" MODIFIED_BY="[Empty name]" ORDER="247" SD_1="4.4" SD_2="4.4" SE="0.8755477433764975" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.06" MODIFIED="2014-02-26 09:55:21 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Emotional</NAME>
<CONT_DATA CI_END="3.570066887805175" CI_START="-1.8900668878051752" EFFECT_SIZE="0.8399999999999999" ESTIMABLE="YES" MEAN_1="5.08" MEAN_2="4.24" MODIFIED="2014-02-26 09:55:21 +0000" MODIFIED_BY="[Empty name]" ORDER="248" SD_1="7.0" SD_2="7.0" SE="1.3929168644626095" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.07" MODIFIED="2014-02-26 09:56:04 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Sleep/energy disturbance</NAME>
<CONT_DATA CI_END="18.210372660628835" CI_START="-12.210372660628831" EFFECT_SIZE="3.000000000000001" ESTIMABLE="YES" MEAN_1="9.13" MEAN_2="6.13" MODIFIED="2014-02-26 09:56:04 +0000" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="39.0" SD_2="39.0" SE="7.760536816291682" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.18.08" MODIFIED="2014-02-26 09:56:43 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>Symptom severity</NAME>
<CONT_DATA CI_END="37.26982272000365" CI_START="-29.889822720003657" EFFECT_SIZE="3.6899999999999995" ESTIMABLE="YES" MEAN_1="14.62" MEAN_2="10.93" MODIFIED="2014-02-26 09:56:43 +0000" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="86.1" SD_2="86.1" SE="17.132877432890098" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-010.19" MODIFIED="2014-08-28 13:22:46 +0100" MODIFIED_BY="[Empty name]" NO="19" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="12.87808841059134" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="52" TOTAL_2="46" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Health status measure SF-36 within 3-6 months</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.19.01" MODIFIED="2014-03-13 12:14:36 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Physical composite score</NAME>
<CONT_DATA CI_END="-6.833206286439583" CI_START="-11.166793713560416" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-57.0" MEAN_2="-48.0" MODIFIED="2014-03-13 12:14:36 +0000" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="3.7" SD_2="4.0" SE="1.1055273110382688" STUDY_ID="STD-Park-2012" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-010.19.02" MODIFIED="2014-03-13 12:14:42 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0" Z="0.0">
<NAME>Mental Composite score</NAME>
<CONT_DATA CI_END="-2.1459535213946186" CI_START="-3.8540464786053814" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-49.0" MEAN_2="-46.0" MODIFIED="2014-03-13 12:14:42 +0000" MODIFIED_BY="[Empty name]" ORDER="252" SD_1="1.6" SD_2="1.45" SE="0.435746006223579" STUDY_ID="STD-Park-2012" TOTAL_1="26" TOTAL_2="23" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-010.20" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2014-08-28 13:22:46 +0100" MODIFIED_BY="[Empty name]" NO="20" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="86" TOTAL_2="84" WEIGHT="0.0" Z="0.0">
<NAME>Adverse events</NAME>
<GROUP_LABEL_1>Treatment A</GROUP_LABEL_1>
<GROUP_LABEL_2>Treatment B</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours A</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours B</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-010.20.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-03 10:42:51 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="56" TOTAL_2="46" WEIGHT="0.0" Z="0.0">
<NAME>PFMT pre and post op vs PFMT post op</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2014-02-24 12:30:35 +0000" MODIFIED_BY="[Empty name]" ORDER="226" O_E="0.0" SE="0.0" STUDY_ID="STD-Dijkstra_x002d_Eshuis-2013" TOTAL_1="56" TOTAL_2="46" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-010.20.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2014-03-19 12:18:28 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="38" WEIGHT="0.0" Z="0.0">
<NAME>PFMT + Penile vibration pre and post op versus PFMT pre and post op</NAME>
<DICH_DATA CI_END="240.77355733521182" CI_START="0.7953941772321558" EFFECT_SIZE="13.838709677419354" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.3816087893383444" LOG_CI_START="-0.09941759263744139" LOG_EFFECT_SIZE="1.1410955983504516" MODIFIED="2014-03-03 10:42:51 +0000" MODIFIED_BY="[Empty name]" ORDER="227" O_E="0.0" SE="1.4573671780512374" STUDY_ID="STD-Fode-2014" TOTAL_1="30" TOTAL_2="38" VAR="2.123919091661027" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-011" MODIFIED="2015-01-19 10:21:18 +0000" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Treatment of UI after TURP: PFMT ± biofeedback versus no treatment</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="541" EVENTS_2="517" I2="0.0" I2_Q="0.0" ID="CMP-011.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-18 10:37:13 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="795" TOTAL_2="814" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinent men</NAME>
<GROUP_LABEL_1>PFMT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="142" EVENTS_2="132" I2="0.0" ID="CMP-011.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:13:04 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="205" TOTAL_2="208" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="1.2525753914563487" CI_START="0.9511388015860199" EFFECT_SIZE="1.09150036954915" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="132" LOG_CI_END="0.09780387514454929" LOG_CI_START="-0.021756100976121497" LOG_EFFECT_SIZE="0.038023887084213885" MODIFIED="2011-11-17 10:13:04 +0000" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.07023012180470872" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="205" TOTAL_2="208" VAR="0.004932270008704224" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="140" EVENTS_2="129" I2="0.0" ID="CMP-011.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:13:18 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="201" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="1.257280672576167" CI_START="0.9557193373909635" EFFECT_SIZE="1.096178567254879" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="129" LOG_CI_END="0.09943223945549028" LOG_CI_START="-0.019669626675947776" LOG_EFFECT_SIZE="0.03988130638977124" MODIFIED="2011-11-17 10:13:18 +0000" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.0699610257293524" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="199" TOTAL_2="201" VAR="0.004894545121103109" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="133" EVENTS_2="131" I2="0.0" ID="CMP-011.01.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:13:31 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="197" TOTAL_2="202" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="1.1978617295111174" CI_START="0.9047410327452434" EFFECT_SIZE="1.0410353779982175" ESTIMABLE="YES" EVENTS_1="133" EVENTS_2="131" LOG_CI_END="0.07840668985961696" LOG_CI_START="-0.04347571266691218" LOG_EFFECT_SIZE="0.01746548859635238" MODIFIED="2011-11-17 10:13:31 +0000" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.07159432657170607" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="197" TOTAL_2="202" VAR="0.005125747597256098" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="126" EVENTS_2="125" I2="0.0" ID="CMP-011.01.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:13:44 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="1.2254378350903883" CI_START="0.9078589832036279" EFFECT_SIZE="1.0547628865979382" ESTIMABLE="YES" EVENTS_1="126" EVENTS_2="125" LOG_CI_END="0.08829128493776228" LOG_CI_START="-0.041981604752775556" LOG_EFFECT_SIZE="0.02315484009249336" MODIFIED="2011-11-17 10:13:44 +0000" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.07652294026542608" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="194" TOTAL_2="203" VAR="0.005855760386865969" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.02" MODIFIED="2011-11-18 11:15:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0155839612125535" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="718" TOTAL_2="726" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Number of incontinence episodes per day</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.02.01" MODIFIED="2011-11-17 10:25:25 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="182" TOTAL_2="184" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.39232956707276734" CI_START="-0.572329567072767" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="1.31" MEAN_2="1.4" MODIFIED="2011-11-17 10:25:25 +0000" MODIFIED_BY="[Empty name]" ORDER="282" SD_1="2.2" SD_2="2.5" SE="0.24609103579316827" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="182" TOTAL_2="184" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.02.02" MODIFIED="2011-11-17 10:25:44 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="184" TOTAL_2="181" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.1764252649477701" CI_START="-0.7764252649477698" EFFECT_SIZE="-0.2999999999999998" ESTIMABLE="YES" MEAN_1="1.1" MEAN_2="1.4" MODIFIED="2011-11-17 10:25:44 +0000" MODIFIED_BY="[Empty name]" ORDER="283" SD_1="2.0" SD_2="2.6" SE="0.24307858139524582" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="184" TOTAL_2="181" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.02.03" MODIFIED="2011-11-17 10:26:18 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="177" TOTAL_2="182" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.3872929932830736" CI_START="-0.6072929932830737" EFFECT_SIZE="-0.1100000000000001" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.31" MODIFIED="2011-11-17 10:26:18 +0000" MODIFIED_BY="[Empty name]" ORDER="284" SD_1="2.5" SD_2="2.3" SE="0.2537255772073657" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="177" TOTAL_2="182" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.02.04" MODIFIED="2011-11-17 10:26:34 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="175" TOTAL_2="179" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="0.669032435079525" CI_START="-0.2690324350795251" EFFECT_SIZE="0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.4" MEAN_2="1.2" MODIFIED="2011-11-17 10:26:34 +0000" MODIFIED_BY="[Empty name]" ORDER="285" SD_1="2.3" SD_2="2.2" SE="0.23930666011171278" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="175" TOTAL_2="179" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="121" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-011.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2011-11-18 11:15:22 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.199127179033894" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="584" TOTAL_2="565" WEIGHT="0.0" Z="0.0">
<NAME>Number of men using pads</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="45" EVENTS_2="30" I2="0.0" ID="CMP-011.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:15:26 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="153" TOTAL_2="147" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="2.1558145661051604" CI_START="0.9634361192435914" EFFECT_SIZE="1.4411764705882353" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="30" LOG_CI_END="0.3336114019781821" LOG_CI_START="-0.01617707600566505" LOG_EFFECT_SIZE="0.15871716298625854" MODIFIED="2011-11-17 10:15:26 +0000" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.20546748344860283" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="153" TOTAL_2="147" VAR="0.04221688675470188" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="27" EVENTS_2="21" I2="0.0" ID="CMP-011.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:15:38 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="150" TOTAL_2="145" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="2.095941563942418" CI_START="0.7369928170351692" EFFECT_SIZE="1.2428571428571429" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" LOG_CI_END="0.3213791701002712" LOG_CI_START="-0.13253674489154774" LOG_EFFECT_SIZE="0.0944212126043617" MODIFIED="2011-11-17 10:15:38 +0000" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.2666324553862115" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="150" TOTAL_2="145" VAR="0.07109286626528005" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="25" EVENTS_2="23" I2="0.0" ID="CMP-011.03.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:15:51 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="135" TOTAL_2="137" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<DICH_DATA CI_END="1.8442548310268791" CI_START="0.659746375323506" EFFECT_SIZE="1.103059581320451" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="23" LOG_CI_END="0.2658209297666203" LOG_CI_START="-0.1806229871349295" LOG_EFFECT_SIZE="0.04259897131584539" MODIFIED="2011-11-17 10:15:51 +0000" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.2622433667210004" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="135" TOTAL_2="137" VAR="0.06877158338916511" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="24" EVENTS_2="24" I2="0.0" ID="CMP-011.03.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2011-11-17 10:16:02 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="146" TOTAL_2="136" WEIGHT="0.0" Z="0.0">
<NAME>after 12 months</NAME>
<DICH_DATA CI_END="1.5595190391318616" CI_START="0.556392700921376" EFFECT_SIZE="0.9315068493150684" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="24" LOG_CI_END="0.19299068113832749" LOG_CI_START="-0.2546185759667667" LOG_EFFECT_SIZE="-0.030813947414219608" MODIFIED="2011-11-17 10:16:02 +0000" MODIFIED_BY="[Empty name]" ORDER="273" O_E="0.0" SE="0.26292789332508937" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="146" TOTAL_2="136" VAR="0.06913107708836959" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.04" MODIFIED="2011-11-18 11:26:38 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.2695253092204082" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="787" TOTAL_2="805" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Urinary Incontinence Score (ICI-short form)</NAME>
<GROUP_LABEL_1>PFMT + extra stimulation</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT + Estim</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.04.01" MODIFIED="2011-11-17 10:17:00 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.8612687624945962" CI_START="-0.8612687624945962" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="4.6" MODIFIED="2011-11-17 10:17:00 +0000" MODIFIED_BY="[Empty name]" ORDER="249" SD_1="4.0" SD_2="4.8" SE="0.4394309126535866" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="201" TOTAL_2="203" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.04.02" MODIFIED="2011-11-17 10:17:17 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="199" TOTAL_2="201" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.7859040592343061" CI_START="-0.7859040592343061" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="4.1" MEAN_2="4.1" MODIFIED="2011-11-17 10:17:17 +0000" MODIFIED_BY="[Empty name]" ORDER="250" SD_1="3.7" SD_2="4.3" SE="0.40097882687305325" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="199" TOTAL_2="201" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.04.03" MODIFIED="2011-11-17 10:17:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="193" TOTAL_2="198" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.922917418144086" CI_START="-0.7229174181440849" EFFECT_SIZE="0.10000000000000053" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="4.1" MODIFIED="2011-11-17 10:17:35 +0000" MODIFIED_BY="[Empty name]" ORDER="251" SD_1="4.0" SD_2="4.3" SE="0.41986354067480475" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="193" TOTAL_2="198" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.04.04" MODIFIED="2011-11-16 17:21:18 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="0.688019489230873" CI_START="-0.8880194892308731" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="4.0" MODIFIED="2011-11-16 17:21:18 +0000" MODIFIED_BY="[Empty name]" ORDER="265" SD_1="3.7" SD_2="4.3" SE="0.40205814772448384" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="194" TOTAL_2="203" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-011.05" MODIFIED="2011-11-18 11:26:38 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0155839612125535" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="778" TOTAL_2="798" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Quality of life related to urinary incontinence</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.05.01" MODIFIED="2011-11-17 10:22:53 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="201" TOTAL_2="203" WEIGHT="0.0" Z="0.0">
<NAME>less than 3 months</NAME>
<CONT_DATA CI_END="0.35006029445576975" CI_START="-0.55006029445577" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.6" MODIFIED="2011-11-17 10:22:53 +0000" MODIFIED_BY="[Empty name]" ORDER="276" SD_1="2.1" SD_2="2.5" SE="0.22962681865880596" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="201" TOTAL_2="203" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.05.02" MODIFIED="2011-11-17 10:23:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="194" TOTAL_2="198" WEIGHT="0.0" Z="0.0">
<NAME>within 3-6 months</NAME>
<CONT_DATA CI_END="0.21727177133906783" CI_START="-0.6172717713390677" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.4" MODIFIED="2011-11-17 10:23:11 +0000" MODIFIED_BY="[Empty name]" ORDER="277" SD_1="1.9" SD_2="2.3" SE="0.2128976729319795" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="194" TOTAL_2="198" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.05.03" MODIFIED="2011-11-17 10:23:35 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="193" TOTAL_2="198" WEIGHT="0.0" Z="0.0">
<NAME>within 6-12 months</NAME>
<CONT_DATA CI_END="0.3460582298870673" CI_START="-0.5460582298870671" EFFECT_SIZE="-0.09999999999999987" ESTIMABLE="YES" MEAN_1="1.3" MEAN_2="1.4" MODIFIED="2011-11-17 10:23:35 +0000" MODIFIED_BY="[Empty name]" ORDER="278" SD_1="2.2" SD_2="2.3" SE="0.22758491146037252" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="193" TOTAL_2="198" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-011.05.04" MODIFIED="2011-11-17 10:23:51 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="190" TOTAL_2="199" WEIGHT="0.0" Z="0.0">
<NAME>after first year</NAME>
<CONT_DATA CI_END="0.3079438360028052" CI_START="-0.5079438360028055" EFFECT_SIZE="-0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="1.3" MODIFIED="2011-11-17 10:23:51 +0000" MODIFIED_BY="[Empty name]" ORDER="279" SD_1="1.9" SD_2="2.2" SE="0.20813843479809538" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="190" TOTAL_2="199" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="66" EVENTS_2="154" I2="0.0" I2_Q="0.0" ID="CMP-011.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2015-01-07 13:36:14 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="4.3782187347644985" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="188" TOTAL_2="193" WEIGHT="0.0" Z="0.0">
<NAME>Number of men not carrying out pelvic floor muscle contractions at 12 months</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5411055747362967" CI_START="0.35773657164377937" EFFECT_SIZE="0.4399696048632219" ESTIMABLE="YES" EVENTS_1="66" EVENTS_2="154" LOG_CI_END="-0.26671799172858973" LOG_CI_START="-0.4464366593724112" LOG_EFFECT_SIZE="-0.3565773255505005" MODIFIED="2011-11-17 10:20:24 +0000" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.10556763499573325" STUDY_ID="STD-Glazener-TURP-2011" TOTAL_1="188" TOTAL_2="193" VAR="0.011144525558592366" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-012" MODIFIED="2014-03-03 09:11:31 +0000" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Treatment of UI after TURP: electric or magnetic energy versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-013" MODIFIED="2014-02-27 10:29:51 +0000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Treatment of UI after TURP: lifestyle interventions versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-014" MODIFIED="2014-02-27 10:29:45 +0000" MODIFIED_BY="[Empty name]" NO="14">
<NAME>Treatment of UI after TURP: combinations of treatments versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-015" MODIFIED="2014-02-27 10:29:40 +0000" MODIFIED_BY="[Empty name]" NO="15">
<NAME>Treatment of UI after TURP: one active treatment versus another active treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-016" MODIFIED="2015-01-19 10:21:28 +0000" MODIFIED_BY="[Empty name]" NO="16">
<NAME>Prevention of UI after TURP:  pre or post-operative PFMT ± biofeedback versus no treatment</NAME>
<DICH_OUTCOME CHI2="0.6166533636188789" CI_END="1.2947835477399003" CI_START="0.2449111876719666" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5631225234841006" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-016.01" LOG_CI_END="0.11219717237158358" LOG_CI_START="-0.610991375621616" LOG_EFFECT_SIZE="-0.24939710162501622" METHOD="MH" MODIFIED="2014-03-03 11:49:56 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.7346753139089963" P_Q="0.8427162886294268" P_Z="0.17643381988743878" Q="0.03937063476248591" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="82" TOTAL_2="71" WEIGHT="200.0" Z="1.3518171392235712">
<NAME>Number of incontinent men</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5527533741588044" CI_END="1.771713299119459" CI_START="0.20523108647199897" DF="1" EFFECT_SIZE="0.6030013642564802" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="0.0" ID="CMP-016.01.01" LOG_CI_END="0.24839344515587045" LOG_CI_START="-0.6877568557399426" LOG_EFFECT_SIZE="-0.21968170529203607" MODIFIED="2009-11-09 09:28:44 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.45719494291478624" P_Z="0.3576407733780036" STUDIES="2" TAU2="0.0" TOTAL_1="56" TOTAL_2="49" WEIGHT="100.0" Z="0.9198698756443644">
<NAME>less than 3 months</NAME>
<DICH_DATA CI_END="2.818450789093803" CI_START="0.034341604909805916" EFFECT_SIZE="0.3111111111111111" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.4500104563243494" LOG_CI_START="-1.4641794125185608" LOG_EFFECT_SIZE="-0.5070844780971057" ORDER="103932" O_E="0.0" SE="1.1244046043509934" STUDY_ID="STD-Porru-2001" TOTAL_1="30" TOTAL_2="28" VAR="1.264285714285714" WEIGHT="41.22003508088092"/>
<DICH_DATA CI_END="2.850229408729776" CI_START="0.22888223028898472" EFFECT_SIZE="0.8076923076923077" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.4548798168280878" LOG_CI_START="-0.6403879233018853" LOG_EFFECT_SIZE="-0.09275405323689868" MODIFIED="2009-11-09 09:28:44 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="0.6433656922150993" STUDY_ID="STD-Tibaek-2007" TOTAL_1="26" TOTAL_2="21" VAR="0.41391941391941395" WEIGHT="58.77996491911908"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.889009283990593" CI_START="0.1364479685062386" DF="0" EFFECT_SIZE="0.5076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" I2="0.0" ID="CMP-016.01.02" LOG_CI_END="0.27623409237179464" LOG_CI_START="-0.865032925901731" LOG_EFFECT_SIZE="-0.2943994167649681" MODIFIED="2009-11-09 09:28:22 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.31193108661527713" STUDIES="1" TAU2="0.0" TOTAL_1="26" TOTAL_2="22" WEIGHT="100.0" Z="1.0111783564933328">
<NAME>within 3-6 months</NAME>
<DICH_DATA CI_END="1.889009283990593" CI_START="0.1364479685062386" EFFECT_SIZE="0.5076923076923077" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.27623409237179464" LOG_CI_START="-0.865032925901731" LOG_EFFECT_SIZE="-0.2943994167649681" MODIFIED="2009-11-09 09:28:22 +0000" MODIFIED_BY="[Empty name]" ORDER="106" O_E="0.0" SE="0.6703858958967212" STUDY_ID="STD-Tibaek-2007" TOTAL_1="26" TOTAL_2="22" VAR="0.4494172494172494" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-016.02" MODIFIED="2014-06-02 14:50:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="47.68198083957376" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="320" TOTAL_2="290" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Health status measure SF-36 within 3-6 months</NAME>
<GROUP_LABEL_1>PFMT +/- biofeedback</GROUP_LABEL_1>
<GROUP_LABEL_2>No treatment control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PFMT</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours no treatment</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.01" MODIFIED="2014-03-03 10:13:27 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Physical component</NAME>
<CONT_DATA CI_END="0.06214844230173888" CI_START="-10.062148442301739" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-54.86" MEAN_2="-49.86" MODIFIED="2014-03-03 10:13:27 +0000" MODIFIED_BY="[Empty name]" ORDER="233" SD_1="8.62" SD_2="11.23" SE="2.5827762562125223" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.02" MODIFIED="2014-03-03 10:13:31 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Physical functioning</NAME>
<CONT_DATA CI_END="5.98029210046824" CI_START="-13.72029210046825" EFFECT_SIZE="-3.8700000000000045" ESTIMABLE="YES" MEAN_1="-89.69" MEAN_2="-85.82" MODIFIED="2014-03-03 10:13:31 +0000" MODIFIED_BY="[Empty name]" ORDER="234" SD_1="17.13" SD_2="21.6" SE="5.025751584297513" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.03" MODIFIED="2014-03-03 10:13:39 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Body pain</NAME>
<CONT_DATA CI_END="5.61321836525555" CI_START="-13.973218365255535" EFFECT_SIZE="-4.179999999999993" ESTIMABLE="YES" MEAN_1="-93.66" MEAN_2="-89.48" MODIFIED="2014-03-03 10:13:39 +0000" MODIFIED_BY="[Empty name]" ORDER="235" SD_1="15.16" SD_2="22.71" SE="4.996631796555039" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.04" MODIFIED="2014-03-03 10:13:43 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>General Health</NAME>
<CONT_DATA CI_END="-6.0813110125657825" CI_START="-28.118688987434204" EFFECT_SIZE="-17.099999999999994" ESTIMABLE="YES" MEAN_1="-82.03" MEAN_2="-64.93" MODIFIED="2014-03-03 10:13:43 +0000" MODIFIED_BY="[Empty name]" ORDER="236" SD_1="14.05" SD_2="27.16" SE="5.621883399056424" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.05" MODIFIED="2014-03-03 10:13:49 +0000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Physical role limitation</NAME>
<CONT_DATA CI_END="1.9544062327954137" CI_START="-36.014406232795416" EFFECT_SIZE="-17.03" ESTIMABLE="YES" MEAN_1="-68.75" MEAN_2="-51.72" MODIFIED="2014-03-03 10:13:49 +0000" MODIFIED_BY="[Empty name]" ORDER="237" SD_1="36.48" SD_2="38.92" SE="9.686099531696494" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.06" MODIFIED="2014-03-03 10:13:52 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Mental health component</NAME>
<CONT_DATA CI_END="-2.8424118383208077" CI_START="-12.537588161679189" EFFECT_SIZE="-7.689999999999998" ESTIMABLE="YES" MEAN_1="-56.21" MEAN_2="-48.52" MODIFIED="2014-03-03 10:13:52 +0000" MODIFIED_BY="[Empty name]" ORDER="238" SD_1="6.2" SD_2="11.94" SE="2.4733047137173676" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.07" MODIFIED="2014-03-03 10:13:58 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Mental role limitation</NAME>
<CONT_DATA CI_END="-4.298456512549361" CI_START="-35.58154348745063" EFFECT_SIZE="-19.939999999999998" ESTIMABLE="YES" MEAN_1="-93.75" MEAN_2="-73.81" MODIFIED="2014-03-03 10:13:58 +0000" MODIFIED_BY="[Empty name]" ORDER="239" SD_1="21.48" SD_2="37.8" SE="7.980525974369496" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.08" MODIFIED="2014-03-03 10:14:03 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Vitality</NAME>
<CONT_DATA CI_END="-6.470146768111984" CI_START="-26.189853231888012" EFFECT_SIZE="-16.33" ESTIMABLE="YES" MEAN_1="-80.47" MEAN_2="-64.14" MODIFIED="2014-03-03 10:14:03 +0000" MODIFIED_BY="[Empty name]" ORDER="240" SD_1="13.16" SD_2="24.02" SE="5.030629802211305" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.09" MODIFIED="2014-03-03 10:14:08 +0000" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Mental health</NAME>
<CONT_DATA CI_END="-2.907504445068728" CI_START="-18.33249555493128" EFFECT_SIZE="-10.620000000000005" ESTIMABLE="YES" MEAN_1="-88.0" MEAN_2="-77.38" MODIFIED="2014-03-03 10:14:08 +0000" MODIFIED_BY="[Empty name]" ORDER="241" SD_1="10.51" SD_2="18.68" SE="3.9350190185975134" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-016.02.10" MODIFIED="2014-03-03 10:15:53 +0000" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0" Z="0.0">
<NAME>Social functioning</NAME>
<CONT_DATA CI_END="-2.506547467673622" CI_START="-26.17345253232636" EFFECT_SIZE="-14.33999999999999" ESTIMABLE="YES" MEAN_1="-90.63" MEAN_2="-76.29" MODIFIED="2014-03-03 10:15:53 +0000" MODIFIED_BY="[Empty name]" ORDER="242" SD_1="14.2" SD_2="29.57" SE="6.037586723872035" STUDY_ID="STD-Hou-2013" TOTAL_1="32" TOTAL_2="29" WEIGHT="0.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-017" MODIFIED="2014-03-03 09:12:17 +0000" MODIFIED_BY="[Empty name]" NO="17">
<NAME>Prevention of UI after TURP: electric or magnetic energy versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-018" MODIFIED="2014-02-27 10:29:24 +0000" MODIFIED_BY="[Empty name]" NO="18">
<NAME>Prevention of UI after TURP: lifestyle interventions versus no treatment/ sham treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-019" MODIFIED="2014-02-27 10:29:14 +0000" MODIFIED_BY="[Empty name]" NO="19">
<NAME>Prevention of UI after TURP: combinations of treatments versus no treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-020" MODIFIED="2014-02-27 10:29:35 +0000" MODIFIED_BY="[Empty name]" NO="20">
<NAME>Prevention of UI after TURP: one active treatment versus another active treatment</NAME>
</COMPARISON>
<COMPARISON ID="CMP-021" MODIFIED="2015-01-19 10:21:37 +0000" MODIFIED_BY="[Empty name]" NO="21">
<NAME>Containment of urinary incontinence from any cause: external penile compression devices (penile clamps) versus no treatment</NAME>
<OTHER_OUTCOME COLS="4" ID="CMP-021.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Number of men satisfied with device</NAME>
<TR>
<TH>
<P>Control (no device)</P>
</TH>
<TH>
<P>U-Tex</P>
</TH>
<TH>
<P>C3</P>
</TH>
<TH>
<P>Cunningham</P>
</TH>
</TR>
<OTHER_DATA ORDER="261" STUDY_ID="STD-Moore-2004">
<TR>
<TD>
<P>0/12</P>
</TD>
<TD>
<P>0/12</P>
</TD>
<TD>
<P>2/12</P>
</TD>
<TD>
<P>10/12</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-021.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mean urine loss (grams of urine on pad test)</NAME>
<TR>
<TH>
<P>Control (no device)</P>
</TH>
<TH>
<P>U-Tex</P>
</TH>
<TH>
<P>C3</P>
</TH>
<TH>
<P>Cunningham</P>
</TH>
</TR>
<OTHER_DATA ORDER="262" STUDY_ID="STD-Moore-2004">
<TR>
<TD>
<P>122.8 gm (SD 130.8)</P>
</TD>
<TD>
<P>53.3 gm (SD 65.7) <BR/>P&lt;0.05 vs Control (no device)</P>
</TD>
<TD>
<P>32.3 gm (SD 24.3)<BR/>P&lt;0.05 vs Control (no device)</P>
</TD>
<TD>
<P>17.1 gm (SD 21.3)<BR/>P&lt;0.05 vs Control (no device)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-021.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Penile Doppler blood flow (mean systolic velocity)</NAME>
<TR>
<TH>
<P>Control (no device)</P>
</TH>
<TH>
<P>U-Tex</P>
</TH>
<TH>
<P>C3</P>
</TH>
<TH>
<P>Cunningham</P>
</TH>
</TR>
<OTHER_DATA ORDER="263" STUDY_ID="STD-Moore-2004">
<TR>
<TD>
<P>N=12 men<BR/>R: 12.4 (SD 2.8)<BR/>L: 12.3 (SD 3.0)</P>
</TD>
<TD>
<P>N=12 men<BR/>R: 11.9 (SD 4.4)<BR/>L: 13.8 (SD 7.3)</P>
</TD>
<TD>
<P>N=12 men<BR/>R: 12.4 (SD 5.5)<BR/>L: 11.7 (SD 4.7)</P>
</TD>
<TD>
<P>N=12 men<BR/>R: 9.5 (SD 2.3)<BR/>L: 7.3 (SD 3.0)<BR/>P&lt;0.05 vs Control (no device)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="4" ID="CMP-021.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Penile Doppler blood flow (mean resistence to flow index)</NAME>
<TR>
<TH>
<P>Control (no device)</P>
</TH>
<TH>
<P>U-Tex</P>
</TH>
<TH>
<P>C3</P>
</TH>
<TH>
<P>Cunningham</P>
</TH>
</TR>
<OTHER_DATA ORDER="264" STUDY_ID="STD-Moore-2004">
<TR>
<TD>
<P>N=12 men<BR/>R: 0.9 (SD 0.1)<BR/>L: 0.87 (SD 0.1)</P>
</TD>
<TD>
<P>N=12 men<BR/>R: 0.93 (SD 0.08)<BR/>L: 0.91 (SD 0.11)</P>
</TD>
<TD>
<P>N=12 men<BR/>R: 0.92 (SD 0.1)<BR/>L: 0.92 (SD 0.11)</P>
</TD>
<TD>
<P>N=12 men<BR/>R: 0.92 (SD 0.13)<BR/>L: 0.86 (SD 0.29)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-01-19 10:14:22 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAWxCAYAAAC89RRxAACAAElEQVR42uydD6RWyf/Hf6y11lqJ
JFdyRZKsJJIkK5Fk5SuRJEkiyZUkkmQlkZUk65JcSRLJSpJIrlxJJEmSS7JWVmIlWWud333P3Xma
Z+45M3PO8/95Xi+uep7zd+bMfN5n/jzz/r/M4f/+7//4G6C/boNnQvmD3uT/3EoMA/bwu+iZU/4o
f9DjQsIDpTITUIBnDw08Rx4kheD/BvLaQPkDhAQQEqD8AUICCAnlj/JHGUBIgIpMEAHKAEICVGSC
CFAGACEBhAQofzCYQvL8+fOByOhuTme/CUnZvB6UMkj5g7YLSbt+kfrNN9+UKlS9+iM6P51U5PC1
G7mnsnlddv/Qvf3111/ROnPkyJHs+++/z7799tts69at2bt37+q2X716NRseHjb3tXLlyuzZs2cI
CfSukHSiEPVSoSpzr92crn4TkrLHNnP/W7duGXEo4syZM9n58+ezf//91/ydPHky+/HHH2vbHz9+
nK1atSp78+aN2X7lypVsyZIlCAn0t5Do7eq7774zb1eqEL///nvdOR49epTNnTs3W7FiRbTVY787
d+5ctmDBguyrr77Kvv766+zOnTu593X79m2zXfv98MMP2YMHD0oVVvc7/X9sbCybM2eOSc+BAwey
z58/17arUu/fv9+8SQ4NDZm3Rvf4ycnJ7KeffjL5oHtavHhxdvPmzcJ0ip9//jmbNWuWud7BgweD
+Rw6f78Lif5/6dKlwjIRK1Ohcpq3fyyvQ/klYVD5LWLhwoXZp0+f6r7TNSzbt283YjNgQYhIPMhC
8ssvv9S9Xf3666/Zzp07686hgKxtf/zxR3KLZNOmTbWKroDhVjR3fzeg3L1711TSRoRk+fLl5rq6
XwX5kZGR2vazZ89mp06dMtv+/PPPbM2aNXXHL1u2zLw92rxQvkhAi66vvFJw1L7//POPEabTp08X
3n/s/P0uJArsRWUids6Uclomr0P5tWXLlmz9+vXmBUEvHRKwUDeYypnEwyKxHLQxG4Skz4Uk1te7
dOnS7O+//6591v/1Ru+ew22hpAqJf4wfVCyq3NevX69cWP3zTkxM1D7rrXH+/Pm1z2pRuWl98uRJ
tALo7bno+hItBSn/bbUM7vn7XUhCZSJ2zpRyWiavQ/vPmzcvu3z5cq0VOzo6mh0/fnzGftu2bTMt
JP09ffq07uVIL0VqBdkxlA8fPiAk0L8tkrxAVtR6KCMksaBiUYWzLYkTJ040LCR+YHfT4r8Ba1//
nOrGU9DQG6aCV9F92/P5Ih0ThtD5+11Iytyzv61KOS3zLEOonEhcilCLRd2y7rn37dtnWiu29eS2
WBAS6DshyeteKFvhGhESW+E1wLlhw4bs8OHDDQlJKH2xtGp8RYOiFy9ezO7du2e68kLnL9uaiJ0f
IcmCol3m/GWfZSMtR3Vruven7jC39SQx6eYZfwgJNCwkepPyuwzcQt8OIbFoimSZ4KJZMf553WmW
6k5QpbZoJo2b1hcvXtQdr331Fhk6v5937v4xYudHSLJgXpcpp2WfpYu6zD5+/Fh3LXVTWdQdqzG2
om62jRs3zmjRqIsLIYG+FRINYmqGih2UvHDhQrZo0aJS51AlUf+3rehlhERvjZq5JWIDsO7A/Nu3
b83grX9ezeZRJVdajh49agZOLRp81YwcO9i+bt26uuM1SGpn9khkNP/f3e6nU3lnB+/1p8/uNFCf
2PkRkiyY16Fy6u8fy+vQtQ8dOmQG0O21NIFC13O7stQNa7ernOnPojE//dntum9dHyGBvhUSWzHs
oKFmwrx+/brUOVTR9HZo3xDLCIm6tdR/baeEWlHJwwqN9lUQ0b7+eRU81J+tt0YFBH+QU9My9fao
GTnqu3aPHx8fN4PluoYETsHA3e6nUxw7dsy8/eo7CVvRzLaU8yMkWTCvQ+XU3z+W16Fra8r43r17
zblmz55tXhb8rizNZNR23UverC6Jh8qgLRevXr1CSKA3hWQAM4K0k+9AGQCEhMKMkADlDxCSDtHv
M2MQEqD8AUICCAlQ/gAhASoyQQQoAwgJUJEJIkAZAIQEEBKg/AFCAggJUP6g24UEu1IqMkEEKAPQ
kJB00q40hjW00qq/ReeOraybamfazF+QU5F7P4gQ9MhTKCEknbQrjRFyyMvjt99+M8uRWFLtTLUm
l9a/QkgIIgQ98hRKCkmn7UrLXiuEhEKOd+6KrKl2plqaXuscISTtv3aRTXPInliLLmodLZUZlTfX
qCxUpoquF7NXTrV6Vsv3/fv35v92JWG9zIh3796Z7Snpq5InlD/oqhZJO+1Ky14rhI51WyMixc5U
K/3qHgahoHerkPg2zTF7YhlRWcdMedS4rcwqttAxe+VUq+cdO3ZkN27cMP+/du2a6U7V9e1nex+x
9FXJE8ofdJWQtNOutBnXcgVNb4F+11jIzlRvi/LdHpSC3q1C4tvrxuyJJRz+9jJlyr9ezF451epZ
RllyPRR79uwxLWLrerhr1y4T/FPSVyVPKH/QVULSTrvSZlj4ipcvX+Z6OYTsTNUFpgCiLgeEpLNC
klcGQpMoQn40VcpUzF451epZ5VAvNEJdYJrYMX/+fPNZLzP2RSeWvip5QvmDrhKSdtqVNsPCV8jX
Ic/vIWRnqjdE2w2BkHSXkMQCZMzYrGyZih1jX5ZSrJ7lTaLuMSsg6l6VaZb9nJK+KnlC+YOuEpJ2
2pU2w8JXyOFQldwnZGeaN3U4dWCfitxaIYnZE8uwrKhrq0qZitkru8SsnlUWd+/eXWv52u4t+zkl
fVXyhPIHHRWSTtqVNsPCV6ivOM91sKydKS2S7hCSmD2xulHV3STu378/Y7C9bJmK2SuXsXrWtTUm
Y213R0dHTZ3RQHlq+qrkCeUPOioknbQrjV0rteDp2kVvqGXsTBGS7hASEbInls2tJk7ouWtMToPj
jZapkL1yGavnhw8f1k37tQP3frkLpa9KnlD+oKNCAgNVCAgiQBkAhAQQEqD8AUICCAlQ/gAhASoy
QQQoAwgJUJEJIkAZAIQEEBKg/AFCAggJUP4AIQEqMkEEKAMICVCRCSJ9QrfaYVMGEBIKHULC82xB
2mN20lXw7bC7Je+p0wgJhQ4h4Xm2IO1l7aSrXA8hgZYLCVanWJ128toxq+bQs4+Vi9DzatV5Y2XZ
z5MyVtehshk6p/7VmnNaYNWuF+aLVzvKNkLS50KC1SlWp526dsyqOfTsQ9tiz6tV542V5Vi+VKk/
KS2STZs21QTJX8G4XWUbIelzIcHqFKvTbrq2a+IUevahbbHn1arzxspyLF+q1J8UIfGPcfdpV9lG
SPpcSHywOsXqtJ3XDlk1h559aFvsebXqvLGyHMuXZthPp4yR+C3+dpRthGTAhASrU6xO23XtmFVz
7NkXbUt5Xq04b0pZDm1rhv10WSFpV9lGSAZMSLA6xeq0XdeOWTWnPnt/W5nn1czzlinLefnSDPvp
skLSrrKNkAyYkGB1itVpu64ds2oOPfvQttjzatV5Y2U5li/NsJ/27bBjQtKuso2QDJiQCKxOy+UJ
QlLt2jGr5tCzj5WL0PNq1XljZTklXxq1n/btsGNC0q6yjZD0sZDAQBWCgbw2UP4AIQGEBCh/gJAA
QkL5o/xRBhASoCITRIAygJAAFZkgApQBQEgAIQHKHyAkgJAA5Q8QEqAiE0SAMoCQtJ9usQDtVitS
hAQof9CTQhJ7uM18+CELUN9ytNHrho7vVivSVt8TQjIYwaxb04iQDHCLpJkPv52Wo2WWpUBICCJA
GYAmtUhSbEJjFrVaHDHP0rPIAjS2LeW6jdqbxqxIi+xNY5aosYqkNOmetfS9XPH85cJj9qj9ICT6
XkvJa20q5aXc/7SWWyzv88rDx48fjV2Ae7zQ4oVa4TbvPhp5hikW0Cn3lFKv/DwIXbtsGovqbGoa
ERKEpO7hxmxCUyxqteBbkaVnqCUQ2tZqe9OYFWmevWmKJWroukqPfC7sPa9evXpGfoTuqZ+ERN2Z
SqfyQgF1ZGQkmPeh8iCHTD0bF5UPnde/j0afYaoFdOyeqlg/h65dNo2hOpuaRoQEIan9P2YTWsWi
NlUsQttabW+act/+9hRL1NB15Vvx7t27wnuO3VM/CcnExETt86dPn+pMyMraHsslU8fb7fp3eHi4
dg73Php9hqkW0LF7qlKvQtcum8ZQOUtNI0KCkNS9ffhdRmUsOWMVr6qQtNretOx9iyqWqO53/oC/
f88pXWP9IiR+EE2xZg6Vh7Vr19b8Z+QPojfuvPM1+gxTLaBj91SlXoWu3ak0IiQISW5ATimUjQTk
1G2ttjetIiRVLFHLiPYgCUnZQBcrD7LIXbx4sfm/+vVl4VulvKc8g1QL6NA9ValXoWt3Ko0ICUJS
624J2YRWsahthpC02t60ipCUtUT1LWTlBKixEcvTp08HVkhkZ2v58OGDmYAQy/uYNawGjzUOoS6k
ULlq5Bm6xCygQ/dUpV6Frt1IGkPXS0kjQoKQRG1Cq1jUut+FLEBDwb3Z9qZlrUiLrHdDlqjuIOXb
t29NV0ZosF3pGVQhUdqVB8qLo0ePZlu2bInmfcwaVoPVmsHnDlrnlatGnmEZC+jQPVWpV6Frl0lj
rJyVTSNCgpAYYjahZS1q3e9CFqCxVkIz7U3LWpEWnStkiWornbotVHFVGf3zSPx0vwouuueqb4q9
LiTybJ83b54Z2D106JBplcSOi5WH9+/fm21uqy/vfI08wzIW0KF7qlKvQtcuk8ZYOSubRoRkQIUE
ugP9zsCdrdTOYN5pIYGBCUJkAkICzUStJw1g2t8O6K2xkYFMhAQQEkBIBgzN2tHvX9SVoV+2q0tH
gjJoQuJPgwaEBBASoCITRIAygJAAFZkgApQBQEgAIQHKHyAkgJAA5Q8QEqAiE0SAMoCQDAqDYL/b
j0IyqLbJlD9ASCoWtFamoRfsdwdRSHwL5kafG5a/pBkGXEjaeW2EpDuuHXOGHITnRvmDrheSmJVm
yAJ0cnLSrAukRRB1Di2TrXWT3ILjW4RqoUSt96NjtL9rapRieev+P2QRau+9yMrWL+Bl7XdjeUNF
Tr92kRVs3nNp9LmVtcoNleWiMlDF8reoLGmlYK3RJezqw48fPzafZYzmryRM+YOOCEnISjNmAbps
2TKz8q5dWVTBWhXNLTi+Rejx48drjmtaIkSri7r7xyxv3f+HLEJjVrYpb7ahe4nlDRU57dpV7G4b
eW5VrHKLynKzLH9D59mxY0d248YN8/9r166Zrjztbz+7eYWQQMeEJGSlGbMAzcN3dvNtPCUc/jlD
+xetwhvbN2ZlmxKQQuevkjcIyUyq2N028tyq2si20vI3dJ6xsTEjSmLPnj3Z9u3bzZ/YtWuXER2E
BDouJCErzZgFqFBzX60MFW4FhSrOgqH9Q0IS2jdmZZsSkEL7pOQNFTl+7SpWsI08t6o2sq20/A2d
R4Kklr9Qt5jMpewq0eoaVncXQgIdFxIrBnlWmrHAqLcltTAuXrxoFiFUk79bhKTVPu7dLhq9IiRV
rGCbJSShsp9y/82y/I2dR2N86p61AqLxH7mAttp2ACGBUkJi8a00YxagGsh2t/tWpHnXlEFQqGur
WUISs7JtNCCl2L1SkePXrmIF20whKSr7KfffTMvf0HnkGLl79+5al5bt3rKfKX/QcSEJWWnGLEBV
SewsLb0hKXjHKq26wdSlIO7fvz9jsL1ZQhKzsvUpa7+bYvdKRY5fu4oVbCPPraqNbKstf0PnUf5o
3Eh5I0ZHR026bbcZQgIdF5KYlWbIAnR8fNwMCuo4VUoNXMaCvaZEbt261Ryj62oQvBVCIkJWtj5l
7XdjeUNFTr92WSvYRp5bVRvZVlv+hs7z8OHDumm/duLIq1evEBLovq6tfqYdVrZUZIIIUAYQkj6i
E1a2VGSCCFAGEJI+ohNWtlRkgghQBhASoCITRIAyAAgJICRA+QOEBBASoPwBQgJUZIIIUAYQEqAi
E0SAMgAICSAkQPmDFgtJzMo0VBiaXTAoaAgJUP6gB4UkZmXaTiEBhAQof9BjQlJkZVpkfRoTkqLj
Uu1CW2WlCwgJICTQwhaJ/30Z61N/BdOi41LtQltppQsICSAk0CYhKWN96v4/dFyqXWgrrXQBIQGE
BNokJGWsT2Mub/a4VLvQVlrpAkICCAm0SUjKWJ+GrG397Sl2oa200gWEBBASaJOQlLE+9e1CQ8el
2IW20koXOl+ReT6UPRgQISljfeoPtoeOS7ELbaWVLnRHZeYZUe5gAIREpFqfFk3/zTsuxS60lVa6
0D0V2p92zl9//8EACEm/gJUub4bkPwBCUgqsdAlk5D8AQtIQWOkSyMh/AIQECGTkPwBCAgQyIP8B
IQECGZD/AAgJEMjIfwCEBAhk5D/AYArJ8+fPyV0CGZD/gJBUL/Blf01OZSKQkf8ACElDlYPKRCAj
/wH6TEj0y/D9+/cby1qtWSWTKXffyclJ41SoBRa1dLv8Q27evFmrGP6aOqH97TEyrNJaXNpn48aN
Zt2tlOuJ27dvm+/lf6IVhx88eFCXHtnvav0trfd18ODBum2hYwehkhPIyH+AlgjJ2bNns1OnTtVW
0V2zZk1dgZch1ZUrV2qr+spOd+7cuYWVI2V/626o7bLglUti6vGud/vdu3ezhQsX1rZp4UatCmyX
TZEonj59OulYAhmQ/wAVhUTLjLg+IimWta4bYkrl8Pd3WyAK+suXL08+XqJy/fr13P10Hp3PxRWL
0LEEMiD/ASoKSYrT4KNHj7Ljx48bEyp5s8eWey+7v38PoePVktBnicaJEydmnMfvbnNFKHQsgQzI
f4AmCYlf4MfGxrIlS5ZkFy9eNAsl/vHHH0FhKLu/cGd+xY63QqOVfzds2FC34m+eb3yeyOUdSyAD
8h+gopBovMLt2pKPuruvBuH/+uuv2uc3b94EhSFl/5cvX9Y+69quj0jseJdnz57NsPt1jw3hH0sg
A/IfoKKQaGBbToN2sH3dunV1BX7BggW1WVMSGXmlu9s1u0qzsKwYxfbX/9evX5+9f//eXFMD/e5g
e+x4tVY0+0po4NxtUcnu104c0J8+y4I35VgCGZD/ABWFRJw5c8YYRWnarGY+ufuOj4+bAWsFXQVi
DVa72zUrSl1Ttnsqtr/+r2voWjpGoiIhSr2euqY0bqJuLO1jhcFy7Ngx06rRuTWNWF1jKccy/RfI
f4AGhAQIZED+AyAkQCAj/wEQEiCQkf8ACAkQyID8B4QECGRA/gMgJEAgI/8BEBIgkJH/AAgJEMiA
/AeEpF1g2UsgI/8BelRIuqVw+5a9VDoCGfkPgJBQyQhkQP7DoAmJ/i+HQS2caNejso6CQgszWotc
WeBOTEzUnevIkSPG4lbbtViiu4ZW6Nx5lr1l7kuELHYbTVfo3AQyIP8BIfECthY6tALgr5Arsynr
MChPDy2qaNFKu7LFtSvvamFGBefUc/v3V+a+Yha7jaQrdm4CGZD/gJB4AdttRfjbFWB9K1uLVtV1
fU30f60onHrumJCEjo1Z7DaSrti5CWRA/gNCEnEvdL8L+XfkuROGWhxlhSR2XyGL3UbSFTs3gQzI
f0BImiQkMcveVgpJLLA3WyAJZED+A0JSMWAvWrSosAtINrd+15Y7pbeVQhKz2G00Xan2vQQyIP8B
IYkEXA1K37171/z//v37Mwbbz507Vxtsv3DhggnQqef2LXvL3FfMYrfRdIXOTSAD8h8QkhIB+/Pn
z9nWrVtNV5AG1588eVK3r53+qz/N2Hr9+nXyuX3L3jL3JUIWu42mK3RuAhmQ/zDwQgIEMiD/ARAS
IJCR/wAICRDIyH8AhAQIZED+A0ICBDIg/wEQEiCQkf8ACAkQyMh/AIQECGRA/gNCAgQyIP8BkoTk
9u3bM1a51ZIlDx486LqEfPz4MRsZGTFL1OuetaS7jKe6MRjEfp3f7nsikCEkAC0REpk8STR8x8Gb
N2+aZUF8t8BOs3379uzy5cu1RRa1NpeWZtHfoAYOhAQhAeiokOitXi2SPCQmvkHUo0ePsrlz52Yr
VqyofR+z2I29qY+NjZkWhs5x4MABs/ZVEXlLvquVMnv27FLnDNnnhqx33XufnJw0a29pP92X9lWe
xVoktgWoJeq1urDf8gvdmwR0//79RuSHhoaMYyNCgpAAdFRIYoVb9rLuvgrKCmZ24cIUi92YkMiF
UOKj4xVE1XVVhFbm1QKP7pL1eecPnTNmnxuy3nXvfdmyZdmVK1dqaVc+SGRjQuJ6xmvVYVesY/d2
9uzZ2mrEf/75Z7ZmzRqEBCEB6G4h8ff1LWtTLHZjQuK+8X/69CmbP39+4T1oZV4FXgXjTZs2ZaOj
o9n4+PiM84fOGbPPDVnvxvKryJnR/b/ExgqVT+ze1BJ081v5gZAgJABdJyS+tWxo32ZY7PqBM+RY
aFEXm97O1bWk/c+cOZN8zph9buj6fnp0H2rBaOxGolqUX+7/1QqxraYTJ07MuM8y96Z0IiQICUBX
t0hiQtJsi91UIXF5/vz5jLGc0Dlj9rmpQqJxGLVeLl68mN27d89096UIiRUgdZtt2LAhO3z4cEP3
hpAgJAAdFRK3v95H38daF2Utdt+8eTMjwD579qz2+cOHD2YguQgNqud1O2lgOvWcMfvckPWue+86
p3uevLTFgojus4xt8KpVq+ry+8WLFwgJQgLQWSEpmv6rmUX63p3RlXeOmMWuK1Rv3741XVF+gNVM
Lw0c6/ijR49mW7ZsKUyIZojpmjqX0GwsXV+TAFLPGbPPDVnvuve+YMGC2iwtBfSVK1cmCYnOZ/PV
F+vYvWlw/+TJk7XB9nXr1iEkCAlAZ4XEDWZuv3xeS6XoHCGLXXtuddlIYBRA/QCrYDxv3jwzCH3o
0CHTggihWVg6l86pgX1d331LTzlnyD43ZL3r3rsG+e3Av8RBA+gpQqJuLZ1X9583/Tpm7avxIKVb
U4Q1ywshQUgAOi4k/Va5qLDkC/kPgJBQYQlk5D8AQpKGOzDfzeckkAH5D5RhCjGFgDJA/gMgJEAg
I/8BEBIgkJH/AAgJEMiA/AeEBAhkQP4D9KeQaN0sIJCR/wA9JCT+SrP6pbV+Vb1v3z5jGNXuStRN
U3f1C3d3uReL8kW/4Ne96hfmMp/yfzmvX9srH7XMjH4l/+7dOwIZlZBMgP4VkrxAqRVp5cQ3qJVN
plJanyvvfvbu3WvMpux6WFrry13LS0uYuGZfWhvLXS+LQIaQAPS9kAgFQHdFXRGygLXb9RauFXoV
SMtazRb5oISuW2T/2ygK/FoYMi9/1BJxVwfW/93VhbX+lsy0XGKrKBPIEBKAvhMS4QpJzAJW29SK
savSrl69upLVrH8/sevm2f/mpTHvL4T8RYryxxcSf+l8Fy0JLyGU8RWBDCEBGBgh0Zu43Afdpdlj
FrDyyXDHAXwL2FSrWf9+YtfNs/9tdeXX+IhdOl/jKPKDzzOk2rZtW21V5KdPnxLIqIRkAvSvkPh/
Q0NDZrBYLQC3FRGygPXfyH0L2FSrWf8+Y9dtdeXMO78G1iUSujcNxis9oUkCykt14RHIEBKAvm+R
qEWxcePGOndBS1kL2JCQiCKrWX+/2HVTKmeVrq0y55eplcS3CAlyWftgAhlCAtCTQmKDnsyUfvvt
t7rvYxawcgfU2IhFXTlVrGb9/WLX7USLxOfGjRt1YyDqunPzQmMomiZMIENIAAZCSGzLROMQ8iC3
xCxg/cF2batiNavfXWjMwzoexq7bCSHR/Us8xOTkpGlVuS6K6spSl529Z1n96o9AhpAADIyQCHmV
r127tu67mAWsfi+habrq5tFsK3fcINVqVjOydJx7bOi6nRASiYamGtsxEn/igFp1mqig+9VAu4Sl
GwIKgQwhAWiJkLQKzWaaP38+OZ/Dnj17CGQICQBC4qMxAA2e29976C3cHUSHLxw/fpxAhpAAICQ+
+gGfunvUnaNfth86dKhu+jAQyMh/8h8QEiCQAfkPCAkQyID8B0BIgEBG/gMgJEAgI/8BEBIgkAH5
DwgJEMiA/AdoipC8f//eGEZpjSj9Wlu/Opfvh18JYosf6v/+cX4FSj1PGftf/Qpf+1kPkXZX3pCt
bl46YwtREsgQEoCeEhIFZv3+Q2tl2fWtHj9+nA0PD2djY2OlKoH20bn0q/aUCtQs+9///e9/Ztvm
zZvbXnnL2upqMUwt+UIgQ0gA+kZI9CtrLYToIzFxrWtThWR0dDTqMVL1+zz7X627ZZdikfi5rYF2
VN6Yra5//8uWLatrVbUzuBDIEBKAlgiJVrKVI2IzKoHdR0vKu66FzRIS4QuJWgB2ZV296cvWtpHK
24h3ScxWVwtZdqo1QiBDSABaJiSphkupYxtifHzcOAg2U0jy7H/FggULzFLuQsveq1XSicqbYqur
1oi7ND+BDCEB6Ash0QBxsyqBu48CqwSlqpCk2P/K4tYfj1i3bl3doHu7K2+Rre7Lly9NS41AhpAA
9J2Q6C3ZdfOzKGDfvHmzspCoBWEDZyMtkpD9r7xJ8kRH31etvI10bdl8y2vlnTt3boYvCYEMIQHo
CyHRwLhmbPlcvnw5W716dWUhsefW4HujXVt59r8ag1G3lgawXfRZ39tB91ZX3lRb3S1btphl9glk
CAlA3wnJhw8fzO9GLly4YGYfKRDLRlZLwduuqapComnAy5cvb8oYiW//K5HKm20mNCXXDrq3uvKm
2urq3n1HSQIZQgLQF0Ii1A21Y8cOM1CsH8tp2q9+5OdXgtTBdhf9QLFZs7Zc+191yfm/V7FIEO04
Rcp9N0LMVtei7i6/9dTu4EIgQ0gAWiYk0DnaabtLGUBIABCSPqSdtruUAYQEACEBAhn5D4CQAIGM
/AdASIBABuQ/ICRAIAPyHwAhAQIZ+Q+AkACBjPwHQEiAQAbkPwy2kDT7l9+9XllCtrnyG0nNp+vX
r3ddXhDIyH+AlgkJlWWamG2uFl2UuMTQkjM6DiEB8h8QEmefixcvmlVttZjjtWvXzIKJenPXGlJ3
7typ21cr8+7cudO81WsJ+CdPntS2y4RKK/lqm45dvHhx3XL1t2/fNt9rzS+tl/XgwYO6e9FijLNm
zTLrWh08eLCpmRSzzZWwaDn4GBs2bMhevXo1I287HUgIZAgJQEeFZNeuXWaBQi3lLgHZu3ev+SwR
cYOt9l21apXpErIrCetYixZbvHLlSu2tXy0ALcXuBm4rTDKuUnC3yKpWS97rOF1bC0KePn06eN/N
tM3VUvDr1683QqY8yFugUWKjNHVj4CCQkf8ALROSlFV9fQ92Bdq8CqL/uy0QBX0tJR9CrQ+LREXj
C3noPP4Kuq7QNIsi29x58+YZnxabLnmtuGtlPX782AhNtwYOAhn5D9DRFknq57zz+Y6Bjx49MgFY
b/vyQnGPUStEnyUa8vnwz+OLnStCzabINtcVSYmL+Pjxo1l+3x2cR0iA/AeEpElCIq8Oy9jYWLZk
yRIz5iJvdZk9+cdIaDSwrbGGw4cP57ZcUituK2xz81pT6r5TN143Bw4CGfkP0DNC8vLly9pnWc/O
nz+/9lljC263mBwPi+5BPu3uNrUO3GObTcw2V/9Xy8PdrskCIdHqpuBBICP/AXpGSDRO8P79e9P1
c+rUqbrBdvmp21laL168yFauXFl3vFormrkl/IF8zRTT+exAvT6703MbJWabe+jQITMAb7droF8W
xb0SOAhk5D9Ay4SkrIVuTEg0u0ozm9SlJVFxB+rlA68BcgmERMP/4Z66tTRuoi4j7WNFxXLs2DHT
qtG5NY24mT7oMdtcWftqtpq2axq0RK0RASaQISQAfSEk0D7aaatLIENIABCSPqSdtroEMoQEACEB
Ahn5D4CQAIEMyH9ASIBABuQ/AEICBDLyHwAhAQIZ+Q+AkACBjPwHQEiAQAbkPyAkeWg5E5lEaa0p
/ZpcvyyX10dRJdD//e1FFeX+/fvmey3QmFqxYotANhMZWe3bt8/8kl2/WJcD4ocPH+r2CdnvEsiA
/IeBFxK7/LkMo7QIoZCvxvDwsFmptyi46xgtGRKrKP/73//MCr6bN2/uSiEZGRkx62XZ9bMkGq6d
bsx+l0AG5D8MvJDo19Za/NBHYiKxKAruMnXy/UL8a2gdLLvyr4TJf5PvBiHRmlmuWZbW23KXvY/Z
7/ZScCCQkf8ALRESLZz49u3bUpXA/l8r9/rOiS56e7er52qxRa2c22ohaXQpd7XKXOtflzz7XQIZ
kP8w8EISM24KBXet5Ctb2qKKoiXjJycnzf/lO6JWSUrQb2eLxEdWunlrYhXZ7xLIgPyHgRcSDSBX
FRIbYCUo/veyzPXHEtatW1c36N4NXVsumnSg9Kh7q4iY/S6BDMh/GDghWbZsWZ0roEXB1BpQhYK7
usXUxeV/L6+QvJaGvm+lkFTt2lJ6d+zYkZsX/n6prTgCGZD/MBBCogFzzdjyURfP6tWrk4K7zqHB
d/u9xk3UreUOYgt91vd20L1bWiRqiWgKsLrffGL2uwQyIP9h4IVEv5nQ70Y0BVazkxTsb9y4YWYz
2S6rWHDXNODly5fXvpew5M0EE5pOawfdu0FIHj58mK1du7bwtyEx+10CGZD/MPBCItQ9pW4dDSTL
4lbTfvVDwjLBXT9QtN+ru8z/jYlFYmXHGFKFpNGZWCE0PTl07pj9LtN/gfwHhAQaotP2uQQyhAQA
IelxOm2fSyBDSAAQEiCQkf8ACAkQyID8B4QECGRA/gMgJEAgI/8BEBIgkJH/AAgJEMiA/AeEBAhk
QP4DlBGSKla77a48zfi1eyfum0AG5D/0vZBUsdrtpkrYqvtCSID8B0gUkqpWu+7/JUJa1VfrdKlF
c+fOndx9JVQ7d+40HiiLFy/OJiYmattkgKUl5rVN59D2omXsUwXm0aNHppVl0+HuW+Z6t2/fNvso
fVon7MGDB8HM1qKU33//vVn4Un7v/j1qvS6t26Vry7NFqyVL0LXul79GmfKsWf4nBDKEBKAlQtKI
1a79vwKytdyViBR5mku0rl+/bv5/69Ytc22LFnq8cuVKbZVdBWDX8raKkGixRZ1L3vH+vmWu54qj
DLvk416ERPXw4cPmnFp+Xkvxu+eSaOta9rq//vqrEVehpex9UT979uwMi2ICGUIC0FVC0ojVrv2/
69se2lfC4XuUhFALoBEhCd1XmetJYKwAxli1alXdkvRPnjypO5fGn2wXom1xWH+Tly9fmlaJzSP9
qy5GPx0EMoQEoKuEpFGr3bzzFm2PiZa6otRq2b59uwm4KQP8Zb73v0u9nloh+izPFXmThNBy8y4S
A/dcrljl5Yu8UazRmFpMrqMkgQwhAehKIWnUardZQqKBfbVYLl68aHzd1R3VSiEpez2JjrrjNmzY
YLquivDT6AtJXh6423UNjdcIjY24HvcEMoQEoCuFpFGr3TJCsmjRosKuLQ1O//XXX7XPsr1tpZBU
vd6zZ8+CAUH+9a4wP336tG5/iYPfteW3YjRxQWMj6tYikCEkAF0vJI1a7ZYREnUjqZtIyIHRHWxX
8LQtoBcvXpiA3EohKXM93admbgl/MoGPP9iuWVn+YPu5c+dqg+3Kdwmsy+nTp7OhoSHzL4EMIQHo
eiERjVjtlhESTW3dunVr7UePGoi2SLQ0G0rbFLg1uN1KISlzPXVr6X7t9GYrKkXXOnnyZDZr1iwj
BpqV5bc47PRf/WnG1uvXr+u26weiOiavy5FAhpAAdKWQQOuQeGomFoEMyH9ASCAJTeXVgLm6rTRh
Qa2P0OA8gQwhAUBIoA7NslLXoLqmNM506NAhIygEMiD/ASEBAhmQ/4CQAIEMyH8AhAQIZOQ/AEIC
BDLyHwAhAQIZkP+AkACBDMh/gA4KiX5o5y/tIbTMinw19KttTYHVL9m1DItF61uVtci16Nfl/pLq
WuZEx+u3Gy7aT/uHKrD/vcyl9LuPefPmmV+w64eE+uyuyUUgA/IfEJImoN9FbNmyJbdijIyMmPWj
7FpSCsQSE4sCvvu5DMeOHctGR0frvpN51Zo1a8x1XbTf0aNHk4VEiyfqPKdOnTJLlAjdv5ZHWb9+
fV+ICYGM/AfoGiHRQoRanyvvnPoRnrvCr0THXWtK61Bp0cIqlU3WvJs3b57RSnn48GGt9WHRftbK
N0VIJCB5lsNCS85rwUkCGZD/gJAUFO6yXU3WIyOlYuhN37WwVUtGb/ha1FBLuavFUgYthGiFSk6E
dgVheXhYS12Jl7qnYhXYt94tanVo8URfqAhkQP4DQtKmiiFfE/dtXgFe3wkJgrqgyrzt7969u7b6
7tWrV2tdWvpXjoJC3We7du2KiqV7//4KvT6x7QQyIP8BIWlBxdBYw7Zt24JrTUlM3NZDDA2ua1xE
6NzW30T/6rPYv39/obtj0f0jJED+A1QUkipdWykVQ+Ihj5MUT408H/PQee1sMbebS/+qu8xud10I
U4REfuyatZWHZqLJ2ZBABuQ/ICRtqhhqiWgKsOxrfbTMuhuwFfCtR3kqP/30kxGp//3vf3Xfa4Bd
323atCnpPvOcC4taQZoxRiAD8h8QkjZUDM2gWrt2rRkIz0PLqv/888+16cGyk9V04TJoXEXXlvtg
yvcpQqKWzLp164yY2EF33Z+cIjdu3Fj3WxgCGZD/gJC0sGLoR3yhrjL9kHHv3r01vw5Nuy1b2TQ7
S/tpCrKLnZLs/2gx9QeJuje1POTnbn+QKFOqfhARAhn5D9CVQtIK9uzZw9MikJH/AAhJdfrhh38E
MiD/ASEBAhmQ/wAICRDIyH8AhAQIZOQ/AEICBDIg/wEhAQIZkP8ACAkQyMh/AIQECGTkP0A3Con/
vdbJOnjwoPEQ0a+75cOh5dr9Y2KLPfrf61zyH9EaXO5aW+4+Wrzx22+/NQ6KKYs9lkG+J7q+Pb+7
hEvMHphABuQ/QKKQKMCvWLEiu3TpUm313MePH2fDw8PGJbBM5cj7XufXkiNa5r1oP61vdePGjdqS
8M3gzJkz2fnz52vre8mlUS6Plpg9MIEMyH+ARCHRr8rz7GYlJhKYRoXECoXe/GP7NdP/Y+HChabV
4aIWkiVmD0wgA/IfIFFIZFvrL4RYtXKEKk1MSHyxyTt3VQ8Vreyr1Ye3b99euI9vD0wgA/IfIFFI
3Lf0VgiJROrs2bM1h8O8/SQi6oZyu7+ahbrLJFD6e/r0aeF+vj0wgQzIf4BEIdFAdDOFxP+To6HG
H1zrXX8fdTP5A/LNRvdQ5HiYYg9MIAPyHxCSgsK9bNmy3NlSCqquB3rZFolmSMkc6tmzZ02pXI10
bdn05LW+ytgDE8iA/AeEJKdwnzhxwszY8lFXz+rVqysLiQ3Sssj97bff2l65NN7hioPGQGT567dE
iuyBCWRA/gMkCol+O6HfjWgqrGY52am46m4aHx9vSEhsy0QzqNxg3Y7Kpa4siaSd3nv06FHzZ4nZ
AxPIgPwHKPGDRA2Iq3tHA9L6gaCm/cq3vGzlKPpe51LQbmflUmtIA/ya0qt0SVhcYvbA/RIECGTk
P0BLhAQIZED+AyAkQCAj/wEQEiCQkf8ACAkQyID8B4QECGRA/gMgJEAgI/8BEBIgkJH/AAgJEMiA
/AeEBAhkQP4DICRAICP/ARASIJCR/wAICRDIyH/yHxASIJAB+Q8ICRDIgPwHQEiAQEb+AyAkQCAj
/wF6rwxTkAliwDMAaFhIKMwEMOA5ADQsJLZA8zc4f4CQADRdSKjIAJQ/AISEigyUPwCEhIoMlD8A
hISKDED5A4SEigxA+QNASKjIQPkDQEioyED5A0BIqMgAlD9ASKjIAJQ/AISEigyUPwCEhIoMlD8A
hISKDED5A4SEigxA+QNASKjIQPkDQEioyED5A0BIqMhA+SMTACGhIgNQ/gAhoSIDUP4AEBIqMlD+
ABASKjJQ/gAQkt6syPzx18k/AIQEeKMGAIQEACEBAIQEEBIAQEgAIQEAhAQQEgBASAAQEgBASAAh
AQCEBBASAEBIACEBAIQEACEBAIQEEBIAQEig+wSENaMAgJoPCAkAICTQHWICAAgJAEICAAgJICQA
gJAAQgIACAkMmpgAAEICgJAAAELSDQGVP3zWKff8DVq5pzbwVg48c/IAGnrmlAIqE/DsSTs09Owp
CVQmoAyQZmioDFAaqFBAGSDNgJBQoYAyQJoBIaFCAWWANANCQmYCZYA0A0ICVCigDJBmQEioUEAZ
IM2AkPRRhfr8+XO2aNGi3G1HjhzJvv/+++zbb7/Ntm7dmr1796627cOHD9lPP/1ktn333XfZtm3b
sj///DN5OwGJNHRruU/ZLq5fvz7z9wo5v7T+6quvKDMISf9WqH/++SfbsmVL7j5nzpzJzp8/n/37
77/m7+TJk9mPP/5Y2/7zzz9nJ06cqG2/fPlyduzYseTtVCjS0I3lPmW7ePv2rakPsbz97bffKPcI
SX9XKFUEVYi8fRYuXJh9+vSp7ruvv/669v/169dnL168qKt8GzduTN6ed5+PHj3K5s6dm61YsaJO
kGbNmmVaNQcPHqw75u+//8527txpWj2LFy/OJiYmZrSodJy2K62///578HoSvP3795tW2NDQUHb1
6tW6vLl9+7bJA71h/vDDD9mDBw8ICn1W7lO2iw0bNmSvXr0K7qPytGzZsuzjx4+Ue4SkfyvUvXv3
kgLNX3/9ZQr29u3ba9+p0KkAuui71O1593ngwAFzzB9//GG++/XXX7NLly6Z7yREKuCnT5+uHXP8
+HHTvSBu3bqVLVmypLbtl19+qWtR6VyqfKHrnT17Njt16pT5Tt1wa9asqcsbVaY7d+6Y/9+9e9eI
LULSf+U+tl2tc5Wt2HVU5mKtEco9QtI3QSS0j8Y29Hajv6dPn+a2TvK+i23Puwf3zUksX758hhi5
hVgVyN9uWbp0qXlzc9/i5syZE7ye3tDcY548eVKXN3qLsxWYbor+LvdF2x8/fmxa2ynnUGvkzZs3
0WtQ7hGSgahQtrmsZq0lbwDRFYrY9pR70P6hgcvQ+WLXL7qe3zXh7qe3MX1WRdf4D0IyWEKiLioF
XXfSSdE5Xr58ma1cubLSPVDuEZK+FRI1sd0Cl9dN5Xdthban3ENstkuoQuVtqytYCRUqbz/1L6s7
QX3khw8fRkgGSEh27dqV3bhxI+kc586dMy9fVe6Bco+Q9E2FUnPWna7rN5FVoNzBeE2XdGd1xban
3INaQBqfKULTM4ua+DrWb+J/8803weutWrWq7hhNFijKv2fPnvVMgEZImiMkZcyUNOtLgbfKPVDu
EZK+qVB6m3Kn7x49etT8WTT4bgfo9Hfx4sW6Zm9se8o9aODQPYc+u2KkQUc1u8X9+/dnDDrqrdAe
e+HChbrfBeRd78qVK2Yg1Q46rlu3rm4/nV8zWIQGH0NvhghJ/wlJmX00pmEHs8seT7lHSPqmQqkr
S7M79DajgXa/ma5KogKn7frbtGmT+RFi6vbU+9SsF3WJ6Rz6gaNbOdXK0Q8lVbA1yKhBQl8M7UQB
zVx5/fp19Hr6/YxaXpp6qRkv7n5q3us66nrQNW3lQkgQkrzuoqJWA+UeIenLCgWUAdIM/VwGKA1U
KKAMkGZASKhQQBkgzYCQUKGAMkCaASEhM4EyQJoBIQEqFFAGSDMgJFQooAyQZkBIqFBAGSDNgJBQ
oYAyQJoBIQEqVKV0W6MerWbakULd5meCkJDmbjhey7pohYt21UOEhArV0nS7Rj0ICeWeNLfneAmG
ltdvVz1ESNpQuEL2mSErzyrWoLHtOqcc4RYsWFBbz8cvYKHjY1ah/rXyVm0ta0/qMzk5adZE0vG6
f+XbzZs3EZIuKvfDw8PZ+/fvzf9lOKV9ZFQl5DGi7anltUodSK0TMpPTYoxuXbU21bG6GUq/+11K
nWlWnRMPHz6cYQjWinqIkLQ5iITsM0NWnlWsQWPbdU4FYVto/BVGY8fHrEJjeVLFntRHbnhaRdWe
Q+dTgUdIuqfc79ixo+Yncu3aNbMgop61/WyfeUp5LVsHfEL765wyxdI2LdCoumnf5GN1M1VIYnWm
2XVuZGQkGxsba3k9REjaHERC9pkhK88q1qCx7XnndO87dnzMKjSWJ1XsSVNwDYoQks6XewWyffv2
mf/v2bMn2759u/kTMq1SsKxaXmPH5HXzhPZXEFWwVvBWEE6tm6lCEqszza5zEkb5nLSzHiIkbQgi
IfvMVljihrbHCn1Z61HfKjSWhir2pHmo2a03RgUnVYqiio2QdCbNeqtXy1GoO1cmTfPnzzef1U1k
/dWrlNfYMVX2V91UILXdcWXqZkqdCtWZZtc5dVX5wtSqeoiQtDmIFNlnlhWSmDVobHus0FexHi0j
JFXsSfPedvW2KAOve/fumaY3QtJ95X727NmmK8YKiMbl9KZsP1ctr7FjquyvGU4qU+0QklbXubzz
taIeIiQdDCK+fWbIyrOKNWhse6zQx44vYxWad70q9qQ+GnR079EO5iIk3VXuZYG7e/fuWpeW7d6y
n6uW19gxZfeXs6HGKPRi4nZtpdZN/x798hirM82ucyktkmbUQ4SkzRUqZJ8ZsvKsYg0a2x4Tktjx
MavQWJ5UsSf10ZutnaWlSqU+YYSk+8q9nrO6i/SMxejoqAlyCtqNlNfYMWX2V2t29erVdQH21atX
peqmO5nm7du3ZjKLuz1WZ5pd51QffCfHVtRDhKTNFSpknxmy8qxiDRrbHhOSlPOHrEJT8qSKPanL
+Pi4GYxUnqlyayIDQtJ95V7TUN1pv3aQ2AbqquU1pYym7q+6507/1f+1vUzdtC+Hqt8Kxqrf/n3H
6kwz65xaVXaGXCvrIUJCEAHKAGnuU/R7l1ALrdVlgNJAhQLKAGnuAzQL7fnz5wgJFQooA6QZqqHu
ts2bNyMkVCigDJBm6L0yQGmgQgFlgDQDQkKFAsoAaQaEhAoFlAHSDAgJmQmUgX5KU9nfCgFCAgSR
ttPOqYqUgWpCUuRrQbmn/iAkfRZEurVSx6w+3XV+ejk42fsuCr79+tdw8OmS5z0o9afZ6URIeBtt
CzGrTz/vel1IaJH0ppBQfxCSrgwiWjJba/a4aKVNLQ5nKWs1GrLu9e8hZqcZst0NXSePomvF3l7z
tutfLSpX1RIYIWm+kJRNc6OWyB8/fqT+tKj+uOcpe58ISQeCiFzitNKmi9zYVPhFFavRkHWvv6po
zE4zZLsbuo5PyrXK5J0+yyOiqiUwQtL5NDfDEpn605r6U7R6cew+EZIOVSg5xemtyvoD6N/h4eHa
A65iNRqy7nXvoYqdpnt86Do+KdcqWxEasQRGSLozzWUtkak/rak/Ve8TIelghVq7dm3Ng0FvaHaZ
avs2UNZqNGTdG3Nei9lput+FrhMKEKnXKtvHW8aeFCHpjjQ3wxKZ+tP8+lP1PhGSDlYoWeyqf1io
D1L2sKEClHLOIuveMhafKd4kRdcJFfqygaJKRegG0UBIwmluliUy9ae1QlLmPhGSDgcRDXqpb1fN
cpcqVqMuvnWvb+FZ1k6z6Hr+dXwate4sWxHK2q0iJO1PczMtkak/rRWS1PtESDocRDQAODQ0NGNA
uIrVaMi61x8sLGun6X4Xuo5Po9admqmiPl1bmRq1BEZIOp/mZloiU3+aW3+q3idC0uEg8v79e/OG
Ic9ln7JWoyHr3qLpi6l2mu53oevk0Yh1pwKE0m/fwpphCYyQdDbNzbREpv40t/40cp8ICUEEKAOk
GVpaBigNVCigDJBmQEioUEAZIM2AkFChgDJAmgEhITOBMkCaASEBKhRQBkgzICRUKKAMkGZASKhQ
QBkgzYCQUKGAMkCae51+sYNGSKhQCBZlgHLfIXw7W59Pnz4Z/xT9Ml37bt26Nfvw4UNtu/5vjb60
z7Zt23J/qS8jL3d5lDz8VQKEzn3//n2EhAoFlAHS3KvpHBkZMWtk2fWytOSJxMQiMy4t0263X758
2Szv4iJzri1btgSv9fbtW7OemL+PvFusCyRC0ocFLc/u0xYs3yI0xV7Uv06R1ahWStUaRcKuvPr4
8WPz+d27dzNWUgWC6iCX+5A1cMzuVsyePbvOZEui4LZi1q9fbxavdLdv3Lix7hwSCAlFqBxpqfdX
r17l7qNrPHz4ECHp1wrl232GLEJj9qLudULn2bFjR3bjxg3z/2vXrplCrf3tZ9fKExCSQS/3ZayB
U5AIusdrYUnfzVHfuVivlaJrnTx50txX0T7yflHLCCHp0wrl216GLEJj9qKplrMyFlLlFHv27DEu
dfoTu3btMpUPEBLKfTExt8UQ6rqSO6Qlb3n2oiXb866lVpVaHKF97HL9CEmfVqi8AhSyCA3Zi6Za
zqpi6i1LqHtApjWqqELNdjX7ASGh3H8h1Ro4hrrWNJiu1lKeKJUVEnX9qXtQXXOh+5G4qqsPIRmQ
ChWzCA3Zi5axnFW/rWaG2IoksyG9tdjPgJBQ7rNaSybVGjiExEPda/6MLL8bq+i7vGupJWW762L3
U8WYCiHp0QqVYhVbZC9axnJWM0B2795da9rbZr79DAgJ5f5LUE+1Bg61RNStltfq0SC5pghbNLGg
yNUzzzq36M8XMVokA1ShUqxii+xFy1jOyr5zzpw5ZlqiGB0dNbNSbPcBICSU+y8CFrIG9u1sfTRb
Sl1zbveTiyYNuPeslo+mA1ctR3n7PH36lDGSQapQImYVW2QvWsZyVoXbnf745MkT81nTBwEhodx/
IWYN7NvZ+qjbLNRi0P2tW7eudo5NmzbV/WCxGUIiwWTWFkEEKAOkGSqzZs0aM2EAIaFCAWWANENp
1B2nadGdLgOUBioUUAZIc4+yefNm1tqiQgFlgDRD75cBSgMVCigDpBkQEioUUAZIMyAkVCigDJBm
QEjITKAMkGZASIAKBZQB0gwICRUKKAOkGRASKhRQBkgzICRUKKAMkGZASIAKBZQB0gwICRUKKAOk
GRASKhRQBkgzICRUKKAMkGZASIBKBTx70g45z56SQKUCnjl5AA09c0pBkzOYv8H5A8o95R4hAd5K
AaAZMYAsAIQEABASQEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBIAAAhAYQEABASAIQEABAS
QEgAACEBhAQAEBJASAAAIQFASAAAIQGEBAAQEkBIAAAhAYQEABASAIQEABASQEgAACEBhAQAEBJA
SAAAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQEgCE
BAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQEqAQISQACAkAQgIACAkg
JNCx58/f4PwhJICQAM8emv7MKQVAMAGeOzT07CkJQEABnjk0VAYoDUBQAZ45ICRAUAGeOSAkQFAB
njkgJECBAp45ICQABBXgmQNCAgQV4Jk3l+fPn/PQERIgqEC7n/n169cL9/v8+XO2aNGinknvN998
07Jz3759O/v666+z5cuXF+5z5MiR7Pvvv8++/fbbbOvWrdm7d+/qtl+9ejUbHh4297ly5crs2bNn
CAkgJNDbz/zt27fZjz/+mLvfP//8k23ZsqWnyk0r71UicufOncLtZ86cyc6fP5/9+++/5u/kyZMm
by2PHz/OVq1alb1588Zsv3LlSrZkyRKEBBAS6O1nvmHDhuzVq1e5+ykISmhSyo32efToUTZ37txs
xYoVte9//vnnbNasWdl3332XHTx4cMYxY2Nj2Zw5c8z2AwcOmBaQ/4avbXrD1/38/vvvhdfMW2vK
tiK++uqr7IcffsgePHgQTEfR9VLWsVq4cGH26dOnGeJj2b59uxGbTpYBIgAgJNDUZ643Zr1BF+13
79695HKjfSQEetP+448/zHe//vprdunSJfOdWjfq1jl9+nTdMeomUrDWPhKdkZGR2vZffvml7g1f
59u5c2fwmv69uq2Iu3fvmmBfRMr1Uvnrr79MeiQelgULFnRkDAchAYQEWvLM1c2yfv36pLKRKiRu
a0FIJBSQ/bd295iJiYnaZ73Nz58/v/Z56dKl2d9//137rP+r9RK6pn+vaq1oDCiFlOulsG3bNtOq
0d/Tp0/rRE1itnjx4toYyocPHxASQEig9575x48fTVeQOxDcDCHxUeD0u4TUxeQe4wuN2xXk7pu3
PXd1W+87BW7b8jlx4kQwDVWuF0LdZOpOc4/ft2+faa3YFo/bYkFIACGBnnnmu3btym7cuJFcNqoK
SV5gThGfvP/nBsUEIREaR7l165YZDzp8+HDh/VS5Xgh157nn1Gwut8UjMWnlLDOEBBASaNkzL22G
VFFI9Daut+/QMe70V3XzKNi6x/tdTW7gTRUSi64V2l7lei7qRvvzzz/rjne7xjZu3Fi3v4REXVwI
CSAk0BfPvBUtEg1enzp1qjZ4rc/udFgdo88Kvtp+9OhRM93YPf7cuXO14y9cuFD3m5a8ayowa9zE
CoKm12rmltCge16ro5HruagrS91n9nilR38WjdXoz27XtfRbEoQEEBJASAL7HDt2zLQy9Gb/008/
1WZX2WNu3ryZzZs3z7zNHzp0aMbgs52Oqz/NoHr9+nXwmpoVpmvZloS6tTSIrm42iYgVlZAYlLme
i7qyNItM19bxOpePxENptfmhqdcICSAkwDOnPPZMGSDHgYoLCAkgJEDFBZ65pR0zlgAhAYQEeOaA
kABBBXjmgJAAQQV45oCQABBUeOZAGaA0AEEFeOaAkABBBbr/mWNXi5AAICTQ0DNvxrTcRhY7BIQE
EBLo8WfejHJCWUNIgKACff7Miyxo81YDjq2yqwUI9+/fb9bUGhoaMk6IoRZJyH431Rp3eHg4e//+
vfm/PNB1DZl1CfmsaHvK9apYBCMkQFABnnkWtqD1j4kJydmzZ2ur/Gol3zVr1hQKScx+N9Uad8eO
HTVPlWvXrpnuOJ3bfrYWuSl2v2UtghESIKgAzzwLW9CWFRK9ybs+Hk+ePCkUkpj9bqo17tjYmHEb
FHv27DFOg9ZtUMZdCv4p16tiEYyQAEEFeOZZ2IK2rJD4Hh8KwkVCErPfTbXGffnyZbZs2TLzf3WB
ybTK+r3LE13dXSnXq2IRjJAAQQV45v9RZEHbqJDMCF7O/1MCcqo17uzZs01XmhWQBQsWZC9evKh9
TrleFYtghAQIKsAz9/AtaGNCYge3LatWrarr2lIwLzpfzH43dF8+clPcvXt3rUvLdm/ZzynXq2IR
jJAAQQV45lnYgta3q3UHwN++fWuc/dzzXrlyJTt58mRtsH3dunWFQhKz3y1jjSu3QXmiyxJXjI6O
mnvXQHnq9apYBCMkQFABnnkWtqD17WptQNe+8jDXvv55z5w5Y4K6psxq1lOohROy3y1jjfvw4cO6
ab92kN+3r43Z/eYROgYhAYIK8MxhYMsApQEIKsAzB4QECCrAMweEBAgqwDMHhAQoUMAzB4QEgKAC
PHNASICgAjxzQEiAoAI8c0BIgKACPHNASAAIKtDxZ97otTp9fL/WJ4QEEBJASBAShAQQEujOZ15k
J7tt27bs/v37tc9a72rjxo3m/1rIUe6DWhxRvh8TExP5AatBe97Q/aUe7zI5OWnWzNJ9aw0v3fvN
mzfr7k2LPWopervOl12ossr1EBJASKDvn3nITlYLFK5cudJs+/z5s3EHlJGUOH78eM3BUJ4hWq23
ipDE7Hljdrex431kgqVViu2KvufPnzdujO69SWisW6K/8nDZ6yEkgJBA3z/zmJ2sArmCp4L3yMhI
7XsJh39cFSGJ2fPG7i92fAq+U6JvuVvmfhESQEhg4J55ip2sgrmWhn///n3dcUkBq0F73tj9xY7P
Q0vUq0Ul4ystVd/M+0VIACGBgXvmKXaymzZtMi2QdgiJvz12f7HjfcbGxkxaLl68mN27d8903zXz
fhESQEhg4J55zE5WroMao1Dgdbu2ZGxVpWurrD1v7P5ix/tokNw9n38/MSEpez2EBBAS6PtnHrKT
1dv66tWr64K6dR1U19Ddu3fN/zWzq2iwvVF73pjdbex4H83GsrO0JAKaTFBGSMpeDyEBhAQG4pkX
2clu3bq1bvqv/q/tQrO4tF1CoXEGDTrnXatRe97Q/aUe7zI+Pm4G63VPEj/NPCsjJGWvh5AAQgI8
c+jLMkBpAIIK8MwBIQGCCvDMASEBggrwzAEhAQoU8MwBIQEgqADPHBASIKgAzxwQEiCoAM8cEBIg
qADPHBASAIIK8MzJd4QEWluQ/D8goAEtEgCEBCoLib6XP4dcAmXaZAnZ28bsarWell1fSws9Pnjw
oO74I0eOmPPqeC3A6BpJxaxuY+cuc59V0p6H9tdaYLNnzzaOi/7aXR8/fszmz59v1idz0SrCSkPK
dWP5gpBAx8QEEBJ9f+DAAbOarV0MMWZvG7OrdYOcVgh2HQ21eq/2t8fqWvJ+d+8nZHUbOrdPiq1u
2bT7aN/Dhw/XVgPWasl5i0Du27fPpN1FzpMSj5TrxvIFIQGEBDoqJL61bMzeNg/XgErB2vq5+2il
YNfPQ//XSrqh+3HvPXTuFGK2umXTLn+Sd+/e1T771rv2//K6V6vEnlv/Dg8P164fu24sXxASQEig
o0Lik2K/G7KrVUtBnxUcT5w4URjI3euF7if13HmUtdVNSbuLlrZ38a133f+vXbvWtDqEWkp2Sf6U
66Ysb4+QAEICXSMkMXvbmF2tDeC3bt3KNmzYYLp+8kQjN8AlBMyic5e9zyppD4lgTEh0zxqnERob
0T2lXhchgZ4JKoCQ2CAXsreN2dW6PHv2bIZ1rt+15b7VlwmY/rnL3meVtPvIYVFjI5anT58Gr6HB
co2NqFurzHUREkBIoKeEJGZvG7OrVStAs6uEPyisc507d652bnnCyzkxNWCGzu1TxVY3lnYff7Bd
+4auoQH0oaGhGQP4sesiJD3SzcNf//8hJOnfh+xtY3a16nrSeISdpmoDv8VO/9WfZmy9fv06OWDG
zu1SxVY3lvY85OGuabsSCM2+CrWw3r9/b7a7rZiU6yIkvJUDz5y0Dwj6rYhmZ3V7GaA0UKmAZ0+6
uwRNXdYguv39h1pboQkACAkVCigDpBnq0Mwr/Spe3VH6ZfuhQ4eMoCAkVCigDJBm6OsyQGmgQgFl
gDQDQkKFAsoAaQaEhAoFlAHSDAgJmQmUAdIMCAlQoXJ4/vx5V52HMtCfae7X8oGQQMMVSj8ocpds
sGgdnNivpTWHXL9MlZHO1q1b65aX9rEGPVrFtHQhiKTBX5G0Ks06D0LSvWluJC/88kGrByFBSKbQ
/O8tW7bk7qMfHUkcijhz5kydYY+WTQit0VPW4ayMkDSrQvdrYEBIWnNOhAQhoUJNocD/9u3b3H0k
DFpsrgit6fPp06cZYlF0D36rJraWTqqQFLWYimw8t23blt2/f7+upbRx48a+XqcKISkuY6l2rkVl
WHUkdHxZG1tASHouiFh/gLx91FJZv369qQTqvlI3VhHqBlOFkZlOI29zVYQkb3vIxlMLw2lVVG1T
t54EUW5utEgGU0jK2LnmleFNmzYVHl/WxhYQkp4OInn7zJs3L7t8+bL5vyrC6OiocV7z0Ru+XdlU
3gTdICQxG09VcHkkqFKPjIz0fcBFSIrLWBk717wyHDq+ioUvICR9JSQ+qhASlyLUYpFZTTcISYp9
qCq5FqDTMtcIyeAKSZm8KluGy9rYAkLS90IiQpVATfey3QJlhaRoHMM/V0plVZeEPBsQEoSkVUKC
aCAkAy8kelv/+PFj7bMsQq3/spg7d26dWY2265iqlTBkC1q2RRKz8ZRLnfqu5W1N1xZC0iohKWtj
CwhJ3wmJlofWALqd3qvxBAVgi7qyTpw4Udt+9OhR85d6DXeGi2aOadCzqpDodyzqq7be2CEbTw22
r169uq6yv3r1Kvc8CAlCEipnsePL2tgCQtJ3QqIZTXv37q35DqhCuKgr68CBA2a7BtpDs7ryrmFn
uKj5rx9EahpuVSGRyOk+3B+MFdl46rcx7vRf/V/bi86DkCAkReUs5fiyNraAkBBEgDJAmgEhoUIB
ZYA0A0ICVChASCj3lHuEhAoFlAHSDAgJFQooA6QZEBIqFFAGSDMgJGQmFYoygJAAQgJUKKAMkGZA
SPqiQmE1ShkgzZ2hnVWvX6o5QtKlFaqq1ShvhwTVbkqz1umUx9TcuVqqJ8uWLs2yq1f947srPc1Y
bCE1Tf61OpEXt29PP5tEZ26EpJeCSNVzISQISbekWeuQrliRZZcuaaHR6e8eP86y4eEsGxvrXiFp
5/10Q9olIiWcuRGSTlWoyclJs/aPFqLTmlda2ffmzZt1xz169Mis8rtiqubF7HK1kN3OnTvN+XSu
iYmJwnsI2Y9qzS27BpcWVHzw4EHu/Q9P1Xy7BLxdOfixIsIU7969M9tTruenM+UYhKR30yxvtl9+
mfm9io7z+E0wldP0ggVaDn5mYJuqPpmWaJsq7mabFsZ2qo85fqpYmVaPPW/sGAnbVBUy27XNViGd
y/37UkazqTKaTZXR6RaWLwb+9d1j7Ru/0iYbIVvN8q7lHld0j6FzFqHl+XTvOpfWsrQeYUXpRUi6
sEItW7Ysu3LlSm1l0vPnz5tg6h6nRRm1zS40F1pGW+6J169fN/+/deuW8frI2y9mP+quCnz37t1C
R7kdO3ZkN27cMP+/du2a6XbTue1niVrK9fLS2W8WqQjJF1Qs375NeyvftOlLcFORdO12pqrPVP2R
4dv031T1yZzqY46fKlZmm12nMXaMRO6/KjRVh6bvtaiVoKKuVpXOM1VETdecW0Tzru+ewxXGqWqW
udXMv5b7OXSPoXP6SMyVfpsXSs9/VbZprSKEpENBxDXiSbEhdT9LOHxb0bz9YvajEjMrSCHGxsay
ffv2mf/v2bPH+MVbz/hdu3aZ4J9yvbx09ptFKkJSH+xSu3e8YhENbq6PVd7xsWMUlAuq0Ixra+zA
39cXg9D9S8CKqllISEL3GDqnj8alXLcG/d+1M0JIeiiIqEtHLQkF4KVTT7bsEtu+rWjKPcTsR9UK
0XcK5vI7KeLly5emVSXUBfbs2bNs/vz55rO61tTdlXK9vHT2m0UqQvIFdaOkCknsO3Ud6Q1d7y8K
jO72oiwPHRMSOf982tfvAvKFLHQOtRj0WYLkV7OQkITuMXTOkIDmnRsh6ZEKpTd6tSLkEnjv3j3T
rdMOIUkJyBI4dY9t2LAhO3z4cOF+8kmRS6MVkAULFmQvXryofU65Xl46+80iFSGp75JyjD1rqHvI
H+MIBWINzOvtfKr6TNWf6e6jmJDEjikjJLEimiqE6p6aqmaZW82qCknonCktwxQhRki6rELJbMe1
AQ1Z3aYIicypUrq2ytiPqpURCoJbtmzJdu/eXevSst1b9nPK9fLO328WqQjJF/SmrLEFn8uXs8wx
zowG4qnqk7lFRA3gWCCMHTNVhZK7tjSYHSqiKULypZ6F7z31HkPnnFnHZnZtudOOEZIeqVB6e7ez
tPQWv3LlyqiQhKxG1UWmbikh18GiwfaY/aiO08wtYV0Uizh37pzxibcWwKOjo+YeLzmRIna9vHT2
m0UqQvKFDx+mu5RUZD59mg6KmrMx1bjNxsfTA7Fmc9kWzFT1mao/cSGJHaMur/+qUCYTT3cgW11y
GvOwwVeD1TIttYPV+uwW0dj969z/VbMZEwn8a6XeY+icM+vY9Kw4e/96HhIphKTHKtT4VK3RALIC
tYK3BrhjQhKyGpU1r2xsdT6Ntzx58qTwXCH7UXVr6Xh1L+lcVlTyePjwYd20X11Tn60He8r1ivKn
nyxSEZJ6NGtrx47pqafqItL0WMd9OSkQS3Q0uK1gqQCqQeaYkMSOmapCU3Xoy48knSpkZmSp2rlv
7VNF1LRy9J2mFbtFNHb/6oLSNezUZrea+ddKvcfQOfOw03/1pxlbr18jJAQRoAyQZujSMkBpoEIB
ZaApafZnOfHXO38ICUEEKAOkGWiRUKGAMkCaASEhM4EyQJoBIQEqFFAGSDMgJFQooAyQZkBIqFBA
GeiGNIXSRbkHhIQgApSBJCHJ88mh3KfR787ZCAlBpOVptwZayxvx8uyxfCgKvv3617787c3jm23f
232ukggJQtLitLsGWpQBWiSDKCTNWYaEFslAB5GY1W7I8jZmh1vVSreR82pxxf3795v1sYaGhoyx
VVHai4LPkSNHzLmVJ1qk0TW8KrLkRUg6KyRV0lxkUbttW/2aW1orauPG6f+HLGZjb+Xud1qgcKqY
mjWypoqpcTb0jwlZ6KYcX1/fqlnqVrn3Mukoa8uLkHRpEIlZ7YYsb0PbGrHSbeS8Z8+era3YK4+S
NWvWlAo0WuFXeWDzQ9fb6Xh/5lnyIiS9l+aQRa0eq1bk1TYtTqji9/Ll9LZUG9xYMJ4qprVVe+WL
MlVM67bHLHRjx89seVez1K1y72XSUcaWFyHpsSDiGjqFLG9D2xqx0m3kvGol/O0YHNiVgFPzRSsO
u8fr/3Mc7888S16EpPfSHLOoVQBUwFTQGxn58n2qDW4sGKsx6/pwaPVcd3vs/mLHz6xT1Sx1q9x7
mXSUseVFSLo8iISsdkOWt6FtjVjpNnJe37dEolNGSPJcEd1z9nIwRkjq34RDFrU2COod4v37+uOK
r5UejP3zKNj620P3Fzvep6qlbpV7L5OOMra8CEkXV6iY1a4VmiLL26JtjVrpVj1vngFWGSGJHY+Q
9EeaU1yUN22aboG0Q0j87bH7ix2fX9/KW+pWufcy6QjdF0LSQxUqZrXrErK89bc1y0q37HlXrVpV
1zUl18cyQqLz+11b3zjzIxGS/khzzKJWTn3q25evutu1lWqD61/Wt9OdKqZ13UNySnS3x+4vdny4
vqVb6la59zLpCN0XQtJDFSpmtRuyvA1ta8RKt5HzauLAyZMna4Pt69atKz3YLutee37Z9y5yvD8R
kv5Ic8iiVoPtrm+7gqE12wxZzPpv7XYQWU6Mci50t08V06ly+mXAeqqY1m2PWejGjvcpY6nb6L2X
SUcZW16EpIsrVMxqN2R5G7PDrWql28h5xZkzZ8wAuaYIa9ZV2emhdvqv/jRj67Xj/YmQ9E+aiyxq
ZSHrTv/V/7VdhCxm3UvZoKiuHb2HqAj7tzJVTM0YjKbGanDf3x6y0E053u8+SrXUbfTey6SjrC0v
QkIQAcoAaYaOlgFKAxUKKANNSTOWtf1rq4uQEESAMkCagRYJFQooA6QZEBIqFFAGSDMgJECFAsoA
5R4QEioUUAZIMyAkVCigDJBmQEioUF3D8373A6UMtDXNlCeEBNoYRKouWFjmuKJ93f9/0ww/UMoA
aa5YnsqUYUBICCItqCBVBYiKipC0Ks1l8wIhQUggi1mOFlvXhloWOk5rXs2ePdu4CoZaFjKD0rpV
sq/duHGjMZxKbZH4/iNydfSRW+L8+fOzjx8/8rAJdsE051ksxyyny5ThWJ0ChKTvgkjMurYoyOsY
+YTYVXZXr14dFAQt7/7u3Tuz/40bN7Jdu3YlC4n/f63o6/u463727t3Lg0ZIKrVIYpbTZcpwrE4B
QtJ3FSpmXVsUzG2lsviWtv7/3bc3XU/XrSok1vDKRRa7T58+5UEjJJWEJA/XRK1MGY7VKUBI+q5C
xaxrUwe/fUvb2GB7kX1t6jnko/Ly5cuaiElIACFpREhCltNlynCsTgFC0ncVKlbAiypTzBs9VgmL
XAdTzyHzqn379pn/q996dHSUh4yQVBaSmOV0mTKMaCAkA1ehYta1RZVJTooaG7GoWykkArb1IGRf
q4HxRoRE19agp7rXNKj5WY5DgJBUFJKY5XSZMlzGZhoQkr6oUDHr2tTBdh0TEoH169dn79+/N/vr
emUH2yUamjXj+qmrJbJ58+bswIEDPGCEpFSa/fIUs5wuU4ZjdQoQkr4MIiHr2lj3kloDQ0NDZqZK
qLtK27Wv9lGFVCUuIySa9aJj3WtMTEyYffiVMkJSNs1+eYpZTpcpw7E6NajPAiEhiERR15Lb1G8H
qpx6kwSEhDQDQtKDFWrOnDlmGq6dK3/kyBHT1dUudF299Z04cYKHS1AlzYCQ9GKF0swWTblV012/
bD906JARlHahPm51LzDITlAlzYCQUKGAMkCaASGhQgFlgDQDQkKFAsoAaQaEBKhQQBkgzYCQUKGA
MkCaASGhQgFlgDQDQkKFAsoAaQaEBKhQQBmg3ANCQoUCygBpBoSECgWUAdIMCAkVCigDpBkQEqBC
AUICCAlQoYAyQJoBIaFSAc+etEOnnj0lgUoFPHPyABp65pSCJmcwf4PzB5R7yj1CAryVAkAzYgBZ
AAgJACAkgJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkAAgJACAkgJAAAEIC
CAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkAAgJACAkgJAAAEICCAkAICSAkAAAQgII
CQAgJAAICQAgJICQAABCAggJACAkgJAAAEICgJAAAEICCAkAICSAkAAAQgIICQAgJAAICQAgJICQ
AABCAl0nIP4fACAkAAgJACAk0BkxAQCEBAAhAQCEBBASAEBIACEBAIQEBk1MAAAhAUBIAAAh6YaA
yt/g/AEAQsJbOfDMARASAgrw7AEQEgIJUAYAEBKCCFAGABASIIgAZQAAISGIAGUAACEhiABlAAAh
IYgAZQAAIQGCSAHPnz/noSMkAAhJO4LIx48fs507d2bffPNNNmfOnOzgwYPZhw8f6va5evVqNjw8
bPZZuXJl9uzZs65Pr+61Vdy+fTv7+uuvs+XLl+du/+uvv4K/MFf+/vTTT9m3336bfffdd9m2bduy
P//8EyEBQEh6U0j27t2bnT59Ovv333/N37lz57ItW7bUtj9+/DhbtWpV9ubNG7P9ypUr2ZIlSwb6
7VsicufOncLtt27dyrZu3Vq4/eeff85OnDhRy/PLly9nx44dQ0gAEJLeDKx6c1cws+j/33//fe3z
9u3bszNnzpS6zqNHj7K5c+dmK1asqAues2bNMm/gavX4x4yNjZkWkbYfOHAg+/z5c90+R44cMdv0
Fv/jjz9mv//+e+E181oCthXx1VdfZT/88EP24MGDYDqKrpeyjtXJkyeNIBexfv367MWLF7XP//zz
T7Zx40aEBAAh6Q8h+fvvv+u6hRYsWFBqvEHXkRDonH/88Yf57tdff80uXbpkvlPQVFeZWkHuMeom
UrDWPhKdkZGR2vZffvklO3/+fO0NXudTd1zomn563VbE3bt3s4ULFxamIeV6IdSik1hIOCXKEiUX
fefmuf0OIQFASHpSSBQg9faswKZWgAK43trdAKzAu3jxYvN2ri4bfwzFv47bWhASCT9wuoFcx0xM
TNQ+f/r0KZs/f37t89KlS43AuWKn1kvomn561Vq5fv16Ul6lXC/EvHnzTHeVbeGNjo5mx48fr8tT
n7zvEBIAhKQnhESioMFeBbJFixYZ0XBbJDpu3759ZgDZvp2ru6vMdXRuv0vIFSt99oXGDazuvnnb
867pf6d02ZaPxidCVLleCKVN4pJ6foQEACHpKSHxUd/90NBQXZeL+3auoBiaEZV3nbzAmSI+oSDr
HpMiJELjKBoI37BhQ3b48OHC+6lyvRhuHuR1Y9G1BYCQ9I2Q3Lhxo67F4Q8CS0jUxVXmOhrcVosm
dIw7pVitJDew6ni/q8lvNZVJr64V2l7lei7qBtO0avd4dQ1aJGTqvrOoS1ED+ggJAELSk0KiqbwS
DzE5OWmC3JMnT2rbNa6gP3d6sH5LUuY6Grw+depU7Rz67AZOHaPP+i2Fth89erRuCrL2t+M4+rtw
4YLphgtdU2KncRMrCEqnZm4JDbqHupKqXM/l0KFDZsKAPV4TC3QOi7a5+XHx4sVodxtCAoCQdK2Q
SDQ0ZdaOkeQNSCuoarBab+X6Id2rV69KX0e/k1Arw57Dzq6yx9y8edOMI+g6CsT+gL6djqs/TRB4
/fp18JoK3rqWbUmoW0uD6OpiUlqtqBRR9nouamHo9zm69uzZs41ouCjt69atq93fpk2bghMYEBIA
hKSrhYR7owwAICSAkAD5DICQDHYQaeW6WICQACAkBBGgDAAgJAQRoAwAICQEEaAMACAkBBGgDAAg
JEAQAcoAAELSO0EEu1rKAABCAg0FkWZMy210sUNASAAQkh4OIs0IPAQvhAQAIenzIFJkQZtnKRtb
ZVcLEO7fv9+sqaWl6OWEGGqRhOx3y1jjarFJrd+lhRp1jFba1dpd7nXL2v8iJAAICSQGkZAFrX9M
TEjOnj1bW9VWK/muWbOmUEhi9rtlrHGXLVuWXblypbaarmxyJRrudcva/yIkAAgJJAaRkAVtWSHR
277r46GVhYuEJGa/W8YaNw/fgbGs/S9CAoCQQGIQCVnQlhUS3+NDgbpISGL2u2WscYW6ruSLLlMu
LRcfG+SPXR8hAUBIoEQQKbKgbVRI/O3u/1OCdqo17tjYmDGukkHUvXv3TPdVTEj6XTQQEgCEpCNB
xLegjQnJmzdv6r5btWpVXdeW/N+Lzhez3w3dl48G991z+fdVxf4XIQFASCAxiIQsaH27WncA/O3b
t2amlHteDXifPHmyNtguF8CigB6z3y1jjbtgwYLaLC2Jl6yAY0ISuz5CAoCQQGIQCVnQ+na1NqBr
X9nyal//vGfOnMnmzJljptVqZlQooIfsd8tY446Pj5uBcu0nAdIgfcoPIUPXR0gAEBIgiABlAAAh
IYgAZQAAISGIAGUAACEhiABlAAAhAYIIUAaAOkAWEESAMgCAkBBEgDIAgJAQRIAyAICQEEQgmX6y
G6YMAEICLQkizQoujZ6nlcc3cm7fbriXgzFCAggJdHUQ6WYhaeZ5ERIAhAQhCXyv/8s1UIsg2jWu
7CKNQos37ty50yzmKDvbiYmJwvOErhOz5BUhG9yU46um0T8uz2743LlzweO71cIXIQGEBNoiJFq8
0LoJ+qvuyjjKuhbKJ0QLJFYRkpglb8wGN3Z8I2lMaZFs2rSp8PhutvBFSAAhgbYIiW9J626XcPj2
tFWEJGbJG7PBjR3fSBpThCR0fDdb+CIkgJBAW4QktD31zb1RS96YDW7s+EbuLUVIYmnrVgtfhAQQ
EuhbIfG3xwJv7PhOCkk3W/giJICQQMeFRGZWVbq2ylryxmxwY8d3Uki62cIXIQGEBDouJBpsv3v3
rvn//fv3CwfbG7Xkjdngxo5vppD4dsOx47vZwhchAYQEOi4knz9/zrZu3WqEQja4GuTO269RS14R
s8GNHd8sIfHthlOO71YLX4QEEBIgiABlAAAhIYgAZQAAISGIAGUAACEhiABlAAAhAYIIUAYAEBKC
CFAGABASgghQBgAQEoIIUAYAEBLouSBS1sK2nyxvKQMACAlBpOJ13f/7FrYx+snyFiEBQEgIIk24
btn7IQgiJAAISRcHkSNHjpi1oebOnZuNjY2VWptqcnLSrCelxQ21vpYseG/evBlskeRZ2IbOU2R5
+/Hjx2z+/PlmDTAXLbCoVXgt3Wp9i5AAICR9EURkW2tX0tXignIfLCMky5YtM6vx2tVuz58/bwQp
JCR55y1zHvfzvn37zAq7fpokHqKbrW8REgCEpC+CiKxh3Tf6iYmJhlbLFa65U6qQlDmP+/nly5em
VWJ9UvTv8PBwzQ63m61vERIAhKQvgkjMtjZFSB49emS8SrZv326Wl08Rj7zzpp7H/7x27VrT6hBq
1aiLzE1ft1rfIiQACElfCklKwHe/05iKDK4uXryY3bt3z3SPVRGSMufxP9+6dcuMqQiNjej4vFYN
ZYBqBAgJtCCIrF69Ovvw4UPts29bG7PN1SC9ay3rb08VkjLnyfu8YMECMzaibi2Xbra+RUgAEJK+
CCI3btwws7aKbGtjtrkK4HZ2lURo5cqVSeLhW9jGzhOzvNUA+tDQ0IyB9G62vkVIABCSvgkimtmk
GVLz5s0zwbyMbe74+LgZvNY+6pq6fv16kpD4Frax88Qsb9+/f2+2SQx9utX6FiEBQEj6NogQcCgD
AAgJICTAcwVASDoXRMqugwUICQBCQhABygAAQgIEEaAMACAkBBGgDAAgJAQRoAwAICQEEaAMACAk
0OkggjUuZQAAISGINEQ7rXEbOffdu3ezTZs21T5/+vTJeJzIBEtp2Lp1a91aZJQBAIQEIenQ9bo1
iMmvRJ4mlpGRkezChQu1tbm0DpnEhDIAgJCQgQVBRGtn2bW0tFLugwcPstevXxvHQh85DMpESha3
Op88QLTYoo51F3csssY9d+5c7v6WkCVu3n3mpS20n8/Dhw+z9evX1303e/bsOiMspblffqCJkABC
Ai0JIm5AVzePdQ/UKsB+EJZw7N27t3Y+LYBonQjt4o6hFom6kIr2j1niFt2nf63Qfj5qfcgHJYRW
G3YtfxESAIQEIfFQkNRKuz4yi9qwYUPdd/Jzf/r0ae18VhTyrpEnJKH9Y5a4Rffpnye0n4+WqteS
9SEuX75sXBsREgCEhAwsCCJ6a9c2BfITJ07UbVM3lB0/ePLkiRGS0PnKGFHltSRClrih+3TPE9rP
Rx4nvni5aGn6bdu2mRYSQgKAkJCBgSAir3TbAjl8+HDt+5MnT5oZTGLnzp3Z6Ohoy4QkxRK36D7z
POTz9vMJXVPisWPHjlx/E4QEACFBSAp49uxZ3X4Konprf/funRkE//z5c8uEpIwlrn+fRWnz90tt
kaglIgGV3e+glQEAhARKBxG5EWqmk/AHwG1LZPPmzdmBAwdKCUPMGtf/LmaJG7pP9zyx9LhojERd
di6aybV27VojnoP4MgGAkEDpIKJuoKVLl9am5NogbJmYmDDH+r9UjwlDzBo377uQJW7oPt3zxNLj
ollbmi3mounN/lhNvwRghAQQEuhIEFEw16B7PyKRdFs9lAEAhASaHETUxaRWQmz2Uy+j2V2Dsi4Y
QgIICbQ9iGicQ7/8dgfZ+w2No2gMiDIAgJAAQQQoAwAICUEEKAMACAlBBCgDAAgJQQQoAwAICRBE
gDIAgJB0Pohgl0sZAEBIoKEg0gxDp5Q1sZqBfsCu1VB0Cfv37bdZ5vtaDXIsRUgAIYG2B5FmBJ52
BC/5WEk0PMPF7ObNLPv+e/2CHSFBSAAQkpYFkSJr2iK73NB59Uv4/fv3m/WyhoaGjMthqEVS1VrX
Ry2RoiW1JCauSaJ7C5OTWfbTT9MipHMsXjy9v93P/3N/tzh161P3nk3de5Z5t272vXRJfi5aqn76
3L7IxY5/9EgmXTITQ0gAEJIuF5JUC9sUITl79mxtBV8tQb9mzZpCIWnEWnfmPYTT7vpSufvKlv7K
FQng9N/589PB2+fTp2mRsQaPWudRQqFjdO6pW8+cWzfXkEDZ/ZUMdxHilOO12LK2O+tWIiQACEl3
CkmqhW2KkMhB0S4bL7REe5GQNGKtW1ZIyuyb53Ulbyw30E/deubbmPitHs9VuO66VY5HSAAQkq4V
klQL2xQh8b0/JBRFQtKItW6KOPjdUkX7qgtJluzbt2fZ0qUzt8vSXYG/vhU38/yuABXdTyPHIyQA
CEnXCsl0ME2zsC0rJP72Zlnrlm1lFAnJ2JiMsLLs4sUsu3dvuhvJP9fq1Vn2+HG81ZIibI0cj5AA
ICRdLSSWmIWt/1lWtO53q1atquvaejH1Ol90vkasdX3yBrMt/viEexrN6HJvQc667nYJjGcM+d+9
1x9XVkiqHI+QACAkXSskIWta3y7XHQB/+/atcTF0z3vlypXs5MmTtcH2devWFQpJI9a6eWKRN/1X
h+t7d0aXmw2aVWVnaakLa+XKL9vfv8+yI0fyrzd1q1P3/mWQXp9df6yYkFQ5HiEBQEi6VkhC1rS+
Xa4N6Np30aJFZl//vGfOnMnmzJljpvVqZlaohVPVWjfU8nDHHfJaKu4tjI9PD3JrP3VxaWzfbt+x
I38K8Jd7n27RKGs0Q8udXRUTkirHIyQACEnXCglQBgAQEhjoIJLXaujHP8oAAEKCkABlAAAhIYgA
ZQAAISGIAGUAACEBgghQBgAQEoIIUAYAEBKCCFAGABASgghQBgAQEmg0iPi/V9CvvPWL6337suzj
x/z9tOiglh7ZujXL/vyz+Jry8dB5ZN6kX3Br/w8fvmzX/62xlPbZti3/fJ8/Z9miRcXXiW0nOCMk
AAhJi4XERwKixXb37y/eT2tE3bgxHfyLGBnJsgsXvqwppbWrJCYWuQRqhXi7/fLl6aVDXGT8tGVL
8Y/yYtsJzggJAELSASGxQqFWQmy//5bhymX27HoDJwV9d//166cXS3S3b9xYfw4tZvj2bfH1Y9td
JicnzZpeWoxS63ctXrw4u2lXbfwvj+TauGDBgtoaX3ecxbpiVsIICQBCgpB4xITEF5sYWkTYtbJV
F5rvFKjvXOQTErrP2HaXZcuWmRWK7YrD58+fN06Mbh5JaH7/z57QX3U4ZiWMkAAgJAjJf+gNfypm
1nlx5HVtyePc7f6Koa4ruRFa8laGL1otvox5VRlcgy3l0e+ex20ZK2GEBAAhGVgh8f+GhqbHM9TV
VLSfuq38AfkQ8vfQeIp7zjynwFYLiZanPz6lZtu3bzfL1IeWufe/i1kJIyQACMnAt0jevZseo3j2
rHlv/ELiIX8Pf0aW341V9F2zhGRsbMwYZl28eDG7d++e8T9pREh6LTgjJICQQMuFxAZ9Tcn97bfm
CIlaImq5yMbWZ8OG6SnCFk3jdZ0Cmy0kGiR37X19q+CYkMSshBESAIQEIXFaJnIOdIN/lRj08GGW
rV07fb48NP3XtZyVR7qmA7dKSDQby87SkgisXLmylJDErIQREgCEBCFxuH9/WgQaEZL588MmTbKX
nYrFZkqw/jZtqv/BYrOFZHx8fEogF5ouKnVxXb9+vZSQiJCVMEICgJAMpJAAZQAAIYHKQQR7WsoA
AEICBBGgDAAgJAQRoAwAICQEEaAMACAkBBGgDAAgJEAQAcoAAEJCEAHKAABCQhABygAAQjJYQeT2
7elVd93fYMj+9sED/xz9khfx354UpdXfp1U2xQgJAELSM0IiA0AFNscI0KAlqRQUJyb6T0hSxDFV
SHyaZVOMkAAgJD0jJHqLVoskD4mJFm/MC4iTk9OrBEuEdI7Fi6f3L3rj37z5y7FarHHWrGl3xYMH
ZwbqS5e0wOL027vO7Ytc7PhHj6adGFesaL+QWKFo1KYYIQFASHpGSGKxxTe3sixbptVwv6zcK7dE
10bXomXiJTLWePDXX6eFQsfo3FevZtnp0/XXkEDZ/SUirg1IyvFydtR2LQrZCSERzbYpRkgAEJKe
FZIy++Y5Hqqbxw30y5fP9Gn3Wz2e223ddasc304haZVNMUICgJD0lJCkDkCrC0ke7Nu3Z9nSpTO3
v3gxHfhd/EF9OwAdu59Gjm+lkLTDphghAUBIerpFUiQkY2NZtmTJtBnVvXvT3Uj+uVavzrLHj+Ot
lhRha+T4KvvnjV+oJaExobxjW2VTjJAAICRdLyR5g9kWf3zCPYVmdDmutcZN0d0ugXG7dyw//FB/
XFkhqXJ8FSHRGNDLl+EWVqttihESAISkJ4SkaPqvZnLpe3dGl3sKzaqys7QUYFeu/LJdPu3q3snj
l1/q7XX12fVpjwlJleOrCMno6LR7o7Ub1iy19eunB/pDxzbLphghAUBIekZI3JaH/+M6X1zcU4yP
TwdM7acuruvXv2zfsSP8Y79jx6ZbNOo+0hu8O7sqJiRVjq8iJEID4sPD02nUv/qccmwzbIoREgCE
pKeEBCgDAAgJVAoi/W61iy0wQgKAkBBEgDIAgJAQRIAyAICQEESAMgCAkABBBCgDgJAAQQQoAwAI
CUEEKAMACAlBBCgDAAgJQeQL8gvRSrTyxtAvxWUB++HDl+36vzWw0j5y9cuziP38OcsWLSq+fmw7
ICQACEmPBpGRkSy7cOHL2lVaI0tiYpEb4YkTX7Zfvjy9RImLFivcsqX4h3Wx7YCQACAkPRxE5I3h
GkUp6LtLqGuhQi3K6G7XcukuWjRRhk5FcSq23WVycnKqBfTTVAvo2+zrr7/OFi9enN20q0P+l45H
jx5lc+fOzVY4Xro/TynerFmzplpN32UHff9dQEgAEJL2BZG//663zNXiiL4job5zkR/J9DXyzxnb
7rJs2bLsypUrU9f81/ydP3/eiIabjgMHDphtf/y3WuOvv/6aXbp0yXz3z5TSXb16NTvt2jICQgKA
kLQviKjrSq6HFtePJPRdilBUjWNfOW5WSsfvnpfu8uXLjYi4LHT9dwEhAUBI2hNE5COiwXTXJjbP
kbDVQqKuq+NTarZ9+/Zs6dKldfeelw51gel79++rmJUiZQAAIYHmBhGJh3xE/BlZfjdW0XfNEpKx
sbFsyZIl2cWLF7N79+6Z7quYkCAaCAkAQtLhIKKWiKYAu65+lg0bpqcIWzSN13UkbLaQfD+lUn85
Xrpvpm4qJiQ//PBD3TGAkAAgJG0MIg8fTrv5ySI2D03/da1t5cWu6cCtEpIFCxbUZmm9ePEiW7ly
ZVRIfvnll6l7PFUboNfnH4vUjjIAgJBAc4PI/PlhoyVNjJJ3uaYE62/TpvofLDZbSMbHx81AucY9
1MV1/fr1qJCIY8eOmdbMN1M3qenDf7j+u4CQACAkBBGgDAAgJF0YRAbFYhYQEgCEhCAClAEAhIQg
ApQBAISEIAKUAQCEhCAClAEAhAQIIkAZAEBICCJAGQBASAgi8B/Pnz+nDAAgJAhJNwSclF+wtyoP
GrneN64TWBcHbIQEEBLoeyFp9T20Kl3+eRESAIRkoIREixzu37/frFM1NDRk3AX9fUM2trdv3zbr
Ymkpd63C++DBg9q2v//+O9u5c6exzZVl7sTERN39+Ja5fotEBlb2+I0bN2ZPnjxJvq+UdIVaQ3Jc
1AKSSpfSd+fOncLj3D/73blz54LHd8IaGCEBhARaEkTO/n975wOZ1/X/8R8zXzNTIaqiqr5UTU18
jYqJ+opQFVNTYWKifn5KVdVXVamqqagRUxFVJSYqqkpE1UyFmKioCVVT8VUhaiYqylTF1Jxf3vfZ
eXqe03vPuff5k+dPXi9iyfPcP+fenn1ez73nPud9/Xp55tyXL1+a/v7+imVjMbZukXz48GFFMqHC
qTTponjw4EEyCaPbHj8y1y/mfX19Zn19PVlmdnbWnDx5Mne7YscVE4kmfrRJjDq+D7PSvDKuSIaG
hjLXb1Y0MCIBRAINKSK6GtCVg0Wf+t1lYzG2uqKwsvCROPx1/SuOUDF3r0C0HbUlb7tixxUTSaht
eUQSWr9Z0cCIBBAJNKSI+J+0VeDcZWMxtroK0Wsqjt96QSVFPsWnFfNQW2Ptih1X0X0XFUlomWZF
AyMSQCSwLSLxl81T4DTWoVtXR48eNRcuXGiYSNyno2Ltih1XM0XSrGhgRAKIBBpSRDQO4d4CUiqh
u2yRGNunT59WrHvgwIHgra1YMV9ZWSn/rTbuVQpXznbFjquZImlWNDAiAUQCDSkiMzMzZmxsrDwo
PTAwULFsLMZW4yB6ckv4g8oabNetL7GwsPDeYHusmA8ODpqNjY1kv2qDO9gea1fsuOopEj1VpjER
K67Y+s2KBkYkgEigYUVkfHzcdHd3J4+j6okif9lQjK1uax06dKj8mKuVitjc3DTDw8PJ61rGHTzP
IxK1RW3SfiUVfwA7Fq8bO656iURPXKkN9tZbnvWbEQ2MSACRAEUE6AMAiIQiAvQBAERCEQH6AAAi
oYgAfQAAkQBFBOgDAIiEIgL0AQBEQhEB+gAAIqGIAH0AAJEARaRFaOXYXfoAIBLYUUXk9evXSaiV
vvmtb6cr/OnVq1ct324/djeEvtGuqWPoAwCIBJE0gFOnTiVTj9j5qJQ4eOLEiY46z5qU0qZD0gcA
EEnbFrhQVO7q6mryqVmTEmoZxeXOzc1VbHNqaiq5Yujq6jJ3795NJiDUHFK1xsvqk707c7B+13ZD
x+dH98b2qXWmp6eT9ut9JTZqfjCXixcvJu/pHGhiRXe+L3+fabG7ofMrNIfYo0ePEAkAImlfkYSi
cnt7e5NZdO1VweTkZFI03W1qRl7Fxd6/fz8p9LqS0N+1xsv6ItHMuqHbRmnRvbF92kAuyUHLSDrn
zp0rvy8p6pjt8Wt7ut0W2qd/nkPnV0jE7j4RCQAiaTuRhKJy03BDmfxIWf3t5mzUEi+rgq3bWVpH
VwkqtqFAqLR429g+tc7S0lL57zdv3lRknmjGYjfTRL/r6iW0T/88x86vclIOHz6MSAAQSfuKJBSV
K3TrRrkiIyMjSWENTbce+rtovKwG1r/++utkPQVkqZ2xK5K0q63QPvW3Lxr3Kiqtfe77eaaLj51f
7V+3zhAJACJpW5FYWaRF5Wr8QGFUuv0yPz+f3L6pViS1xsvqk3tPT0+h44vtM08ufGidvLklWec3
tB9EAoBI2kokFj8qV2Me7q2qtbW1qkVSa7zs7OxsclVU5Phi+9Q6Omb3Ksgd0Nf6/q0t96qoaACW
f36Fxm64IgFAJG0tklBU7r59+8pPadl7+dWKpGi8rNoleQg9PaZP827CYp7ji+1T6+hvRfHq/UuX
LlU8Yqzl7TiNfm7cuJHcZgvt04/dDZ1f8eTJE8ZIABBJe4skFJW7uLiYDE7rdRVEDRpXKxJRJF5W
0tAjtXaMJPZAQNbxhfapdSTKPXv2JIPi58+ff+9Lj/bxX/3oAYDnz58H9+nH7obOr7h16xZPbQEg
kvYWCeekufT39yeyoQ8AIBKKJuekMLpdqKe56AMAiISi2aYUmRerERw/fpy5tgAQCSIB+gAAIqGI
AH0AAJEARQToAwCIhCIC9AEAREIRAfoAACKhiOwwWjkalz4AgEjapohohtqhoaG2K0g2NKqW72L4
jwBvx7Gtr6+br776Ktm3plQZHh5OpmlBJACIpG1FokKs2Nd2K0hpKYy1npftOLaBgYEkTdLO4aXf
lZSISAAQSVuKRDGvfhGLRdAWmUo9FjXrEov29ffhx9rG2pInGlf/1USNmrDSzo9VJDI4K/LXF2Ce
1xAJACJpC5FowkBJw182FEFbRCSxqFmXWLRvNVcTfltj0bj6W7f5bPJh0cjgtH1kXZFYNCHlkSNH
EAkAImlPkWgKc8355C8biqAtIpKiUb4+sXjdoiKJRePGlskT3+uv76PbiF1dXeUrIf1e5NYiIgFA
JC0lEt1G8gtjLIK2iEhiUbM+oWjfeoik1m3kie+Nodt3yjqxV17j4+MVOSiIBACRtJVI0j7xxyJo
ixbnWNSsJRbt2woiqSa+10dPa7mi1u8SOiIBQCQddUUSiqANFWc/jtclLWrWJRbtW1QCsWjgakSS
J743hi8Nnf/tiNtFJIBIoCFFRGMkfoRtLII2azD9xYsXyW0b9/1Y1KxLLNo3dkyxtuSJxo2JJE98
bwwNxuuqS4P12sb169fNmTNnEAkAImlPkehpLD2J5C8biqB1t2XloFs+isSVNNz3Y1GzLrFo39gx
xdqSJxo3z1VLLL43hh6llkzsfiUR9/FqRAKASNpKJHo6y/1ETcHZeX0AAJFAzUVET1S5c05RcBAJ
ACKBQkVEt4QU+2ppdgQtIBIAREIRAfoAACKhiAB9AACRAEUE6AMAiIQiAvQBAERCEQH6AAAioYg0
mp0UeUsfAEAkFJEG0MhHjvNE8ipXZP/+/Uk7NDWLO9cYfQAAkUAbFJFGti8WyfvLL7+Yvr6+ZJJH
zX2lcC1N0UIfAEAkkKOIZEXDxuJkQ1G84uLFi8l7mhRRU7C4YU95Im+LRPSG9pe2bR9lnygThA8T
AIgEqhSJHw2bJ042FMWrGXEVk2tnyNX2RkdHg/sMzeQbi+jNs78QmnV4J4zRIBJAJNAwkfjRsHni
ZENRvJrt107LLvS7rl5C+/TbVySiN8/+QkhaktXBgweTK5rh4eGK2Y4RCQAigYhI0gprLE42FMWb
liKYlbCY9VqRiN5q9ufv+/Tp00lglb2i0e0uRAKASKBKkVQTJ+sW7rTwqqJJhSJvRG81+3NRtoh7
RSOZdOLElYgEEAlsm0jyxMmGoni1vn+ryS3MeUViiUX0VrM/l2PHjlX8vV0Z6ogEAJF0rEjyxMmG
oni1/MTERHn9GzduJImFoX36kbdFInqr2Z+LxmL0Y9fXtvRdEkQCgEigSpGIWJxsKIpX2Mdx9aMn
qJ4/fx7cpx95WySit5r9+UgeOhZ7vP/9738RCQAigUYVEQoSfQAAkVBEKEj0AQBEAs0rIkTx0gcA
EAlFBOgDAIgEKCJAHwBAJBQRoA8AIBKKCNAHABAJRQToAwCIBBpRRIi/pQ8AIBKoqYjU4zHfIpMn
AiIBQCQdVkTqUXgoXogEAJF0eBHJirRNi6iNzdqrCQ/PnDmTzNHV09OTJCuGrkhCcb5FonZXV1eT
+bE08aPWUUCV5gJz91s0ThiRACASyFlEQpG2/joxkVy/fr08a7BmBu7v788USSzOt0jUbm9vr5mZ
mSnP3qvYXUnD3W/ROGFEAoBIIGcRCUXaFhWJPu27uSDLy8uZIonF+RaJ2k3DT3QsGieMSAAQCeQs
IqFI26Ii8TNDVKizRBKL8y0StSt06+rKlStJRK6mn48N8sf2j0gAEAkUKCJZkba1isR/3/09T9HO
G7U7PT2dBGFNTU2Z+fn55PZVTCSdLg1EAoBImlJE/EjbmEjW1tYqXuvr66u4tfXs2bPM7cXifEPt
8tHgvrstv13VxAkjEgBEAjmLSCjS1o+/dQfAX7x4kTwp5W5XA95jY2PlwfaBgYHMgh6L8y0Stbtv
377yU1qSl2JyYyKJ7R+RACASyFlEQpG2fvytLehaVpnoWtbf7vj4uOnu7k4eq9WTUaGCHorzLRK1
u7i4mAyUazkJSIP0eb4IGdo/IgFAJEARAfoAACKhiAB9AACRUESAPgCASCgiQB8AQCRAEQH6APD/
AKeAIgL0AQBEQhEB+gAAIqGIAH0AAJFQRKCutEskMX0AEAlsWxFpVsFpdCxvaJu17M+PJG7Vgo1I
AJFAx4uk0W1o1HHlmSUZkQAgko4VSSweV1QbiavJHkdHR5PJHxV/u7S0VNEeP/7WvyLRhJF2/WPH
jiVBWXnblee4QldDSk/UZJB2ri87WWXaemmRxBMTE8H1mxHzi0gAkUBDikgsHreWSFwFTdmUQ+WK
aEJFtz1+/K1fzDUt/fr6erLM7OysOXnyZO52xY4rJhJN4mhTFWOzD6ddkQwNDWWu36yYX0QCiAQa
UkRi8bi1ROJKHP66/hVHqJi7VyDajtqSt12x44qJJNS2PCIJrd+smF9EAogEGlJEYvG4tUTiFvkU
n1bMQ22NtSt2XEX3XVQkoWWaFfOLSACRwLaIxF+2lkjceovEfToq1q7YcTVTJM2K+UUkgEigIUUk
Fo9bSySuwq9Ct7ZixXxlZaX8t9q4d+/e3O2KHVczRdKsmF9EAogEGlJEYvG4tUTiarBdt77EwsLC
e4PtsWI+ODhoNjY2kv2qDe5ge6xdseOqp0j8SOLY+s2K+UUkgEigYUUkFI8rqo3E3dzcNMPDw8nr
WsYdPM8jErVFbdJ+JRV/ADsWlRs7rnqJxI8kzrN+M2J+EQkgEqCIAH0AAJFQRIA+AIBIKCJAHwBA
JBQRoA8AIBKgiAB9AACRUESAPgCASCgiQB8AQCQUEaAPACAS2HFFZDvTbdskSReRACCS5hWRjQ1j
lK20e7cmOzTm0CFj7tzx12+t4/HSbas8J9XtqxnnQhMG6N/GmUkfkQAgktYQyevXyu4w5ocfNDFi
6bVffjFm/35jpqdbVyTb2Z5WOHZJJCOkEZEAIJLmiuTKFcTBtyMAADOpSURBVE0i+P7rksnfCbjl
YjoxYcy+fZoG/f3CtrpqzJdfagLD0nsHDxozN1e5/uPHpaseu93YOhLb6Gjpfb1nk3q1LffHcvWq
Mbt2GfPxx6UrLF8G/v7dde0nfh3bZ58ZYxOD0/blrpfVxtA2s7h4sdR2bUtzONqpxbKOF5EAIJKW
EIkm5H3xIt+n8qGhd8VNEnEjP3p7NeOuAqRKP5OTpaLtrn/2bOk9Oz9hbB1JzoYvPnhQamvWVcLN
m6WrKm3n7dvSrTk3vTZt/+42XDFqwmI3sNDfl/t3qI2hbfpI5jp+ey50PBJUPa+KEAkgEmhIEQlk
T71XPL3Jd6PFzc1vSls/to6KckacyXv71tiBv6wvg1D7JbCMxOCgSEJtDG3TR+NSTnxK8nt3NyIB
QCRtIBLdRskrkthrunWkT+gjI6XC6L6fVcNC64Qk529Py/q3gHyRhbahKwb9LSF5icFBkYTaGNpm
SKBp20YkAIikZUWi20svX77/um4P+WMcoUKsgXl9Op+aMmZ+vnT7KCaS2DpFRBJLr80rQt2eOnrU
GCcxuGqRhLaZ58owj4gRCQAiabpI9ElZYws+t28b88UX+QvxJ58Y46bHrq3FC2FsnQMH8t/a0mB2
KL02j0gsT5+G2563jaFt+qj9/q0t97FjRAKASFpWJK9elW4p3bhhzJs3paI4O2tMV5cxi4v5C7Ge
5rJXMM+eGXP4cFwksXV0y+vvpF6zsFA5kK1bchrzsMVXg9XXrr0brNbfbnptrP3atg139B8k8PeV
t42hbfqovXoqzrZf/x6SFCIBQCQtLxKhp7a++ab06KluEenxWBXFIp/oJR0NbqtYqoBqkDkmktg6
m5vGDA+/+5Kkk9SbPJGlT+zup/bLl0tXOXpNjxW76bWx9usWlPZhH212EoPf21feNoa2mYZ9/Fc/
emLr+XNEAoBI2kQkQB8AQCRQVRHxn3Lip31+EAkAIuHTKNAHABAJRQToAwCIhCIC9AEARAIUEaAP
ACASigjQBwAQCUUE6AMAiIQi4tEpEbP1pl3PCyIBRALbXkTqHWfbznXMbXsrRO8iEgBE0hZFpD7T
cnTiueSKBACRIJIy1UbMphVVTTZ45kxpvquenlJKYeiKJBSNWySmNhTZq+z5jY3S73Z2YcUIi/X1
0vuxbbhtj50X/a7ZlLMiie1x6xxpYkylIm5XfUckgEigIUWk2ojZtNeuX383A68yTvr7s0USi8Yt
ElMbiuzVZJSazVjcvVu6LaV9279tnG2eqOA850W/S0hZkcQ6ZuWS2HOkqfoRCQAiaWuRVBsxm/aa
Zg12MzU0E25WAY5F4xaJqU3DBl0pPOv06dLv//d/pSRG/YiTJ0sCi22jqEhCkb59faUroaxzhEgA
EEnbiaTaiNm01/y8DYkiqwDHonGLxNSKrMjelZXS1YbQLTIFTO3dW/pbt690uyu2jaIiCZ0jf6De
P0eIBACRtJ1IbAEtGjGbRyShIhuLxg21yycW2auxCN1GsgLR+IWCtOzfebZRL5HEZItIABBJW4rE
UiRiVvjRuLpt497aUrHO2l4sGjfULp9YZO+JE8b87/++u6Vlb2/Zv/Nso14iUQqkpGZ58gSRACCS
NhdJkYhZdwBcqYoaVHY3q8HqsbF3A8kDA9lFNhaNWySmNhbZqwjb7u5SfK24dat0bG5WfZGo4FD0
bkwk/mC7jhmRACCSthZJkYhZW9C1rPLEtay/2fHxUtHWY716OipUZEPRuEViamORvY8eVT72awe4
//vf/Ntwfw9F78ZEIiRbnR89Iq1zVI8vfiISAERCEdmhKPPdHauhDwAgkrYSCZG1nRGhi0gAEAmf
RncQeiJM37fR7Sw9TXb+fOkLmfQBAESCSIA+AIBIKCJAHwBAJEARAfoAACKhiAB9AACRUESAPgCA
SCgincN2RuP+2sI5vIgEEAlsexHZjrrj7sOGWWnG33rufzujcf9R8GvqsX+XehZ/RAKIBDpSJC5p
aYL1llWrnWdEAoBI2l4kmnhQKYGaiFD5HEtL6QU4FkUbisYNvZc3wjbUzlDb8kQGX7xYivvV+ppE
0Q2myhOd655j96fUttWttn25te2Pttb9cKttB7faNlexzm9bOxzdOjgtc+zYMbOsycAy/t2uXr1q
du3atdXej81//HxiRAKASJohEgU52SRCZX9owsI0kcSiaEPRuHnjfEPTs4faWSQm1/9bsw5rebuu
JlG08bt22VB0buw89241bmarcX9tbVw/k1s72+00Tsv39fWZ9fX15P3Z2VlzUtGNKdu7udW4H7as
puXevn1r7ty5Y75z84kRCQAiaYZIVJD9yNu8t4TccKpQNG7eON9QwQ+1M9a20HY1w7CboaLfNXux
u2woOreaYv2B0zgt716BSBL/soNE3vb0+l/eSfhnKMwekQAgku0QSfjTdeXfoSjaUDRu3jjfUMEP
tTPWttB205Ia3X3lmRY+dp4fbzXuylbjRrYad2irce4yact/6DTAfV+v+7fPPsgTNYlIABBJK4gk
FkVri3lWNG6eON9qRVIkJjfPdovmi4TO8/RW4z7datzUVuPmtxr3+1bjYiJxn/xy3y8iDUQCgEi2
TSQKqMpzaysWResSisYNxfmGCn6onUVicv2/Nfjv39pyn+CtVSSfbDXuD6dxa1uN80WysrLi7P9P
s9cJKHGX/WyrsX/kzSdGJACIZLtEottBuvUkFhayB9tjUbShaNzQe0UG27PaGWtbKBpXg+2K4rWD
7YrjlbSqFYmevNJTWH/+vbN9W42zT2k922rc4a3G+SIZHBw0GxsbyfjHtWvXMgfbv99qrN63A/f6
+99uPjEiAUAkzRCJEvqGh0vFXWMLzrhvRcGMRdGGonFD7+UVSaidsbaFonGFffxXP3pi6/nz6kWi
p6h0a8renlrcapwGxDW+oVtc97Ya54tET2PpkV6tI6n85ozu+/9uly9fTq5ytKweK/7dzSdGJACI
pBkiAfoAACKBqosI0batHY2LSAAQCUUE6AMAiIQiAvQBAEQCFBGgDwAgEooI0AcAEAlFBOgDAIiE
IgL0AQBEQhHZwbRyDC59AACRdGwRaZXi8+OPPybfDnenWC+KH4O7HcemnJGvvvoq2bemTxkeHjYv
X75EJACIBJFsN5LITzXm8PrHsh3HNjAwYO7evVueH0u/axoURAKASDpGJHpdU513d3cn8a1nz541
m5rYKmW99G/H/897Vw2a7lwz1f7sZup6xCJo/X34Ebaxtuh35YAojfDzzz/P3MbExEQysaLanCar
ULStv48sAeZ5DZEAIJK2FoluF2miQH1iVuE8d+5cVSJxC/HDhw+D6X2xCNpqrib8tkqK2rad2DBt
G0NDQ+VJEtV2t8jHom3T9pF1RWLRpI1HjhxBJACIpLNEsrS0VP77zZs3mXkYseItEdzLytTNQSi4
qRqR/OZl5KZtI7RMLNo2bX0fZY10dXWVr4T0u5s/gkgAEElHiMQvlllRr7HirasQe4XzrZ+pm0Io
grYeIql1G7Fo2zyFWbfvlBtir7zGx8fNiRMnEAkAIukskfhUKxIrhwcPHpijR4+aC37erkMsgrYV
RBKLts1TmPW0litq/a5xIUQCgEg6SiRPlX/7N69evUqCk/IUZz821kXbDBWuWARtUQmkRdjWKpJY
tG2ewuxLQyLRwD0iAUAkHSUSxbXquw0qcpcuXaq49ZI1mP7ixYvkto37vq4wfvw7/tAfuPaJRdDG
2h9rS9q2/BjcmEhi0bZ5CrMG43XVpcF6beP69evmzJkziAQAkXSWSFTQ9+zZkwyWnz9/PrkqSVvP
ykG3fA4cOJBIw31ft7U01mEfpf3RzdT1iEXQxtofa0vatvwY3DxXLaFo2zyFWY9SSyZ2v5KI+3g1
IgFAJB0hEtjZfQAAkQAiAUQCgEiaV0T8+acAkQAgEqCIAH0AAJFQRIA+AIBIKCJAHwBAJBQRoA8A
IBKgiAB9AACRNKuI7PRoWvoAACKBGotIPR4Njn3bHBAJACLp4CJSj8JD8UIkAIikw4tIVjxuNfG2
mpRQc0lpbqqenp4kUTB0RRKKsa1nbG9WJG5o/4gEAJFAziISisctOu26Zra1s+VqNuH+/v5MkcRi
bOsZ25sWiRvbPyIBQCSQs4iE4nGLikSf9u0U7WJ5eTlTJLEY23rG9qZF4sb2j0gAEAnkLCKheNxq
omldVKizRBKLsa1nbG9WCmRo/4gEAJFAgSKSFY9bq0j894vE2Iba5ROL7U1rd6dLA5EAIJKmFBE/
HrdovG1fX1/FrS0lH2ZtLxZjG2qXTyy2N23dIvtHJACIBAJFJBSP60fTxuJtNeA9NjZWHmwfGBjI
LOixGNt6xvamHXts/4gEAJFAziISisf1o2lj8bZifHzcdHd3J4/V6smoUEEPxdjWM7Y369hD+0ck
AIgEKCJAHwBAJBQRoA8AIBKKCNAHABAJRQToAwCIBCgiQB8A/h/gFFBEgD4AgEgoIkAfAEAkFBGg
DwAgEooI1JV2iSSmDwAigW0rIs0qOI2O5Q1ts5b9+ZHErVqwEQkgEuh4kTS6DY06rjyzJCMSAETS
sSKJxeOKaiNxNdnj6OhoMvmj4m+XlpYq2uPH3/pXJJow0q5/7NixJCgrb7vyHFfoakjpiZoM0s71
ZSerTFsvLZJ4YmIiuH4zYn4RCSASaEgRicXj1hKJq6Apm3KoXBFNqOi2x4+/9Yu5pqVfX19Plpmd
nTUnT57M3a7YccVEokkcbapibPbhtCuSoaGhzPWbFfOLSACRQEOKSCwet5ZIXInDX9e/4ggVc/cK
RNtRW/K2K3ZcMZGE2pZHJKH1mxXzi0gAkUBDikgsHreWSNwin+LTinmorbF2xY6r6L6LiiS0TLNi
fhEJIBLYFpH4y9YSiVtvkbhPR8XaFTuuZoqkWTG/iAQQCTSkiMTicWuJxFX4VejWVqyYr6yslP9W
G/fu3Zu7XbHjaqZImhXzi0gAkUBDikgsHreWSFwNtuvWl1hYWHhvsD1WzAcHB83GxkayX7XBHWyP
tSt2XPUUiR9JHFu/WTG/iAQQCTSsiITicUW1kbibm5tmeHg4eV3LuIPneUSitqhN2q+k4g9gx6Jy
Y8dVL5H4kcR51m9GzC8iAUQCFBGgDwAgEooI0AcAEAlFBOgDAIiEIgL0AQBEAhQRoA8AIBKKCNAH
ABAJRQToAwCIhCIC9AEARAI7rohsZ7ptmyTpIhIARNK8IrKxYYyylXbv1mSHxhw6ZMydO/76rXU8
Xrptleekun0141xowgD92zgz6SMSAETSGiJ5/VrZHcb88IMmRiy99ssvxuzfb8z0dOuKZDvb0wrH
LolkhDQiEgBE0lyRXLmiSQTff10y+TsBt1xMJyaM2bdP06C/X9hWV4358ktNYFh67+BBY+bmKtd/
/Lh01WO3G1tHYhsdLb2v92xSr7bl/liuXjVm1y5jPv64dIXly8Dfv7uu/cSvY/vsM2NsYnDavtz1
stoY2mYWFy+W2q5taQ5HO7VY1vEiEgBE0hIi0YS8L17k+1Q+NPSuuEkibuRHb69m3FWAVOlncrJU
tN31z54tvWfnJ4ytI8nZ8MUHD0ptzbpKuHmzdFWl7bx9W7o156bXpu3f3YYrRk1Y7AYW+vty/w61
MbRNH8lcx2/PhY5HgqrnVREiAUQCDSkigeyp94qnN/lutLi5+U1p68fWUVHOiDN5b98aO/CX9WUQ
ar8ElpEYHBRJqI2hbfpoXMqJT0l+7+5GJACIpA1EotsoeUUSe023jvQJfWSkVBjd97NqWGidkOT8
7WlZ/xaQL7LQNnTFoL8lJC8xOCiSUBtD2wwJNG3biAQAkbSsSHR76eXL91/X7SF/jCNUiDUwr0/n
U1PGzM+Xbh/FRBJbp4hIYum1eUWo21NHjxrjJAZXLZLQNvNcGeYRMSIBQCRNF4k+KWtswef2bWO+
+CJ/If7kE2Pc9Ni1tXghjK1z4ED+W1sazA6l1+YRieXp03Db87YxtE0ftd+/teU+doxIABBJy4rk
1avSLaUbN4x586ZUFGdnjenqMmZxMX8h1tNc9grm2TNjDh+OiyS2jm55/Z3UaxYWKgeydUtOYx62
+Gqw+tq1d4PV+ttNr421X9u24Y7+gwT+vvK2MbRNH7VXT8XZ9uvfQ5JCJACIpOVFIvTU1jfflB49
1S0iPR6roljkE72ko8FtFUsVUA0yx0QSW2dz05jh4XdfknSSepMnsvSJ3f3Ufvly6SpHr+mxYje9
NtZ+3YLSPuyjzU5i8Hv7ytvG0DbTsI//6kdPbD1/jkgAEEmbiAToAwCIBKoqIv5TTvy0zw8iAUAk
fBoF+gAAIqGIAH0AAJFQRIA+AIBIgCIC9AEAREIRAfoAACKhiAB9AACRUER2EJ0Sn0sfAEAkO76I
NKtZ9Y7qbYcajUgAkQBFpMUE1m6nlD4AiAQaVkSyIl5tsdTswFkRu0IRt5rjShM9KuXP31Vs+/Xc
l0u18blpbdNEimfOlPbd01NKYAxdkYRif4tG8CISAETS0iLJE/GqCRCzInZV+JWzoXWVa6Kp591d
FYmQrXVfPtXG56a9dv36u9mFte/+/myRxGJ/i0TwIhIARNLyIskT8RqKqO3rM2Z9/d3fmv3Wfb9I
hGyt+/KpNj437TXNiOweh79v9/dY7G+RCF5EAoBIWl4k1US8uq/5g9YqoO77RbZf6758qo3PTXvN
zxLx9+0vG4r9LRLBi0gAEEnLi6SaiNciBbbI9mvdVxrVxOfm2Xeo7bHY31C7EAkAImk7kVQT8eq+
plRDN/P9yZPK94tsv9Z9hSgSnyv82F/dVnOPQ4mOWduLxf6G2oVIABBJ24mkmohX9zV/AFxPZfmD
7Xm3X+u+fIrE57oD4EqM1KC/u+2ZGWPGxt7te2Agu+2x2N8iEbyIBACRtLxIRNGIV/81FVg96qrH
YvXEkj+WkXf79diXS5H4XFvQtaxEp2X9fY+Plx4U0P6171DbQ7G/RSN4EQkAIml5kdQTZZjv3Ws6
bl/0AQBEwgkkardjI3QRCQAiaetPo/Pzpe9Y6BaOvm1+/nzpS3jtvi/6AAAiAYoI0AcAEAlFBOgD
AIiEIgL0AQBEQhEB+gAAIgGKCNAHgP8HOAWNKSK/7sTMWfoAACKB+hWRfxTMnI0VoyLF6ssvvzQL
Cwv84yASAETSzkWkaHGpp0hWVlbM5/piCCASAETSnkVEr7k/YnV1NblS+Oijj8yHH35oDh48aObm
5irW+e2338zo6GiyzLFjx8yyUp4y9nP16lWza9cu8/HHH5v/+JmzWwwODppHjx7xD4RIABBJp1yR
9Pb2mpmZGfPXX38lP5OTk2a3Iv2c5fv6+sz6+nry/uzsrDl58mTq9m7evGl++OGHZLm3b9+aO3fu
mO/czNktpqamzLlz5/gHQiQAiKRTRJLGB05Sk5Z3r0AkiX8p6i9le3r9Ly9z9p9eQPmzZ8/MYQWN
ACIBQCSdI5LHjx+bK1eumJGREXPo0KGKZdKW/9AJ1HDf1+v+7bMPvPhAiUa3vQCRACCSDhHJ9PS0
+fTTT5NbTvPz8+b333+PisR98st9/4M8mbOeiACRACCSNhfJJ598Yv5wcmLX1tbeE4metrL8+eef
Zq8TCuIu+9lnn1VsKw2NnXBFgkgAEEkbFxE9eaWnsP78O3N237595ae07PiFLxI9abWxsZHclrp2
7VrmYPv333+fvG8H7vX3v93MWaPc9SeMkSASAETSzkVET1Hp1pS9PbW4uJgMiOt2k25x3bt37z2R
6GksPdKrdSQViShrP5cvX06ucrSsHiv+3c2c3eLWrVs8tYVIABAJRaR6+vv7k8F9QCQAiIQiUhjd
OnMfHQZEAoBIKCKFOH78OHNtIRIAREIRAfoAACKhiAB9AACRAEUE6AMAiIQiAvQBAERCEQH6AAAi
oYgAfQAAkQBFBOgDAIiEIgL0AQBEQhEB+gAAIqGIAH0AAJEARQToAwCIhCIC9AEAREIRAfoAACKh
kAD/9gCIhILCqeTfHACRQB0KCz875wcAEAnwyRwAEAkgEgBAJIBIAACRACIBAEQCgEgAAJEAIgEA
RAKIBAAQCSASAEAkAIgEABAJIBIAQCSASAAAkQAiAQBEAoBIAACRACIBAEQCiAQAEAkgEgBAJACI
BAAQCSASAEAkgEgAAJEAIgEARAKASAAQCQAiAQBEAogEABAJIBIAQCSASAAAkQAgEgBAJIBIAACR
ACIBAEQCiAQAEAkAIgEARAKIBAAQCSASAEAk0JEC8X8AAJEAIBIAQCTQHJkAACIBQCQAgEgAkQAA
IgFEAgCIBHaaTAAAkQAgEgBAJK1QUPnZOT8AgEj4VA78mwMgEgoK8G8PgEgoJEAfAEAkFBGgDwAg
EqCIAH0AAJFQRIA+AIBIKCJAHwBAJBQRoA8AIBKgiGTw66+/8o+OSAAQyXYUkT/++CP4bejXr1+b
0dFR849//MN0d3eb//znP+bVq1ctf7xqb6P48ccfzYcffmj+9a9/pb7/5s0bc/r0afPxxx8n7Rge
Hq44Z2nn+4MPPkAkAIikPUXy4MGDpNBlcerUKfPdd9+Zv/76K/mZmJgwJ06c2NGfviWRn376KfP9
c+fOmRs3bpTP2cWLF4Pn+P79++by5cuIBACRtGdhHRsbS+QQ+mSvYmjR75988klwP48fPza7d+82
n3/+efn1q1evml27diWf0nVV468zPT2dXPHo/bNnz5rNzc2KZVSM9d5HH31k/v3vf5vffvstc59p
V1f2KkKf/D/77DPz888/B89X1v7yzGPV1dVVcc7evn2beYWk5Xp7e5MrP0QCgEjaUiS6uhgcHEyK
vAShAhoSyZ9//hm8baT9SARa5/fff09eu3nzpvnhhx+S11RU79y5k1zluOvoNpGKtZaRdPSp3vL9
99+bycnJ8id8bU+320L79I/XvYp4+PCh+ec//5l5DHn2VwSdM0kuDW17O65GEAkAImlYEdmzZ4+5
fft2+dPxrVu3zJUrV8rvq4DqikXv6SpBBT50P1/7ca8WhCThyki4hVzrLC0tlf/WGMPevXvLfx86
dCgpxm5h1tVLaJ/+8aqQ37t3L9e5yrO/Iuj8uufURVcja2triAQAkbSvSNJutUguFg0Sf/3118kn
+gMHDiSf5mNXJD5aNzS4rL990WgdS5q43PfT9um/pnbbK59vv/02eA6q2V8WGxsbyfnTlZjPysqK
OXz4cMv1AQBEAjUXkdAVx7Nnz0xPT0+h/cSeSMqST9rvaevkEYnQOIoeLjh69Ki5cOFCZnuq2V8a
ksc333xjXr58mfq+rvT8W4mIBACRtJ1IdMvGHejVbZyDBw9mbmd2dtaMjIwU2o8Gt/WYcWidp0+f
VlwFuQP6Wt+/1eReFeUViUX7Cr1fzf7SrkT0CHDotpXGpyQ2RAKASNpaJOfPn08Gt+3AsgbB9eiq
5dNPP03kIVZXV5NP88vLy4X2o8Hra9eulfehv/UklLuO/tYnd71/6dKlikeMtbwdp9GP2qfbbKF9
6mkrjZtYIeg49OSW0KB72lVHLftzefTokTly5IhZX18PLqdxIvtwACIBQCRtKxINoOu7IvrErcdW
VfBdJA09UmvHSGID1ln70ZNJusrQfr788suKAqp15ubmkrEZDYpLbv6XHu3juPrRAwDPnz8P7lNC
1L7slYRua2kQXbfZdCxWKlkU3Z+LHhTIE3mrdvhjQ4gEAJG0nUhoG30AAJEAIgHOMwAi2dlFpJHz
YgEiAUAkFBGgDwAgEooI0AcAEAlFBOgDAIiEIgL0AQBEAhQRoA8AIJL2KSLE1XbWeUAkgEhg24tI
PR7LrWayw2rQ7L5DQ0Plv2Nxt516HhAJACJpqSJSj8KzXcVL08NrWnZL0bjbTjkPiAQAkWx7EcmK
oE2bJyo2y64K9pkzZ5I5tTTVvJIQQ5/EQ/G7RaJxNUmiUh5disTddsp5QCQAiKQpIglF0PrrxAro
9evXy7P8aibf/v7+zAIai98tEo2rqw9lvocIxd12ynlAJACIpCkiCUXQFi2gmiXYzfHQzMFZBTQW
v1skGlcpgwrcChGKu+2U84BIABBJU0QSiqAtWkD9jA8VyKwCGovfLRKNq+yR0HTsobjbTjoPiAQA
kTRFJCIrgrbWAuq/7/4ei98NtcsntK1Y3G0nnQdEAoBImiYSix9BGyugipF1X+vr66u4paPbTVnb
i8XvhtqV94okT9xtJ50HRAKASJoiklAErR9X6w78vnjxIkk6dLc7MzNjxsbGyoPMAwMDmQU0Fr9b
JBpXYyR+/G/euNtOOg+IBACRNEUkoQhaP67WFjItq9hdLetvd3x83HR3dyePs+qJpNAn+1D8bpFo
XD21pX255I277aTzgEgAEEnTb221K0tLSxWf4gGRACASikhh9FQTc4MhEgBEQhGpGt1uOn78OP/Q
iAQAkVBEgD4AgEgoIkAfAEAkFBGgDwAgEqCIAH0AAJFQRIA+AIBIKCJAHwBAJJ1eRGx4kvsNcE0L
4ocodUoh8r/trmPXN8s1L9fr169Tl9M3y3VOlLIYmgAyFvGr3/XtdW1Ly2hW4rTtbW5uJt+azyL2
PiIBQCTbJhJ9/0JFzc4dZZmbm0uKq7413oki8ZFANLOukg2zltNcWLOzs0nxzyIW8as0RE0Hb99X
ToqmSHHRjMUnTpzIPN+x9xEJACLZVpGE5m+STLKSAldXV8ufrLWNgwcPJsunfeLXj/tlwVC0rJZV
YuC+ffvK80v5koutr/mpFAilgKki50KFXduMLReK7I1F/CoS2A3h0vvHjh2r2Iame9FkkFn7j72P
SAAQybaKJFZc3DAod9ne3t5kllv7yXpycjI1yla3eiQZzZ4rYtGy2ocEZZf3Z7zNs/7Zs2eT993J
D/Mec0wkvmxi+BG/usrzp7zXay7z8/PBdsbeRyQAiKSlRFJk2bSQJt0ucgt9LFpW+7ASSdtvNevn
OQ59wlfWuiSUtZwVpnv7K4Yf8Zs2DXzW1PCx841IABBJy4oka+p1f1ndQlKRHBkZSaY699/XLRwV
fr9ohqJl86QPFl0/dnz66enpScYz/Csw90e3rfwB+RBpEb9pskUkAIiko69IskQyPT2dhC5NTU0l
t1p0G8nf1hdffGF++eWX6FVLHrHVsn5oGQVfaYxC6YP1LLxZEb/+bays1xAJACJpG5GkDWZb/PEJ
dxsqfm5ErB83K8G4t4kssWjZmEiqWT+2jIq+xmXu379fl8IbivhV7rrGjSx6jDcrSwWRACCSthBJ
1uO/epJLr7tPdLnb0FNV9ikt3cJS3K19X4VUt4nSiEXLxkRSzfp5zoWuTDTW4hb/agpvLOJXT5y5
7Zdw9TgwIgFAJG0rEvfKw/+Sni8XdxuLi4tJ4dVyusV179698vu6pROKuQ1Fy8ZEUs36ec/FwsJC
IoFaCm8s4ldtVYa7je4dGhqq+MIiIgFAJG0pEqAPACASoIgAfQAAkVBEgD4AgEgoIkAfAEAkFBGg
DwAgEqCIAH0AAJFQRIA+AIBIKCJAHwBAJBQRoA8AIBLY9iIS29dOi/ZFJACIhCJSx33txGhfRAKA
SDq6iIQic+16oehbTTyooCdJQJkeSiwMFaydGO2LSAAQSUeLJBaZG4u+Vaqgnc1W2Rv9/f3BgrUT
o30RCQAi2XG3NfzEwVD0rT6FK5fcsry8XJNIiizbLtG+iAQAkXS8SEKRuXmib11UdIuKpNOjfREJ
ACLpaJHEInOLiiRWsHZitC8iAUAkHS2SWGRurND29fVV3NrSVUFssH2nRfsiEgBE0tEiCUXm5im0
GgAfGxsrD7Yr/a+ax387OdoXkQAgko4WSSgyN0+hFePj46a7uzt5RFZPOcUK1k6L9kUkAIiko0UC
9AEARAIUEaAPACASigjQBwAQCUUE6AMAiIQiAvQBAEQCFBGgDwAgEooI0AcAEAlFBOgDAIiEIgL0
AQBEAtEikvaN8NgsvGmv++vqG+j6Nvjp06fN69evU5fThIiaFmV4eDiZXiULZYxoOwqW0rfLtfyr
V6/K7+t3G3qlZb7++uvU7W1ubpoDBw5k7if2PiIBQCSIpAbZ5BGJjwSifBAlKGYtp/mrZmdnk+Kf
xblz58yNGzfK811pXi3JxKIEw2+//bb8/u3bt5NpTVwUSnXixInMY4m9j0gAEAknsAkisaLQVUJs
OV1pZNHV1VURLqWi7y4/ODiYTOTovn/s2LGKbWiixRcvXmTuP/a+S5544rT43VBkLyIBQCSIJLD9
mEh82cTQtPVuzK5uofkphnrNRRkmoXbG3nfJE0/sx+/GInsRCQAiQSQpy+gTvjLd3ZyQtFtbKsTu
7a8YunWlpERLWrhW2mt5zkO1xTYWTxyL7EUkAIgEkaQM1vf09CTjGfoEnrWcblv5A/IhlD2i8RR3
m2kpho0WSdF44lhkLyIBQCQdLZK08Qt9utYYQdq66+vryRjF06dP61rMJA9lj/hPZPm3sbJeq5dI
qokn3m5pIBIARNJSItGYwMrKSsVrGtzW7ZqsdVX0NSB9//79uhQzXYnoykURuz5Hjx5NHhG26DFe
N8Ww3iKpJp44FtmLSAAQSUeL5NatW0mEri3iempJT0pp8Di0rq5MNA7gFv9qitmjR4/MkSNHku2l
oaeh3DhcXSnoceBGiaSaeOJYZC8iAUAkHS0SoQHx/fv3J/f69V/9nWfdhYWFRAK1FLO9e/cGvzCp
W0sSnW7B6WdoaKjiC4v1Fkk18cQiFNmLSAAQSUeIBOgDAIgEKCJAHwBAJBQRoA8AIBKKCNAHABAJ
RQToAwCIBCgiQB8AQCQUEaAPACASigjQBwAQCUUEsvn111/pAwCIBJG0QsHJm2/SiHNQy/78SS1b
tWAjEkAk0PEiaXQbGnVc/nYRCQAi2VEi0QSCCpXSHFDKD1Fyn79sKCL2xx9/TOac0jTpmuH2559/
Lr+nJMPR0dFkunnF0S4tLVW0x4+j9a9IFA5l19e09MvLy7nblee4QldDmpBSkzPquHR8P/30U+Z6
/vxf+u/ExERw/WbE7iISQCTQkCKiBEM7K61yPvr7+yuWjUXEukXy4cOHFal/Cn7ShIbiwYMHyQSH
bnv8OFq/mPf19SUz/mqZ2dlZc/Lkydztih1XTCSaVNGmHOr4soKysq5INHFk1vrNit1FJIBIoCFF
RFcDunKw6FO/u2wsIlZXFFYWPhKHv65/xREq5u4ViLbj5p/E2hU7rphIQm3LI5LQ+s2K3UUkgEig
IUXE/6StAucuG4uI1VWIXlNx9DNAinyKTyvmobbG2hU7rqL7LiqS0DLNit1FJIBIYFtE4i+bp8Bp
rEO3rpRUeOHChYaJxH06Ktau2HE1UyTNit1FJIBIoCFFROMQ7i0gJf65yxaJiFVGu7vugQMHgre2
YsXcjfdVGxVwlbddseNqpkiaFbuLSACRQEOKyMzMjBkbGysPSitp0F02FhGrcRA9uSX8QWUNtuvW
l1BSoj/YHivmivNVVrv2qza4g+2xdsWOq54i0VNlGhOx4oqt36zYXUQCiAQaVkTGx8dNd3d38jiq
nijylw1FxOq21qFDh8qPuVqpiM3NTTM8PJy8rmXcwfM8IlFb1CbtV1LxB7Bj0bWx46qXSPTElY35
zbt+M2J3EQkgEqCIAH0AAJFQRIA+AIBIKCJAHwBAJBQRoA8AIBKgiAB9AACRUESAPgCASCgiQB8A
QCQUEaAPACASoIi0CK0cu0sfAEQCO6qIaC4qf4bcdjgGP3Y3hL7Rrqlj6AMAiASRNADNJqzpVTr5
PGtSSpsOSR8AQCRtW+BCUbmrq6vJp2ZNSqhlFJc7NzdXsc2pqalkPquuri5z9+7dZAJCzSFVa7ys
JlxUXG2R4/Oje2P71DrT09NJ+/W+Ehs1P5jLxYsXk/d0DjSxojvfl7/PtKun0PkVmkPs0aNHiAQA
kbSvSEJRub29vcksunaW2snJyaRoutvUjLyKi71//34ikFOnTiV/1xove+LEiaTISgLargp67Pj8
6N7YPm0gl+SgZSSdc+fOld+XFHXM9vi1PWXIh/bpn+fQ+RUSsbtPRAKASNpOJKGo3DTcUCY/UlZ/
uzkbtcTL7tmzx9y+fTv5XevdunUrmZY+dHz+7MCxfWqdpaWl8t9v3rypyDzRjMVupol+19VLaJ/+
eY6dX+WkHD58GJEAIJL2FUkoKlfo1o0K+MjISFJYQ9Oth/6uNV5WQpBcihxfbJ/62xeNexWV1j73
/TzTxcfOr/avW2eIBACRtK1IrCzSonI1fqAwKt1+mZ+fT27fVCuSesTLhraRdnyxfebJhQ+tkze3
JOv8hvaDSAAQSVuJxOJH5Wpswr1Vtba2VrVIisbL6hbS69evy3/rtpIG+4scX2yfWkfHbHn16lVy
zO76/q0t9/HeogFY/vkVGrvhigQAkbS1SEJRufv27Ss/pWXv5VcrkqLxsufPn08Gv+3yGiS/ceNG
oeOL7VPr6G9F8er9S5cuJYP87vp6csyur/0rhz60Tz92N3R+xZMnTxgjAUAk7S2SUFTu4uJiMjit
11UQNWhcrUhEkXhZPYarJ8C0rB4tlhCqOb7QPrWORKmxFw2KS166KnGxj//qR09sPX/+PLhPP3Y3
dH6FHiLgqS0ARNLWIuGcNJf+/v5ENvQBAERC0eScFEa3C/U0F30AAJFQNNuUIvNiNYLjx48z1xYA
IkEkQB8AQCQUEaAPACASoIgAfQAAkVBEgD4AgEgoIkAfAEAkFBGgDwAgEihSROpVXGrdTiPXp4By
HgAQSRsUkVYWCXCOABDJNl2R6HclCmqyRjs3lBuXq4kINd+UJibUTLxuKFSR6dU1AeKZM2eSObB6
enqS5EJ/nVBEbp71qz1GRAKASKBGkWhiQ5v6589Wq4Arm/anfA1N5FiNSK5fv16elVcz72q+Kff9
WERubP1ajhGRACASqFEkoehYicNPFKxGJJ9//nlFzsfy8nKhWN7Y+rUcIyIBQCRQo0hC74c+udey
HUmjSCxvbP1a2oZIABAJtKFI/PdjEbmx9REJIgFAJC0qEqUDVnNry4/o7evrq7g1penUi8TyxtZH
JIgEAJG0qEg02P7w4cPkd01/njXY7j4J9eLFi2Rw231/ZmbGjI2NlQfLBwYGCsXyxtZHJIgEAJG0
qEgUfzs8PJyIQvGxGuROW84+CaVbVLqKUbysv+3x8XHT3d2dPOKrp7SKxvLG1kckiAQAkVBEgD4A
gEgoIkAfAEAkFBGgDwAgEqCIAH0AAJFQRIA+AIBIKCJAHwBAJBQRoA8AIBKKCNAHABAJdFAR+fXX
X6t6rx7L0wcAEAl0QBHRN9ez2um/V8u2gPMBwP8BHVpE6pm1TqHk/AAgkiYVkYsXLybzWu3evdtM
T08XmptqdXU1mQtL8buaX0sRvHNzcxXLZkXb+pkj7rbT3gvtK2tbr1+/Nnv37k3mCXPR7MGaZdgS
ivZFJACIBAJFRLG1diZdTYyo9MEiIunt7U1m47Uz9U5OTiZCcpcNRdv62w/tO8++0rZ1+vTpZAZh
/7glDxGL9kUkAIgEAkVEsbbup/WlpaWaZ8t1g6li0bZFRJJnX2nbWllZSa5KbJaK/rt///5yu2LR
vogEAJFAoIjEYmvziOTx48dJVsnIyEgyvXyR9YuKpMi+3L+PHDmSXHUIXdXoKsk9B6FoX0QCgEig
gEjyFHP3NY2pKOBqamrKzM/PJ7fHGiWSovty/37w4EEypiI0NqL1065qdmIfAEAkUFMR+eKLL8yr
V6/Kf/uxtbHYXA3Su7G4/vv1FEnRffl/a8BfYyO6reUSi/ZFJACIBAJFZHZ2NnlqKyu2Nhabq+Js
n5yShA4fPlxIJHoCS2MVNoM99F5sX6FtCQ2g9/T0vDeQHov2RSQAiAQiRURPLenppz179iSFukhs
7uLiYjIwrWV02+nevXuFRKKiri8S2i8Tht6L7Su0LbGxsZG8J2H6xKJ9EQkAIuEEFigiFBz6AAAi
AUQC/LsCIJLmFZGic1wBIgFAJBQRoA8AIBKgiAB9AACRUESAPgCASCgiQB8AQCQUEaAPACASaHYR
IfaWPgCASCgiNbGdsbcUSM4TACLpwCISm0AREAkAIumQIqK5s+xcWpoF9+effzbPnz9P0gh9lB6o
gCjF11YToTsxMZG6vCUUd5vWzrRjCy1HH+B/I0Ak0IAi4hb0hw8flpMBNQuwX4QljlOnTpW3VzRC
d2hoKHP5WNxtVjv9fYWWow/wvxEgEmhAEdGsv5pF10dBUEePHq14TXnuT548KW+vaIRuaPlY3G1W
O/3thJajD/C/ESASaEAR0ad2vadC/u2331a8p9tQyjsXy8vLiUhC2ysSMpV2JRGKuw21091OaDn6
AP8bASKBBhUR5aDbK5ALFy6UXx8bGzOnT59Ofh8dHTW3bt1qmEjyxN1mtTMtQz5tOfoA/xsBIoEG
F5GnT59WLKcAKKUOrq+vJ4Pgm5ubDRNJkbhbv51Zx+YvRx/gXAAigQYUESUN6kkn4Q+A2yuR48eP
m7NnzxYSQyz21n8tFncbaqe7ndjx0AcAEAnUuYjoNtChQ4fKj+TaImxZWlpK1vW/qV5LhG7WNkJx
t6F2utuJHQ99AACRwDYXERVzDboDIgFAJBSRwuvoFpOuEnj6CZEAIBKoqohonGNwcLBikB0QCQAi
oYgAfQAAkQBFBOgDAIiEIgL0AQBEQhEB+gAAIqGIAH0AAJFAKxcRInfpAwCIZAcUEc2Yq6yQRuBH
7nZqgc27DX1jf2FhAZEAIJLOEommXLfTxe/E4rWdbdR5dqfjRyQAiKTtRfLo0aPkS4f+slNTU6a7
u9t0dXWZu3fvJpMoah6sIhG5aZG7q6uryadyfdlR2zp48KCZm5sLtj22Tij2N+/6eeKF6xX3q/Ot
845IABBJR4jk3LlzZnp6+r1lT548mRTR+/fvJwJRxK7+LhqR6+9XxXpmZqY8y+/k5GSSahgitk4s
9jfP+iIWL1yvuF9JWucdkQAgko4QyeHDh82zZ8/eW9aNxdXfblZIkYjcPMUrT6hVaJ1YjG+e9UUs
Xrhecb863zrviAQAkXSESHS7xxdBLJSqSERu2n411fuVK1fMyMhIMuV7ngIXWifPFPV51w/FC9cr
7lfnW7cBEQkAIukIkaRdDRQRSexqwl9Xt9EUPqXbO/Pz88k09XaZtDGV2Dp5RFJk/VC8sBVSPeJ+
mxG4hUgAkUBLXpHEInL9dTXe4i6/trYWLXCxdWIiKbJ+KF7YpZa4X40lcUUCgEg6RiS6V69bONWK
JBaR60fu6taRfWLKjhXEClxsnZhIiq6fFS9cr7hfjbkwRgKASDpGJHp6SE9eVSsSEYrI9SN3FxcX
k8F4FVcVXA1KxwpcbJ2YSIqunxUvXK+4X90u46ktAETSMSJR0XSvIKDx8cL9/f2JbBAJACLpCJEI
PV3EnFglGh0vrFtrOt+t1gcAEAnUVER0H19jAtD4eGGdZ+baAkAkHScSoA8AIBKgiAB9AACRUESA
PgCASCgiQB8AQCQUEaAPACASoIgAfQAAkVBEgD4AgEgoIkAfAEAkFBGgDwAgEqCIAH0AAJFQRIA+
AIBIKCJAHwBAJBQRoA8AIBIKCfBvD4BIgIIC/JsDIJKmFxZ+ds4PAJT4f+ykWbyzS83gAAAAAElF
TkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-01-19 10:14:22 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAjAAAAFkCAMAAAAJ2PEhAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-01-19 10:14:22 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAe4AAAcDCAIAAAAff0VnAACAAElEQVR42uydsU7rytqwLSEhihQU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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-02-26 16:40:59 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-02-26 16:40:59 +0000" MODIFIED_BY="[Empty name]">Searches performed for the previous versions of this review up to and including Hunter 2007</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-30 10:12:44 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the searches performed for previous versions of this review, up to and including 2007 (<LINK REF="REF-Hunter-2007" TYPE="REFERENCE">Hunter 2007</LINK>) are given below.<BR/>
</P>
<SUBSECTION>
<HEADING LEVEL="3">Systematic searches of electronic bibliographic databases</HEADING>
<P>MEDLINE (January 1966 to January 2006), EMBASE (January 1988 to January 2006), CINAHL (January 1982 to January 2006), PsycLIT (January 1984 to January 2006), ERIC (January 1984 to January 2006)</P>
<P>The following electronic bibliographic databases were searched (date search was performed: 10 January 2006):<BR/>MEDLINE - dates searched: January 1966 to January 2006;<BR/>EMBASE - dates searched: January 1988 to January 2006;<BR/>PsycLIT - dates searched: January 1984 to January 2006;<BR/>CINAHL - dates searched: January 1982 to January 2006;<BR/>ERIC - dates searched: January 1984 to January 2006.</P>
<P>The following search terms were used in each database (no limits were applied to the searches):<BR/>incontinence, urinary, male, postprostatectomy, stimulation, electrical stimulation, biofeedback, pelvic muscle exercises, Kegel exercises, behavioural, behaviour, behavior, therapy, behaviour modification, therapy, physiotherapy, lifestyle, weight loss, caffeine, smoking, extracorporeal magnetic innervation, external penile compression devices, continence, bladder control, quality of life, randomised (randomized) controlled trial, evaluation, effectiveness, efficacy, outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Handsearching of conference proceedings</HEADING>
<P>The following conference proceedings were handsearched:<BR/>
</P>
<UL>
<LI>American Urological Association (years searched: 1989-2005) Supplement to the Journal of Urology, published as a supplement.</LI>
<LI>Society of Urologic Nurses and Associates (SUNA) (formerly American Urologic Association Allied) these abstracts are not published but are available in the SUNA office. Annual meeting (years searched: 1991 to 2003);1991-Las Vegas, NV; 1992-Washington, DC; 1993-San Antonio, TX; 1994-San Francisco, CA; 1995-Las Vegas,NV; 1996-Orlando, FL, 1997-New Orleans, LA. Biannual incontinence meeting: 1992-Tampa, Fla (1st meeting), 1994-Phoenix, 1996-Dallas, 1998-Orlando, 2000-Nashville, 2004-Chicago, 2006-NYC; Understanding urodynamics seminar:1993-Denver, CO; 1994-San Antonio, TX; 1995-Cleveland, OH; 1996-St Louis, MO.</LI>
<LI>Wound Ostomy and Continence Nurses (years searched: 1996, 1997,1999 to 2006). Annual meeting: 1996- Seattle, WA; 1997-Nashville, TN; Incontinence meeting (biannual); 1997-Beverly Hills (1st meeting); 1999-Austin, TX. (No further Incontinence meetings.)</LI>
<LI>International Continence Society (years searched: 1980 to 2006). Published proceedings in Neurourology and Urodynamics.</LI>
</UL>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2014-02-26 16:43:04 +0000" MODIFIED_BY="[Empty name]">Searches performed for the previous version of this review (Campbell 2012)</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Extra specific searches (additional to the Specialised Register search) were performed for previous version of the review (<LINK REF="REF-Campbell-2012" TYPE="REFERENCE">Campbell 2012</LINK>). These are detailed below:</P>
<UL>
<LI>CINAHL on EBSCO (January 1982 to 20 November 2009) was searched on 7 December 2009;</LI>
<LI>EMBASE on Ovid (January 1980 to Week 48 2009) was searched on 3 December 2009.</LI>
</UL>
<P>The search strategies used to search these databases can be found below:</P>
<P>CINAHL on EBSCO (January 1982 to 20 November 2009) was searched on 7 December 2009:</P>
<TABLE COLS="2" ROWS="38">
<TR>
<TD VALIGN="TOP">
<P>S38</P>
</TD>
<TD VALIGN="TOP">
<P>  S31 and S35 and S37  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S37</P>
</TD>
<TD VALIGN="TOP">
<P>  S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S36  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S36</P>
</TD>
<TD VALIGN="TOP">
<P>  TI ( singl* N25 blind* OR singl* N25 mask* OR doubl* N25 blind* or doubl* N25 mask* OR trebl* N25 blind* OR trebl* N25 mask*OR tripl* N25 blind* OR tripl* N25 mask* ) or AB ( singl* N25 blind* OR singl* N25 mask* OR doubl* N25 blind* or doubl* N25 mask* OR trebl* N25 blind* OR trebl* N25 mask*OR tripl* N25 blind* OR tripl* N25 mask* )  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S35</P>
</TD>
<TD VALIGN="TOP">
<P>  (S32 or S33 or S34)  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S34</P>
</TD>
<TD VALIGN="TOP">
<P>  TI postprostat* OR AB postprostat*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S33</P>
</TD>
<TD VALIGN="TOP">
<P>  TI post-prostat* OR AB post-prostat*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S32</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Prostatectomy")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S31</P>
</TD>
<TD VALIGN="TOP">
<P>  (S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30)  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S30</P>
</TD>
<TD VALIGN="TOP">
<P>  AB overactive N3 bladder*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S29</P>
</TD>
<TD VALIGN="TOP">
<P>  TI overactive N3 bladder*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S28</P>
</TD>
<TD VALIGN="TOP">
<P>  AB urin* N3 leak*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S27</P>
</TD>
<TD VALIGN="TOP">
<P>  TI urin* N3 leak*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S26</P>
</TD>
<TD VALIGN="TOP">
<P>  AB incontinen* OR continen*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S25</P>
</TD>
<TD VALIGN="TOP">
<P>  TI incontinen* OR continen*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S24</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Incontinence")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S23</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Overactive Bladder")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S22</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Urinary Incontinence+")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S21</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Comparative Studies")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S20</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Clinical Research+")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S19</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Static Group Comparison")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S18</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Quantitative Studies")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S17</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Crossover Design") or (MH "Solomon Four-Group Design")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S16</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Factorial Design")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S15</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Community Trials")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S14</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Random Sample")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S13</P>
</TD>
<TD VALIGN="TOP">
<P>  TI balance* N2 block* or AB balance* N2 block*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S12</P>
</TD>
<TD VALIGN="TOP">
<P>  TI "latin square" or AB "latin square"  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S11</P>
</TD>
<TD VALIGN="TOP">
<P>  TI factorial or AB factorial  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S10</P>
</TD>
<TD VALIGN="TOP">
<P>  TI clin* N25 trial* or AB clin* N25 trial*  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S9</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Study Design")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S8</P>
</TD>
<TD VALIGN="TOP">
<P>  (AB random*) OR (TI random*)  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S7</P>
</TD>
<TD VALIGN="TOP">
<P>  (AB placebo*) OR (TI placebo*)  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S6</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Placebos")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S5</P>
</TD>
<TD VALIGN="TOP">
<P>  PT Clinical Trial  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S4</P>
</TD>
<TD VALIGN="TOP">
<P>  (MH "Clinical Trials+")  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S3</P>
</TD>
<TD VALIGN="TOP">
<P>  MH (random assignment) OR (crossover design)  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S2</P>
</TD>
<TD VALIGN="TOP">
<P>  cross-over  </P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S1</P>
</TD>
<TD VALIGN="TOP">
<P>  crossover  </P>
</TD>
</TR>
</TABLE>
<P/>
<P>EMBASE on Ovid (January 1980 to Week 48 2009) was searched on 3 December 2009:</P>
<TABLE COLS="2" ROWS="80">
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P> Randomized Controlled Trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>controlled study/</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>clinical study/</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>major clinical study/</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>prospective study/</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>meta analysis/</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>exp clinical trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>8</P>
</TD>
<TD>
<P>randomization/</P>
</TD>
</TR>
<TR>
<TD>
<P>9</P>
</TD>
<TD>
<P>crossover procedure/ or double blind procedure/ or parallel design/ or single blind procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>Placebo/</P>
</TD>
</TR>
<TR>
<TD>
<P>11</P>
</TD>
<TD>
<P>latin square design/</P>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>exp comparative study/</P>
</TD>
</TR>
<TR>
<TD>
<P>13</P>
</TD>
<TD>
<P>follow up/</P>
</TD>
</TR>
<TR>
<TD>
<P>14</P>
</TD>
<TD>
<P>pilot study/</P>
</TD>
</TR>
<TR>
<TD>
<P>15</P>
</TD>
<TD>
<P>family study/ or feasibility study/ or pilot study/ or study/</P>
</TD>
</TR>
<TR>
<TD>
<P>16</P>
</TD>
<TD>
<P>placebo$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>17</P>
</TD>
<TD>
<P>random$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>18</P>
</TD>
<TD>
<P>(clin$ adj25 trial$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>19</P>
</TD>
<TD>
<P>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>20</P>
</TD>
<TD>
<P>factorial.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>21</P>
</TD>
<TD>
<P>crossover.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>22</P>
</TD>
<TD>
<P>latin square.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>23</P>
</TD>
<TD>
<P>(balance$ adj2 block$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>24</P>
</TD>
<TD>
<P>factorial design/</P>
</TD>
</TR>
<TR>
<TD>
<P>25</P>
</TD>
<TD>
<P>parallel design/</P>
</TD>
</TR>
<TR>
<TD>
<P>26</P>
</TD>
<TD>
<P>triple blind procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>27</P>
</TD>
<TD>
<P>community trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>28</P>
</TD>
<TD>
<P>intervention study/</P>
</TD>
</TR>
<TR>
<TD>
<P>29</P>
</TD>
<TD>
<P>experimental study/</P>
</TD>
</TR>
<TR>
<TD>
<P>30</P>
</TD>
<TD>
<P>prevention study/</P>
</TD>
</TR>
<TR>
<TD>
<P>31</P>
</TD>
<TD>
<P>quasi experimental study/</P>
</TD>
</TR>
<TR>
<TD>
<P>32</P>
</TD>
<TD>
<P>or/1-31</P>
</TD>
</TR>
<TR>
<TD>
<P>33</P>
</TD>
<TD>
<P>(nonhuman not human).sh.</P>
</TD>
</TR>
<TR>
<TD>
<P>34</P>
</TD>
<TD>
<P>32 not 33</P>
</TD>
</TR>
<TR>
<TD>
<P>35</P>
</TD>
<TD>
<P>exp urine incontinence/</P>
</TD>
</TR>
<TR>
<TD>
<P>36</P>
</TD>
<TD>
<P>incontinence/</P>
</TD>
</TR>
<TR>
<TD>
<P>37</P>
</TD>
<TD>
<P>overactive bladder/</P>
</TD>
</TR>
<TR>
<TD>
<P>38</P>
</TD>
<TD>
<P>(incontinen$ or continen$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>39</P>
</TD>
<TD>
<P>(urin$ adj2 leak$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>40</P>
</TD>
<TD>
<P>(overactive adj2 bladder$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>41</P>
</TD>
<TD>
<P>35 or 36 or 37 or 38 or 39 or 40</P>
</TD>
</TR>
<TR>
<TD>
<P>42</P>
</TD>
<TD>
<P>prostatectomy/</P>
</TD>
</TR>
<TR>
<TD>
<P>43</P>
</TD>
<TD>
<P>post-prostat$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>44</P>
</TD>
<TD>
<P>postprostat$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>45</P>
</TD>
<TD>
<P>42 or 43 or 44</P>
</TD>
</TR>
<TR>
<TD>
<P>46</P>
</TD>
<TD>
<P>electrostimulation/ or electrostimulation therapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>47</P>
</TD>
<TD>
<P>stimulation.mp.</P>
</TD>
</TR>
<TR>
<TD>
<P>48</P>
</TD>
<TD>
<P>(electric$ adj2 stimulat$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>49</P>
</TD>
<TD>
<P>electrostimulat$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>50</P>
</TD>
<TD>
<P>magnetotherapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>51</P>
</TD>
<TD>
<P>exmi.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>52</P>
</TD>
<TD>
<P>(magnet$ adj2 (stimulat$ or innervat$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>53</P>
</TD>
<TD>
<P>feedback system/</P>
</TD>
</TR>
<TR>
<TD>
<P>54</P>
</TD>
<TD>
<P>biofeedback.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>55</P>
</TD>
<TD>
<P>pelvis floor/ or muscle training/ or pelvic floor muscle training/ or muscle exercise/ or muscle strength/</P>
</TD>
</TR>
<TR>
<TD>
<P>56</P>
</TD>
<TD>
<P>(pelvi$ adj5 (exercis$ or train$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>57</P>
</TD>
<TD>
<P>pfmt.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>58</P>
</TD>
<TD>
<P>pfe.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>(kegel adj2 exercis$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>behavior therapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>61</P>
</TD>
<TD>
<P>(behavio?r$ adj3 (therap$ or train$ or treat$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>62</P>
</TD>
<TD>
<P>physiotherapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>63</P>
</TD>
<TD>
<P>home physiotherapy/ or physiotherapy practice/</P>
</TD>
</TR>
<TR>
<TD>
<P>64</P>
</TD>
<TD>
<P>physiotherapist/ or physiotherapist assistant/</P>
</TD>
</TR>
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>physiotherap$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>66</P>
</TD>
<TD>
<P>(physi$ adj3 (therap$ or treat$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>67</P>
</TD>
<TD>
<P>lifestyle/ or lifestyle modification/</P>
</TD>
</TR>
<TR>
<TD>
<P>68</P>
</TD>
<TD>
<P>(lifestyle$ adj3 (chang$ or modif$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>69</P>
</TD>
<TD>
<P>(life adj2 style$ adj3 (chang$ or modif$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>70</P>
</TD>
<TD>
<P>weight reduction/</P>
</TD>
</TR>
<TR>
<TD>
<P>71</P>
</TD>
<TD>
<P>(weight adj3 (los$ or reduc$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>72</P>
</TD>
<TD>
<P>caffeine/</P>
</TD>
</TR>
<TR>
<TD>
<P>73</P>
</TD>
<TD>
<P>caffeine.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>74</P>
</TD>
<TD>
<P>smoking cessation/</P>
</TD>
</TR>
<TR>
<TD>
<P>75</P>
</TD>
<TD>
<P>smoking cessation.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>76</P>
</TD>
<TD>
<P>(peni$ adj3 (device$ or clamp$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>77</P>
</TD>
<TD>
<P>"quality of life"/</P>
</TD>
</TR>
<TR>
<TD>
<P>78</P>
</TD>
<TD>
<P>quality of life.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>79</P>
</TD>
<TD>
<P>or/46-78</P>
</TD>
</TR>
<TR>
<TD>
<P>80</P>
</TD>
<TD>
<P>34 and 41 and 45 and 79</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2014-02-26 17:12:26 +0000" MODIFIED_BY="[Empty name]">Searches performed for the current version of this review</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-19 10:14:21 +0000" MODIFIED_BY="[Empty name]">
<P>Specific searches were also performed for this update of the review. These are detailed below:</P>
<UL>
<LI>CENTRAL (on OvidSP) (2014, Issue 1) was searched on 26 February 2014;</LI>
<LI>Embase (on OvidSP) (January 1980 to Week 3 2014) was searched on 20 January 2014;</LI>
<LI>CINAHL (on EBSCOhost) (January 1982 to 18 January 2014) was searched on 22 January 2014;</LI>
<LI>ClinicalTrials.gov (via the Cochrane Register of Studies (CRS) interface) and WHO ICTRP (both searched on 29 January 2014)</LI>
</UL>
<P>The search strategies used to search these databases can be found below:</P>
<P>
<B>CENTRAL</B> (on OvidSP) (2014, Issue 1) was searched on 26 February 2014</P>
<P>1. exp urinary incontinence/<BR/>2. (incontinen$ or continen$).tw.<BR/>3. (urin$ adj2 leak$).tw.<BR/>4. or/1-3<BR/>5. prostate/<BR/>6. prostatectomy/<BR/>7. prostatic hyperplasia/<BR/>8. prostatic neoplasms/<BR/>9. prostatitis/<BR/>10. prostatic diseases/<BR/>11. prostat$.tw.<BR/>12. post-prostat$.tw.<BR/>13. postprostat$.tw.<BR/>14. or/5-13<BR/>15. 4 and 14<BR/>16. cochrane incontinence group.gc.<BR/>17. 15 not 16</P>
<P>
<B>EMBASE</B> (on OvidSP) (January 1947 to Week 3 2014) was searched on 20 January 2014 and limited to entry month January 2010 to Week 3 2014 (using 201$.em.) as the Cochrane Collaboration searches EMBASE centrally and is currently bringing this search up to date.</P>
<TABLE COLS="2" ROWS="80">
<TR>
<TD>
<P>1</P>
</TD>
<TD>
<P>Randomized Controlled Trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>2</P>
</TD>
<TD>
<P>controlled study/</P>
</TD>
</TR>
<TR>
<TD>
<P>3</P>
</TD>
<TD>
<P>clinical study/</P>
</TD>
</TR>
<TR>
<TD>
<P>4</P>
</TD>
<TD>
<P>major clinical study/</P>
</TD>
</TR>
<TR>
<TD>
<P>5</P>
</TD>
<TD>
<P>prospective study/</P>
</TD>
</TR>
<TR>
<TD>
<P>6</P>
</TD>
<TD>
<P>meta analysis/</P>
</TD>
</TR>
<TR>
<TD>
<P>7</P>
</TD>
<TD>
<P>exp clinical trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>8</P>
</TD>
<TD>
<P>randomization/</P>
</TD>
</TR>
<TR>
<TD>
<P>9</P>
</TD>
<TD>
<P>crossover procedure/ or double blind procedure/ or parallel design/ or single blind procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>10</P>
</TD>
<TD>
<P>Placebo/</P>
</TD>
</TR>
<TR>
<TD>
<P>11</P>
</TD>
<TD>
<P>latin square design/</P>
</TD>
</TR>
<TR>
<TD>
<P>12</P>
</TD>
<TD>
<P>exp comparative study/</P>
</TD>
</TR>
<TR>
<TD>
<P>13</P>
</TD>
<TD>
<P>follow up/</P>
</TD>
</TR>
<TR>
<TD>
<P>14</P>
</TD>
<TD>
<P>pilot study/</P>
</TD>
</TR>
<TR>
<TD>
<P>15</P>
</TD>
<TD>
<P>family study/ or feasibility study/ or pilot study/ or study/</P>
</TD>
</TR>
<TR>
<TD>
<P>16</P>
</TD>
<TD>
<P>placebo$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>17</P>
</TD>
<TD>
<P>random$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>18</P>
</TD>
<TD>
<P>(clin$ adj25 trial$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>19</P>
</TD>
<TD>
<P>((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>20</P>
</TD>
<TD>
<P>factorial.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>21</P>
</TD>
<TD>
<P>crossover.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>22</P>
</TD>
<TD>
<P>latin square.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>23</P>
</TD>
<TD>
<P>(balance$ adj2 block$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>24</P>
</TD>
<TD>
<P>factorial design/</P>
</TD>
</TR>
<TR>
<TD>
<P>25</P>
</TD>
<TD>
<P>parallel design/</P>
</TD>
</TR>
<TR>
<TD>
<P>26</P>
</TD>
<TD>
<P>triple blind procedure/</P>
</TD>
</TR>
<TR>
<TD>
<P>27</P>
</TD>
<TD>
<P>community trial/</P>
</TD>
</TR>
<TR>
<TD>
<P>28</P>
</TD>
<TD>
<P>intervention study/</P>
</TD>
</TR>
<TR>
<TD>
<P>29</P>
</TD>
<TD>
<P>experimental study/</P>
</TD>
</TR>
<TR>
<TD>
<P>30</P>
</TD>
<TD>
<P>prevention study/</P>
</TD>
</TR>
<TR>
<TD>
<P>31</P>
</TD>
<TD>
<P>quasi experimental study/</P>
</TD>
</TR>
<TR>
<TD>
<P>32</P>
</TD>
<TD>
<P>or/1-31</P>
</TD>
</TR>
<TR>
<TD>
<P>33</P>
</TD>
<TD>
<P>(nonhuman not human).sh.</P>
</TD>
</TR>
<TR>
<TD>
<P>34</P>
</TD>
<TD>
<P>32 not 33</P>
</TD>
</TR>
<TR>
<TD>
<P>35</P>
</TD>
<TD>
<P>exp urine incontinence/</P>
</TD>
</TR>
<TR>
<TD>
<P>36</P>
</TD>
<TD>
<P>incontinence/</P>
</TD>
</TR>
<TR>
<TD>
<P>37</P>
</TD>
<TD>
<P>overactive bladder/</P>
</TD>
</TR>
<TR>
<TD>
<P>38</P>
</TD>
<TD>
<P>(incontinen$ or continen$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>39</P>
</TD>
<TD>
<P>(urin$ adj2 leak$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>40</P>
</TD>
<TD>
<P>(overactive adj2 bladder$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>41</P>
</TD>
<TD>
<P>35 or 36 or 37 or 38 or 39 or 40</P>
</TD>
</TR>
<TR>
<TD>
<P>42</P>
</TD>
<TD>
<P>prostatectomy/</P>
</TD>
</TR>
<TR>
<TD>
<P>43</P>
</TD>
<TD>
<P>post-prostat$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>44</P>
</TD>
<TD>
<P>postprostat$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>45</P>
</TD>
<TD>
<P>42 or 43 or 44</P>
</TD>
</TR>
<TR>
<TD>
<P>46</P>
</TD>
<TD>
<P>electrostimulation/ or electrostimulation therapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>47</P>
</TD>
<TD>
<P>stimulation.mp.</P>
</TD>
</TR>
<TR>
<TD>
<P>48</P>
</TD>
<TD>
<P>(electric$ adj2 stimulat$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>49</P>
</TD>
<TD>
<P>electrostimulat$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>50</P>
</TD>
<TD>
<P>magnetotherapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>51</P>
</TD>
<TD>
<P>exmi.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>52</P>
</TD>
<TD>
<P>(magnet$ adj2 (stimulat$ or innervat$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>53</P>
</TD>
<TD>
<P>feedback system/</P>
</TD>
</TR>
<TR>
<TD>
<P>54</P>
</TD>
<TD>
<P>biofeedback.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>55</P>
</TD>
<TD>
<P>pelvis floor/ or muscle training/ or pelvic floor muscle training/ or muscle exercise/ or muscle strength/</P>
</TD>
</TR>
<TR>
<TD>
<P>56</P>
</TD>
<TD>
<P>(pelvi$ adj5 (exercis$ or train$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>57</P>
</TD>
<TD>
<P>pfmt.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>58</P>
</TD>
<TD>
<P>pfe.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>59</P>
</TD>
<TD>
<P>(kegel adj2 exercis$).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>60</P>
</TD>
<TD>
<P>behavior therapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>61</P>
</TD>
<TD>
<P>(behavio?r$ adj3 (therap$ or train$ or treat$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>62</P>
</TD>
<TD>
<P>physiotherapy/</P>
</TD>
</TR>
<TR>
<TD>
<P>63</P>
</TD>
<TD>
<P>home physiotherapy/ or physiotherapy practice/</P>
</TD>
</TR>
<TR>
<TD>
<P>64</P>
</TD>
<TD>
<P>physiotherapist/ or physiotherapist assistant/</P>
</TD>
</TR>
<TR>
<TD>
<P>65</P>
</TD>
<TD>
<P>physiotherap$.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>66</P>
</TD>
<TD>
<P>(physi$ adj3 (therap$ or treat$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>67</P>
</TD>
<TD>
<P>lifestyle/ or lifestyle modification/</P>
</TD>
</TR>
<TR>
<TD>
<P>68</P>
</TD>
<TD>
<P>(lifestyle$ adj3 (chang$ or modif$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>69</P>
</TD>
<TD>
<P>(life adj2 style$ adj3 (chang$ or modif$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>70</P>
</TD>
<TD>
<P>weight reduction/</P>
</TD>
</TR>
<TR>
<TD>
<P>71</P>
</TD>
<TD>
<P>(weight adj3 (los$ or reduc$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>72</P>
</TD>
<TD>
<P>caffeine/</P>
</TD>
</TR>
<TR>
<TD>
<P>73</P>
</TD>
<TD>
<P>caffeine.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>74</P>
</TD>
<TD>
<P>smoking cessation/</P>
</TD>
</TR>
<TR>
<TD>
<P>75</P>
</TD>
<TD>
<P>smoking cessation.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>76</P>
</TD>
<TD>
<P>(peni$ adj3 (device$ or clamp$)).tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>77</P>
</TD>
<TD>
<P>"quality of life"/</P>
</TD>
</TR>
<TR>
<TD>
<P>78</P>
</TD>
<TD>
<P>quality of life.tw.</P>
</TD>
</TR>
<TR>
<TD>
<P>79</P>
</TD>
<TD>
<P>or/46-78</P>
</TD>
</TR>
<TR>
<TD>
<P>80</P>
</TD>
<TD>
<P>34 and 41 and 45 and 79</P>
</TD>
</TR>
</TABLE>
<P>
<B>CINAHL </B>(on EBSCOhost) (January 1982 to 18 January 2014) was searched on 22 January 2014</P>
<TABLE COLS="2" ROWS="38">
<TR>
<TD VALIGN="TOP">
<P>S38</P>
</TD>
<TD VALIGN="TOP">
<P>S31 and S35 and S37</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S37</P>
</TD>
<TD VALIGN="TOP">
<P>S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S36</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S36</P>
</TD>
<TD VALIGN="TOP">
<P>TI ( singl* N25 blind* OR singl* N25 mask* OR doubl* N25 blind* or doubl* N25 mask* OR trebl* N25 blind* OR trebl* N25 mask*OR tripl* N25 blind* OR tripl* N25 mask* ) or AB ( singl* N25 blind* OR singl* N25 mask* OR doubl* N25 blind* or doubl* N25 mask* OR trebl* N25 blind* OR trebl* N25 mask*OR tripl* N25 blind* OR tripl* N25 mask* )</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S35</P>
</TD>
<TD VALIGN="TOP">
<P>(S32 or S33 or S34)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S34</P>
</TD>
<TD VALIGN="TOP">
<P>TI postprostat* OR AB postprostat*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S33</P>
</TD>
<TD VALIGN="TOP">
<P>TI post-prostat* OR AB post-prostat*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S32</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Prostatectomy")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S31</P>
</TD>
<TD VALIGN="TOP">
<P>(S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or S30)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S30</P>
</TD>
<TD VALIGN="TOP">
<P>AB overactive N3 bladder*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S29</P>
</TD>
<TD VALIGN="TOP">
<P>TI overactive N3 bladder*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S28</P>
</TD>
<TD VALIGN="TOP">
<P>AB urin* N3 leak*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S27</P>
</TD>
<TD VALIGN="TOP">
<P>TI urin* N3 leak*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S26</P>
</TD>
<TD VALIGN="TOP">
<P>AB incontinen* OR continen*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S25</P>
</TD>
<TD VALIGN="TOP">
<P>TI incontinen* OR continen*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S24</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Incontinence")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S23</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Overactive Bladder")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S22</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Urinary Incontinence+")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S21</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Comparative Studies")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S20</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Clinical Research+")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S19</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Static Group Comparison")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S18</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Quantitative Studies")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S17</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Crossover Design") or (MH "Solomon Four-Group Design")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S16</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Factorial Design")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S15</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Community Trials")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S14</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Random Sample")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S13</P>
</TD>
<TD VALIGN="TOP">
<P>TI balance* N2 block* or AB balance* N2 block*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S12</P>
</TD>
<TD VALIGN="TOP">
<P>TI "latin square" or AB "latin square"</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S11</P>
</TD>
<TD VALIGN="TOP">
<P>TI factorial or AB factorial</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S10</P>
</TD>
<TD VALIGN="TOP">
<P>TI clin* N25 trial* or AB clin* N25 trial*</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S9</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Study Design")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S8</P>
</TD>
<TD VALIGN="TOP">
<P>(AB random*) OR (TI random*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S7</P>
</TD>
<TD VALIGN="TOP">
<P>(AB placebo*) OR (TI placebo*)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S6</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Placebos")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S5</P>
</TD>
<TD VALIGN="TOP">
<P>(PT Clinical Trial) OR (PT "randomized controlled trial")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S4</P>
</TD>
<TD VALIGN="TOP">
<P>(MH "Clinical Trials+")</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S3</P>
</TD>
<TD VALIGN="TOP">
<P>MH (random assignment) OR (crossover design)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S2</P>
</TD>
<TD VALIGN="TOP">
<P>cross-over</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>S1</P>
</TD>
<TD VALIGN="TOP">
<P>crossover</P>
</TD>
</TR>
</TABLE>
<P>
<B>ClinicalTrials.gov</B> (via the Cochrane Register of Studies (CRS) interface) (searched on 29 January 2014)</P>
<P>(Continent OR continence OR incontinent OR incontinence OR overactive OR overactivity) AND (prostate OR prostatectomy OR postprostatectomy OR prostatic OR prostatectomies OR prostatic OR prostatectomies OR postprostatectomies)</P>
<P>
<B>WHO ICTRP</B> (searched on 29 January 2014)</P>
<P>Simple search with each of these lines searched and assessed separately:</P>
<P>Incontinent AND postprostatectomy</P>
<P>Incontinence AND postprostatectomy</P>
<P>Incontinent AND prostatectomy</P>
<P>Incontinence AND prostatectomy</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_74740356430336605589110415170237_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="74740356430336605589110415170237">
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>London School of Hygiene and Tropical Medicine</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;59 reports of 27 studies (2 studies Glazener RP 2011 and Glazener TURP 2011 are described in the same 5 reports) included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;96 reports of 50 studies are included in the qualitative synthesis (2 studies &lt;a link_type=&quot;STUDY&quot; protected=&quot;true&quot; href=&quot;Glazener RP 2011&quot;&gt;Glazener RP 2011&lt;/a&gt; and &lt;a link_type=&quot;STUDY&quot; protected=&quot;true&quot; href=&quot;Glazener TURP 2011&quot;&gt;Glazener TURP 2011&lt;/a&gt; are described in the same 9 reports) (plus a further 8 reports of 6 studies are described in the &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_AWAITING_STUDIES&quot;&gt;Characteristics of studies awaiting classification&lt;/a&gt; table plus a further 8 studies are described in the &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_ONGOING_STUDIES&quot;&gt;Characteristics of ongoing studies&lt;/a&gt; table)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;153 full-text articles were assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1300 records screened for all versions of the review&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;For this update a total of 764 records were identified through searching the following databases: Incontinence Group Specialised Register = 193; CENTRAL = 37; Embase = 354; CINAHL = 23; ClinicalTrials.gov = 125; WHO ICTRP = 32.&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;In total 536 records were assessed for the previous versions of this review&lt;/p&gt;" WIDTH="120"/>
<OUT TEXT="&lt;p&gt;1147 records were excluded (for all versions of this review at 2014)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;41 reports of 36 studies were excluded and reasons are given in the &lt;a link_type=&quot;SECTION&quot; protected=&quot;true&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table.&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>